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Abstract
CD44 is a transmembrane cell surface glycoprotein which has been implicated in 
various cell processes such as cell adhesion, lymphocyte migration and 
lymphocyte activation. However, although an important function for CD44 has 
been suggested by antibody-blocking studies, CD44'7' mice paradoxically show few 
defects in immune function.
Since compensatory mechanisms, operable in the complete absence of CD44 
expression, could account for these apparently contradictory findings, we 
compared the development and function of CD44+/+ and CD44‘/' lymphocytes when 
these cells were in direct competition. Radiation bone marrow chimeras made 
with different combinations of CD44+/+ and CD44'7’ donor and recipient mice were 
employed.
CD44'/‘ progenitor cells were able to fully reconstitute both T and B cell pools when 
injected into irradiated CD44+/+ or CD44/' recipients. However, chimeras 
reconstituted with a mixture of CD44'/' and CD44+/+ progenitors showed a 
deficiency in the generation of CD44‘A T cells. This deficit appeared to be due to 
both reduced thymic homing and impaired intrathymic maturation of CD44'/‘ 
precursors. In contrast, a slight increase in the production of B cells derived from 
the CD44 7* progenitors was observed in mixed chimeras, which was independent 
of precursor trapping in the thymus, as shown in experiments in thymectomised 
mice.
3
The function of mature CD44‘/* lymphocytes was investigated by assessing 
immune responses after immunisation or infection of mixed chimeras. As 
measured by tetramer and intracellular cytokine staining, CD44_/' CD8+ T cells were 
shown to respond less well than CD44+/+ cells, while CD44'7' B cells exhibited a 
subtle defect in antibody production.
Overall, the results demonstrate that CD44 plays a role during lymphocyte 
development and in the function of mature lymphocytes, which is only apparent 
when CD44 positive and negative cells are in direct competition.
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1. Introduction
1.1.Organisation and development of the immune system
1.1.1. An overview of the immune system.
The immune system has over time evolved to assist the body’s defence against 
harmful invading pathogens, and as the body has become more complex, so has 
the immune system. The body must therefore have a system in place that can 
provide protection against a multitude of pathogens without damaging itself. When 
this regulation is disrupted, damage to the body is caused by the immune system 
attacking self and causing autoimmune diseases or by “overreacting” to harmless 
antigens, which results in allergy.
In higher organisms such as mammals, the immune system can be divided into two 
parts, the innate and the adaptive. The innate immune system is the first to 
respond to pathogens, mainly microbes. It is the most primitive part of the immune 
system and comprises mainly of phagocytic cells such cells as macrophages. 
These cells phagocytose the invading microbes and produce anti-microbial factors 
such as cytokines, which alert neighbouring cells of potential attack. Certain 
cytokines also recruit other innate and adaptive cells to the area of infection. After 
physical barriers such as epithelia and mucosal secretions, the innate immune 
system is the first line of defence against invading pathogens. Mediators of innate 
immunity recognise conserved molecules or motifs on microbes that identifies them 
as pathogenic allowing for an immediate response. This response may be
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sufficient to prevent the initial colonisation of the body by the invading microbes, 
and in instances when the innate immune system is not successful in containing 
the pathogens, allows time for an adaptive immune response to be mounted. 
Although innate immunity functions rapidly, there is no recall or ‘memory’ of the 
microbes encountered. In addition, since innate pathogen receptors are germ-line 
encoded, recognition is restricted to pathogen structures that cannot be altered 
without loss of viability, and so do not adapt to microbial variation.
Conversely, the adaptive immune response can adapt to recognise pathogen 
variation. Receptors on lymphocytes of the adaptive immune system are 
generated through somatic recombination of multiple gene segments so that they 
are able to recognise an almost limitless variety of antigenic molecules, or 
antigens. A drawback to having such a wide variety of cells is that there are only 
low numbers of lymphocyte specific for any particular antigen. For this reason, 
there is a requirement for antigen specific cells to undergo multiple divisions 
following recognition of antigen in order to generate a sufficient population of 
pathogen reactive cells. Therefore the adaptive immune response is much slower 
than the innate response, at least on first encounter with a pathogen. On the other 
hand, antigen specific lymphocytes persist at a high frequency as memory cells 
after pathogenic clearance, and provide a more rapid response to re-infection. 
There are two parts of the adaptive immune system, the humoral and the cellular 
arms. The humoral system is comprised of antibodies, secreted into the blood 
system and mucosal secretions by B cells, which can block and disable invading 
pathogens and toxins. The cellular arm is mediated by T cells, which recognise 
infected cells. Effector T cells travel to the site of infection and release chemical
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factors which can kill the target cell. At the start of an infection, both aspects of the 
immune response are typically initiated in secondary lymphoid organs, such as 
lymph nodes (LN), where fragments of pathogen components are presented to 
naive T cells by specialised antigen-presenting cells (APCs), mainly dendritic cells 
(DCs). Antigen recognition by naive cells leads to activation and cell multiplication. 
The resultant population of T cells travels to the site of infection where it interacts 
with infected cells and destroys the recognised pathogen. Responding B cells 
secrete immunoglobulins (which bind to the pathogen and label it for phagocytosis 
or complement cytotoxicity).
1.1.2. Development of haematopoietic stem cells
The cells of both the adaptive and innate immune system are derived from self- 
renewing haematopoietic stem cells (HSC). Early In embryo formation, three 
germ layers are formed, the ectoderm, the endoderm and the mesoderm (1). HSC 
are derived from the mesodermic layer and are capable of generating all erythroid, 
myeloid and lymphoid cell lineages. As these cells are undifferentiated, they do 
not express lineage specific cell markers on the cell surface, such as CD3 or 
CD19; in practical terms this enables cellular enrichment by negative selection. 
HSCs are thought to be non-cycling and are unresponsive to a multitude of growth 
factors such as IL-1, IL-3, IL-4, IL-6, CSF-1, G-CSF, and GM-CSF (2). The 
differentiation of HSC to specific lineages involves multiple transcription factors 
(Figure 1.1) (3). For example, the transcription factor PU-1 is necessary for 
differentiation of the HSC’s into myeloid lymphoid progenitors (4), while high levels
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of Pu-1 and BLIMP-1 in the myeloid lymphoid progenitor are implicated in the 
differentiation into a myeloid progenitor. These myeloid progenitors can develop 
into myeloid cells such as macrophages (5, 6), and with the aid of other 
transcription factors such as Notch3, into mast cells (7). Low levels of Pu-1 and 
high levels of the transcription factor ikaros are thought to differentiate the 
lymphoid myeloid progenitor into a common lymphoid progenitor (8, 9). One way 
that Pu-1 is thought to help differentiate the lymphoid myeloid progenitor is by 
altering the cells responsiveness to IL-7, since low levels of PU-1 present in the 
myeloid lymphoid progenitor activates IL-7Ra gene, whereas high levels of PU-1 
prevents IL-7Ra expression (10, 11). The Ikaros transcription factor is involved in 
regulating genes essential in T and B cell development, including gene 
rearrangement genes such as RAG and TdT, essential B cell genes e.g. Ig-H and 
Ig-L, as well as T cell CD3 complex genes. It is from this common lymphoid 
progenitor in normal development that the T and B cell lineages diverge. The 
existence of a common lymphoid progenitor is not a matter of consensus; this 
debate is reviewed by Katursa (12).
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Figure 1.1. Diagram of transcription factors and cytokines 
involved in haematopoiesis and B and Tcell development.
EP, erythroid progenitor. RB, red blood cell. MLP, myeloid lymphoid 
progenitor. CLP, common lymphoid progenitor. MC, myeloid cells. 
Mac, Mast cells. NK, natural killer cells. DN, Double negative T cell. 
DP, double positive T cell. SP single positive T cell. Pro, pro-B cell. 
Pre, pre-B cell. iB, immature B cell. mB, Mature recirculating B cell. T 
cells enclosed in box represent thymic development. DC and NK 
enclosed in a broken box indicates bone marrow or thymic development.
 ► indicates potential positive selection of B-1a cells. — ► indicates
differentiation. indicate action of cytokines. _L Indicates a blocking
action
1.1.3. Development of B cells
There are two types of B cells: the B-1 and B-2 B cells. The majority of B cells are 
B-2 and are the cells typically involved in T-dependent immune responses. The B- 
1 cells are considered more primitive and are self-renewing. They are not thought 
to derive from HSC cells. B-1 cells are mainly distributed in the mucosal tissues 
and the peritoneal cavity. B-2 cells are discussed first.
1.1.3.1. B 2B  cells
The differentiation from the common lymphoid progenitor to the first stage of B cell 
development is dependent on the transcription factors E2A, EBF and Pax 5 (3). It 
is thought that E2A and EBF act by activating important B cell genes, such as 
RAG1 and RAG2 which co-ordinate with E2A and EBF to control V(D)J 
recombination. Pax 5 encourages B cell development by blocking Nbtchl gene 
expression and therefore T cell development (13, 14). Notchl is not the only 
lineage-inducing gene that Pax 5 inhibits. Pax 5 also blocks expression of M-CSF- 
R (monocyte-colony stimulating factor receptor), which therefore inhibits the pro-B 
cells from developing into monocytes (15).
Mature B cells express immunoglobulins at the cell surface which serve as antigen
receptors. Immunoglobulins are made up of two heavy chains and two light
chains. There are two types of light chain, k  and X. The light chain consists of
variable (V), joining (J), and constant (C) regions. V and J regions consist of
multiple gene segments that undergo somatic recombination, during B cell
development, to create a functional light chain. This excision and rejoining of
sections generates diversity of the immunoglobulin. The heavy chain consists of V,
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diversity (D), J and C regions. The V, D and J regions of the heavy chain also 
consists of multiple gene segments which undergo somatic recombination and 
rejoining to generate a diverse functional chain.
The pro-B cell stage is the earliest stage of B cell development, and according to 
Hardy, can be divided into three stages (Figure 1.2). At the second pro-B cell 
stage, the heavy chain locus undergoes D-J rearrangement to form a V-DJ heavy 
chain. At the third pro-B cell stage V-DJ heavy chain rearrangement occurs to 
form a VDJ rearrangement. During rearrangement, double stranded breaks in the 
DNA are initiated by RAG1 and RAG2 proteins at a specific sequence, a hairpin 
structure is formed that is ‘nicked’ open and subjected to varying amounts of 
digestion, before TdT adds a random number of nucleotides to the 3’ DNA strands. 
The DNA polymerase fills in the partner strand before the two ends are ligated 
together. The processes digestion and TdT activity add more diversity to the 
resulting of immunoglobulins. Successful heavy chain gene rearrangement allows 
the cell to receive survival and proliferative signals upon expression if the receptor 
on the cell surface, while unsuccessful rearrangements (for example, when the 
heavy chain is out of frame) force the cell to undergo apoptosis.
44
Endosteum
Blood
Flow
Sinusoid
Central sinus
V
Blood flow, exiting 
bone marrow
Figure 1.2. Schematic diagram o f haematopoiesis and B cell 
development in the bone marrow.
HSC, haematopoietic stem cells. MLR, myeloid lymphoid progenitor. 
CLP, common lymphoid progenitor. M, macrophage. D, Dendritic 
cell. RSC, reticular stromal cells. 1, Pro-B cells. 2, Pre-B cells. 3 , 
Immature B cells. 4, Mature recirculating B cells.— ► Differentiation.
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The next stage in B cell development is the pre-B cell stage. This stage can be 
divided into two separate stages. After successful rearrangement, the heavy chain 
is expressed on the cell surface as part of the pre-B cell receptor together with a 
surrogate light chain. BLNK helps facilitate signalling through the pre-BCR via syk- 
kinase (16, 17). During the first pre-B cell stage, cells proliferate extensively, a 
process that is facilitated by the transcription factor LEF-1 (18). The pre-B cell then 
returns to a stable resting state and starts to rearrange the k  light chain. The V-J 
gene segments are recombined by somatic recombination as with the heavy chain. 
If this is not successful recombination repeated until either it is successful or there 
are no more J gene segments to rearrange. If this is still unsuccessful, the cell 
starts X  light chain gene rearrangement. As with the k  chain, the gene segments 
are recombined until there is either a successful in frame somatic recortibination or 
the cells undergo apoptosis.
Once the cell has successfully rearranged its heavy and light chains, these are 
expressed on the cell surface as slgM. The immature B cell now undergoes 
negative selection. All B cells that recognise cell-surface self molecules are 
deleted, and those B cells that recognise soluble self molecules are rendered 
anergic. The latter still migrate to the periphery and mature but are soon out- 
competed and die. These mechanisms prevent autoimmunity. The OCT-2 
transcription factor is thought to facilitate the selection and maturation of the 
immature B cells by acting with the BCR (19).
Once immature B cells leave the bone marrow and enter the spleen they are 
referred to as transitional T1 B cells. These cells express the phenotype: CD19+,
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slgM+, CD21* and CD23\ These T1 B cells develop successively into T2 B cells 
and then mature follicular B cells, which are CD21+ CD23+, and found in the 
follicular area of the spleen, or marginal zone B cells, which are CD21+ CD23" (20). 
However the majority of B cells do not appear to fully mature, presumably because 
they are competing for space with mature B cells already present.
1.1.3.2. Marginal zone B cells
Marginal zone B (MZB) cells are found in the marginal zone area of the spleen, 
between the B and T cell areas and develop from the T2 B cells. It is thought T2 B 
cells develop into marginal zone B cells rather than follicular B cells through the 
activation of Notch2, although a characteristic of MZB cells is that their BCR 
recognises more innate motifs than random adaptive variation would predict (21) 
(20). Notably, B1 cells also mainly recognise more innate motifs, ancTMZB cells 
also share other characteristics with B1 cells.
1.1.3.3. B-1 B cells.
B-1 B cells were originally thought to develop primarily from precursors among 
foetal liver cells, due to limited reconstitution after bone marrow transfer into 
irradiated recipients (22). They can be divided into two groups based of surface 
CD5 staining: B-1 a CD5+ and B-1b CD5' cells. It is thought that during the pro-B 
cell stage the CD5+ B-1 cells may undergo positive selection via strong BCR 
signals. The B-1 cells constitutively express IL-5 receptor, unlike the B-2 cells (23). 
B1 B cells leave the bone marrow early in their development and migrate either to 
the spleen or the peritoneal cavity (24, 25). They have been found to secrete
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antibodies without germline immunoglobulin rearrangement, and they do not 
always express the enzyme TdT (26-28). High levels of B-1 cells are found in the 
peritoneal cavity are a major source of autoimmune and anti-carbohydrate (innate) 
antibodies. These anti-carbohydrate antibodies typically recognise the same 
motifs targeted by the innate immune system, such as lipopolysaccaride (LPS) and 
are referred to as natural IgM antibodies.
1.1.4. Development of T cells
The common lymphoid progenitor can potentially differentiate into T, B or NK cell 
lineages. When it enters the thymus it is not clear whether it does so as a 
lymphoid progenitor or has committed to the T cell lineage developmental pathway 
(Figure 1.3). The progenitor is first recognisable as a double negative thymocyte 
when it enters from the blood stream to the medulla near the cortico-medullary 
junction (29). If the T cell develops into an ap T cell, then the DN thymocyte 
migrates to the sub-capsular zone of the thymus, but if the T cell forms a y d  T cell, 
then the DN thymocyte migrates to the centre of the cortex. The mechanism 
determining ap vs. yd T cell differentiation is unknown. One thought is that if the 
TCR p chain has successfully rearranged before the y  and 6 chains then the cell 
will continue on and rearrange the a chain to become an ap T cell. However, if the 
y and 8 chains are successfully rearranged before the TCR p chain, then the cell 
becomes a yd  T cell. Another hypothesis is that notch activity favours the 
development of TCR ap T cells.
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Figure 1.3. Schematic diagram of T cell development.
DN, Double negative T cell. DP, double positive T cell. SP, single 
positive apT cell, yS, y5T cell. M, macrophage. D, DC. CE, cortical
epithelial cell. ME, medullary epithelial cell.— ► Differentiation ...... •>
Apoptosis and phagocytosis.
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It is thought that TCR y5 signals may block notch activity and therefore prevent ap 
gene rearrangement, although TCR signals are still necessary for survival (30-33). 
ap T cells can be broadly divided into four thymic populations based on expression 
of the cell surface markers CD4 and CD8. The first or double negative stage (DN, 
CD4CD8), is followed during maturation by the double positive stage (DP, 
CD4+CD8+). The most mature thymocytes are the single positive (SP) populations: 
CD4SP (CD4+CD8 ), or CD8SP (CD4*CD8+). The DN stage can be divided into 
four further stages depending on CD44 and CD25 expression: DN1 (CD44+CD25 ), 
DN2 (CD44+CD25+), DN3 (CD44‘CD25+), and DN4 (CD44CD25). The 
transcription factors Notch and Ikaros are essential forT cell development.
During the DN1 stage the T cell begins recombination of the TCR 8 chain with 
recombination between the D-V gene segments. As with the B cells, both RAG 
proteins and TdT are present to provide genetic variation in the generation of the 
TCR (34). During the DN2 stage recombination of the y chain starts. It is at this 
stage that the y8 T cells diverge from the ap T cell lineage. In the DN3 stage 
recombination between the D-J gene segments on TCR p gene occurs. At the 
DN4 stage, the TCR p chain rearranges the V-DJ chain segments. Once the TCR 
p chain has rearranged, the cell is committed to becoming an ap T cell. 
Subsequently, the TCR p chain is expressed on the cell surface with a surrogate 
TCR a chain. Signalling through the pre-TCR prevents further gene 
rearrangements and initiates proliferation.
The cell then enters the double positive stage, expressing both CD4 and CD8 on
the cell surface, and proliferating extensively. During this stage any TCR 8 genes
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remaining in the TCR a gene are removed through V-J TCR a chain gene 
rearrangements. Since there are multiple V and J gene segments, multiple 
rearrangements can occur to provide a successful rearrangement. The rearranged 
TCR a chain is then expressed on the cell surface with the TCR p to form an ap 
TCR. Signalling through the TCR turns off the gene rearrangement machinery 
such as the RAGs and TdT. It has also been found that Notch is expressed in 
double positive thymocytes and Notch inhibits E2A transcriptional activation (35). 
thus also preventing further gene manipulation.
After the TCR is expressed on the cell surface, a process of selection, based on 
TCR specificity occurs. This is necessary to (a) delete all unfunctional T cells that 
can not recognise MHC, and (b) delete all T cells that could potentially become 
activated by and therefore attack self. First, cells that have produced a TCR that 
can recognise MHCs present on the thymic stroma are positively selected. Cells 
unable to recognise the MHC fail to receive a survaival signal and undergo 
apoptosis. However, cells expressing TCRs that bind the MHC too strongly 
receive a pro-death signal and also undergo apoptosis. The actual mechanisms 
for this are not fully understood, but the different outcomes could reflect either 
qualitative or quantitative differences in signalling. It is thought to be either a 
combination of affinity and avidity or differential signalling.
The last choice for the T cell to make is whether it develops from the double 
positive into either a CD4+ or CD8+ T cell. This decision is thought result from the 
nature of signal delivered through the TCR. It has been proposed that weak 
signalling, usually through MHCI leads to CD8+ T cells, while strong signalling, 
mostly through binding to MHCI I, leads to the development of CD4+ T cells (36).
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This process is also thought to involve notch, for notch 1 can regulate TCR signal 
strength and CD4 vs. CD8 T cell development by modulating MAPK kinase, which 
is part of the differential signalling cascade (33, 37). Increased notch activity has 
been shown to promote CD8 T cell development.
Once the T cell has developed into either a CD4+ or CD8+ T cell, it is actively 
released into the periphery, where it re-circulates between the blood and the 
lymphoid tissues.
1.1.5. Development of other cell types
1.1.5.1. Natural Killer cells (NK)
NK cells have an innate ability to lyse cells that they recognise as targets, and 
produce cytokines, with which they regulate the local immune response. NK cells 
are thought to develop from the T cell progenitor in the bone marrow, and do not 
need to enter the thymus to mature. The cytokine IL-15 and lymphotoxin are 
essential for NK cell development and survival. The transcription factors Ets-1, 
Id2, Ikaros are essential for the development of NK cells from the T cell progenitor. 
(38-42).
NKT cells are T cells that posses NK cell markers. NKT cells have ap TCR
rearrangement, and express an invariant TCRa chain, but also express inhibitory
MHC-specific NK receptors. They are auto-reactive and recognise self-peptides,
but instead of being deleted in the thymus they are selected for. NKT cells
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possess a high frequency of the specific Va14-Ja18 gene rearrangement. NKT 
cells are also thought to regulate T cell responses. A disruption in NKT cell 
functions frequently leads to auto-immunity and tumour development. It is not 
known at what stage they diverge from the conventional T cell lineage, although 
they express both rearranged TCR a and p chains. It is not thought that they 
enter the double positive stage, but they have been found both in the CD4 single 
positive and the double negative stages. However, it has been observed that intra- 
thymically injected DP T cells can develop into NKT cells (43-46).
1.1.5.2. Dendritic cells (DCs)
Although the precise developmental pathways of DCs remain poorly understood, it 
appears that these cells can be derived from the myeloid lineage as well as the 
lymphoid lineage. Myeloid lineage DCs can be generated from lineage-committed 
macrophages and granulocytes, whereas lymphoid derived DCs can apparently be 
produced from both DN1 thymocytes and pre-B cells (47-51). Immature DCs are 
present in peripheral tissues and in lymphoid organs and are involved in immune 
surveillance, sampling the environment for foreign and self-antigens.
1.2.The immune response.
T cells become specifically activated via the TCR by peptide presented by the
MHC. MHC class 1 (MHCI) presents peptides to CD8+ T cells, whereas MHC
class 2 (MHCII) presents antigen to CD4+ cells. Antigen is taken up by antigen
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presenting cells, APC’s, the most efficient being the DC. The APC then migrates 
to the T cell area of secondary lymphoid tissue such as the lymph node and 
presents the antigen to naive T cells. A specific interaction with the T cell results in 
the T cell becoming activated, clonaly expanding and producing effector cells to 
fight pathogens, either directly in the case of CD8+ T cells or indirectly by CD4+ T 
cells by supporting the B cell response.
This next section is divided into three sections the initiation of the immune 
response, the T and B cell responses, and the contraction and memory stage of 
the immune response.
1.2.1. The initiation of the immune response 
Initiation of immune responses requires that APCs receive an activation signal. 
DCs become activated by either inflammatory signals such as type-1 IFN, or by the 
engagement of its Toll-like receptors (TLRs) or other innate receptors. TLRs 
recognise pathogen components such as LPS and double stranded RNA. DC 
activation triggers a series of events that lead to the stimulation of antigen-specific 
T cells (see below). Central to T cell stimulation is the processing and presentation 
of antigens (52).
1.2.1.1. Antigen uptake and processing
DCs continuously sample their environment, taking up moleculaes by pinocytosis, 
endocytosis or phagocytosis. After uptake, antigens are processed for 
presentation of peptides on MHCI or MHCII.
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Different pathways are involved in the processing of antigens for presentation on 
MHCI and MHCII.
1.2.1.2. MHCI processing
Newly synthesised cellular proteins are used to generate MHCI peptides. They are 
approximately 8-10 amino acids long, and generated by proteolysis of cytosolic 
proteins by the proteosomes. The peptides are transported to the endoplasmic 
reticulum (ER) by the transport associated with antigen processing molecule or 
TAP, (53). After post-translational modification, the MHCI molecule associates 
with TAP and is assembled with the transported peptide present in its binding 
groove (54).
In addition to presenting peptide derived from newly transcribed proteins, MHCI 
molecules can also present peptides from internalised antigens through a prossess 
known as cross-presentation. Unlike traditional MHCI presentation, which all cells 
can carry out, cross-presentation is thought to be unique to APCs. Cross­
presentation appears to involve fusion between phagosomes (containing 
internalised antigens) and the endoplasmic reticulum or access of soluble antigens 
to the endoplasmic reticulum, and requires the same machinery as that necessary 
for conventional MHCI presentation (55-61).
1.2.1.3. MHCII processing
MHCII molecules bind peptides that are between 13-24 amino acids long and are 
generated from proteins present in endocytic vesicles. The majority of proteins 
present in endocytic vesicles have been endocytosed from outside the cell (62).
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However some intracellular proteins have been found to enter the endocytic 
vesicles (63, 64). Whilst in the endocytic vesicles, the proteins are denatured and 
degraded through a series of chemical reactions, until peptide fragments are 
produced. The peptide binds the assembled MHCII molecule in more ‘mature’, 
endocytic vesicles when all the denaturing has been completed and the peptide 
fragments have been generated. Newly assembled MHCII molecules associate 
with a molecule called the invariant chain. Association between the MHCII 
complex and the invariant chain, facilitates the transport of the MHCII complex out 
of the ER (65, 66). A segment of then invariant chain, class II MHC-associated 
invariant chain peptide (CLIP), binds to the peptide binding groove and stabilises 
the molecule. Disassociation of CLIP from the MHCII complex in late endosomes 
is followed rapidly by the binding of the degraded peptide. This complex is then 
transported and expressed on the cell surface. MHCII presentation is thbught to 
occur in APC’s such as macrophages, DCs and certain subsets of B cells.
1.2.1.4. Maturation and migration of the APC
Receipt of activation signals causes DCs to mature. As the DC matures, their 
function and phenotype changes. Pinocytosis is down regulated, and the cells 
express a different set of molecules controlling migration. For example CCR7 is 
upregulated, allowing DCs to migrate out of peripheral tissues and into the T cell 
areas of secondary lymphoid organs (67). Inaddition, DCs upregulate co­
stimulatory molecules such as CD80 and CD86 which bind CD28 present on the 
naive T cell, and express a range of chemokines and cytokines.
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1.2.2. B cell response
1.2.2.1. T-independent B cell response.
This response produces a rapid expansion of antibody producing B cells, which 
lead to the formation of plasma cells. The T-independent response usually 
consists of either B-1 cells and/or marginal zone B cells. The T-independent 
response can be divided into two categories: TI-1, which is triggered by the 
antigens that can polyclonally activate the B cell without BCR signalling, or TI-2, 
which requires BCR activation and co-stimulation, though this can be provided by 
the APC (68-70). The antigens which trigger TI-1 responses are usually, 
commonly associated with pathogens, such as capsular polysaccharide from 
bacterial cell walls or repetitive viral antigenic epitopes. Once activated, cells 
responding to TI-2 antigens rapidly turn into plasma cells and secrete vast amounts 
of antibody. The responding B cells are mainly found in areas where there is a 
high potential for pathogenic encounters such as the intestine or the peritoneal 
cavity. In addition, the marginal zone B cells can also respond efficiently if the 
pathogens are present in the blood. This immediate production of antibodies could 
potentially delay the infection and allow the T cells and B2 cells to respond (71-73).
1.2.2.2. T dependent B cell response
The B cell recognises its antigen via the BCR, which consists of numerous Ig
chains including the newly rearranged specific IgM, with an Iga and Igp (CD79 a &
b) complex. The B cell synapse, like the T cell synapse, is supported by rafts to
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increase the stability and focus the signalling molecules into close proximity, this is 
stability is induced within seconds of BCR signalling (74).
1.2.2.3. The initiation and the B cell response.
As described above, the antigen is brought to the lymphoid organ such as the 
lymph node by the dendritic cell. After presentation of antigen to the CD4+T helper 
cell, the Th cell is activated and clonaly expands, and then migrates to the T/B cell 
zone border. At the same time B cells recognise intact, cellular antigen. The 
antigen binds to the BCR, triggering signalling and the internalisation of the 
antigen-BCR complex. The naive B cell degrades and processes the antigen and 
presents it on its MHCII. The B cell then migrates to the T/B cell zone border, 
where it presents the antigen to the clonaly expanded Th cell to receive T cell help. 
This is provided in the form of cytokines and CD40L. The activated B cells then 
either remains in the T/B cell zone border and becomes a short lived clonal plasma 
cell secreting antibodies, or it returns to the B cell area and to form germinal 
centres.
Isotype switching has been shown to be influenced by the Th cell, via the cytokines 
that it produces, and signalling through CD40. CD40 signalling and cytokine 
signalling induce germline recombination so as to produce different Ig molecules. 
Plasma cells are terminally differentiated. They down regulate most cell surface 
molecules, only produce antibodies, and die within a few days.
B cells which form germinal centres in the B cell area of the secondary lymphoid 
tissue undergo massive clonal expansion to form this structure. Further T cell help 
within the GC is then required for somatic mutation. Somatic mutation involves
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substitution, and occasionally insertions and deletions in the variable regions of the 
Ig gene (75). These mutations are generally thought to be carried out by an error 
prone DNA polymerase (76). These mutations allow the B cells response to 
produce antibodies with high affinity for antigen, which are selected from the 
population of cells expressing mutated receptors. Cells produced from the 
germinal centres can form plasma cells or memory B cells. Plasma cells formed 
from germinal centre B cells preferentially migrate to the bone marrow (77).
1.2.2.4. Antibody isotypes and functions
Antibodies bind to their target antigen, which results in numerous effects, 
depending on the type of antibody bound.
1 .2 .2 .4 .1 .  N e u t r a l is in g  A n t ib o d ie s
These antibodies bind toxins present in the extracellular fluid, such as bacterial and 
snake toxins. Specific high affinity antibodies bind the toxin and therefore blocks 
its action. It is also possible for the high affinity antibodies to prevent viral infection 
by binding to free virus and preventing its binding to the cellular receptor.
Some of the processes that can eliminate these antigen-antibody complexes are 
described below.
1 .2 . 2 .4 . 2 .  O p s o n is a t io n
This occurs when antibodies bind to antigens such as bacteria, and then bind to 
phagocytic cells such as neutrophils. Binding to the cell triggers the neutrophil to 
engulf the antigen-antibody complex and destroy it, thereby killing the bacteria.
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1 .2 .2 .4 .3 .  A c t iv a t io n  o f  P h a g o c y t e s
In addition to inducing phagocytosis, antigen-antibody complexes bound to the 
surface of phagocytes can trigger cellular activation. Activation leads to the 
production of toxic moleculaes that can kill the pathogen.
1 .2 .2 .4 .4 .  A  c t iv a t io n  o f  N K  c e lls .
Antigens present on the cell surface, such as viral proteins expressed by a virally 
infected cell, can be bound by high-specificity antibodies. These can activate NK 
cells to kill the infected cell or bacteria by antibody dependent cell mediated 
cytotoxicity.
1 .2 .2 .4 .5 .  A c t iv a t io n  o f  c o m p le m e n t
Specific antibodies bound to antigen can activate the complement cascade. This is 
a series of enzymatic reactions, that result in the production of a membrane attack 
complex, which will destroy the cell bound to the antibody. Alternatively, deposition 
of specialised complement proteins procide a signal for the cell to be opsonised, or 
cause inflammation resulting in the recruitment of phagocytotic cells.
1 .2 .2 .4 .6 .  Ig A
IgA is associated with mucosal sites, and is transported across the epithelial cells 
into the lumen. IgA binds to invading pathogens, preventing their entry though the 
mucosal walls. The majority of the plasma B cells secreting IgA in the intestine 
appear to be derived from B-1 cells.
1 .2 .2 .4 .7 .  I g D
The function of IgD is unknown. slgD is typically used to describe different stages 
in B cell maturation.
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1 .2 .2 .4 .8 .  I g E
IgE the rarest of antibodies, is thought to be important in combating large parasites 
and is implicated in allergic reactions. It binds to mast cells and esoinophils. 
Binding and cross-linking triggers de-granulation, leading to secretion of 
inflammatory cytokines such as histamine, which in turn facilitates the recruitment 
of other immune cells.
1 .2 .2 .4 .9 .  I g G
IgG includes different sub-types such as IgGi, lgG2a lgG2b and lgGa(in mice). The 
different sub-types can bind complement with different affinities, trigger 
opsonisation, and mediate NK cell cytotoxicity. IgG antibodies can be of high 
affinity and can act as neutralising antibodies.
1 .2 . 2 .4 . 1 0 .  I g M
IgM mainly activates the complement pathway, though it can also mediate 
opsonisation. In addition been shown to have neutralising activity.
1.2.3. T cell response
1.2.3.1. Activation of the T cell response.
The naive T cell first encounters antigen in the peripheral lymphoid tissues such as
the lymph node. Naive T cells are generally found in the T cell area of the
secondary lymphoid tissue. T cells enter LN due to the adhesion molecules
present on the cell surface, which bind specific molecules on the lymph node blood
vessels. Naive T cells use CD62L, CCR7 and CD11a/CD18 for entry into the LN,
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via the high endothelial venules (HEV) (78). If a naive T cell recognises the 
antigen presented by the DC, and there is sufficient co-stimulation available, then 
the T cell is primed.
For a naive T cell to be efficiently activated it is thought that 3 signals are required: 
1, a specific TCR-MHC complex; 2, co-stimulation from the APC; 3, cytokines 
providing survival and/or proliferative signals.
A high affinity TCR-MHC-peptide interaction activates downstream signalling 
events in the T cell, involving the intracellular signalling molecule Lck. 
Subsequently a signalling cascade results in the activation of lymphocyte genes 
involved in the immune response (79, 80). The extent of Tcell division is thought to 
depend on a multitude of factors including the availability of the peptide ^ antigen. If 
only low amounts of antigen are present, this is thought to limit the TCR-APC 
interactions and therefore the size of T cell response (81). If co-stimulation, 
provided by the APC, is absent, functional activation of the T cell is prevented (82). 
One of the ways in which co-stimulation is thought to enhance T cell activation is 
by increasing the responsiveness of T cells to growth factors, such as IL-2 (83). 
Co-stimulation is also thought to stabilise the interaction between the T cell and the 
APC, increasing the binding time between the TCR and the MHC and recruiting 
more intracellular signalling molecules to the TCR.
Cytokines act on the T cell to provide a multitude of signals, including those 
regulating proliferation and survival. The magnitude of the response is greatly 
affected by the amount of inflammation and inflammatory cytokines, such as TNF-
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a, present at the initiation of the immune response. Inflammatory cytokines 
increase the co-stimulatory molecules on the APC and induce migration into the T 
cell areas. Therefore, more inflammation leads to more DCs available to present 
antigen and grater co-stimulation (84). Inflammatory cytokines can also act on T 
cell’s directly, increasing their responsiveness to growth factors (85-87).
1.2.3.2. Raft and intracellular proteins.
Successful TCR stimulation and co-stimulation result in signalling cascades at a 
very concentrated area of the T cell membrane. It has been found that this area of 
intense activity, the immunological synapse, is more rigid than other parts of the 
plasma membrane. This is due to the presence of lipid rafts, which corresponds to 
a high concentration of insoluble glycosphingolipids and cholesterol in the plasma 
bi-layer (88, 89). It has been suggested that the formation of a tight immune 
synapse decreases the presence of negative signalling regulators such as CD45 
by steric-hindrance (90).
Changes in the cells’ morphology, and potentially lipid rafts movements, are carried 
out by the cytoskeleton. The cyoskeleton consists of a web of actin, which 
contracts to change the cells’ morphological shape, that is essential in the 
formation of the immunlogical synapse (91-93). Other proteins are involved with 
the cytoskeleton such as the ERM family proteins. These are explained further in 
the next section.
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1.2.3.3. The effector stage of the immune response
Once a cell becomes activated it undergoes multiple divisions and turns on 
numerous genes associated with effector activity. Activation also changes the 
adhesion profiles of the effector cells, allowing them to infiltrate non-lymphoid 
tissues. PSGL-1 is thought to allow entry into the skin, whilst integrin ct4 p7 (LPAM- 
1) is used to enter into the mucosal tissue (94). At the site of infection there is 
usually inflammation. Inflammatory cytokines change the adhesion molecules 
present on the stroma of the capillaries and venules, permitting effector cells to the 
site of infection.
Effector CD4 cells are often separated into Th1 or TH2 subsets that differ both in 
their function and in the cytokines that they produce. For example, IFNy is a 
characteristic TH1 cytokine that activates macrophages and stimulates B cells to 
produce opsonizing lgG2a antibody (95). Th2 cells characteristically produce IL-4, 
which stimulates B cells to produce IgGi neutralising antibodies. The different 
types of effector cell are effective against different pathogens. TH1 effectors are 
mainly used against intracellular bacteria, fungi and protozoa, whereas the Th2 
response is mainly concerned with eliminating helminth parasites and bacterial 
toxins. Flow the decision to generate a T h1 vs . T h2 CD4+T cell response is poorly 
understood. The cytokine environment present during T cell activation is likely to 
play an important role.
Cytotoxic CD8+ T cells, or CTLs, once activated, divide and produce a multitude of 
different effector molecules including IFN-y, granzyme and perforin, which enables 
them to directly kill a cell expressing a MHCI complex loaded with the specific 
peptide. Perforin released from the CTL punches holes in the membrane of the
64
target cell and destroying it. Serine proteases, such as granzyme, are produced in 
vesicles that fuse with the membrane of the target cell, thereby releasing the 
granzyme into the cytoplasm of the target cell and activating apoptosis. CTLs can 
also trigger apoptosis by ligating Fas on the target cell with Fas ligand on the CD8+ 
cell. Fas initiates a signaling cascade resulting in the activation of caspases and 
apoptisis of the target cell. It has been reported that the CTLs can not produce IL- 
2, simultaneously with IFN-y in sufficient quantities and therefore are dependent on 
the IL-2 produced by the CD4+ T cell (96). CTLs generally target virally infected 
cells; by killing the cell, the virus is also destroyed.
1.2.4. Termination of the immune response and memory 
formation
Due to the limited space available in the body of an organism it is impractical for all 
the effector cells generated during an immune response to remain alive and viable. 
In fact, the vast majority of activated cells die after clearance of the pathogen. 
However, a propotion of the cells do survive and persist as memory cells. These 
cells provide a stronger and faster immune response should there be a re-infection. 
This is due to both the higher frequency of antigen specific cells among memory 
cells, and altered properties of memory cells on a per cell basis.
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1.2.4.1. Memory B cells.
Memory B cells, like plasma cells, are generated in the germinal centre reaction 
(77). These cells have the capacity for rapid expansion and the formation of 
plasma cells if the specific antigen is re-encountered, with the help of the memory 
Th cells. It is thought that memory B cells can act as APC’s to stimulate the TH 
cells, which in turn, can stimulate the memory B cell. In addition, to memory B 
cells, some plasma cells survive and produce antibodies long-term in the absence 
of antigen (97).
1.2.4.2. T cell memory
1 .2 . 4 .2 . 1 .  C D 8 + m e m o r y  c e l ls  
After the initial contraction of the effector cells, the frequency of CD8+ memory cells 
remains constant. This is associated with a small amount of turnover, in which 
proliferation is balanced by death from the pool. Turnover is likely regulated by a 
number of factors, including contact with cytokines and specific cross-reactive 
antigen (98, 99). There are thought to be thought to be two types of CD8+ memory 
cells, effector memory and central memory cells. Effector memory cells retain 
expression of effector genes, for example, perforin and granzyme, and are thought 
to circulate through the peripheral tissue (67, 100). Central memory cells do not 
have stores of cytotoxic enzymes and re-circulate between the blood and lymphoid 
tissues, much like naive CD8+T cells.
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1 .2 .4 .2 .2 .  C D 4 + T  m e m o r y  c e l ls
Unlike CD8+ memory cells, CD4+ memory T cells appear to gradually decrease in 
number over time (101-103). These different kinetics likely reflect different 
requirements for survival and proliferation (104). As for with CD8 memory cells, 
CD4+ memory cells can be divided into effector and central memory populations 
(105).
1.3.CD44
CD44 is an 85KDa transmembrane glycoprotein, which is expressed on numerous 
cell types including epithelial cells and most haematopoietic cells. CD44 has 
restricted expression in embryogenesis including the mesoderm layer (106). It has 
been implicated in numerous processes including cell adhesion, lymphocyte 
migration and activation, embryogenesis and tumour metastasis (107-113). CD44 
has a complex gene structure, in which multiple isoforms can be generated. 
Interest in the function of different isoforms has stemmed largely from observations 
on tumour cells, where expression of certain variant exons of CD44 has been 
shown to correlate with tumour progression and the expression or absence of 
certain isoforms have a certain amount of prognostic value. However, CD44 
appears to mediate important functions on T cells, as both activated and memory T 
cells express high levels of CD44 on the cell surface. Nevertheless, the pattern of 
variant CD44 exon expression on normal T cells and how they influence cellular
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function remains poorly understood. Below is a brief review of the properties of 
CD44 and it possible functions on various cell types.
1.3.1. CD44 gene structure and homology
The murine CD44 gene is found on chromosome 2 close to the RAG genes. It 
consists of 20 exons, 10 of which can be alternatively spliced (v1-v10) potentially 
generating over 1000 isoforms (Figure 1.4). The most common form of CD44, 
otherwise known, as the standard isoform (CD44s), is the lowest molecular weight 
form at 85KDa of this molecule and contains no variant exons. The variable exons 
are inserted near to the plasma membrane on the extracellular side on the 
molecule (Figure 1.5). These variant exons add extra functions to the CD44 
molecule, e.g. v3 contains a heparin binding site, which facilitates binding of the 
heparin binding growth factor. The variant exons are of interest to cancer 
biologists, for the presence of certain variant CD44 exons has been used as a 
prognostic maker for particular types of tumours.
Diversity of the CD44 molecule is also generated at the post-translational level, for 
the mature protein contains multiple glycosylation sites (114). Therefore the RNA 
and protein diversity exhibited by the CD44 molecule can generate a huge variety 
of CD44 isoforms, although most of these isoforms have not been detected on 
cells.
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Figure 1.4. Diagram of murine CD44 genomic structure.
A schematic diagram of the murine CD44 gene structure, showing the 
orientation of the 10 variable exons (v). This diagram also shows the 
exons present in the extracellular, transmembrane and intracellular 
domains. The exon lengths are not to scale.
69
s -s .
HA
binding
site
-s—s-
b x7b
Variant exon 
insertion Site"
1iWifWirn?iiW^
Figure 1.5. Diagram of tertiary structure of CD44.
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The extracellular region of CD44 has 85% homology amongst mammalian species. 
It contains six cysteine residues, which have the potential to form disulphide bonds, 
as well as five conserved N-glycosylation sites.
A non-conserved region flanks the variant exon region, which shows 35% 
homology between mammalian species and contains potential sites for multiple 
carbohydrate modifications. The membrane proximal domain has 50% homology 
between mouse and man, while the transmembrane domain has 100% homology 
between mammalian species; the latter is required for dimerization of CD44 
molecules, which has been shown to increase hyaluronic acid (HA) binding (HA is 
one of the major ligands for CD44, see below) (115). The cytoplasmic domain of 
CD44 has 85% homology between mammalian species. It does not seem to be 
required for extracellular ligand binding, although it has been suggested that it is 
needed to aggregate CD44 in clusters at the cell surface and therefore facilitate 
ligand binding. Some molecules of CD44 are phosphorylated on their serine 
residues in the cytoplasmic region. The cytoplasmic domain also contains binding 
site for tyrosine kinase and other signalling molecules.
1.3.2. Function of CD44
Multiple functions have been attributed to CD44. In general though, CD44 seems 
to be involved in cell movement, by cell-to-cell or cell-to-matrix interactions, and 
cellular activation, by its association with the intracellular cytoskeleton and src 
kinases. The function of variant exons has mainly been determined by antibodies
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specific for the variant regions, although these do not always bind due to variable 
post translational modification (116).
1.3.2.1.Adhesion and cell migration.
CD44 binds to a number of molecules in the extracellular matrix, with its principle 
ligand being HA. Not surprisingly, therefore, an important function of CD44 is 
thought to be as an adhesion molecule. On T cells, a variety of adhesion 
molecules play essential roles in regulating cell migration and activation. When T 
cells become activated, they acquire the ability to migrate into sites of 
inflammation. Upregulation of CD44 on activated T cells implies that this molecule 
is involved in migration into tissues, and there is some evidence to support this 
idea. DCs also upregulate CD44 upon activation, which is associated with the 
expresion of v3, v6 and v9 (117). In fact, most haematopoietic cell upregulate 
CD44 in repose to inflammatory cytokines. Moreover, HA is produced by 
endothelial cells in response to TNFa and IL-1 p, thereby facilitating the 
extravasation of activated immune cells into inflamed tissue (107, 118-120). 
Treatment of mice with anti-CD44 has been shown to inhibit the infiltration of 
inflammatory cells (121-124). Notably, some metatastic tumours which exhibit de­
regulated migration, express CD44 variant exons.
Haematopoietic cells have been shown to interact with stromal cells via CD44. 
Disruption of these interactions leads to a marked reduction in T and B cell 
development and myelopoiesis (125, 126). The ligand on the stromal cells is not 
known (127). Variant exons of CD44 are expressed in early thymocytes, and
72
antibodies to these variant exons have been shown to block haematopoietic- 
stromal cell interactions (128).
1 .3 .2 .1 .1 .  H y a lu r o n ic  a c id
The primary ligand of CD44s is the glysosaminoglycan (GAG), HA (129). HA is 
found as an integral part of the extracellular matrix. It acts by binding salt and 
water and expanding the extracellular space (130-136). CD44 binding to HA is 
seen in processes that involve cell-to-cell contact, adhesion, and transport through 
extracellular matrices.
Binding of cells to HA via CD44 is a highly regulated process. In fact, there are 
three states of HA binding: active, inducible and inactive. The active form of CD44 
binds HA; this is the form of CD44 on some cancer cell lines and activated T cells. 
Inducible isoforms of CD44 can bind HA after activation. This form is expressed on 
naTve lymphocytes, and cytokines such as TNF-a, TGF(3 and those signalling 
through the murine IL-2R y-chain have been shown to induce activation of CD44 
by post-translational mechanisms; conversely, IL-4, IL-10, and IL-13 inhibit this 
activation (136-139). Cells expressing the inactive form can not bind HA even after 
activation. The ability of inflammatory cytokines to enhance CD44 binding to 
extracellular matrix is in keeping with their role in recruiting cells of the immune 
system to sites of inflammation and infection. By corollary then, it would seem that 
regulation of the CD44 binding state is an important process regulating leukocyte 
migration. This regulation is quite complex, however, as cellular activation per se is 
insufficient to induce CD44 binding to HA. For example, HA adhesion is not 
stimulated by activation of B cells with LPS, pokeweed mitogen, or anti IgM, but is 
following treatment with PMA (140-144).
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The CD44-HA interactions have been demonstrated in numerous models using 
various cell types. The importance of HA binding during lymphocyte extravasation 
has been shown using a rat model. In these experiments, intra-peritoneal 
injections of low molecular weight HA, (which should block CD44-HA interactions) 
in conjunction with cyclosporin treatment was found to prolong allograft survival 
compared to cyclosporin treatment alone. It was thought that the injected HA 
functioned by preventing the lymphocytes from entering the graft (145). In this 
respect, the importance of interactions with HA in mediating cell movement 
between tissues and the blood stream is also exemplified by the behaviour of 
tumour cells. In particular, tumours that produce HA are known to have a poor 
prognosis, presumably because they can use the HA as a scaffolding in 
metastasis.
Other cell types apart from leukocytes also express HA binding CD44. For 
example, platelets express the active HA-binding form of CD44. This contributes 
to the ability of platelets to respond readily to vascular injury, since HA is found 
immediately beneath the endothelial cells of many blood vessels in the dermis, the 
lamina propina of the intestine, the lungs, and pericardium. Thus, when these 
vessels are damaged, HA becomes exposed, allowing platelets to bind and initiate 
the repair process (146).
As discussed above, regulation of CD44 binding to HA is complex. The ability of 
CD44 to bind HA can be altered by post-translational modifications, dimerisation, 
and by the presence of certain variant exons, which can increase the binding ability 
of CD44 to HA (135). It has been found that v6 and v9 are essential for HA 
binding, while expression of CD44 v4-7 increases the ability of CD44 to bind
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soluble HA (147, 148). Furthermore, binding to HA also depends on the cell type 
in which CD44 is expressed (149). This is likely due to the glycosylation 
competency of the cell, since both O- and N-linked glycosylation of the CD44 
molecule changes its affinity for HA (114, 135,150-152).
Another factor to take into consideration is the action of hyaluronidase. 
Hyaluronidase is an enzyme that degrades HA, and somehow modulates CD44 
expression. It has been proposed that the CD44 isoforms, containing splice 
variants are unstable, and that they require the continuous presence of their ligand 
for stable expression: this could explain their transient expression (153). HA in the 
extracellular matrix is also continuously endocytosed and replaced, HARE 
(hyaluronic acid receptor for endocytosis) was found as an endocytic receptor for 
HA on liver sinusoidal epithelial cells (154), therefore HARE and RHAMM are two 
other cell surface proteins which can bind HA.
1 .3 .2 .1 .2 .  E - s e le c t in
CD44 also binds to the adhesion molecule E-selectin. E-selectin is expressed on 
inflamed (cytokine or endotoxin stimulated) but not unstimulated endothelium, and 
is thought to play a role in mediating tissue specific homing of T cells into the skin 
and of primitive progenitor cells into the bone marrow. However, the major ligand 
of E-selectin on T cells is PSGL-1 rather than CD44. The CD44 found on the 
progenitor cells, which can bind E-selectin, has sialyated and fucosylated binding 
determinants on the N-glycans; this is not found on mature haematopoietic cells 
(155).
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1 .3 .2 .1 .3 .  L -s e le c t in ,  ( C D 6 2 - L )
A sialofucosylated glycoform of CD44 expressed on human haematopoietic cells 
binds L-selectin. L- selectin is mainly expressed on lymphocytes and is involved in 
the rolling of lymphocytes to the endothelial cells. It is also mediates trafficking of 
lymphocytes to lymph nodes. In this report by Dimitroff e t  a/, L-selectin was shown 
to be also expressed on human haematopoietic cells, hence in this situation, 
promote CD44 appears to promote homotypic interactions (156).
1 .3 .2 .1 .4 .  C h o n d r i t in  S u lp h a t e  A ,  ( C S - A )
CS-A along with HA accounts for the majority of extracellular matrix components in 
the bone marrow (125). CS-A has been shown to bind to CD44v expressed by 
myeloid progenitors, implying that CD44 may be involved in the migration of these 
cells in the bone marrow. v10 promotes cellular adhesion through recognition of 
chondritin sulfate (157)
1 .3 .2 .1 .5 .  A g g r e c a n
Aggrecan, is a chondrition sulphate proteoglycan and a major component of 
cartilage. CD44 has been found to bind to aggrecan side chains independently of 
HA, in a similar manner to that of chondriton sulphate A (158).
1 .3 .2 .1 .6 .  C h o n d r i t in  S u lp h a t e  fo r m  o f  In v a r ia n t  c h a in
As discussed in the previous section, the Invariant chain (li) associates with MHCII 
(159). A small proportion of the MHCII molecules on antigen presenting cells 
(APC) has been modified by the addition of chondritin sulphate, (li-CS). The 
binding of CD44 on the T cell to the modified MHCII on DCs is thought to enhance 
the stimulation of the cells provided by the APCs.
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1 .3 .2 .1 .7 .  F ib r o n e c t in
CD44 binds the extracellular matrix protein fibronectin. An insoluble form of 
fibronectin is found in the connective tissue. It is also present as a soluble plasma 
protein in the serum. Fibronectin can be attached to other extracellular matrix 
proteins such as fibrin, and collagen and GAG’s (160,161).
1.3.2.2. Morphological changes by cytoskeletal rearrangement
Different changes in cell morphology are observed when CD44 is bound by HA 
versus immobilised anti CD44 antibody (162). For example, monocytes have been 
shown to bind and spread when cultured on plate-bound anti-CD44, while they 
bound but did not spread when put on plates coated with HA. In the presence of 
HA, the cells remained small and actin was diffuse. In contrast, on the plate bound 
anti-CD44, the cells were enlarged and the actin was concentrated in cellular 
extensions. While this may reflect the much higher affinity of the anti-CD44, it also 
suggests that the binding of CD44 on the cell surface can produce different results. 
In nerve cells CD44 is only expressed in astrocyte projections, which suggests its 
involvement in the maintenance of a stable central nervous system 
cytoarchitecture (163). Bacteria have also manipulated the cytoskeletal 
arangement properties of epithelial cells and use CD44 as a receptor to induce 
cytoskeletal rearrangement to allow invasion (164)
1 .3 . 2 .2 . 1 .  E z r in ,  r a d ix in  a n d  m o e s in
Morophological changes induced by CD44 binding may be related to the ability of 
this molecule to associate with a number of molecules involved in cytoskeletal 
organisation. Three such molecules are ezrin, radixin and moesin, (ERM), which
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are cytoplasmic proteins (165, 166). These proteins act as cross linkers between 
cortical actin filaments and the plasma membrane, and are involved in the 
formation of microvilli, cell adhesion sites and clefts and ruffles in the plasma 
membrane. ERM are activated via Rho signaling pathways, and it is thought that 
they link the actin filaments and CD44. There is also evidence that there is an 
increase in affinity for ERM binding when v9 and/or v10 are present in CD44, even 
though the cytoplasmic domain is the same as in CD44s. ERM mediate outside- 
in, not inside-out signaling of adhesive receptors (167). ERM proteins share a 
FERM domain (band four point one, ezrin, radixin moesin homlogy domain) with 
Merlin. Therefore, both the ERM and Merlin (see below) could potentially bind 
CD44 via the FERM domain. Due a 60% homology between the two FERM 
domain of Merlin and ERM, this could contribute to the differences seen in the 
binding of CD44 to either Merlin or the ERM proteins (168).
13.2.2.2. M e r l in
Another cytoskeletal associated molecule to which the cytoplasmic portion of CD44 
binds is Merlin, an ERM related protein. At high cell densities, merlin mediates cell 
growth inhibition in response to HA binding of CD44. Merlin seems to form the 
basis of a molecular switch that specifies whether cells continue to divide (169). 
Although CD44 can bind both ERM and Merlin, these complexes appear to have 
contrasting roles, as shown by studies of tumour metastasis. Thus, it is thought 
that CD44 binds ERM and promotes invasiveness, but that cell confluence leads to 
CD44 binding merlin and inhibition of tumour metastasis (170).
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1 .3 .2 .2 .3 .  A n k a r y in
CD44 also binds to ankaryin, which serves as an adapter between the plasma 
membrane and the cytoskeleton (171, 172). Ankaryin is thought to be involved in 
phagocytosis of bacteria, by CD44 linkage to cytoskeletal elements (173). CD44- 
ankarin binding is thought to be modulated by protein 4.1 (174,175).
1.3.2.3. CD44 signalling
Studies have shown that in addition to acting as an adhesion molecule, CD44 
triggering can result in the transmission of signals to the cell, and activate it. Many 
experiments have been carried out using monoclonal CD44 antibodies to 
investigate the consequences of CD44 signalling in different cell types. 
Administration of anti-CD44 antibodies to in  v itro  human NK cells was shown to 
result in a dose dependent enhancement in NK cell cytotoxicity against tumour 
cells (176). Furthermore, an importance for CD44 signalling in NK cell activity was 
suggested by the fact that NK cells from CD44"7' mice could not adhere properly to 
target cells and therefore could not kill them (177). In nerve cells, CD44 has been 
implicated in enhancing neuroregulin signalling by schwann cells through 
constitutive association with erbB2 and erbB3, which are receptor tyrosine kinases 
expressed in schwann cells. Blocking CD44 expression in schwann cells by sense 
and antisense oligonucleotides, resulted in a loss of signalling and an increase in 
apoptosis (178).
CD44 also acts on T cells as a co-stimulating molecules as well as an adhesion 
molecule. Co-stimulation of a T cell through CD44 leads to an increase in T cell 
proliferation. T cells that express rat v4-v7 (as well as their own normal CD44) had
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an accelerated response when exposed to antigen. Whether this is a property of 
v4-v7 or the fact that there is more CD44 on the cell surface was not discussed 
(179). v6 and v7 have been implicated in T cell activation (180, 181). v7 seems to 
be important for survival of effector lymphocytes in the intestine, since 
experimentally induced colitis in mice could not be induced in v7 deficient mice, 
and administration of anti-v7 antibody led to complete remission of the colitis in 
control mice. Also, administration of anti-v7 antibody in another study led to a 
decrease in IL-12 production (180, 182, 183). v6 has also been implicated in 
cellular activation. Not only is v6 upregulated after T cell interaction, but 
experiments have shown that anti-v6 antibody can block lymphocyte activation and 
decrease IL-2 and IFN-y production (182,184).
CD44 is also associated with apoptosis as well as proliferation. It is thought that 
CD44 supports both apoptosis and proliferation by enhancing signal transduction 
via TCR-CD3 complexes. A low level of signalling through CD3 and CD44 cross- 
linking results in apoptosis but higher levels (still sub-proliferation levels) of CD3 
signalling and CD44 cross-linking results in proliferation (185). The presence of 
HA can also act as a co-stimulator for activated human T cells (176). Furthermore, 
signalling through HA-CD44 interactions can also induce murine B cell activation 
(186).
1 .3 .2 .3 .1 .  R a f t s
Rafts are organised by actin to create a firm platform for synapse interactions. 
Signalling through CD44 initiates cytoskeletal rearrangement and membrane 
reorganization; this involves GTPase Rac association. The rafts in which CD44 
localizes have been shown to contain Annexin II. Annexin II is a calcium binding
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protein that can associate with actin filaments and membranes and is a major 
cellular substrate for src-family of protein kinases, which are associated with lipid 
rafts (187, 188). Shigella protein IpaB binds CD44 and invades using increased 
concentration of rafts, probably due to CD44 signalling to the cytoskeleton (189).
1 .3 .2 .3 .2 .  In t r a c e l lu la r  s ig n a l l in g
Signalling through CD44 also involves the tyrosine kinase molecules Ick and fyn, 
molecules which co-localise with the TCR to initiate the signalling cascade. (185, 
190). Signalling through P56lcK leads to ZAP-70 phosphorylation (same as for the 
TCR) and this leads to an association between ZAP-70 and the TCR (191). 
Signalling through CD44 also induces an interaction with Tiaml which increases 
Rac-1 signalling. HA binding to v3 stimulates Tiaml associated -  rac1 signalling, 
while v3 binding of heparin sulphate binding growth factors also induces Rac-1 
signalling. Cross-linking CD44 has been shown to lead to the same signalling 
cascades as those initiated by cross-linking CD3. This is likely related to the fact 
that CD44 has also been found to associate with CD4 and CD3 on the cell surface. 
In this respect, it is interesting to note that binding CD4 with gp120 (from HIV) 
potentiates CD44-HA adhesion (192).
Rac-1 GTP binding protein activates actin cytoskeletal rearrangement, during 
processes such as the production of lamellipodia and reorientation of the cells in 
the direction of a migratory stimulous (171,193-195).
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1.3.2.4. Receptor for chemotactic and growth factors
CD44 can bind certain growth factors and chemotactic factors. This property has 
been propsed to play a role in the ability of tumor cells, for expression of variant 
CD44 exons responds with an increasing responsiveness to more growth factors 
(196).
1 .3 .2 .4 .1 .  O s t e o p o n t in
CD44 has been shown to bind to certain chemotactic factors, that have been 
produced in response to infection. One of these is osteopontin (OPN), a 
chemotactic factor that is secreted by a number of cell types including activated T 
cells and macrophages and which induces macrophage migration. When OPN is 
secreted from activated T cells, it induces chemotaxis by specific binding to CD44 
present on macrophages and T cells. OPN can augment IFN-y and CD40 
expression after anti-CD3 stimulation (197). It has been shown that OPN is 
produced as a result of IL-3 or GM-CSF signalling, and can subsequently bind to 
surface CD44 and promote the anti-apoptotic activities of IL-3 and GM-CSF (198). 
This might explain some studies that have shown that cells responding to 
osteopontin exhibit enhanced cell survival through inhibition of apoptosis. 
Osteopontin deficient mice have an impaired Type 1 immunity to viruses and 
bacterial infection. They exhibit decreased IFN-y and IL-12 but an increased IL-10 
production. The mice show decreased granuloma formation in response to 
polyvinylpyrrolidone. These mice also exhibit reduced experimental autoimmune 
encephalomyelitis, in which there was less inflammation and infiltration of 
inflammatory cells seen in the OPN'7' mice compared to the controls (199). These 
observations may be relevant to the metatastic proficiency of tumour cells with
82
elevated OPN expression (200-202). CD44 binding of OPN can inhibit IL-10 
production in macrophages (203). OPN can also inhibit nitric oxide production in 
macrophages. This is part of a negative feed back loop to limit the production of 
inflammatory cytokines since OPN expression can be induced by nitric oxide (204).
1 .3 .2 .4 .2 .  M a c r o p h a g e  In f la m m a t o r y  P r o te in -1  p . ( M I P - 1 p )
A second chemotactic factor to which CD44 has been shown to bind is 
macrophage inflammatory protein-1 p (MIP-1p) (205). This cytokine induces both 
chemotaxis and adhesion of T cells to the endothelium. Binding of MIP-ip to 
CD44 has been shown to increase the ability of CD44s to bind HA. Whether it 
binds to both CD44 and HA directly to produce this effect, or binds to CD44 and 
induces a conformational change which results in an increased binding of CD44 to 
HA is not known (206).
1 .3 .2 .4 .3 .  M a t r ix  M e t a l lo p r o t e in - 9 ,  M M P - 9  ( g e la t in a s e  B )
A proteolytic form of MMP-9 associates with CD44 on the surface of mouse 
carcinoma and human melanoma cells. CD44 associated cell surface MMP-9 
promotes cell-mediated collagen IV degradation in  v itro . It is thought that CD44 
serves to anchor MMP-9 on the cell surface possibly explaining a mechanism for 
CD44-mediated tumour invasion (207). In this regard it is worth noting that MMP-9 
deficient mice have suppressed experimental metastasis (208).
1 .3 .2 .4 .4 .  C h o n d r i t in - 4 - s u lp h a t e d  s e r g ly c in
The serglycins are a family of proteogylcan molecules which have a core protein in
common (209). Their expression is restricted to the yolk sac, haematopoietic cells
and some tumours. In haematopoietic cells the serglycins are found in secretory
granules, where they are thought to act as scaffolding during packaging, and
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chaperone the secreted serine proteases. Serglycin has also been implicated in 
the differentiation of myeloid cells. Chondritin-4-sulphated serglycin binds CD44 
on the HA binding site, and provides a co-stimulatory signal when present with 
CD3 stimulation. Serglycin also enhances the release of granzyme A from 
cytotoxic T cells (158, 210).
1 .3 .2 .4 .5 .  H e p a r in  b in d in g  g r o w th  fa c to r .
It is thought that sCD44 can not bind heparin binding growth factor, but expression 
of v3, plus modification of CD44 by the addition of heparin sulphate induces CD44 
binding to heparin-binding growth factors (113). Expression of v2-10 has been 
shown to confer a metastatic phenotype on tumour cells, probably due to the 
presence of the heparin sulphate attachment site on v3 (211).
The heparin sulphated proteoglycan v3 of CD44 on monocytes has also been 
demonstrated to bind macrophage derived growth factor FGF-2, vascular 
endothelial growth factor, and heparin binding epidermal growth factor (212).
1.3.2.5. Soluble CD44
As well as the normal transmembrane form of the protein, CD44 has also been 
found in the soluble form. Soluble CD44 is released from the cell surface through 
metaloproteinases or serine proteases, but CD44-shedding from adherent cells is 
controlled by protein kinase C and Rho GTPase through the cytoskeleton (213, 
214). Naturally occurring soluble CD44 enhances HA binding of surface bound 
CD44 instead of blocking it. It is thought to act in this way by adhering to chondritin 
sulphate side chains which are attached to cell surface CD44, thus, generating a 
multivalent complex with increased avidity for HA (215). However, secretion of
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soluble CD44 can be enhanced by PMA treatment with anti-CD44 in some cell 
types and this soluble CD44 contributes to anti-invasive and anti-angiogenic 
properties (216). CD44 shedding may be a mechanism that allows the cell to be 
released from its interaction with the extracellular matrix, although it is interesting 
to note that unbound as well as anti-CD44 bound molecules are released in 
response to the plate-bound antibody.
Soluble CD44 has been found in serum of cancer patients and is generally 
associated with a poor prognosis. Membrane type 1 matrix metalloproteinase 
(MT1-MMP) has been shown to cleave CD44 from the surface of the cell and 
promote cell migration. In this process MT1-MMP degrades the extracellular 
matrix at the pericellular region and acts as a processing enzyme by releasing 
CD44H into the medium, which then stimulates cell motility (217). However, it 
should be bome in mind that some experiments have shown that soluble CD44 
inhibited melanoma binding to HA, and that co-transfection of cells with a soluble 
form of CD44 led to decreased tumorigenesis (218).
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Statement of scientific objectives
The aim of this thesis is to investigate the function of CD44 on T and B 
lymphocytes. Radiation bone marrow chimeras will be generated to allow CD44- 
deficient and CD44-wild type cells to develop in the same environment, and the 
fate of the two cell types will be compared in steady state and in response to 
immunisation.
1. To investigate the role of CD44 in T cell development
2. To investigate the role of CD44 in B cell development
3. To investigate the contribution of CD44 to mature T and B cell function.
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2. Chapter 2: Materials and Methods
2.1. Materials
2.1.1. Mice
All strains were obtained from the specific pathogen free unit at the institute for 
animal health (Compton, UK). Some C57BI/6 mice were purchased from Charles 
Rivers UK.
Strain Description
C57BI/6 H-2b, CD45.2, CD229.2, CD44+/+
Ly5.2 H-2b, CD45.1, CD229.2, CD44W
CD44*'* H-2b, CD45.2, CD229.1, CD44-'-
129Sv H-2b, CD45.2, CD229.1, CD44*'+
Balb/c H-2k, CD44+'*
2C
CD8 TCR transgenic recognising H-2Ld + LSPFPFDL or H- 
2Kb + SIYRYYGL peptide (C57BI/6 H-2b background)
RAG*'*
B6RA61
C57BI/6 mice with a deficient RAG gene, therefore no mature 
T or B cells
OT2
CD4 TCR transgenic specific for OVA323-339 peptide + l-Ad. 
(RAGKO B6 H-2b background)
Table 2.1: Table of mice used
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2.1.2. Normal Reagents
Reagent Supplier Catalogue
Number
Agar BDH 20768292
Ammonium chloride Sigma A5666
Ammonium Sulphate Sigma A2939
Betaplate Scintillant Wallac SC/9200/21
Bovine serum albumin Sigma A4503
Ethanol Absolute Sigma E7023
Ethylendiaminetetra-acetic acid 
disodium salt (EDTA)
BDH 100935V
Golgi Plug BD-Pharmingen 555029
Metrizamide Sigma 69753
Paraformaldehyde Sigma P6148
PBS 10X Invitrogen 14200-083
Polyoxyethylenesorbitan monolaurate 
(Tween-20)
Sigma P1279
Saponin Sigma S7900
Sodium Azide Sigma S5886
Sodium Bicarbonate Sigma S6014
Sodium Chloride Sigma S5886
Sodium phosphate, dibasic 
anhydrous
Sigma S7907
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Reagent Supplier Catalogue
Number
Sodium phosphate, monobasic 
anhydrous
Sigma S8282
Sterile Water Baxter/ 3S 
healthcare
TRF7114
Table 2.2: Table of reagents
2.1.3. Tissue Culture reagents
Name Supplier
Catalogue
Number
2 beta mecaptoethanol 500mM Invitrogen 31350-010
Alkaline phosphatase substrate kit Bio Rad 172-1063
Antibiotic/Antimycotic solution (Pen/ 
Strep)
Invitrogen 15240-062
Chicken egg albumin (OVA) Sigma A7641
Chicken gamma globulin (CGG)
Stratatech
Scientific
003 000 002
Collagenase Type III Lome Laboratories LS004183
Crystal Violet Sigma C3886
Deoxyribonuclease I (DNase I) Sigma D25
DNP-ficoll
Biosearch
Technologies
F-1200-10
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Name Supplier
Catalogue
Number
Dynabeads M459 Sheep anti-mouse 
IgG
Dynal UK 110.02
Dynabeads M459 Sheep anti-rat IgG Dynal UK 110.08
Fetal Calf Serum (FCS) Lot 40Q1282F Invitrogen 10106-169
Formalin BDH 352276Y
Gentamycin Invitrogen 15750-045
Guinea Pig Complement VH Bio CL4051
HBSS (Hank’s Buffered Salt solution) Invitrogen 14085-049
Heparin LEO 505
Hepes Buffer 1M Invitrogen 1530-056
Histopaque 1.083 Sigma 1.083-1
Horse Serum Invitrogen 16050.098
Hydrocloric Acid HCI BDH 190665R
Iscoves Modified Medium Invitrogen 31980-022
Low endotoxin FCS Lot Harlan S-0001E
Modified Earles medium Invitrogen 10370-021
NCTC Inwitrogen 41350-026
Neomycin Sulphate Sigma N1876
Nycoprep 1.077A Invitrogen 1002380N
OPD tablets Sigma P9187
Polyinosinic-polycytidylic acid (PolykC) Sigma P1530
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Name Supplier
Catalogue
Number
Polymyxin ‘B’ sulphate Sigma P1004
RPMI 1640 medium Invitrogen 21870076
Table 2.3: Table of tissue culture reagents
2.1.4. Solutions
2.1.4.1. Red cell lysis buffer 
PBS with 0.83% ammonium chloride
2.1.4.2. RP10
RPMI with 10% FCS, 5% NCTC media, 1% Penstrep, 1% Hepes, 0.5%. 
gentamycin, 1% 2pME solution.
2.1.4.3. FACS buffer
HBSS solution, 2% horse serum, 0.1% sodium azide.
2.1.4.4. RP2.5
RPMI with 2.5% FCS, 5% NCTC media, 1% penstrep, 1% 2pME solution, 0.5% 
gentamycin.
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2.1.4.5. Carbonate coating buffer 
0.05M Na2C03l 0.05M NaHC03l pH9.6
2.1.5. Plastics and Miscellaneous
Product Company Catalogue number
40pm cell strainers Fahrenheit 352340
70pm cell strainers Fahrenheit 352350
6 well plates SLS 152795
24 well plates SLS 143982
48 well plates SLS 150687
96 well ‘IT bottomed plates SLS 163320
ELISA plates SLS 168055A
ELISPOT plates Millipore MAHAS4510
FACS tubes Fahrenheit 352008
Glass slides Sigma S8400
MoFlo tubes Fahrenheit 352054
Petri dishes SLS 101VR20
Table 2.4: Table of plastics and miscellaneous
2.1.6. Radioactive isotopes
Tritiated [3H] thymidine was purchased from Amersham Pharmacia Catalogue 
Number TRA120.
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2.1.7. Recombinant cytokines
Cytokine Company Catalogue Number
Murine recombinant IL-2 R&D systems Europe 402-ML-020
Murine recombinant GM-CSF R&D systems Europe 415-ML-005
Table 2.5: Table of recombinant cytokines used
2.1.8. Peptides
All the peptides were purchased from Mr Laurence Hunt of the IAH, Compton.
Name Sequence Description
2C peptide SIYRYYGL CD8 2C Transgenic TCR 
peptide.
GP1-1 KAVYNFATC Dominant H2-KD restricted 
epitope in LCMV.
GP1-3 SGVENPGGYCL Sub Dominant (3ra) H2-KD 
restricted epitope in LCMV
GP2-1 SGEGWPYIACRTSIVGRAWE Dominant l-AD restricted 
epitope in LCMV Armstrong.
NP1-2 FQPQNGQFI Sub Dominant (2n0) H2-KD 
restricted epitope in LCMV
NP2-2 GLKGPDIYKGVYQFKSVEFD Sub Dominant (2na) l-Ab 
restricted epitope in LCMV 
Armstrong.
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Name Sequence Description
NP2-3 GLKGPDIYKGVYQFKSVEFD Sub Dominant (3na)l-A° 
restricted epitope in LCMV.
OVA SIINFEKL Dominant H2-KD restricted 
epitope in ova. OT2 specific
Table 2.6: Table of peptides used
2.1.9. Antibodies, cell sorting, and FACS reagents
Antibody Clone Isotype Supplier
Conjugate/
Format
Catalogue
Number
Anti-Mouse
CD2
RM2-5 Rat lgG2b BD-Pharmingen Biotin 553110
Anti-mouse
CD3e
145-2C11 ArmH
IgGi
BD-Pharmingen Purified
NA/LE
R-PE
553057
553064
Anti-mouse
CD4
GK1.5 Rat lgG2b BD-Pharmingen
EJIVR
EJIVR
EJIVR
BD-Pharmingen
Biotin
Cy5
FITC
Supernatant
R-PE
553728
553730
Anti-Mouse
CD5
57-7.3 Rat lgG2a BD-Pharmingen R-PE 553022
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Antibody Clone Isotype Supplier
Conjugate/
Format
Catalogue
Number
Anti mouse 
CD8a
YTS.169 Rat lgG2b 
Rat lgG2b
EJIVR
EJIVR
Cy-5
Supernatant -
Anti Mouse 
CD11a
2D7 Rat lgG2a BD-Pharmingen Biotin 01202A
Anti-Mouse
CD11b
M1/70 Rat lgG2b BD-Pharmingen
BD-Pharmingen
EJIVR
Biotin
R-PE
Supernatant
553309
553311
Anti-Mouse 
CD11c
HL3 ArmH
IgGi
BD-Pharmingen
BD-Pharmingen
BD-Pharmingen
Biotin
FITC
R-PE
553800
553801
553802
Anti-mouse 
Fc Block 
(CD 16/32)
2.4G2 Rat lgG2b BD-Pharmingen Purified 553142
Anti-mouse
CD18
C71/16 Rat lgG2a BD-Pharmingen R-PE 553293
Anti-mouse
CD21
7G6 Rat lgG2b BD-Pharmingen FITC 553818
Anti-mouse
CD23
B3B4 Rat lgG2a BD-Pharmingen R-PE 553139
Anti-Mouse
CD24
M1/69
M1/69
Rat lgG2b 
Rat lgG2b
BD-Pharmingen
BD-Pharmingen
Biotin
R-PE
01572D
553262
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Antibody Clone Isotype Supplier
Conjugate/
Format
Catalogue
Number
Anti-mouse
CD25
PC61 Rat IgGi BD-Pharmingen R-PE 09985B
Anti-mouse
CD28
37.51 SyrH
IgGi
BD-Pharmingen Purified
NA/LE
553294
Anti-Mouse
CD31
MEC 13.3 Rat lgG2a BD-Pharmingen R-PE 553373
Anti-mouse
CD40
3/23 Rat lgG2a BD-Pharmingen Biotin 553789
Anti-mouse
CD43
S7 Rat lgG2a BD-Pharmingen R-PE 553271
Anti-mouse
CD44
IM7 Rat lgG2b BD-Pharmingen
BD-Pharmingen
Biotin
CyChrome
553132
553135
Anti-mouse
CD45.1
(Ly5.2)
A20 Mouse
igG2a
EJIVR
BD-Pharmingen
Biotin
R-PE 553776
Anti-mouse
CD45.2
(Ly5.1)
104 Mouse
igG2a
BD-Pharmingen
BD-Pharmingen
Biotin
FITC
553771
553772
Anti-mouse
CD45R
(B220)
RA3-6B2 Rat lgG2a BD-Pharmingen
BD-Pharmingen
Caltag
Biotin
CyChrome
Cy-5
553086
553091
RM2611
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Antibody Clone Isotype Supplier
Conjugate/
Format
Catalogue
Number
Anti-mouse
CD49b
DX5 Rat IgM BD-Pharmingen R-PE 553858
Anti-mouse
CD54
3E2 ArmH
IgGi
BD-Pharmingen Biotin 553249
Anti-mouse
CD80
16-10A1 ArmH
igG2
BD-Pharmingen Biotin 553767
Anti-mouse
CD86
GL1 Rat lgG2a BD-Pharmingen Biotin 09272D
Anti-mouse 
CD 102
3C4
(mlC2/4)
Rat lgG2a BD-Pharmingen Biotin 557441
Anti-mouse
CD117
2B8
ACK45
Rat lgG2b 
Rat lgG2b
BD-Pharmingen
BD-Pharmingen
APC
R-PE
553356
553869
Anti-mouse
CD127
B12-1 Rat lgG2b BD-Pharmingen Biotin 555288
Anti-mouse
CD138
281-2 Rat lgG2a BD-Pharmingen Biotin 09342D
Anti-mouse
CD162
2PH1 Rat IgGi BD-Pharmingen R-PE 555306
Anti-mouse
CD229.1
30C7 Rat lgG2b BD-Pharmingen
BD-Pharmingen
Biotin
FITC
557363
553117
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Antibody Clone Isotype Supplier
Conjugate/
Format
Catalogue
Number
Anti-mouse
IFN-y
R4-6A2
XMG1.2
XMG1.2
Rat IgGi 
Rat IgGi 
Rat IgGi
BD-Pharmingen
BD-Pharmingen
BD-Pharmingen
Purified
Biotin
R-PE
551216
554410
18115A
Anti-mouse
lgMpan
Polyclonal goat Southern
biotech
R-RE 1021-09
Anti Mouse 
lgDpan
11-26c.2a Rat lgG2a BD-Pharmingen FITC 02214D
Anti Mouse 
igMa
DS-1 Mouse
IgGi
BD-Pharmingen Biotin 05092D
Anti Mouse 
igMb
AF6-78 Mouse
IgGi
BD-Pharmingen Biotin 05102D
Anti Mouse 
IgGi3
10.9 Mouse
igG2a
BD-Pharmingen Biotin 05002D
Anti Mouse 
igG,b
B68-2 Mouse
IgM
BD-Pharmingen Biotin 05172D
Anti Mouse 
igG2aa
8.3 Mouse
igG2ab
BD-Pharmingen Biotin 05022D
Anti Mouse 
igG2ab
5.7 Mouse
igG3
BD-Pharmingen Biotin 05032D
Anti-mouse
IL-4
11B11 Rat IgGi BD-Pharmingen R-PE 554435
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Antibody Clone Isotype Supplier
Conjugate/
Format
Catalogue
Number
Anti-mouse
LPAM-1
DATK32 Rat lgG2a BD-Pharmingen R-PE 553811
Anti-mouse 
Class II
TIB-120 EJIVR Supernatant
Anti-mouse
MADCAM-1
MECA-89 Rat lgG2a BD-Pharmingen Biotin 553808
Anti-mouse
TER119
TER-119 Rat lgG2a EJIVR Supernatant
Anti-mouse 
Thy 1.2
J1J.10 Rat IgM EJIVR Supernatant
Streptavidin Invitrogen
BD-Pharmingen
BD-Pharmingen
BD-Pharmingen
RED670
PerCP
Alkaline
phosphatase
Horse
Raddish
Peroxidase
19543-024
1303PA
13043E
13047E
TCRvp
panel
Various Various BD-Pharmingen FITC 557004
Table 2.7: Table of antibodies used.
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2.1.9.1. Tetramers
Tetramer Peptide Conjugate Restriction Company
LCMV-GP KAVYNFATC R-PE H2-DD Prolmmune
OVA SIINFEKL R-PE H2-KD Prolmmune
LCMV-NP FQPQNGQF R-PE H2-DD Prolmmune
Table 2.8: Table of tetramers used.
2.1.9.2. In vitro fluorescent reagents
Name Size/MW Company Calalogue
Number
Fluoresbrite®YG
Microspheres
0.5pm Polysciences Europe 
GmbH
17152-10
Alexa Fluor 647 
Dextran
10000 Molecular probes D1825
Alexa Fluor 488 
Hydrazide
975 Molecular probes A-10436
Dextran- fluorescein 40000 Molecular probes D1845
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Name Size/MW Company Catalogue
Number
Hyaluronic Acid, 
bodipy FL conjugate
Molecular probes H23270
Table 2.9: Table of miscellaneous fluorescent reagents
2.2.Methods
2.2.1. Mice
All the mice were bred under specific pathogen free conditions at the Institute for 
Animal Health, Compton, UK or supplied by Charles River UK. The culling of mice 
was carried out using either the scheduled 1 method of asphyxiation by a rising 
concentration of CO2 or by terminal anaesthesia.
2.2.2. Chimeras & Irradiation
Mice were irradiated using a Nordion Gammacell 40 irradiator (GC40 exactor, MDS 
Nordion International Inc. Kanata, Canada). The mice received varying amounts of 
irradiation depending on the protocol, as indicated in the results section. Mice were
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given antibodies (polymixin B sulphate, 13mg/ml, and neomycin sulphate, 
25mg/ml) for 8 weeks following Irradiation.
Cells for in  v itro  assays were irradiated for 3000 rads using a Nordion Gammacell 
1000 irradiator (GC1000 elite, MDS Nordion International Inc. Kanata, Canada)
2.2.3. Thymectomies, and Sham Thymectomies
Mice were anaesthetised using hypoderm and ketamine, supplied by the staff of 
the small animals unit, at the Institute for Animal Health, Compton. Once suitably 
anaesthetised and immobilised, a small incision was made at the top of the 
sternum, and the thymus was removed by suction. The incision was then clamped 
together and the mice were allowed to recover. Sham thymectomies were carried 
out as normal thymectomies but without the removal of the thymus by suction. 
Mice were given antibiotics (polymixin B sulphate, 13mg/ml, and neomycin 
sulphate, 25mg/ml) for 5 weeks following the operation. The mice were left for 5 
weeks to recover, before further manipulation occurred. Operations were 
performed by Dr David Tough.
2.2.4. Intrathymic injections
Mice were anaesthetised using hypoderm and ketamine. Once suitably 
anaesthetised and immobilised, a small incision was made in the top of the 
sternum, the thymus was then injected with approximately 20pl (10pl per lobe) of 
B220+ depleted bone marrow. The incision was clamped together and the mice 
allowed left to recover. Mice were given antibiotics (polymixin B sulphate,
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13mg/ml, and neomycin sulphate, 25mg/ml) for 5 weeks following the operation. 
Injections were performed by Dr David Tough.
2.2.5. Immunisations and infections
2.2.5.1. Ova Immunisation
Ova immunisations were carried out by the subcutaneous administration, of 100pg 
OVA and 100jig/ml polyl:C dissolved in 200pl of PBS. Mice which were 
immunised with Ova and polyl:C were then given two subsequent subcutaneous 
injections of 100pg/ml polyl:C (in 200pl of PBS), 24 and 48 hours after the primary 
inoculation. The spleen and LN were removed 8 days after the primary 
immunisation.
2.2.5.2. CGG Immunisations
Mice were pre-bled prior to immunisation to determine the titre and affinity of cross­
reactive antibodies. CGG immunisations were carried out by the administration 
s.c. of 100pg CGG and 100pg/ml polyl:C dissolved in 200pl of PBS. Mice which 
were immunised with CGG and polyl:C were subsequently injected s.c. with 
polyl:C alone 24 and 48 hours after the primary immunisation. The serum was 
then collected 10 and 50 days later. Mice were then re-immunised with the same 
protocol of ova and polyl:C injections. The mice were then sacrificed 10 days after 
secondary immunisation, their blood and several organs were removed for in  v itro  
analysis.
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2.2.5.3. DNP Ficoll Immunisations
Mice were pre-bled prior to immunisation to determine their titre of cross-reactive 
antibodies. DNP-ficoll immunisations were carried out by the administration s.c. of 
5pg DNP-ficoll in 200pl of PBS. The serum and spleen were then collected 10 
days later.
2.2.5.4. LCMV Immunisations
Mice were infected i.p. with 2 x105 pfu of LCMV-Armstrong. The mice were 
sacrificed at various time points later, and various organs removed. The mice were 
housed under Category 3 conditions and all further manipulations of tissues were 
also carried out under Category 3 conditions, until rendered safe through viral 
inactivation.
2.2.6. Tissues
The tissues collected can be divided into three categories primary, secondary and 
tertiary lymphoid organs. The media in which the organs were collected, was 
determined by the fate of the organs. If the organs were to be used for FACS 
analysis then they were collected in PBS 2%FCS, if the organs were to be used for 
in  v itro  assays they were collected in sterile RPMI 2% FCS.
2.2.6.1. Primary Lymphoid organs
The thymus and bone marrow were surgically removed in an aseptic manner from 
dissected mice after confirmation of death.
104
2.2.6.2. Secondary Lymphoid tissues
Spleen, LN and peyer’s patches, were aseptically removed from dissected mice 
after confirmation of death.
2.2.6.3. Tertiary lymphoid tissues,
Occasionally peritoneal cells, liver lymphocytes, blood lymphocytes and serum 
were also harvested.
2.2.6 .3 .1 .  P e r i t o n e a l  c e lls
To obtain peritoneal cells the peritoneal cavity was injected with 5ml of ice cold 
RPMI supplemented with 5mM EDTA and 2%FCS media immediately upon 
confirmation of death. This was left for 2 minutes whilst gentle manipulation of the 
distended cavity was performed; the majority of media was then collected 
subsequently. A further injection of 5ml of ice-cold medium was given. This was 
again left for 2 minutes whilst gentle manipulation of the distended cavity was 
repeated; the remaining media was then harvested and pooled.
2.2.6.3 .2 .  L iv e r  ly m p h o c y te s
To obtain liver lymphocytes, 10ml of PBS supplemented with 2% FCS, 5mM EDTA 
and 0.01% heparin, was injected into the hepatic portal vein using a 25 gauge 
needle to perfuse the liver so as to remove any blood lymphocytes. The liver was 
continuously perfused until white in colour. The liver was then carefully removed so 
as to allow the gall bladder to be excised without rupture.
2.2.6.3.3. B lo o d  L y m p h o c y te s
To obtain blood lymphocytes, as soon after confirmation of death as possible, the
mouse was dissected, renal veins severed, and the blood collected with a 1ml
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syringe into 3ml PBS 0.01% Heparin. If peritoneal lymphocytes were also to be 
harvested from the same animal, then a thoracic cardiac puncture was performed 
to obtain the blood.
2.2.6.4. Serum
To obtain total serum, as soon after confirmation of death as possible, the mouse 
was dissected, renal veins severed, and the blood collected with a 1ml syringe into 
a plastic eppendorf without PBS or Heparin. If the animal was not to be culled, 
then a tail bleed was performed.
2.2.6.5. Tissue acquisition for LCMV titre determination
The spleen was surgically removed after death and a piece of tissue was taken 
and put in an eppendorf without media and then placed on dry ice. It was 
subsequently stored at -80°C until plaquing.
2.2.7. Tissue processing and cellular isolation
The cells were processed to a single cell suspension according to their fate and the
organs that they originated from. The samples from the thymus, spleen and LN, if
not isolating DC, were processed by using an abrasive method. The tissues were
gently disrupted using two frosted glass slides (sterile glass slides if in  v itro  assays
followed), thereby releasing the cells into media. If the cells were to be used for in
v itro  assays, they were re-suspended in RPMI supplemented with 2% FCS. Red
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blood cells in the splenic cell samples were lysed using a hypo-osmotic, 0.83% 
ammonium chloride solution, red cell lysis buffer. If the cells were to be used for 
FACS (florescence activated cellular sorting) analysis, they were re-suspended in 
FACS buffer.
2.2.7.1. Bone marrow cells
Cells from the bone marrow were obtained by first cleaning the bones so that no 
muscle or sinew remains. Both ends of the bone were removed, and the contents 
flushed using a 25 gauge needle with either PBS, if the cells were to be used for 
FACS analysis, or sterile RPMI, if they were to be used for in  v it ro  assays, both of 
which were supplemented with 2% FCS. If the cells were to be used to derive 
BMDCs then they were flushed with Iscoves modified medium supplemented with 
10% LE FCS and Pen/Strep.
2.2.7.2. DC isolation
The organ from which the DCs were isolated was injected with a solution of 
Dnasel and Collagenase IV. They were then placed in a rocking 37°C incubator 
for 30 minutes; 1ml of RPMI 2% FCS + 5mM EDTA was added for the last 5 
minutes. The samples were pushed though 70pm filters, pelleted and re­
suspended in 3ml of Nycodenz. This suspension was layered on top of 5ml of 
Nycodenz, with 1 ml of LE-FCS placed on top of the sample. This was then spun at 
2800rpm for 30minutes at 20°C (with the brake off). The enriched DCs were 
located at the interface of the Nycodenz and FCS.
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2.2.7.3. Liver Lymphocyte isolation
The liver was dissected into small pieces using a razor blade before being pushed 
through a metal sieve, and re-suspended in RPMI 5% FCS. The cells were pelleted 
at 1200 rpm (4°C) for 7 minutes, then re-suspended in RPMI 5% FCS. The 
majority of hepatocytes were pelleted by centrifugation at 300rpm for 3 minutes at 
4°C with the brake off. The supernatant, which contains the lymphocytes, was 
collected and spun down and the pellet re-suspended in digestion media (RPMI, 
0.02% Collagenase IV, 0.002% Dnasel), where it was left at 37°C for 45 minutes 
with gentle agitation to digest the remaining tissue architecture and freeing the 
lymphocytes. The cells were then washed in RPMI before being re-suspended into 
a final volume of 1.6ml of RPMI, 2.4ml of 40% metrizamide in PBS. The cells were 
gently mixed, 1 ml of RPMI was overlaid and the cells were spun at 2600rpm 4°C 
for 25 minutes. Lymphocytes, found at the interface of the metrizamide solution 
and PBS, were then collected.
2.2.7.4. Blood Lymphocyte isolation
The blood from the mouse was collected in PBS supplemented with 0.01%heparin. 
It was the passed over an equal volume of histopaque 1088; the cells were then 
spun at 1600 rpm, 20°C for 30 minutes with the brake off. Lymphocytes, found at 
the interface of the histopaque and PBS, were then collected.
2.2.7.5. Plaque assays to determine the titre of LCMV
The tissue after being stored at -80°C was brought to room temperature before a
known weight of the sample was homogenised using an electronic homogeniser in
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1ml of RPMI until a single cell suspension was achieved. Dilutions of the sample 
were then made, and an aliquot of the dilutions was gently placed on a 95% 
confluent layer of vero cells in a 6 well plate. The cells were then left for 1 hr at 
37°C before a layer of 1% Agar, 5%FCS, 0.5% pen/strep solution, 1x MEM, was 
placed over the top. The plates were incubated for 6 days before being fixed with 
1% formalin. The plates were developed with crystal violet, so as to determine the 
number of plaques present in each sample.
2.2.7.6. Counting Cells
Cells were counted using a haemocytometer. Remaining red blood cells and non- 
viable cells were discriminated using phase-contrast whilst being counted.
2.2.8. Cell sorting and purification
2.2.8.1. Dynal Purification
Cells at a concentration of 2 x 107 cells/ml in RPMI 2%FCS were incubated with
the appropriate antibody concentration for 20 minutes at 4°C. During this time,
dynal beads were washed three times with RPMI 2%FCS to remove the
preservative using a strong magnet, which allows the removal of the supernatant
without disturbing the beads. The antibody labelled cells were washed to remove
the excess antibody, and re-suspended with the appropriate amount of washed
dynal beads (150pl of each dynal species per 1x108 total cells). The sample was
gently agitated at 4°C for 45 minutes, before being placed on the magnet leaving
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non-labelled cells in the supernatant. The beads were then re-suspended in fresh 
media before being replaced on the magnet, allowing for maximal yield of non­
labelled cells.
2.2.8.2. Cell Purification by complement-mediated killing
Cells were incubated with the appropriate antibody concentration at 2x107 cells/ml 
2.5% FCS RPMI with 10% guinea pig complement for 45 minutes at 37°C. The 
cells were then filtered to remove dead cell clumps and washed to remove excess 
antibody and complement.
2.2.8.3. Cell Sorting on the MoFlo
Fluorescently-labelled cells were purified using a MoFlo sorter; cells were labelled 
with florescent antibody as described in section 2.2.10. Although a higher 
concentration of antibody was frequently needed due to a reduced sensitivity of the 
Moflo (compared to the FACS Calibur which was used for analysis), as well as the 
greater staining volumes used. The cells were also stained in PBS 2%FCS, to 
allow their further use in functional assays. Immediately before sorting they were 
filtered through a 40jim filter to prevent blockage of the MoFlo. The cells were 
sorted into 0.5ml of FCS to increase cell viability. Either Mr Andrew Worth or Miss 
Janine Oldham operated the MoFlo.
2.2.8.4. Purification for Bone marrow For Chimeras
Bone marrow cells to be injected into an irradiated mouse were manipulated to
remove a variety of cell types, the most common of which was the CD3+ subset.
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This was done mainly by complement-killing, using an antibody against Thy 1.2. 
Occasionally B cells were also removed. This was done by dynal bead depletion 
using anti-B220 and anti-mouse IgG; the latter has cross reactivity to murine IgM 
and IgD thereby removing the majority of the B cells. Where indicated, all lineage 
positive cells were removed this was done by using an antibody cocktail and dynal 
bead negative selection. More details of this method can be found in the text. 
Purified cells were washed three times with PBS to remove residual FCS before 
being filtered through a 40jim filter in preparation for i .v . injection.
2.2.9. Cell Culture
2.2.9.1. Bone Marrow derived Dendritic cells
A single cell suspension of bone marrow cells was re-suspended in Iscoves 
Modified Medium supplemented with 10% LE FCS, 1% Pen strep, 5 mM 2(3ME, 
and 10pg/ml GMCSF. The medium was changed 3 days after culture set up, and 
the cells harvested 8 days after initial culture.
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2.2.10. Immunoflourescent staining
2.2.10.1. Surface FACS Staining
Cells for FACS staining were aliquoted out into 5ml polypropylene tubes with 1 
x106 cells per tube; the cells were then washed with FACS. Fc sites were blocked 
by the addition of Fc Block (anti-CD16/CD32) for 15 minutes whilst the cells were 
kept at 4°C. Antibodies were added at an appropriate dilution for 20 minutes at 
4°C in the dark to prevent photobleaching. The sample was then washed with 2ml 
of FACS buffer to remove excess antibody. If any of the antibodies were 
biotinylated, binding was visualised by adding flurochrome-conjugated streptavidin, 
and the samples were incubated for 15 minutes at 4°C in the dark. The sample 
was then washed with 2ml of FACS buffer to remove excess antibody. If stained 
samples were not to be analysed by FACS within 12hrs the cells were fixed with 
0.5ml PBS and 2%PFA, and left overnight at 4°C in the dark.
2.2.10.2. Tetramer Staining
Cells to be tetramer stained were depleted of B cells and Fc+ cells, usually by dynal 
depletion B220+ and CD16/CD32+ cells. The cells to be stained were then 
incubated with an appropriate quantity of tetramer in wells of a 96-well u bottomed 
plates, for 45 minutes at room temperature in the dark. Samples were then 
washed before further staining of cell surface markers.
112
2.2.10.3. Intracellular staining
Cells were stimulated with the appropriate peptide or protein for 8hrs in RP10 at 
37°C, before golgi stop was added (2pl/ml) for an additional two hours with 10units 
per ml of IL-2. The cells were then harvested and washed in FACS buffer, before 
surface staining, as described previously (section 2.2.10). After washing, the cells 
were fixed using 4%PFA/PBS, and then left for a minimum of 2hrs. Samples were 
then washed twice in permeabilisation buffer (PBS with 0.1% saponin, 0.1% 
sodium azide, 1% FCS). Anti-cytokine antibodies were then added for one hour at 
4°C in the dark. Cells were then washed with FACS buffer and analysed on the 
FACS.
2.2.10.4. Flow cytometry and analysis
For examining cell surface phenotype, flow cytometry was carried out using a 
FACScalibur, and the data was analysed using mainly Cell Quest (BD). Summit 
(cytomation) was used for analysis of MoFlo acquired samples.
2.2.10.5. Statistical analysis
Analysis of results was perfomed using Microsoft Excel 2002 software, where two- 
sample Student’s t-tests were performed. Student's t-tests were used to provide 
an exact test of the equality of normally distributed means from two independent 
sample populations. Assumptions made: 1, the samples were drawn from normally 
distributed populations, 2, the population difference was less than 2, and 3, there 
were no outliers.
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2.2.11. Ex vivo Assays
2.2.11.1. Elispots
There were two types of Elispots used in this thesis, IFN-y Elispots, and B cells 
specific Elispots. They differ in the setting up and the biotinylated detection 
antibodies used, but after that the procedure is identical.
2 .2 . 1 1 . 1 .1 .  I  F N y  E l is p o ts .
Elispot plates were coated with purified anti-IFN-y antibody in 0.05M carbonate 
coating buffer (pH9.6) overnight at 4°C. The plate was washed 3 times with filtered 
PBS, and blocked for at least 1 hr at 37°C with RP10. Stimulator cells, which were 
CD8 depleted splenocytes (negative depletion by dynal beads see section 2.2.8.1), 
were added a 5x105 cells/well. A variety of effector cell concentrations were added 
to each well; usually between 5x103 and 5x105. The cells were stimulated with a 
known concentration of peptides and/or protein. The cells were then left at 37°C 
for between 12 to 36hrs, depending on stimulation, before development.
2 .2 . 1 1 . 1 .2 .  B  c e l l  s p e c if ic  E l is p o t
CGG or DNP-ficoll was coated at 10fig/ml in carbonate coating buffer (pH9.6) 
overnight at 4°C. This was then removed and the plate washed 3 times with PBS. 
The plate was then blocked for 1 hour at 37°C using RP10. To focus on antibody 
production by plasma cells, slg+ B cells were depleted using sheep anti-mouse 
dynal beads, before being plated out at various concentrations. The plates were 
left at 37°C and 5% CO2 for 12 hours before development.
2.2.1 1 .1 .3 .  D e v e lo p m e n t  o f  E L I S P O T  P la t e s
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After the incubation period described above, media and cells were discarded. The 
plates were washed six times with PBS and five times with PBS-0.05%Tween20 on 
both sides of the membrane. The biotinylated detection antibody, specific for either 
IFNy or a particular Immunoglobulin isotype, was then added in a suitable dilution 
of PBS-0.05%Tween20 and left for 4 hrs at room temperature. Subsequently, the 
antibody was discarded and the plate blotted. The plate was then washed five 
times with PBS-0.05%Tween-20 on both sides of the membrane, and an anti-biotin 
alkaline phosphatase antibody was added in a suitable dilution of PBS- 
0.05%Tween20 for 4hr at room temperature. The plate was then washed on both 
sides of the membrane, 3 times with PBS-0.05%Tween-20 and then 3 times with 
PBS. The plate was then developed using an alkaline phosphatase development 
kit, as described by the manufacturer. The development time was variable each 
time, and then the reaction was stopped using tap water. The ELISPOT plates 
were then counted using a Lecia stereo microscope.
2.2.11.2. Antigen Specific ELISAs
Antigen-specific antibodies found in the sera of immunised mice were measured by 
ELISA. The antigen was coated on a plastic plate (FACON 3912) at 5pg/ml in 
0.05M Carbonate coating buffer (pH9.6) overnight at room temperature in a 
humidified box. The plates were then blocked using a solution of 4% milk powder 
in PBS and incubated for 45 minutes at 37°C. The plates were washed three times 
in wash buffer, PBS 0.05% tween-20. 100pl of diluted serum was added, dilutions 
were made in PBS 1% milk powder and 0.2% Tween-20. After one-hour 
incubation at room temperature in a humidified box, the plates were washed three
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times in PBS-0.05% tween-20. 100pl of the secondary antibody was then added in 
PBS 0.1% Milk powder. After one-hour incubation at room temperature in a 
humidified box, the plates were washed three times in PBS-0.05% tween-20. 
10Opil of streptavidin - horseradish peroxidase, in PBS 1% milk powder, was added 
and the plate left for one hour at room temperature in a humidified box. The plates 
were washed three times in PBS-0.05% tween-20. The ELISA was developed 
using Sigma OPD tablets; the reaction was stopped by adding 50pl 3M HCI. The 
plates were read at 492nm, using a Spectramax 340, from molecular devices 
(Wokingham, UK) and analysed using Softmax Pro software.
2.2.12. In vitro functional Assays
The ability of the DCs to stimulate T cells can be measured by their ability to 
uptake, and to present antigen. The uptake ability of DCs was assayed using 
fluorescently labelled particles of different sizes, which are internalised by different 
uptake pathways; uptake of fluorescent particles was monitored by FACS. The 
ability of DCs to present antigen was assayed by loading the DCs with specific 
peptides and/or protein and measuring the proliferation of transgenic T cells by the 
incorporation of tritiated thymidine. Mixed leukocyte reactions (MLR’s) were also 
used to assess the responsiveness of the T cells to allotypic stimulation and the 
responsiveness of the DCs to affect allotypic stimulation. T and B cells were non- 
specifically stimulated by cross-linking of either their cell surface molecules by 
immobilised antibodies.
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2.2.12.1. Uptake Assays
BMDCs were assessed for their ability to internalise antigen. This was performed 
by measurements of phagocytosis of fluorescent microspheres (0.5|im in 
diameter), endocytosis of different sizes of fluorescent dextran beads (mw 10,000 
& 40,000) and pinocytosis using a fluorescent dye (mw 975).
DCs were isolated using nycodenz (see Section 2 .2 . 7 . 2 . )  and were re-suspended 
in RPMI-2%FCS, at a concentration of 1 x 107/ml. 100jal solutions of the particles to 
be used were added to DCs in a FACS tube. The tubes were kept on ice in the 
dark, until either transferred to a 37°C water bath, or left on ice for a negative 
control, for various periods of time. The uptake assay was then halted by the 
addition of 4ml of ice cold FACS solution. The cells were washed 3 times before 
proceeding to surface staining (see section 2.2.12.)
2.2.12.2. Non-specific in vitro proliferation assays
2.2 .1 2 . 2 . 1 .  M ix e d  le u k o c y te  r e a c t io n s  ( M L R s )
CD44+/+ and CD44'/_ cells were assessed for their ability to act as either stimulators 
or responders in allogeneic MLRs with Balb/c cells. 105 responder cells in RP10 
were added to wells of 96 well plates with 2x105 - 5 x104 CD8 depleted irradiated 
(3000 Rads) splenocytes or 104 - 103 irradiated BMDCs.
2.2.1 2 .2 .2 .  N o n - s p e c if ic  T  c e l l  s t im u la t io n  a s s a y
An optimal concentration of anti-CD3 (l^g/ml) and anti-CD28 (2.5ng/ml) in 100|al 
PBS was added to wells of 96 well U bottomed plates, and left overnight at 4°C.
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The plate was washed 3 times with PBS, before 105 cells per well of T cells were 
added.
2.2.1 2 .2 .3 .  N o n - s p e c if ic  B  c e l l  s t im u la t io n  a s s a y
An optimal concentration of anti-IgM (5pg/ml) in 10Ojul PBS was added to wells of a 
96 well U bottomed plates, and left overnight at 4°C. The plate was washed 3 
times with PBS, before 105 B cells were added for non-specific stimulations.
2.2.12.3. Antigen specific T cell assays
Either BMDCs or CD8-depleted splenocytes were incubated with a range of 
concentrations of protein or peptide at 37°C in RP10 for 2-4 hrs. The cells were 
then irradiated (3000 rads) and washed three times to remove the free protein or 
peptide. For splenocyte 105 stimulators were then added to wells of a 96 well U 
bottomed plate. Different numbers of BMDCs were tested for stimulation of 
antigen specific transgenic T cells. The effector T cells were MHCII depleted.
2.2.12.4. Proliferation assays
All proliferation assays were set up in 96 well u bottomed plates. The cells were
stimulated by various methods (see section 2.2.12.2 -  2.2.12.3).
At various times after the start of the culture 1pCi. of tritiated thymidine was added
per well. This was left for 16hrs after which the plate was placed at -20°C to stop
further proliferation. The plates from the proliferation assays were thawed to room
temperature before being harvested. The solid contents of the wells were
transferred on to a filtermat, which was then washed 5 times with distilled water to
remove the non-incorporated thymidine. The filtermats were left to dry, then
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saturated with beta scintillant and sealed in plastic bags. The tritiated thymidine 
present on the filter was then measured by a Wallac 1450 microbeta trilux 
(PerkinElmer, Boston, USA).
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3. Chapter 3: Fitness of the CD44'/_ lymphocytes when 
placed in direct competition with CD44+/+ 
lymphocytes in a steady state.
3.1. Introduction
CD44, a widely expressed transmembrane glycoprotein, has had many functions 
ascribed to it (see Section 1.3.). Most of the studies which have attributed some 
functional relevance to CD44 have been accomplished by using monoclonal 
antibodies which interfere with the ability of CD44 to bind to its various ligands. 
CD44-dependent processes have been shown to include lymphocyte activation 
and migration, adhesion, and haematopoiesis. Surprisingly, when CD447* mice 
were generated, there were only a few minor defects in the mature adult. These 
included (1) an altered tissue distribution of myeloid progenitors, (2) an increase in 
the size of granulomas in response to C r y p to s p o r id iu m  p a r v u m  infection, and (3) 
increased tumorigenicity of tumours derived from transformed CD44/_ fibroblasts, 
(219). In this study, T and B cell development were found to be normal, as were T 
and B cell functional responses to VSV or LCMV infection, or ovalbumin 
immunisation. Another group also found normal T and B cell development, 
although they did observe that mature CD44*/_ T cells appeared to have a slight 
deficiency in entering the adult thymus; this was observed whether the recipient 
thymus was CD44'7' or CD44+/+(220).
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Further studies using these mice, and other transgenics which have deletions in 
certain various exons, have provided additional information on the functional 
importance of CD44, which will be covered in greater detail in Section 6.
However when examining the literature as a whole, there appears to be a 
discrepancy in the functional evidence for the importance of CD44 in lymphocyte 
development. Antibody blocking studies in CD44+/+ mice show essential roles for 
CD44 in T cell development and bone marrow homing, but CD44'7' mice have 
subtle deviancies in lymphocyte re-circulation and myeloid progenitor distribution.
A functional role for CD44 in T cell development has been demonstrated by several 
groups each using different assays. Anti-CD44 antibodies prevented foetal liver 
cells, which are comparable to adult bone marrow cells, from entering the foetal 
thymus in thymic organ cultures (221). Anti-CD44 antibodies prevented rosette 
formation between thymocytes and stromal cells and therefore T cell development 
in in  v itro  cultures (222), and again anti-CD44 antibodies reduced T cell 
development in Foetal Thymic Organ Cultures. (128).
A functional role for CD44 in bone marrow homing has been shown in studies
where co-injection of anti-CD44 antibodies with bone marrow cells, inhibited entry 
of the bone marrow cells to the bone marrow, (223). Anti-CD44 antibodies injected 
for 3 days before injection of bone marrow cells, still inhibited the bone marrow 
cells from seeding, (224). In addition anti-CD44v10 antibodies have been shown 
to prevent homing of myeloma cells to bone marrow and to prevent the adhesion of
the myeloma cells to the bone marrow epithelium. (225).
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A role for CD44 in B cell development has been described by the blocking of 
lympho-haematopoiesis in long-term bone marrow cultures by anti-CD44 
antibodies (226).
Why an important role for CD44 has been indicated by antibody blocking studies 
but not in CD44'7' mice is unclear. One possibility is that when CD44 is absent 
from early on in embryogenesis, the resulting deficit leads to the induction of other 
genes, which could replace CD44 function. As described in the introduction, CD44 
binds to its ligand, mainly hyaluronate as part of the extracellular matrix, which is in 
turn bound to CD44 expressed by the epithelial or stromal cells. Since CD44 is not 
the only receptor for hyaluronate, in the CD447' mice other receptors could 
potentially bind hyaluronate, and together with other adhesion molecules, 
compensate for the lack of CD44 and therefore allow normal development and 
normal function of lymphocytes in the CD44'/_ mice. However, it is also possible 
that blocking antibodies, in addition to disrupting interactions between CD44 and its 
ligand, cause unintended effects (e.g. cross-linking and signalling, targeting to 
phagocytes) that are unrelated to a physiological function for CD44.
Therefore, there are potential drawbacks to investigating the role of CD44 in 
lymphocyte development and function by comparing CD44+/+ and CD44_/' mice, or 
by injecting large quantities of blocking antibodies. To avoid these problems, we 
chose to compare directly the behaviour of CD44 /_ and CD44+/+ cells in the same 
host. Mixed bone marrow chimeras were generated by the injection of CD44+/+ 
and CD44'/' progenitors into an irradiated CD44+/+ host. This allows CD44'/_ and 
CD44+/+ haematopoietic cells to develop in an environment where CD44 is present 
and bound naturally to its ligands. This system should reveal any advantage of
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CD44 expression in lymphocyte development, in an environment where 
compensatory mechanisms are unlikely to be established, and without the potential 
problems associated with antibody injections.
3.2.AIM
To generate mixed bone marrow chimeras and to compare the fitness of CD44+/+ 
and CD44*7' cells when they are placed in direct competition with each other. This 
was executed in both CD44+/+ and CD44’7' hosts, so as to investigate any influence 
of the environment.
123
3.3. Results
3.3.1. Phenotypic description of Chimeras: CD44+/+ (Ly5.2+) and 
CD44"'" (Ly5.1+) donors -> CD44+/+ (Ly5.2+) hosts
Ly5.2 (CD44*/+) and CD44~' mice were sacrificed and their bone marrow T cell 
depleted by antibody mediated complement cytotoxicity. The cells were mixed in a 
1:1 ratio and injected into irradiated host Ly5.2 mice (900 rads). Once immune 
reconstitution had occurred they were sacrificed, and their phenotype was 
analysed by FACS. Cells derived from the CD44'7' progenitor cells were identified 
using an anti-Ly5.1 (CD45.2) antibody.
These mice had normal cell numbers in spleens (see appendix 1), thymi and LN, 
and normal numbers and percentages of total T and B cells, (Figures 3.1A, 3.2A). 
However when the T and B cells from these chimeras were analysed there was a 
statistical difference in the origin of these cells (Figures 3.1 B, 3.2B). It appeared 
that CD44'7' progenitors preferentially developed into B cells whereas the CD44+/+ 
cells developed into T cells. This was more noticeable when the B:T cell ratio 
among the CD44'7' cells was calculated and compared to the total B:T cell ratio 
(Figures 3.1 C, 3.2C). There were 6.2 CD447* B cells to every CD44_/‘ T cell in the 
spleen, but overall 1.9 B cell to every T cell in the spleen. In the LN there was a 
similar pattern with 2.8 CD44'7' B cells per T cell in the LN and overall 0.8 B cell to 
every T cell in the LN. After finding this discrepancy it was decided to further 
investigate the contribution of CD44*7* cells to T cell subsets and B cell subsets.
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Figure 3.1. Analysis of T and B cells in spleens of CD44+/+ & CD44"/' 
CD44+/+ chimeras.
A. Percentages of T and B cells in spleen. B. The percentage of 
Ly5.1+ cells in each splenic population. C. The B:T cell ratio among 
total, CD44'a and CD44+/+ populations. The data are mean ± s.e.m. 
obtained from 3 independent groups of chimeras (3 mice per group), 
over an 8-month period from date of reconstitution. P values, 2-sample 
t test; ****, P0.001
125
CD3+ CD19+
CD3+ CD19+
****  c
Total CD44+/+ CD44-/-
Figure 3.2. Analysis of T and B cells in lymph nodes of CD44+/+ & 
CD44'7'—► CD44+/+ chimeras.
A. Percentages of T and B cells in lymph nodes. B. The 
percentage of Ly5.1+ cells in each population. C. The B:T cell 
ratio among total, CD447" and CD44+/+ populations. The data are 
mean ± s.e.m. obtained from 3 independent groups of chimeras. 
(3 mice per group), over an 8-month period from date of 
reconstitution. P values, 2-sample t test; ****, P<0.001
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In the spleen and LN, a difference was observed in the ability of CD44'7' 
progenitors to develop into either CD4+ or CD8+ T cells (Figures 3.3, 3.4). 
Although the overall percentage of CD4+ and CD8+ T cells in the spleen and LN 
were normal (Figures 3.3A, 3.4A), it appeared that the CD44'7' progenitors had a 
bias towards developing into CD4+ T cells (Figures 3.3B, 3.4B). When the 
CD4:CD8 ratio was calculated there were approximately 2 CD4+ T cells per CD8+ T 
cell in the CD44'7' T cell population compared to 1.4 CD4+ T cells per CD8+ T cell in 
the CD44+/+ population (Figure 3.3C, 3.4C). Upon further investigation another 
bias was also found in the CD4+ CD25+ T cell population, a population that 
includes regulatory T cells (Taylor P, 1311) (Figures 3.5, 3.6). In the mixed 
chimeras, there was a normal proportion of CD25+CD4+ T cells (Figure 3.5A, 3.6A), 
but there was a higher contribution from the CD44'7' cells in the CD3+CD4+CD25+ 
subset than in the CD3+ CD25CD4* subset (Figure 3.5B, 3.6B). When the CD25' 
CD4+:CD4+CD25+ T cell ratio in the spleen was calculated, there were 6 CD25' 
CD4+ T cells to every CD25+CD4+ T cell in the CD44'7' population, compared to 11 
CD25'CD4+ T cell per CD25+CD4+ T cell in the CD44+/+ population (Figure 3.5C). 
This difference was also seen in the LN, where there were 3.5 CD25'CD4+ T cells 
to every CD25+CD4+ T cell in the CD44'/_ population, compared to 6.5 CD25CD4* 
T cell per CD25+CD4+ T cell in the CD44+/+ population (Figure 3.6C).
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Figure 3.3. Analysis of CD4 and CD8 T cells in spleens of CD44+/+ & 
CD44'1'—► CD44+/+ chimeras.
A. Percentages of CD4+ and CD8+ CD3+ cells in spleen. B. The 
percentage of Ly5.1+ cells in each splenic population. C. The 
CD4:CD8 cell ratio among total, CD44'7' and CD44+/+ populations. Data 
are mean ± s.e.m. obtained from 4 independent groups of chimeras (3 
mice per group). P values, 2-sample t test; *, P<0.05
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Figure 3.4. Analysis of CD4 and CD8 T cells in lymph nodes of 
CD44+/+ & CD44'/_—► CD44+/+ chimeras.
A. Percentages of CD4+ and CD8+ CD3+ cells in lymph nodes. B. The 
percentage of Ly5.1+ cells in each T cell subset. C. The CD4:CD8 cell 
ratio among total, CD44_/' and CD44+/+ populations. Data are mean ± 
s.e.m. obtained from 2 independent groups of chimeras (3 mice per 
group). P values, 2-sample t test; ****, P<0.001
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Figure 3.5. Analysis of CD4 subsets in spleens of CD44+/+ & CD44 
CD44+/+ chimeras.
A. Percentages of CD25+ and CD25' CD4+ T cells. B. The percentage 
of Ly5.1+ cells in each C D 4 T  cell subset. C. The CD25":CD25+ CD4+ T 
cell ratio among total, C D 4 4 a n d  CD44+/+ populations. Data are mean 
± s.e.m. obtained from 2 groups of 3 mice. P values, 2-sample t test; 
****, P<0.001, *, P<0.05
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Figure 3.6. Analysis of CD4 subsets in lymph nodes of CD44+/+ & CD44' 
/_—► CD44+/+ chimeras.
A. Percentages of CD25+ and CD25' CD4+ T cells. B. The percentage 
of Ly5.1+ cells in each CD4 subset. C. The CD25':CD25+ CD4+ T cell 
ratio among total, CD44_/' and CD44+/+ populations. Data are mean ± 
s.e.m. obtained from 1 groups of 3 mice, and 1 group of 2 mice. P 
values, 2-sample t test; *, P<0.05
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The distribution of slgM+ and slgD+ cells in the B220+ splenic and lymph node 
populations of the mixed chimeras was not unusual (Figures 3.7A, 3.8A). When 
the composition of the individual B cell subsets was examined it was evident there 
was a similar proportion of CD44'7' B cells in each splenic subset (Figure 3.7B). 
There did appear to be a decrease in the contribution of CD44'7' cells to the slgM' 
slgD’ B cell subset in the LN although this was not statistically significant (Figure 
3.8B). This did corresponded with a higher proportion slgM slgD' B cells in the 
CD44+/+ population of the LN. The CD44+/+ and CD44*7' B cells of the spleen 
displayed similar slgD and slgM expression within their respective B220+ 
populations (Figure 3.7C).
There was a statistical difference in the contribution of CD44'7' vs. CD44+/+ 
progenitors to the production of splenic marginal zone B cells (CD21+CD23'B220+) 
(Figure 3.9). 67% of the marginal zone B cells were CD44'7" derived compared to 
52% of the follicular B cells (CD21+CD23+B220+) (Figure 3.9A). This difference 
was also reflected in the distribution of marginal zone and follicular B cells within 
the CD44+/+ and CD44'7' B cell populations. 10% of the CD44+/+ B cell population 
were marginal zone B cells compared to 14% of the CD44'7' B cells (Figures 
3.9B.C). This is highlighted, when the ratio of marginal zone B cells (CD21+CD23' 
B220+) and follicular B cells (CD21+CD23+B220+) is calculated, (Figure 3.9D). 
Among CD44‘7' B cells, there were 5 follicular B cells for every marginal zone B 
cell. In contrast, there were 8 folicular B cells for every marginal zone B cell 
among the CD44+/+ cells.
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Figure 3.7. Distribution of slgM+ and slgD+ B cells in the spleens of 
CD44t/+ & CD44''-—► CD44+/+ chimeras.
A. Distribution of B cells subsets defined by slgM and slgD expression 
in splenic B220+ cells. B. Contribution of CD44_/' cells to each subset 
of B220+ cells as defined using slgM and slgD staining. C. Distribution 
of slgM and slgD staining among CD44 /' or CD44+/+ B220+ cells. Data 
are mean ± s.e.m. obtained from 1 group of 3 mice.
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Figure 3.8. Distribution of slgM + and slgD+ B cells in the lymph nodes of 
CD44+/+ & CD44"/“—► CD44+/t chimeras.
A. Distribution of B cells subsets defined by slgM and slgD expression 
in the B220+ population of the lymph nodes. B. Contribution of CD44 7' 
cells to each subset of B220+ cells as defined using slgM and slgD 
staining. C. Distribution of slgM and slgD staining among CD44~/_ or 
CD44+/+ B220+ cells. Data are mean ± s.e.m. obtained from 1 group of 
2 mice.
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Figure 3.9. Distribution of follicular and marginal zone B cells among 
the B220* cells in the spleens of CD44t/+ & CD44~/'-> CD44+/+ 
chimeras.
A. CD21 and CD23 expression in the B220+ population of the spleen.
B. Contribution of CD44'7' cells to each subset of B220+ cells as 
deficined by CD21 and CD23 staining. C. Alternative scale of (B) 
focusing on the CD23- populations. D. The ratio of CD21+ CD23+ : 
CD21+ CD23' cells among total, CD44'/‘ and CD44+/+ B220+cells. Data 
are mean ± s.e.m. obtained from 1 group of 3 mice. P values, 2- 
sample t test; **, P<0.01
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It has been proposed that marginal zone B cells are derived from a similar 
precursor to that of B-1 cells (227). Therefore, preliminary studies were carried out 
on CD5+ B220+ B-1 a cells isolated from the peritoneal cavity. In contrast to 
marginal zone B cells, it was found that the percentage of CD44'7' cells was lower 
among the B-1 a cells than non B-1 a (CD5 ) cells in the peritoneum (Figure 3.10).
3.3.2. Phenotypic description of Chimeras: CD44+/+ (Ly5.2+) and 
CD447' (Ly5.1+) donors CD44’'' (Ly5.1+) hosts.
Since adhesive interactions involving CD44 may be modified by a hyaluronic acid 
“sandwich” it was possible that host expression of CD44 contributes to the altered 
generation of T and B cells by CD44'A progenitors. To address this issue, mixed 
chimeras were made in CD44 7' hosts.
Ly5.2 and CD44V' mice were sacrificed and their bone marrow T cell depleted by 
antibody mediated complement cytotoxicity. The cells were mixed in a 1:1 ratio 
and injected into irradiated host CD447' mice (900 rads). Once immune 
reconstitution had occurred the mice were sacrificed, and their phenotype was 
analysed by FACS. As before, cells derived from the CD447' progenitor cells were 
identified using an anti-Ly5.1 (CD45.2) antibody.
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CD44+/* & CD44'/_—► CD44+/+ chimeras.
Data are mean ± s.e.m. obtained from 1 group of 3 
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These mice also had normal cell numbers in spleens, thymi and LN (appendix 1), 
and overall similar numbers and percentages of T and B cells (Figures 3.11 A, 
3.12A). When the T and B cells from the CD44_/‘ host chimeras were analysed 
there was a difference in the origin of the T and B cells (Figure 3.11B). 24% of the 
T cells are CD44'7' derived compare to 35% of the B cells being CD44'/‘ derived. 
This was not apparent in the LN of these chimeras, where there was a similar 
contribution of CD44'/‘ cells to both the CD3+ and CD19+ populations. The bias in 
the spleen was also reflected in the B:T cell ratio, with the ratio of B:T cells among 
CD44'/_ cells being 3.1, compared to 1.8 among total cells (Figure 3.11C).
The T cell populations in the spleen and LN were analysed, and it was observed 
that there was a difference in the ability of the CD44'/_ progenitors to develop into 
CD4+ versus CD8+ T cells (Figure 3.13B, 3.14B). This is again highlighted when 
the CD4+:CD8+ T cell ratio is calculated. There were approximately 4 CD4+ T cells 
per CD8+ T cell in the CD44_/' population of the spleen compared to 3 CD4+ T cells 
per CD8+ T cell in the CD44+/+ population in the spleen (Figure 3.13C). In the LN 
there were approximately 3 CD4+ T cells per CD8+ T cell in the CD44‘/_ population 
compared to 2 CD4+ T cells per CD8+ T cell in the CD44+/+ population in the LN 
(Figure 3.14C). Of note, while the overall ratio of CD4:CD8 in the spleen of the 
CD44+/+ hosts was 1.5, in the CD44'/‘ hosts it was 3, but in the LN of these different 
chimeras the CD4:CD8 T cell ratio was constant at 2.
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Figure 3.11. Analysis of T and B cells in the spleen of CD44+/+ & 
CD447'—► CD44'/_ chimeras.
A. Percentages of T and B lymphocytes in spleen. B. Percentage of 
Ly5.1+ cells in each splenic population. C. B:T cell ratio among total 
and CD44*7’ populations. Data are mean ± s.e.m. obtained from 2 
independent groups of chimeras, one group of 3 and one group of 8. P 
values, 2-sample t test; ****, P<0.001, *, P<0.05
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Figure 3.12. Analysis of T and B cells in lymph nodes of CD44+/+ & 
CD44V'—► CD44'/_ chimeras.
A. Percentages of T and B lymphocytes. B. Percentage of Ly5.1 + 
cells in each population. C. B:T cell ratio among total, CD44+/+ and 
CD44"7' populations. Data are mean ± s.e.m obtained from 2 
independent groups of chimeras, one group of 2 and one group of 7. P 
values, 2-sample t test, ***, P<0.005
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Figure 3.13. Analysis of CD4 and CD8 T cells in spleens of CD44+/+ & 
CD44'7'—► CD44'7' chimeras.
A. Percentages of CD4+ and CD8+ CD3+ cells. B. Percentage of Ly5.1 + 
cells in each splenic population. C. CD4:CD8 cell ratio among total, 
CD44_/' and CD44+/+ populations. Data are mean + s.e.m. obtained from 
2 groups of independent chimeras, one group of 3 and one group of 8. P 
values, 2-sample T test; ***, P<0.005
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Figure 3.14. Analysis of CD4 and CD8 T cells in lymph nodes of 
CD44+/+ & CD44'7"—► CD44''’ chimeras.
A. Total percentages of CD4+ and CD8+ CD3+ cells in lymph nodes. B. 
Percentage of Ly5.1+ cells in each T cell subset. C. CD4:CD8 cell ratio 
among total, CD44~/_ and CD44+/+ populations. Data are mean ± s.e.m. 
obtained from 2 groups of independent chimeras, one group of 3 and 
one group of 8. P values, 2-sample t test; *, P<0.05, ***, P<0.005
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The bias in the CD25+CD4+ T cell population found in the CD44+/+ host mice 
(Figures 3.5, 3.6), was also observed in the mixed chimeras made using CD44'7' 
mice as hosts (Figure 3.15, 3.16). In the CD447' host mixed chimeras, there was 
again a higher percentage of CD3+ CD4+ CD25+ in the CD4+ CD44'7' T cell 
population than in the CD4+CD44+/+ T cell population (Figure 3.15B, 3.16B). In the 
spleen, there were 3 CD25CD4* T cells to every CD25+CD4+ T cell in the CD44'7' 
population, compared to 9 CD25CD4* T cell per CD25+CD4+ T cell in the CD44+/+ 
population (Figure 3.15C). In the LN, there were 2.5 CD25'CD4+ T cells to every 
CD25+CD4+ T cell in the CD44'A population, compared to 6.5 CD25'CD4+ T cell per 
CD25+CD4+ T cell in the CD44+/+ population (Figure 3.16C).
The proportion of CD44'7' B cells within B cell subpopulations defined by slgM and 
slgD expression was again constant in the CD44'7' host mice mixed chimeras 
(Figure 3.17B). The CD44+/+ and CD44_/' B cells also displayed similar slgD and 
slgM distribution within their respective splenic B220+ populations (Figure 3.17C). 
There did appear to be a slight change in the percentage of marginal zone B cells, 
(Figure 3.18). There was an increase in the percentage of CD44'7’ cells present 
among the marginal zone B cells compared to the amount found in the follicular B 
cell population although this is not statistically significant (Figure 3.18B). This 
again is explained by a statistically significantly higher marginal zone frequency in 
the CD44'7' B cell population, 14% in the CD44'7’ B cell population compared to 
12% in the CD44+/+ B cell population (Figure 3.18C).
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Figure 3.15. Analysis of CD4 subsets in spleens of CD44+/+ & CD44 
—► CD44"/_ chimeras.
A. Percentages of CD25+ and CD25‘ CD4+ splenic T cells. B. 
Percentage of Ly5.1+ cells in each CD4 T cell subset. C. The CD25' 
:CD25+ CD4+ T cell ratio among total, CD44'7' and CD44+/+ 
populations. Data are mean ± s.e.m. obtained from 1 groups of 8 mice. 
P values, 2-sample t test; ***, P<0.005, ****, P<0.001.
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Figure 3.16. Analysis of CD4 subsets in lymph nodes of C D 44+/+ & 
C D44'/_—► C D 44'7' chimeras.
A. Percentages o f C D 25+ and CD25' C D 4+ C D3+ cells. B. Percentage 
of Ly5.1+ cells in each C D 4 T  cell subset. C. The CD25":CD25+ C D 4+ T 
cell ratio, am ong the total, C D 447" and C D 44+/+ populations. Data are 
mean ± s.e.m. obtained from  1 group of 5 mice. P values, 2 sam ple t 
test; ***, P<0.005
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Figure 3.17. Analysis of B cell subsets as defined by the distribution
of s lgM + and slgD+ in the spleens of CD44+/+ & CD44'7'—> CD44
A. Distribution of B cells subsets defined by slgM and slgD expression 
in the CD19+ population of the spleen. B. Contribution of CD44 /_ cells 
to each subset of CD19+ cells as defined using slgM and slgD staining. 
C. Distribution of slgM and slgD staining among CD447' or CD44+/+ 
CD19+ cells. Data are mean ± s.e.m. obtained from 2 independent 
groups of chimeras: one group of 3 and one group of 8.
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Figure 3.18. Distribution of fo llicular and marginal zone B cells among 
the B220+ cells in the spleens of CD44+/+ & CD44'7"—► CD44'/_ chimeras.
A. CD21 and CD23 expression in the CD19+ population of the spleen.
B. Contribution of CD44-/' cells to each subset of CD19+ cells as 
defined by CD21 and CD23 staining. C. The ratio of CD21+ C D 23+: 
CD21+ CD23‘ cells among total, C D 4 47' and CD44+/+ B220+cells. Data 
are mean ± s.e.m. obtained from 2 independent groups of chimeras: 
one group of 3 and one group of 8. P values, 2-sample t test; ****, 
P<0.001
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3.3.3. Phenotypic description of Chimeras: CD44 /_ (Ly5.1+) 
donors -> CD44+/+ (Ly5.2+) hosts.
Previous data has shown that CD44'7’ progenitors have an altered T:B cell ratio 
when introduced in conjunction with CD44+/+ progenitors into CD44+/+ but not 
CD44'7’ irradiated hosts. This and previous studies indicating a role for CD44 in the 
entry of pre-T cells into the thymus, may indicate that CD44*7* progenitors are 
disadvantaged in generating T cells due to difficulties in entering the thymus of 
CD44+/+ mice. Therefore it was decided to make chimeras using CD44+/+ host 
mice and to reconstitute with only CD44'7' bone marrow. This will determine 
whether the CD44-7' bone marrow cells are capable of fully reconstituting a CD44+/+ 
host.
CD44'7' mice were sacrificed and their bone marrow T cells depleted by antibody 
mediated complement cytotoxicity. The cells were injected into irradiated host 
CD44+/+ mice (900 rads). Once immune reconstitution had occurred they were 
sacrificed, and the phenotype of their lymphocytes was analysed by FACS. Cells 
derived from the CD44*7' progenitor cells were identified using the anti-Ly5.1 
(CD45.2) antibody.
These mice again had normal spleens, thymi and LN, and numbers (appendix 1) 
and percentages of total T and B cells that were comparable to that found in all of 
the other chimeras (compare Figures 3.1 A & 3.2A, 3.11A & 3.12A, 3.19A & 3.20A). 
Notably, although essentially 100% of the B cells were derived from CD44'7* 
progenitors, there was a significant number of host T cells remaining. Only about 
70% of T cells in the spleen were CD447' (Figure 3.19B), compared to 85% of the 
T cells in the LN (Figure 3.20B). This was due to the relative radioresistance of
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mature T cells which are predominately found in the spleen (228). Nevertheless, it 
was evident that CD44‘/' progenitors were capable of generating T cells in 
irradiated CD44+/+ hosts.
Similar proportions of CD4+ and CD8 + T cells were CD44 7' in the CD44+/+ hosts 
(Figures 3.21, 3.22), indicating that there was no bias in generating CD4 versus 
CD8  T cells in this setting, though there was a significantly larger amount of 
radioresistant CD8 + rather than CD4+ T cells. Interestingly, although there were a 
significant proportion of radioresistant T cells in these chimeras, in the spleen there 
was a higher proportion of radioresistant CD25+CD4+ than CD25'CD4+ host T cells 
(Figure 3.23B). While this difference was small, it enhances the ability of the CD44’ 
' ' progenitors to produce CD25+CD4+ T cells which was observed in other 
chimeras.
All splenic B cell subsets were present in these chimeras and very few 
radioresistant host B cells were detected (Figures 3.25, 3.26). While subset 
composition varied between different chimeras, there was a trend towards an 
increased proportion of both IgM'IgD* cells and marginal zone (CD21+CD23 ) cells 
compared to the control chimeras described next (Figure 3.27). This is again 
consistent with the observations in mixed chimeras.
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Figure 3.19. Analysis of B vs T cells in the spleen of CD44"/_—► CD44+/+ 
chimeras.
A. Percentages of T and B cells in spleen. B. The percentage of donor 
Ly5.1+ cells present in T and B cell populations. C. The B: T cell ratio 
among total and donor splenocytes. Data are mean ± s.e.m. obtained 
from 2 groups of mice: one group of 3 and one group of 4. P values, 2 
sample t test; ****, P<0.001
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F igure 3.20. Analysis of B vs T cells in the lymph nodes of CD44'/-—> 
CD44+/+ chimeras.
A. Percentages of T and B cells in lymph node. B. The percentage of 
donor Ly5.1+ cells present in T and B cell populations. C. The B: T cell 
ratio among total and donor lymphocytes. Data are mean ± s.e.m. 
obtained from 2 groups of mice: one group of 3 and one group of 4. P 
values, 2-sample t test; ****, P<0.001
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Figure 3.21. Analysis of CD4 and CD8 T cells in spleen of CD44 
CD44+/+ chimeras.
A. Percentages of CD4+ and CD8+ CD3+ cells. B. The percentage of 
Ly5.1+ cells in each splenic population. C. The CD4:CD8 cell ratio 
among total and donor CD44'/_ populations. Data are mean ± s.e.m. 
obtained from 2 groups of mice: one group of 3 and one group of 4. P 
values, 2-sample t test; *, P<0.05
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Figure 3.22. Analysis of CD4 and CD8 T cells in lymph nodes of CD44' 
/'—► CD44+/+ chimeras.
A. Percentages of CD4+ and CD8+ CD3+ cells. B. The percentage of 
Ly5.1+ cells in each T cell subset population. C. The CD4:CD8 cell 
ratio among the total and donor population. Data are mean ± s.e.m. 
obtained from 2 groups of mice: one group of 3 and one group of 4. P 
values, 2 sample t test; *, P<0.05
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Figure 3.23. Analysis of CD4 subset in spleen of CD44'7' 
chimeras.
CD44 +/+
A. Percentages of CD25+ and CD25‘ CD4+ CD3+ cells in spleen. B. 
Percentage of Ly5.1+ cells in each CD4 subset. C. The C D 25':CD25+ 
CD4+ T cell ratio among total and donor cells. Data are mean ± s.e.m. 
obtained from 1 group of 3 mice. P values, 2-sample t test; *, P<0.05
154
m CDO> »
1-
«*— + cno •*—>CD
<1) Q cn
cn O _QCO Z3•*->
c c cn
cd V)
pi_
a )
CL
o3o
I_________ 1
CD25+ CD25-
B
CD4+ CD25+ CD25-
+
10
CMQ „ O ^
• ' ‘ CD in o 
cm  , Q H
<■> V
1 8i
COa:
14
12
1 0
8  -I 
6  
4 
2  
0
Total CD44-/-
Figure 3.24. Analysis of CD4 subset in lymph nodes of CD44~ 
CD44+/+ chimeras.
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Figure 3.25. Analysis of B cell subsets in spleens of CD44‘A—► CD44+/+ 
chimeras.
A. Percentages of splenic B cell (B220+) subsets, defined by slgM and 
slgD expression. B. The percentage of Ly5.1+ cells in each B cell 
subset. Data are mean ± s.e.m. obtained from 2 groups of 3 mice.
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3.3.4. Measurement of Radioresistance in chimeras
The presence of radioresistant host T cells in CD44'7' (Ly5.1+) -» CD44+/+ (Ly5.2+) 
chimeras prompted us to investigate further the contribution of radioresistance 
when using donors and hosts of different origins.
CD44+/+ (Ly5.2+) host mice were reconstituted with CD44+/+ (Ly5.1+) bone marrow, 
to measure the level of radioresistance of the CD44+/+ (Ly5.2+) host mice, without 
the potential complications of CD44 7' progenitor disabilities. CD44*/‘ (Ly5.1+) host 
mice were also reconstituted with CD44+/+ (Ly5.2+) bone marrow, to measure the 
level of radioresistance of the CD44'/' (Ly5.1+) host cells; this experiment will also 
ensure that the CD44+/+ bone marrow can fully reconstitute a CD44‘/‘ host, without 
the presence of supporting CD44'/_ bone marrow.
3.3.4.1. Phenotypic description of Chimeras: CD44+/+ (Ly5.1+) -» CD44+/+ 
(Ly5.2+).
CD44+/+ (Ly5.1) mice were sacrificed and their bone marrow T cell depleted by 
antibody mediated complement cytotoxicity. T-depleted cells were injected into 
irradiated host CD44+/+ (Ly5.2) mice (900 rads). Once immune reconstitution had 
occurred, mice were sacrificed, and the phenotype of their lymphocytes was 
analysed by FACS. Donor cells were identified using the anti-Ly5.1 (CD45.2) 
antibody.
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Similar numbers (appendix 1) and percentages of total T and B cells, to those seen 
in the other chimeras were observed (Figures 3.28A & 3.29A, 3.1 & 3.2A, 3.11 & 
3.12A and 3.19 & 3.20A). When the T and B cells from the spleen and LN of these 
chimeras were analysed there was again a significant amount of radioresistance in 
the T cell population but few radioresistant B cells (Figure 3.28B, 3.29B). Although 
the host mice were lethally irradiated with 900 rads, approximately 20% of the T 
cells in the spleen and 15% in the LN were radioresistant host cells. This 
compared to approximately 30% and 15% of T cells in the spleen and LN 
respectively when these mice were reconstituted with CD44'/_ bone marrow (Figure 
3.19B).
The T cell populations in the spleen and LN showed no difference in CD44+/+ 
progenitors developing into either CD4+ or CD8 + T cells in the CD44+/+ hosts.
In the spleen there no difference in the frequency of radioresistant cells among 
CD4+ or CD8 + host T cells, although in the LN there was a significant number of 
CD8 + radioresistant T cells (Figure 3.30, 3.31). In the CD4+ T cell populations, the 
CD25+CD4+ T cells were more resistant to irradiation than the CD25' CD4+ T cells 
(Figure 3.32, 3.33).
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Figure 3.28. Analysis of B vs T cells in the spleen of CD44+/+ (Ly5.1)—» 
CD44+/+ (Ly5.2) chimeras.
A. Percentages of T and B cells in spleen. B. The percentage of donor 
Ly5.1+ cells present in each T and B cell population. C. The B:T cell 
ratio among donor (Ly5.1+) lymphocytes. Data are mean ± s.e.m. 
obtained from 2 groups of 4 mice. P values, 2-sample t test; ****, 
P<0.001
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Figure 3.29. Analysis of B vs T cells in the lymph nodes of CD44+/+ 
(Ly5.1)—>• CD44+/+ (Ly5.2) chimeras.
A. Percentages of T and B cells in spleen. B. The percentage of 
donor Ly5.1+ cells present in T and B cell population. C. The B:T cell 
ratio among donor (Ly5.1+) lymphocytes. Data are mean ± s.e.m. 
obtained from 2 groups of 4 mice. P values, 2-sample t test; ***, 
P<0.005
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Figure 3.30. Analysis of CD4 and CD8 T cells in spleen of CD44+/+ 
(Ly5.1) —► CD44+/+ (Ly5.2) chimeras.
A. Percentages of CD4+ and CD8+ CD3+ cells. B. The percentage of 
Ly5.1+ cells in each splenic population. The CD4:CD8 T cell ratio 
among total and donor cells. Data are mean ± s.e.m. obtained from 2 
groups of 4 mice.
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Figure 3.31. Analysis of CD4 and CD8 T cells in lymph nodes of 
CD44+/+ (Ly5.1) -» CD44+/+ (Ly5.2) chimeras.
A. Percentages of CD4+ and CD8+ CD3+ cells. B. The percentage of 
Ly5.1+ cells in each population. The CD4:CD8 T cell ratio among total 
and donor cells. Data are mean ± s.e.m. obtained from 2 groups of 4 
mice. P values, 2-sample t test; **, P<0.01
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Figure 3.32. Analysis of CD4 subsets in spleens of CD44+/+ (Ly5.1) —j 
CD44+/+ (Ly5.2) chimeras.
A. Percentages of CD25+ and CD25" CD4+ CD3+ cells in spleen. B. 
The percentage of Ly5.1+ cells in each CD4 subset. C. The CD25' 
CD4+:CD25+ CD4+ T cell ratio among total and donor (Ly5.1+) cells. 
Data are mean ± s.e.m. obtained from 1 group of 4 mice. P values, 2- 
sample t test; **, P<0.01
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Figure 3.33. Analysis of CD4 subsets in lymph nodes of CD44+/+ 
(Ly5.1) —► CD44+/+ (Ly5.2) chimeras.
A. Percentages of CD25+ and CD25" CD4+ CD3+ cells in lymph nodes.
B. The percentage of Ly5.1+ cells in each CD4 subset. C. The CD25" 
CD4+:CD25+ CD4+ T cell ratio among total and donor (Ly5.1+) cells. 
Data are mean ± s.e.m. obtained from 1 group of 4 mice. P values, 2- 
sample t test; *, P<0.05
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Although the distribution of B cell subsets defined by slgM and slgD expression in 
the splenic B220+ population varied between groups of mice (Figure 3.34A) it was 
evident that the ratio of lgM+lgD+:lgM'lgD+ B cells was much higher than in the 
CD44'/‘ donor cells into CD44+/+ host chimeras (Figure 3.25) This was not 
apparent in the LN of these chimeras where there was a similar B cell subset 
distribution (Figures 3.35A and 3.26A). The ratio of follicular to marginal zone B 
cells was higher in the CD44+/+ donor cells into CD44+/+ host chimeras than in the 
CD44_/‘ donor cells into the CD44+/+ host chimeras (Figures 3.36 and 3.27). Since 
there was very little host cell contamination in the B cell populations, these results 
are suggestive of a differential ability of the CD44+/+ versus CD44'/‘ progenitors to 
reconstitute these populations.
3.3.4.2. Phenotypic description of chimeras: CD44+/+ (Ly5.2+) -» CD44‘/_ 
(Ly5.1+).
CD44+/+ Ly5.2 mice were sacrificed and their bone marrow T cell depleted by 
antibody mediated complement cytotoxicity. T-depleted bone marrow cells were 
injected into irradiated host CD447’ mice (900 rads). Cells derived from the CD44_/' 
the host cells were identified in the reconstituted chimeras using an anti-Ly5.1 
(CD45.2) antibody, while donor-derived cells were detected with an anti-Ly5.2 
(CD45.1) antibody.
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Figure 3.34. Analysis of B cell subsets in spleens of CD44+/+ (Ly5.1) 
CD44+/+ (Ly5.2) chimeras.
A. Percentages of splenic B cell (CD19+) subsets defined by slgM and 
slgD expression. B. The percentage of Ly5.1 + cells in each B cell 
subset. Data are mean ± s.e.m.obtained from 2 groups of 4 mice.
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Figure 3.35. Analysis of B cell subsets in lymph nodes of 
CD44+/* (Ly5.1) -► CD44+/+ (Ly5.2) chimeras.
A. Percentages of lymph node B cell (CD19+) subsets defined 
by slgM and slgD expression. B. The percentage of Ly5.1 + 
cells in each B cell subset. Data are mean ± s.e.m. obtained 
from 2 groups of 4 mice.
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Figure 3.36. Analysis of follicular and marginal zone B cells in 
spleen of CD44+/+ (Ly5.1) —► CD44+/+ (Ly5.2) chimeras.
A. Percentages of splenic B cell (CD19+) subsets defined by surface 
expression of CD21 and CD23. B. The percentage of Ly5.1+ cells in 
each B cell subset. Data are mean ± s.e.m. obtained from 2 groups 
of 4 mice.
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As in the other chimeras, there was a significant proportion (15%) of T cells that 
represented radioresistant CD44'/' host cells. Of host B cells, conversely only very 
low numbers were found (Figures 3.37, 3.48). Of note, the proportion of CD8 + T 
cells derived from host radioresistant cells was significantly lower than that of the 
CD4+ T cells in both the LN and the spleen (Figure 3.39, 3.40). This is in direct 
contrast to the previous (CD44+/+ CD44+/+) chimeras (Figure 3.30) where host
radioresistant cells made up a higher percentage of total CD8 + T cells in the LN. In 
CD44+/+ -> CD44_/' chimeras, 19% of the CD4+ splenic T cells were host derived 
compared to 7% of the CD8 + splenic T cell population, and 15% of the CD4+ T cells 
in the LN were host derived compared to 5% of the CD8 +T cells in the LN. 
Consistent with the other chimeras, a greater percentage of CD4+ CD25+ than 
CD4+ CD25* T cells were host derived although this difference is not statistically 
significant (Figures 3.41, 3.42).
The distribution of B cell subsets defined by slgM and slgD expression in the 
splenic B220+ population was constant between mice (Figure 3.43A, 3.44A) with a 
similar proportion of radioresistant host CD44'7' B cells (approximately 1.5) (Figure 
3.43B). However, there did appear to be a slightly higher proportion of host slgM' 
slgD' B cells in the LN.
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Figure 3.37. Analysis of B versus T cells in the spleen of CD44 
(Ly5.2)—> CD44'7' (Ly5.1) chimeras.
+/+
A. Percentages of T and B cells in the spleen. B. The percentage 
of host Ly5.1+ cells present in T and B cell splenic populations. C. 
B:T cell ratio among total and donor cells. Data are mean ± s.e.m. 
obtained from 1 group of 6 mice. P values, 2 sample t test; **, 
P<0.01
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Figure 3.38. Analysis of B vs. T cells in the lymph nodes of CD44 
(Ly5.2)—► CD44'7' (Ly5.1) chimeras.
+/+
A. Percentages of T and B cells in the lymph nodes. B. The 
percentage of donor Ly5.2+ cells present in T and B cell populations. C. 
B:T cell ratio among total and donor cells. Data are mean ± s.e.m. 
obtained from 1 group of 6 mice. P values, 2-sample t test; **, P<0.01
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Figure 3.40. Analysis of CD4 and CD8 T cells in lymph nodes of
CD44+/+ (Ly5.2) CD44^‘ (Ly5.1) chimeras.
A. Percentages of CD4+ and CD8+ CD3+ cells in lymph nodes. B. 
Percentage of donor Ly5.1' cells in each population. C. The CD4:CD8 
T cell ratio among total and donor (Ly5.T) cells. Data are mean ± s.e.m. 
obtained from 1 group of 6 mice. P values, 2-sample t test; **, P<0.01
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Figure 3.41. Analysis of CD4 subsets in spleens of CD44+/+ (Ly5.2) 
CD44'7' (Ly5.1) chimeras.
A. Percentages of CD25+ and CD25' CD4+ CD3+ cells in spleen. B. The 
percentage of Ly5.1+ (host) cells remaining in each CD4 subset. C. The 
CD25 CD4+:CD25+ CD4+ T cell ratio among total and donor (Ly5.T) 
cells. Data are mean ± s.e.m. obtained from 1 group of 2 mice.
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Figure 3.42. Analysis of CD4 subsets in lymph nodes of CD44+/+ (Ly5.2) 
—► CD44'7' (Ly5.1) chimeras.
A. Percentages of CD25+and CD25' CD4+ CD3+ cells in lymph nodes.
B. The percentage of Ly5.2+ (host) cells in each CD4 subset. C. The 
CD25 CD4+:CD25+CD4+ T cell ratio among total and donor (Ly5.T) cells. 
Data are mean ± s.e.m. obtained from 1 group of 2 mice.
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Figure 3.44. Analysis of B cell subsets in lymph nodes of CD44+/+ 
(Ly5.2) —> CD44V' (Ly5.1) chimeras.
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Like in the CD44+/+ -» CD44+/+ chimeras, but unlike the CD44‘/_ CD44+/+
chimeras, the proportion of lgM+lgD+ cells in the spleen exceeded that of IgM'IgD* 
cells. This result indicated that the ratio of these cell subsets was a property of the 
donor cells rather than the host. Likewise a high ratio of follicular to marginal zone 
B cells was observed (Figure 3.45), similar to the CD44+/+ donor cells into CD44+/+ 
host chimeras.
In summary, when chimeras were made to examine the level of radioresistant 
cells, there were virtually no radioresistant B cells present in these mice after 
reconstitution. In contrast radioresistant T cells were present in significant 
numbers. This is an important factor to take into consideration with regard to the 
previous observations in the mixed chimeras. Hence, host derived T cells 
complicate the interpretation of a deficient ability of the CD44‘/_ progenitors to 
produce T cells in these chimeras. Of note there were fewer radioresistant cells 
found in the LN of these mice, suggesting that the composition of lymph node cells 
present in these mice are more representative of donor derived cells, with less of 
an influence from host radioresistant cells.
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Figure 3.45. Analysis of follicular and marginal zone B cells in spleens 
of CD44+/+ (Ly5.2) — CD44'7' (Ly5.1) chimeras.
A. Percentages of splenic B cell (CD19+) subsets defined by CD21 and 
CD23 expression. B. The percentage of Ly5.1+ (host) cells in each B 
cell subset. Data are mean ± s.e.m. obtained from 1 group of 6 mice.
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3.3.5. CD229
Previous experiments have shown that to elucidate the role of CD44 in lymphocyte 
development, most especially in the role in T cell development, it is important be 
able to distinguish cells of host origin. Therefore another allotypic marker was 
employed: Ly9 or CD229, which is a member of the CD2 Ig superfamily. Initially, to 
assess distribution of this molecule, Ly9.1 expression was examined in two 
different murine strains, a Ly9.1 positive strain (129Sv) and a Ly9.1 negative strain 
(C57BI/6). (Note that CD44'7' mice are also Ly9.1+). Ly9.1+ expression was found 
on all mature CD3+ and CD19+ cells, all thymocytes, and B1 cells, as well as all 
B220+ cells found in the bone marrow (Figure 3.46). When Ly9.1 expression was 
compared to CD2 expression, co-expression was found on mature CD3+ and 
CD19+ cells. However, in contrast with Ly9.1 expression, CD2 was not expressed 
on all immature B or T cells found in the bone marrow and thymus (Figure 3.47). 
Overall, therefore, these results showed that Ly9.1 could serve as a useful allotypic 
marker to detect T and B cells at all stages of maturation.
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Figure 3.46. Ly9.1 expression in various cell types
A. Ly9.1 + expression in splenic CD3+ cells. B. Ly9.1 expression in splenic 
CD19+ cells. C. Ly9.1 expression in CD11b+ B220+ peritoneal B cells. D. 
Ly9.1 expression in total thymocytes. E. Ly9.1 expression in B220+ slgM' 
bone marrow cells. F. Ly9.1 expression in B220+ lgM+ bone marow cells. 
Data are representative of results from 2 mice. □  129 m ice,- B6 mice
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Figure 3.47. CD2 expression in various cell types.
A. CD2 expression in splenic CD3+ cells. B. CD2 expression in 
splenic CD19+ cells. C. CD2 vs. Ly9.1 expression in total
thymocytes. D. CD2 vs. Ly9.1 expression in double negative 
thymocytes. E. CD2 vs. Ly9.1 expression in B220+ bone marrow 
cells. F. CD2 vs. Ly9.1 expression in B220+ slgM ' bone marrow cells. 
Data are representative of results from 2 129 mice.
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3.3.6. Phenotypic description of mixed (1100 rad) chimeras: 
CD44+/+ (Ly9.1\ Ly5.2+) and CD44'A (Ly9.1+, Ly5.1+) ->  
CD44+/+ (Ly9 .r, Ly5.1+) hosts
Previous experiments have suggested a putative role for CD44 in B cell and T cell
development, and especially in the development of marginal zone B cells and
CD4+ and CD25+CD4+ T cells. However, interpretation of these experiments was
complicated due to the presence of radioresistant host T cells. This difficulty was
resolved in this experiment in two ways: A, by increasing the amount or irradiation
given to the host mice, B, by using Ly9.1 as another allotypic marker.
CD44+/+ (Ly9.1‘, Ly5.2+) and CD44'7' (Ly9.1+, Ly5.1+) mice were sacrificed and their
bone marrow T cell depleted by antibody mediated complement cytotoxicity. The
cells were mixed in a 1:1 ratio and injected into irradiated host CD44+/+ (Ly9.T,
Ly5.1+) mice. The host mice were given a split dose of 1100 rads, i.e. 2 X 550
rads, 5 hours apart. Once immune reconstitution had occurred, the mice were
sacrificed, and their phenotype was analysed by FACS. Cells derived from the
CD44*7’ progenitor cells were identified using an anti-Ly9.1 (CD229.1) antibody,
and cells derived from CD44+/+ donor bone marrow was identified using an anti-
Ly5.2 (CD45.1) antibody. B cells were identified using the anti-Ly9.1 antibody
alone, all other B cells were assumed to be CD44+/+ donor cells due to lack of
radioresistant B cells. Donor T cells were identified using the anti-Ly9.1 antibody
and the anti-Ly5.2 antibody. Occasionally, due to requirements for specific
fluorochrome-antibody combinations, an anti-Ly5.1+ antibody was used with an anti
Ly9.1+ antibody, in which case Ly5.1' lymphocytes were considered to be Ly5.2+
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CD44+/+ donor cells and Ly5.1+ Ly9.1+ cells were determined to be Ly5.1+ CD44_/' 
donor cells.
These mice had normal cell numbers in their spleens and LN (appendix 1), and 
normal percentages of total T and B cells, (Figures 3.48A, 3.49A). However when 
the T and B cells from these chimeras were analysed there was again a difference 
in the origin of these cells (Figures 3.48B, 3.49B). It appeared that CD44'7' 
progenitors still preferentially develop into B cells whereas the CD44+/+ cells 
develop more efficiently into T cells. Although the percentages of donor CD44*'' 
cells found in these chimeras were less than those found in our previous set of 
mixed chimeras, the basic findings were consistent with what was observed before. 
The B:T cell ratio among the CD44‘/‘ cells was calculated and compared to that of 
total and donor (Ly5.2+) CD44+/+ cells (Figures 3.48C, 3.49C). In the spleen there 
were 3.5 C D 4 4 '1' B cells to every CD44 /' T cell, compared to 2 B cells to every T 
cell among CD44+/+ cells (similar for total or donor CD44+/+ cells). In the LN there 
was a similar pattern, with 1.2 CD44 7' B cells per CD44'/_ T cell compared to 0.7 B 
cell to every T cell for CD44+/+ cells.
In the spleen and LN, again there was a significant difference in the ability of CD44' 
' ' progenitors to develop into either CD4+ or CD8+ T cells (Figures 3.50, 3.51).
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Figure 3.48. Analysis of T and B cells in CD44+/+ & CD44'7'—► CD44+/+ 
(1100 rads) chimeras.
A. Percentages of T and B cells in spleen. B. The percentage of 
Ly9.1+ cells in each splenic population. C. The B:T cell ratio among 
total and CD44'A and CD44+/+ donor populations. The data are mean 
± s.e.m. obtained from 2 groups of chimeras: 1 group of 2 and one 
group of 3. P values, 2-sample t te s t; *, P<0.05, **, P<0.01
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Figure 3.49. Analysis of T and B cells in lymph nodes of CD44+/+ & 
CD44'7'—► CD44+/+ (1100 rads) chimeras.
A. Percentages of T and B cells in lymph nodes. B. The percentage 
of Ly9.1+ cells in each population. C. The B:T cell ratio among total 
and CD44'/‘ and CD44+/+ donor populations. The data are mean ± 
s.e.m. obtained from 2 groups of chimeras: 1 group of 2 and one group 
of 3. P values, 2-sample t te s t; *, P<0.05, **, P<0.01
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Figure 3.50. Analysis of T cell subsets in spleens of CD44+/+ & CD44'7' 
—► CD44+/+ (1100rads) chimeras.
A. Percentages of CD4+ and CD8+ T cells in spleens. B. The 
percentage of Ly9.1+ cells in each donor T cell population. C. The B:T 
cell ratio among total and CD44_/' and CD44+/+ donor populations. The 
data are mean ± s.e.m. obtained from 3 groups of chimeras: 1 group of 
2 and 2 groups of 3. P values, 2-sample t test; ****, P<0.001
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Figure 3.51. Analysis of T cell subsets in lymph nodes of CD44+/+ & 
CD44'7'—» CD44+/+ (1100 rads) chimeras.
A. Percentages of CD4+ and CD8+ T cells in lymph nodes. B. The 
percentage of Ly9.1+ cells in each donor T cell population. C. The B:T 
cell ratio among total and C D 44/' and CD44+/+ donor populations. The 
data are mean ± s.e.m. obtained from 3 groups of chimeras: 2 group of 
2 and 1 group of 3. P values, 2-sample t test; **, P<0.01, ****, P<0.001
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The overall percentage of CD4+ and CD8+ T cells in the spleen and LN were 
comparable to the previous mixed chimeras (Figures 3.3A, 3.4A) and the bias of 
the CD44'7' progenitors towards developing into CD4+ T cells remained (Figures 
3.50B, 3.51 B). When the CD4:CD8 ratio in the spleen was calculated there were 
approximately 4 CD4+ T cells per CD8+ T cell in the CD44'7' T cell population 
compared to 2 CD4+ T cells per CD8+ T cell in the donor (Ly5.2+) CD44+/+ 
population (Figures 3.50C, 3.4C). The CD4:CD8 ratio in the LN showed that there 
were approximately 2 CD4+ T cells per CD8+ T cell in the CD44'7' T cell population 
compared to 1.3 CD4+ T cells per CD8+ T cell in the donor (Ly5.2+) CD44+/+ 
population (Figure 3.51 C). The bias previously found in the CD4+CD25+ T cell 
population in the mixed chimeras (Figure 3.5, 3.6), was again demonstrated in 
these 1100 chimeras (Figures 3.52, 3.53). There was again a significantly higher 
contribution from the CD44‘/_ cells in the CD3+ CD4+ CD25+ subset than in the 
CD3+ CD4+ CD25' subset (Figure 3.52B, 3.53B). This was most dramatic in the LN 
of these mice where 30% of the CD25+CD4+ T cells were derived from the CD44 7' 
progenitors compared to 10% of the CD25'CD4+ T cells. There was also a 
difference in these chimeras by their having an overall lower CD25"CD4+: 
CD25+CD4+ in the spleens compared to the pervious mixed chimeras, previously 
the overall ratio of CD25'CD4+: CD25+CD4+ T cells in the spleens was 8, but in 
these mixed chimeras it was down to 4 CD25CD4* T cells to every CD25+CD4+ T 
cell.
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Figure 3.52. Analysis of CD4 T cell subsets in spleens of CD44+/+ & 
CD44_/'—► CD44+/+ (1100 rads) chimeras.
A. Percentages of CD25+ and CD25' CD4+ T cells in spleens. B. The 
percentage of Ly9.1+ cells in each donor CD4+ T cell subset. C. The 
B:T cell ratio among total and CD44'7' and CD44+/+ donor populations. 
The data are mean ± s.e.m. obtained from 3 groups of chimeras: 1 
group of 2 and 2 groups of 3. P values, 2-sample t test; * * * \  P<0.001
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Figure 3.53. Analysis of CD4+ T cell subsets in lymph nodes of
CD44+/+ & CD44-''—> CD44” ’  (1100 rads) chimeras.+/+
A. Percentages of CD25+ and CD25' CD4+ T cells in lymph nodes. B. 
The percentage of Ly9.1+ cells in each donor CD4+ T cell population.
C. The B:T cell ratio among total and CD44'/_ and CD44+/+ donor 
populations. The data are mean ± s.e.m. obtained from 1 groups of 3 
chimeras. P values, 2-sample t test; ***, P<0.005,
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When the CD25'CD4+:CD25+ CD4+ T cell ratio in the spleen of the CD44'7’ 
population was calculated, there were 1.5 CD25CD4* T cells to every CD25+CD4+ 
T cell, compared to 4.5 CD25'CD4+ T cell per CD25+CD4+ T cell in the donor 
(Ly5.2+) CD44+/+ population (Figure 3.52C). This ratio was even lower in the LN, 
there were 0.8 CD25CD4+ T cells to every CD25+CD4+ T cell in the CD44_/* 
population, compared to 4 CD25CD4* T cell per CD25+CD4+ T cell in the donor 
(Ly5.2+) CD44+/+ population (Figure 3.53C).
The distribution of slgM+ and slgD+ in the B220+ splenic populations of the mixed 
1100 chimeras was not unusual (Figure 3.54A). When the composition of the 
individual B cell subsets was examined it was evident there was a similar 
proportion of CD44_/‘ B cells in each splenic subset (Figure 3.54B). The CD44+/+ 
and CD44'7' B cells of the spleen displayed similar slgD and slgM expression within 
their respective CD19+ populations (Figure 3.54C).
There was a significant difference in the contribution of CD44'/_ vs. CD44+/+ 
progenitors to the production of marginal zone B cells (CD21+CD23 B220+) (Figure 
3.55) which is consistent with what was observed in the 900 rads mixed chimeras. 
36% of the marginal zone B cells were CD44"7' derived compared to 20% of the 
follicular B cells (CD21+CD23+B220+) (Figure 3.55BA). This difference was also 
reflected in the distribution of marginal zone and follicular B cells within the CD44+/+ 
and CD44_/' B cell populations. 7.7% of the CD44+/+ B cell population were 
marginal zone B cells compared to 16% of the CD44_/' B cells (Figures 3.55C).
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Figure 3.54. Analysis of B cell subsets in spleens of CD44+/+ & CD44_/‘
CD44+/+ (1100 rads) chimeras.
A. Percentages of splenic B cell (CD19+) subsets defined by slgM and 
slgD expression. B. The percentage of Ly9.1+ cells in each B cell 
subset. Distribution of slgM and slgD staining among CD44'/_ or 
CD44+/+ CD19+ cells. Data are mean ± s.e.m. obtained from 1 group of 
2 and 2 groups of 3 mice.
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Figure 3.55. Analysis of follicular and marginal zone B cells in spleen
of CD44+/+ & CD44"/_—► CD44+/+ (1100 rads) chimeras+/+
A. Percentages of splenic B cell (CD19+) subsets defined by CD21 
and CD23. B. The percentage of Ly9.1+ (CD44'/_) donor cells in each 
B cell subset. D. Ratio of CD21+ CD23+: CD21+ CD23' cells among 
total, CD44'7* and CD44+/+ CD19+ cells. The data are mean ± s.e.m. 
obtained from 3 groups of chimeras: 1 group of 2 and 2 groups of 3. P 
values, 2-sample t test; ****, P<0.001
196
This is highlighted, when the ratio of marginal zone B cells (CD21+CD23'CD19+) 
and follicular B cells (CD21+CD23+CD19+) is calculated, (Figure 3.55D). Among 
CD447' B cells, there were 4 follicular B cells for every marginal zone B cell. In 
contrast, there were 10 follicular B cells for every marginal zone B cell among the 
CD44+/+ cells.
3.3.7. Phenotypic description of RAG chimeras: CD44+/+ (Ly9.1\ 
Ly5.2+) and CD44 7' (Ly9.1+, Ly5.1+) RAG2'' (CD44+/+, 
Ly9.1", Ly5.1+) hosts
Initial experiments in mixed chimeras suggested that there was a significant
propensity for CD44'/‘ progenitors to develop into B cells rather than T cells, CD4+
rather than CD8+ T cells, CD25+CD4+ T cells and marginal zone B cells. Since
some of this bias could have been exaggerated by the presence of contaminating
host T cells, chimeras were made with a higher dose of irradiation 1100 rads, as
opposed to 900 rads to try and eliminate the majority of the host T cells. In the
resultant high dose chimeras, the CD44'/' progenitors still showed a biased
tendency to produce B cells, CD4+ T cells, CD25+CD4+ T cells and marginal zone
B cells. However, although host cells were distinguished from donor cells in the
analysis, there were still radioresistant T cells present in the 1100 rads chimeras.
In addition, the use of higher doses of irradiation could cause damage to the
stromal cell layer in the bone marrow and thymus which is necessary for the
development of B and T cells. Therefore to eliminate all host T cells and the
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possibility that they could interfere with the seeding and development of the donor 
bone marrow, it was decided to create the chimeras in RAG'7' hosts. RAG'7' mice 
lack the enzyme RAG2 which is responsible for initiating double stranded DNA 
breaks, and therefore all T and B cell development is aborted. Hence, these 
chimeras will only have mature T and B cells, which have been derived from cells 
in the donor bone marrow.
Ly5.2+/+ and CD44'7' mice were sacrificed and their bone marrow T cell depleted by 
antibody mediated complement cytotoxicity. The cells were mixed in a 1:1 ratio 
and injected into irradiated host RAG'7' mice (400 rads). The host mice were given 
a lower dose of irradiation, for there are no mature lymphocytes to eliminate, and 
all is required is to provide ‘space’ in the bone marrow for the donor bone marrow 
to fill. The lower dose of irradiation causes less damage to the stromal cells. Once 
immune reconstitution had occurred the mice were sacrificed, and their phenotype 
was analysed by FACS. Cells derived from the CD44'7' progenitor cells were 
identified using an anti-Ly5.1 (CD45.2) antibody.
These mice had normal cell numbers in spleens and LN (appendix 1), and overall 
similar percentages of T and B cells (Figures 3.56A, 3.57A). When the T and B 
cells from the CD44'7' host chimeras were analysed there was a significant 
difference in the origin of the T and B cells (Figure 3.56B, 3.57B).
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Figure 3.56. Analysis of T and B cells in spleens of CD44+/+ (Ly9.1', 
Ly5.2+) & CD44 '" (Ly9.1+, Ly5.1+) ->  RAG-'" (CD44+/+, Ly9.1‘ , Ly5.1+) 
chimeras.
A. Percentages of T and B cells in spleen. B. The percentage of 
Ly5.1+ cells in each splenic population. C. The B:T cell ratio among 
total, CD44_/‘ and CD44+/+ donor populations. The data are mean ± 
s.e.m. obtained from 3 groups of chimeras: 1 group of 2 and 2 groups 
of 3. P values, 2-sample t test; ****, P<0.005
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Figure 3.57. Analysis of T and B cells in lymph nodes of CD44+/+ 
(L y9 .r, Ly5.2+) & CD44'A (Ly9 .1+, Ly5.1+) RAG'/_ (CD44+'+, Ly9.1‘ , 
Ly5.1+) chimeras.
A. Percentages of T and B cells in lymph nodes. B. The percentage 
of Ly9.1+ cells in each population. C. The B:T cell ratio among total, 
CD44"7' and CD44+/+ donor populations. The data are mean ± s.e.m. 
obtained from 3 groups of chim eras: 1 group of 2 and 2 groups of 3. P 
values, 2-sample tte s t; ***, P<0.005,
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In the spleen, 28% of T cells were CD44"7' derived compare to 54% of the B. This 
was also apparent in the LN of these chimeras to a lesser degree, where 29% of 
the T cells are CD44'7' derived compare to 42% of the B cells. The B vs. T cell bias 
in the spleen was also reflected in the B:T cell ratio, with the ratio of B:T cells 
among CD44'7' cells being 3.2, as opposed to 1.5 among total and CD44+/+ cells 
(Figure 3.56C). Similarly, significant differences in B:T cell ratio were observed in 
LN (Figure 3.57C).
Among T cell populations in the spleen and LN, there was a significant difference 
in the ability of the CD44'7' progenitors to develop into CD4+ versus CD8+ T cells, 
especially in the LN of these chimeras (Figure 3.59B). This is again highlighted 
when the CD4+:CD8+ T cell ratio is calculated. There were approximately 1.5 CD4+ 
T cells per CD8+ T cell in the CD44'7' population of the LN compared to 1 CD4+ T 
cells per CD8+ T cell in the CD44+/+ population (Figure 3.59C). In the spleens there 
were approximately 3 CD4+ T cells per CD8+ T cell in the CD44'7* population 
compared to 2.5 CD4+ T cells per CD8+ T cell in the CD44+/+ population (Figure 
3.58C). Of note, whilst the overall ratio of CD4:CD8 in the LN of the RAG"7' hosts 
was 1, in the CD44+/+ hosts it has been consistently approximately 1.5, the splenic 
CD4: CD8 ratio in the RAG'7' hosts is consistent with that in other mixed chimeras. 
The bias in the CD25+CD4+ T cell population found in the CD44+/+ host mice 
(Figures 3.52& 3.53, 3.5 & 3.6), was also observed in the RAG'7' host mixed 
chimeras (Figure 3.60, 3.61).
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Figure 3.58. Analysis of T cell subsets in spleens of CD44 (Ly9.1', 
Ly5.2+) & CD44'/_ (Ly9.1\ Ly5.1+) RAG'/_ (CD44+/+, Ly9.r, Ly5.1 *) 
chimeras.
A. Percentages o f CD4+ and CD8+ T cells in spleens. B. The 
percentage of Ly9.1+ cells in each donor T cell population. C. The B:T 
cell ratio among total, CD44'/_ and CD44+/+ donor populations. The 
data are mean ± s.e.m. obtained from 3 groups of chimeras: 1 group of 
2 and 2 group o f 3. P values, 2-sample t test; *, P<0.05
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Figure 3.59. Analysis of T cell subsets in lymph nodes of CD44+/+ 
(Ly9.1\ Ly5.2+) & CD44’7* (Ly9.1+, Ly5.1+) -> RAG'7’ (CD44+/+, Ly9.1\ 
Ly5.1+) chimeras.
A. Percentages of CD4+ and CD8+ T cells in lymph nodes. B. The 
percentage of Ly9.1+ cells in each donor T cell population. C. The B:T 
cell ratio among total, CD44"7* and CD44+/+ donor populations. The 
data are mean ± s.e.m. obtained from 3 groups of chimeras: 1 group of 
2 and 2 groups of 3. P values, 2-sample t test; ****, P<0.001
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Figure 3.60. Analysis of CD4 T cell subsets in spleens of CD44+/+ 
(Ly9.r, Ly5.2+) & CD44’'- (Ly9.1\ Ly5.1+) -> RAG'7* (CD44+/+, Ly9.r, 
Ly5.1+) chimeras.
A. Percentages of CD25+ and CD25' CD4+ T cells in spleens. B. The 
percentage of Ly9.1+ cells in each donor CD4+ T cell subset. C. The 
B:T cell ratio among total, CD44'/_ and CD44+/+ donor populations. The 
data are mean ± s.e.m. obtained from 3 groups of chimeras: 1 group of 
2 and 2 groups of 3. P values, 2-sample t test; ****, P<0.001
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Figure 3.61. Analysis of CD4+ T cell subsets in lymph nodes of 
CD44+/+ (Ly9.1\ Ly5.2+) & CD44'7' (Ly9.1+, Ly5.1+) -> RAG’7' (CD44+/+, 
Ly9.1", Ly5.1+) chimeras.
A. Percentages of CD25+ CD25' CD4+ T cells in lymph nodes. B. The 
percentage of Ly9.1+ cells in each donor CD4+ T cell population. C. 
The B:T cell ratio among total, CD44'/' and CD44+/+ donor populations. 
The data are mean ± s.e.m. obtained from 3 groups of chimeras: 1 
group of 2 and 2 groups of 3. P values, 2-sample t test; **, P<0.01, 
****, P0.001
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In the RAG*7' host mixed chimeras, there was again a significantly higher 
percentage of CD3+CD4+CD25+ in the CD4+CD44"7* T cell population than in the 
CD4+CD44+/+ T cell population (Figure 3.60B, 3.61 B). In the spleen, there were 2.7 
CD25'CD4+ T cells to every CD25+CD4+ T cell in the CD44*7' population, compared 
to 3.9 CD25*CD4+ T cell per CD25+CD4+ T cell in the CD44+/+ population (Figure 
3.60C). In the LN, there were 1.6 CD25*CD4+ T cells to every CD25+CD4+ T cell in 
the CD44*7* population, compared to 2.6 CD25'CD4+ T cell per CD25+CD4+ T cell in 
the CD44+/+ population (Figure 3.61 C).
The proportion of CD44'7* B cells within B cell sub populations defined by slgM and 
slgD expression was again constant in the RAG2"7* host mice mixed chimeras 
(Figure 3.62B). The CD44+/+ and CD44'7* B cells also displayed similar slgD and 
slgM distribution within their respective splenic CD19+ populations (Figure 3.62C). 
There was a significant difference in the percentage of marginal zone B cells vs. 
follicular B cells derived from CD44*7* progenitors (Figure 3.63). There was an 
increase in the percentage of CD44*7* cells present among the marginal zone B 
cells (CD19+CD21+CD23*) compared to the amount found in the follicular B cell 
population (CD19+CD21+CD23+) (Figure 3.63B). This observation is reinforced by 
a higher marginal zone frequency in the CD44*7* B cell population. Thus there were 
2.4 CD44*7* follicular B cell to every CD44*7* marginal zone B cell, compared to 5 
CD44+/+ follicular B cell to every CD44+/+ marginal zone B cell (Figure 3.63C).
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Figure 3.62. Analysis o f B cell subsets in spleens of C D 44+/+ (Ly9.1‘ , 
Ly5.2*) & C D 44'/_ (L y9 .1 \ Ly5.1*) R A G '' (CD44+/*, Ly9.1', Ly5 .1+) 
chimeras.
A. Percentages o f splenic B cell (CD19+) subsets defined by slgM  and 
slgD expression. B. The percentage of Ly9.1 +cells in each B cell 
subset. D istribution of slgM and slgD staining among C D 44 '/~ or 
C D 44+/+ C D 19+ cells. Data are mean ± s.e.m. obtained from 1 group o f 2 
and 2 groups of 3 mice.
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F igure  3.63. Analysis of follicular and marginal zone B cells in spleens 
of CD44+/+ (L y 9 .r, Ly5.2+) & CD44'/' (L y9 .1 \ Ly5.1+) RAG'/_ (CD44+/+, 
Ly9.1', Ly5.1+) chimeras.
A. Percentages of splenic B cell (CD19+) subsets defined by CD21 and 
CD23 expression. B. The percentage of Ly9.1+ (CD44'/_) donor cells in 
each B cell subset. C. Ratio of CD21+ CD23+: CD21+ CD23‘ cells 
among total, CD44';' and CD44+/+ CD19+ cells. The data are mean ± 
s.e.m. obtained from 3 groups of chimeras: 1 group of 2 and 2 groups of 
3. P values, 2-sample t test; ****, P<0.001.
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In our initial analysis of mixed chimeras, it was shown that the percentage of CD44' 
7‘ cells was lower among the B-1a (B220+, CD5+) cells than non B-1a (B220+, CD5') 
cells in the peritoneum (Figure 3.10). This was in contrast to marginal zone B 
cells, where a constantly higher frequency of marginal zone B cells to follicular 
zone B cells has been observed in the CD447' populations. In these RAG'7' host 
mixed chimeras, B1a and B1b cells were detected in both the spleen and the 
peritoneal cavity. Among these the CD44'7' cells again had a significantly lower 
frequency of B1a-B cells to B1b-B cells than CD44+/+ cells, but overall had similar 
had similar levels of B1 to B2 B cells in both the spleen and peritoneal cavity 
(Figure 3.64).
3.3.8. Phenotypic description of chimeras, reconstituted with 
different ratios of donor bone marrow: xCD44+/+ (Ly9.1\ 
Ly5.2+) and yCD44'/‘ (Ly9.1+, Ly5.1+) -> CD44+/+ (Ly9.1\ 
Ly5.1+) hosts.
Previous experiments have shown a putative role for CD44 in B cell and T cell 
development, and especially in the development of marginal zone B cells and 
CD4+ and CD4+ CD25+ T cells. Since we have shown that this biased lymphocyte 
development occurs in chimeras made with RAG'7' hosts, the phenomenon is not 
related to the presence of host T cells.
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Figure 3.64. Analysis of B1 and B2 cells in spleen and peritoneal 
cavity of CD44+/+ (Ly9.1', Ly5.2+) & CD44’7' (Ly9.1+, Ly5.1+) -> RAG'7' 
(CD44+/+, Ly9.1', Ly5.1+) chimeras.
A. Percentage of Ly5.1+ cells in each B cell (CD19+) subset of spleen.
B. Percentage of Ly5.1+ cells in each B cell (CD19+) subset of 
peritoneal cavity. Data are mean ± s.e.m. obtained from 1 group of 2 
mice. P values, 2-sample t test; **, P<0.01, ****, P<0.001.
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To determine whether biased development of CD44'/_ lymphocytes depends on the 
extent of competition between CD44'/' and CD44+/+ progenitors, we made a series 
of chimeras using different ratios of donor bone marrow.
CD44+/+ (Ly9.r, Ly5.2+) and CD44_/* (Ly9.1+, Ly5.1+) mice were sacrificed and their 
bone marrow T cell depleted by antibody mediated complement cytotoxicity. The 
CD44+/+ (Ly9.1’, Ly5.2+) and CD44V' (Ly9.1+, Ly5.1+) bone marrow cells were 
mixed in either a 1:3, 1:1, or 3:1 ratio and injected into irradiated (900 rads) host 
CD44+/+ (Ly9.1\ Ly5.1+) mice. Once immune reconstitution had occurred the mice 
were sacrificed, and their phenotype was analysed by FACS. Cells derived from 
the CD44'/* progenitor cells were identified using an anti-Ly9.1 (CD229.1) antibody, 
and cells derived from CD44+/+ donor bone marrow was identified using an anti- 
Ly5.2 (CD45.1) antibody. B cells were identified using the anti-Ly9.1 antibody 
alone due to the absence of radioresistant B cells. Donor T cells were identified 
using the anti-Ly9.1 antibody and the anti-Ly5.2 antibody or in some instances with 
an anti-Ly5.1+ antibody and an anti-Ly9.1+ antibody; in this case Ly5.1‘ 
lymphocytes were assumed to be Ly5.2+ CD44+/+ donor cells and Ly5.1+ Ly9.1 + 
cells were determined to be Ly5.1+ CD44‘A donor cells.
These mice had normal cell numbers in their spleens and LN, and consistent 
percentages of total T and B cells, (Figures 3.65A, 3.66A).
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Figure 3.65. Analysis of T and B cells in the spleens of xCD44+/+ & yCD44' 
> CD44+/+ chimeras.
A. Percentages of T and B cells in the spleens in the various chimeras. B. 
The percentage of Ly9.1+ cells in each splenic population per chimeric 
group. C. The B:T cell ratio among CD44'/_ and donor CD44+/+ 
populations. The data are mean ± s.e.m. obtained from 3 groups of 
chimeras: 1 group of 8, 25% CD44_/\  1 group of 4, 50% CD44_/', 1 group of 
6, 75% CD44'/_. P values, 2-sample t test; *, P<0.05, ***, P<0.005, ****, 
P<0.001.
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Figure 3.66. Analysis of T and B cells in the lymph nodes of xCD44+/+ & 
yCD44'/_—► CD44+/+ chimeras.
A. Percentages of T and B cells in the lymph nodes in the various 
chimeras. B. The percentage of Ly9.1+ cells in each splenic population 
per chimeric group. C. The B:T cell ratio among CD44'/_ and donor 
CD44+/+ populations. The data are mean ± s.e.m. obtained from 3 groups 
of chimeras: 1 group of 8, 25% CD44'7', 1 group of 4, 50% CD44'/\  1 group 
of 6, 75% CD44'/\  P values, 2-sample t test; *, P<0.05, **, P<0.01, ***, 
P<0.005, ****, P<0.001.
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The bias of CD44'/_ progenitors to develop into B cells was apparent in chimeras 
generated at each of the donor cell ratios. The percentage of CD44V‘ cells present 
in the T or B cell populations appeared to be directly proportional to the fraction of 
CD44'7* cells in the bone marrow inoculum (Figures 3.65B, 3.66B). The B:T cell 
ratio among the CD44+/+ cells was constant in all three types of chimeras, but the 
B:T ratio changed in the CD44'A cells, depending on the fraction of CD44‘/* cells in 
the donor bone marrow. When reconstituted with 25% CD44';' cells, the B:T ratio 
was 5, but when donor bone marrow was 75% CD44'A this ratio was 7. In the LN, 
the B:T cell ratio was again constant for the CD44+/+ population at different 
reconstitution ratios, while in the CD44'/_ cells the B:T cell ratio decreased directly 
proportional to the fraction of CD447' cells in the donor bone marrow (Figures 
3.65C, 3.66C).
In the spleen and LN the ability of CD44_/' progenitors to develop into either CD4+ 
or CD8+ T cells was investigated (Figures 3.67, 3.68). The overall percentages of 
CD4+ and CD8+ T cells in the spleen and LN of the different chimeras was constant 
(Figures 3.67A, 3.68A). The percentage of CD44_/' cells present in the T cell 
subsets increased in direct proportion with the fraction of CD44_/' cells in the donor 
bone marrow. A higher CD4:CD8 ratio among CD44 7' vs. CD44+/+ T cells was 
observed in all chimeras (Figures 3.67B, 3.68B), and this did not correlate with the 
ratio of CD44'A cells in donor marrow (Figures 3.67C, 3.68C). The bias previously 
found in the CD25+CD4+ T cell population in the mixed chimeras (Figure 3.5 & 3.6, 
3.52 & 5.53) was again demonstrated in spleens of these chimeras (Figure 3.69).
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3.67. Analysis of T cell subsets in the spleens of xCD44+/+ & 
> CD44+/+ chimeras.
A. Percentages of CD4+ and CD8+ T cells in the spleens of the various 
chimeras. B. The percentage of Ly9.1+ cells in each splenic donor T cell 
subset population per chimeric group. C. The CD4+:CD8+ T cell ratio 
among CD44'/_ and donor CD44+/+ populations. The data are mean ± 
s.e.m. obtained from 3 groups of chimeras: 1 group of 8, 25% CD44'7', 1 
group of 4, 50% CD44 /‘ , 1 group of 6, 75% CD44'7-.
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Figure 3.68. Analysis of T cell subsets in the lymph nodes of xCD44+/+ & 
yCD44'/'—> CD44+/+ chimeras.
A. Percentages of CD4+ and CD8+ T cells in the lymph nodes of the 
various chimeras. B. The percentage of Ly9.1+ cells in each donor T cell 
lymph node subset per chimeric group. C. The CD4+:CD8+ T cell ratio 
among CD447' and donor CD44+/+ populations. The data are mean ± 
s.e.m. obtained from 3 groups of chimeras: 1 group of 8, 25% CD44'A, 1 
group of 4, 50% CD44"7', 1 group of 6, 75% CD44_/\  P values, 2-sample t 
test; *, P<0.05, **, P<0.01, ***, P<0.005
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Figure 3.69. Analysis of CD4 T cell subsets in spleens of xCD44+/+ & 
yCD44"/ —> CD44+/+ chimeras.
A. Percentages of CD25+ and CD25' CD4+ T cells in spleens of the 
various chimeras. B. The percentage of Ly9.1+ cells in each donor 
CD4+ T cell subset per chimeric group. C. The CD25+:CD25‘ CD4+ T 
cell ratio among total, CD44'/_ and donor CD44+/+ populations. The 
data are mean ± s.e.m. obtained from 3 groups of chimeras: 1 group of 
8, 25% CD44_/', 1 group of 4, 50% CD44'A, 1 group of 6, 75% CD44 '-. 
P values, 2-sample t test; *, P<0.05, ****, P<0.001.
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There was a higher contribution from the CD44'7* cells in the CD3+CD4+CD25+ 
subset than in the CD3+CD4+CD25' subset which increased in direct proportion 
with the fraction of CD44'7' cells in the donor bone marrow (Figure 3.69B). The 
CD25‘CD4+:CD25+CD4+ T cell ratio was significantly higher for CD44+/+ than CD44' 
' ' cells at all ratio of reconstitution (Figure 3.69C).
The distribution of slgM+ and slgD+ in the CD19+ splenic populations of the various 
chimeras was similar (Figure 3.70A). When the composition of the individual B cell 
subsets was examined it was evident there was a similar proportion of CD44'7' B 
cells in each splenic subset (Figure 3.70B). The CD44+/+ and CD44_/* B cells of the 
spleen displayed similar slgD and slgM expression within their respective CD19+ 
populations (Figure 3.70C).
There was again a significantly higher frequency of marginal zone vs. follicular B 
cells derived from CD44'7* progenitors (Figure 3.71 B). An increased contribution of 
CD447' cells to all B cell subsets was observed with an increased fraction of CD44' 
' ' cells in the donor bone marrow (Figure 3.71 B). However the biased production of 
CD44"7' marginal zone B cells was observed at all ratios of reconstitution. The ratio 
of marginal zone B cells (CD21+CD23'CD19+) to follicular B cells 
(CD21+CD23+CD19+) among CD44+/+ cells decreased as the fraction of CD44'/_ 
cells in the reconstitution increased (Figure 3.71 C).
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Figure 3.70. Analysis of B cell subsets in spleens of xCD44+/+ & yCD44
CD44+/+ chimeras.
A. Percentages of splenic B cell (CD19+) subsets defined by slgM and 
slgD expression in the various chimeras. B. The percentage of Ly9.1 + 
cells in each B cell subset. C. Distribution of slgM and slgD staining 
among CD44';' or CD44+/+ CD19+ cells. The data are mean ± s.e.m. 
obtained from 3 groups of chimeras: 1 group of 8, 25% CD44'/', 1 group 
of 4, 50% CD44*7’, 1 group of 6, 75% CD44 '\
219
<1)o
CD
M—O<D
X )3  =»C W 0)Oi—<u
CL
90
80
70
60
50
40
30
20
10
0 __
□  25% CD44-/-
□  50% CD44-/-
□  75% CD44-/-
!
_L
CD21+ CD23+ CD21+ CD23- CD21- CD23-
****
CD <D
10
T -  tf)
s ?8 
^  8 "
° +co ^  6 
O  CVI Q
Q o ATOa: P ro
CM
Q g 2  O °
B
□  25% CD44-I- 
■  50% CD44-/-
□  75% CD44-/-
CD19 CD21+ CD23+ CD21+ CD23- CD21-CD23-
★***
□  Total
□  CD44+/+ 
■  CD44-/-
25% 50% 75%
Figure 3.71. Analysis of follicular and marginal zone B cells in spleen of 
xCD44+/+ & yCD44~/'—► CD44+/+ chimeras.
A. Percentages of splenic B cell (CD19+) subsets defined by CD21 and 
CD23 in the spleens of the various chimeras. B. The percentage of Ly9.1 + 
(CD44'7') donor cells in each B cell subset in the various chimeras. C. Ratio 
of CD21+ CD23+: CD21+ CD23' cells among total, CD44'7" and CD44+/+ 
CD19+ cells. The data are mean ± s.e.m. obtained from 3 groups of 
chimeras: 1 group of 8, 25% CD44'7', 1 group of 4, 50% C D 44'7', 1 group of 
6, 75% CD44'/_. P values, 2-sample t test; ***, P<0.005, ****, P<0.001.
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3.3.9. Phenotypic description of RAG host chimeras reconstituted 
with C D 44+/+ and CD44_/" haematopoietic stem cells (HSC): 
HSC CD44+/+ (L y9 .r, Ly5.2+) & HSC CD44''’ (Ly9.1 \ Ly5.1+) 
-► RAG'a (CD44+/+, Ly9 .r, Ly5.1+) hosts
To control for possible effects of different numbers of haematopoietic precursors in 
bone marrow preparations, chimeras were also generated by injecting bone 
marrow cells that had first been enriched for haematopoietic stem cells (HSC). 
CD44+/+ (Ly9.1't Ly5.2+) and CD44'7' (Ly9.1+, Ly5.1+) mice were sacrificed and their 
bone marrow was depleted of all lineage positive cells. The bone marrow was 
labelled with purified anti-CD3, anti-Thy1.1, anti Gr-1, anti-CDUb, anti-Ter119 and 
anti-B220 antibodies which were removed by the use of anti-mouse and anti-rat 
IgG and IgM dynal beads. The HSC CD44+/+ (Ly9.1', Ly5.2+) and HSC CD44'7' 
(Ly9.1+, Ly5.1+) bone marrow cells were mixed in a 1:1 ratio and injected into 
irradiated (400 rads) host RAG'7' (CD44+/+, Ly9.1\ Ly5.1+) mice. Once immune 
reconstitution had occurred the chimeras were sacrificed, and their phenotype was 
analysed by FACS. Cells derived from the CD44'7' progenitor cells were identified 
using an anti-Ly5.1 antibody.
These mice had normal cell numbers in their spleens and LN (appendix 1), and 
consistent percentages of total T and B cells, (Figures 3.72A, 3.73A).
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Figure 3.72. Analysis of T and B cells in spleens of HSC CD44+/+ 
(Ly9.1\ Ly5.2+) & HSC CD44'7' (Ly9.1+, Ly5.1+) -> RAG'7' (CD44+/+, 
Ly9.1', Ly5.1+) chimeras.
A. Percentages of T and B cells in spleen. B. The percentage of 
Ly5.1+ cells in each splenic population. C. The B:T cell ratio among 
CD44'7' and CD44+/+ donor populations. The data are mean ± s.e.m. 
obtained from 3 groups of chimeras: 1 group of 2 and 2 groups of 3. P 
values, 2-sample t test; *, P<0.05
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Figure 3.73. Analysis of T and B cell in lymph nodes of HSC CD44+/+ 
(Ly9.1\ Ly5.2+) & HSC CD44'7- (Ly9.1+, Ly5.1+) -> RAG'/_ (CD44+/\  
Ly9.1', Ly5.1+) chimeras.
A. Percentages of T and B cells in lymph nodes. B. The percentage of 
Ly9.1+ cells in each population. C. The B:T cell ratio among CD44_/‘ 
and CD44+/+ donor populations. The data are mean ± s.e.m. obtained 
from 3 groups of chimeras: 1 group of 2 and 2 groups of 3. P values, 2- 
sample t test; ***, P<0.005, ****, P<0.001.
There was a slight but significant bias of CD44‘A progenitors to develop into B cells, 
in both the spleen and in the LN (Figures 3.72, 3.73). This is reflected in the B:T 
ratio of CD44'/* compared to CD44+/+ cells, which indicates that the CD44'7* 
progenitors develop greater numbers of B cells than T cells, compared to the 
CD44+/+ progenitors. The B:T ratio is also greater in the LN of these mice. In the 
spleen there were 3.5 CD44'7' B cells to every CD44'7' T cell, but overall 2.5 B cells 
to every T cell in the spleen. In the LN there was a similar pattern, with 1 CD44'7' B 
cells per CD44*7* T cell versus an overall B:T ratio of 0.4.
In the spleen and LN, again there was a small but significant difference between 
CD44'7' and CD44+/+ progenitors in their ability to develop into either CD4+ or CD8+ 
T cells (Figures 3.74, 3.75). The overall percentages of CD4+ and CD8+ T cells in 
the spleen and nodes lymph were comparable to the previous mixed chimeras 
(Figures 3.3A & 3.4A, 3.50 &3.51). When the CD4:CD8 ratio in the spleen was 
calculated there were approximately 2.6 CD4+ T cells per CD8+ T cell in the CD44'7' 
T cell population compared to 2.4 CD4+ T cells per CD8+ T cell in the CD44+/+ 
population (Figures 3.74C). The CD4.CD8 ratio in the LN showed that there were 
approximately 1.3 CD4+ T cells per CD8+ T cell in the CD44'7' T cell population 
compared to 1 CD4+ T cells per CD8+ T cell in the CD44+/+ population (Figure 
3.75C). The bias previously found in the CD25+CD4+ T cell population in the mixed 
chimeras (Figures 3.5& 3.6, 3.52 & 3.53), was again demonstrated in these HSC 
reconstituted RAG chimeras (Figures 3.76, 3.77). There was a significantly higher 
contribution from the CD44'7' cells in the CD3+CD4+CD25+ subset than in the 
CD3+CD4+CD25* subset (Figure 3.76B, 3.77B).
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Figure 3.74. Analysis of T cell subsets in spleens of HSC CD44 
(L y9 .r, Ly5.2+) & HSC CD44*A (Ly9.1+, Ly5.1+) ^  RAG'a (CD44+/+ 
Ly9.1', Ly5.1+) chimeras.
A. Percentages o f CD4+ and CD8+ T cells in spleens. B. The 
percentage of Ly9.1+ cells in each donor T cell population. C. The 
CD4+:CD8+ cell ratio among CD44~A and CD44+/+ donor populations. 
The data are mean ± s.e.m. obtained from 3 groups of chimeras: 1 
group o f 2 and 2 group o f 3. P values, 2-sample t test; **, P<0.01
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Figure 3.75. Analysis of T cell subsets in lymph nodes HSC CD44+/+ 
(Ly9.1“, Ly5.2+) & HSC CD44‘/_ (Ly9.1+, Ly5.1+) -> RAG'/_ (CD44+/+, 
Ly9.1', Ly5.1+) chimeras.
A. Percentages o f CD4+ and CD8+ T cells in lymph nodes. B. The 
percentage of Ly9.1+ cells in each donor T cell population. C. The 
CD4+:CD8+ cell ratio among CD44'/_ and CD44+/+ donor populations. 
The data are mean ± s.e.m. obtained from 3 groups of chimeras: 1 
group o f 2 and 2 groups o f 3. P values, 2-sample t test; ****, P<0.001.
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Figure 3.76. Analysis of CD4 T cell subsets in spleens of HSC 
CD44*W (Ly9.1', Ly5.2+) & HSC CD44 '- (Ly9.1+, L y5 .r>  ->  RAG'7' 
(CD44+/+, Ly9.1", Ly5.1+) chimeras.
A. Percentages of CD25+ and CD25' CD4+ T cells in spleens. B. The 
percentage of Ly9.1+ cells in each donor CD4+ T cell subset. C. The 
CD4+CD25':CD4+CD25+ T cell ratio among CD44~/_ and CD44+/+ donor 
populations. The data are mean ± s.e.m. obtained from 3 groups of 
chimeras: 1 group of 2 and 2 groups of 3. P values, 2-sample t test; 
****, P<0.001.
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Figure 3.77. Analysis of CD4+ T cell subsets in lymph nodes of HSC
CD44+/+ (Ly9.r, Ly5.2+) & HSC CD44"7" (Ly9.1+, Ly5.1+) -> RAG"7'
(CD44+/\  Ly9.1", Ly5.1+) chimeras.
A. Percentages of CD25+ and CD25" CD4+ T cells in lymph nodes. B. 
The percentage of Ly9.1+ cells in each donor CD4+ T cell population.
C. The CD4+CD25":CD4+CD25+ T cell ratio among CD44"7" and 
CD44+/+ donor populations. The data are mean ± s.e.m. obtained from 
1 group of 2 chimeras. P values, 2-sample t test; *, P<0.05, **, P<0.01
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This was most dramatic in the LN of these mice where 40% of the CD25+CD4+ T 
cells were derived from the CD44_/' progenitors compared to 20% of the CD25' 
CD4+ T cells. When the CD25' CD4+:CD25+CD4+ T cell ratio in the spleen was 
calculated, there were 2.5 CD25'CD4+ T cells to every CD25+CD4+ T cell in the 
CD44_/' population, compared to 4.5 CD25'CD4+ T cell per CD25+CD4+ T cell in the 
CD44+/+ population (Figure 3.76C). This difference was even greater in the LN, 
where there were 2 CD25'CD4+ T cells to every CD25+CD4+ T cell in the CD44'A 
population, compared to 6 CD25'CD4+ T cell per CD25+CD4+ T cell in the CD44+/+ 
population (Figure 3.77C).
The distribution of slgM+ and slgD+ cells in the CD19+ splenic populations of the 
mixed chimeras was consistent with what has been observed previously (Figure 
3.78A). When the composition of the individual B cell subsets was examined it 
was evident there was a similar proportion of CD44'A B cells in each splenic 
subset, even though the overall percentage was lower (Figure 3.78B). The CD44+/+ 
and CD44'7' B cells of the spleen displayed similar slgD and slgM expression within 
their respective CD19+ populations (Figure 3.78C).
There was a significant difference in the percentage of marginal zone B cells vs. 
follicular B cells derived from CD44‘/_ progenitors (Figure 3.79). There was an 
increase in the percentage of CD44 7' cells present among the marginal zone B 
cells (CD19+CD21+CD23‘) compared to the amount found in the follicular B cell 
population (CD19+CD21+CD23+) (Figure 3.79B). This observation is reinforced by 
a higher marginal zone frequency in the CD44‘/_ B cell population.
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Figure 3.78. Analysis of B cell subsets in spleens of HSC 
CD44+/+ (Ly9.1\ Ly5.2+) & HSC CD44‘/" (Ly9.1+, Ly5.1+) -> RAG‘/_ 
(CD44+/\  Ly9.1\ Ly5.1+) chimeras.
A. Percentages of splenic B cell (CD19+) subsets defined by 
slgM and slgD expression. B. The percentage of Ly9.1+ cells in 
each B cell subset. C. Distribution of slgM and slgD staining 
among CD44'7' or CD44+/+ CD19+ cells. Data are mean ± s.e.m. 
obtained from 1 group of 2 and 2 groups of 3 mice.
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Figure 3.79. Analysis of follicular and marginal zone B cells in spleen 
of HSC CD44+/+ (Ly9.1", Ly5.2+) & HSC CD44'7’ (Ly9 .1 \ Ly5.1+) 
RAG'7' (CD44+/+, Ly9.1', Ly5.1+) chimeras.
A. Percentages of splenic B cell (CD19+) subsets defined by CD21 
and CD23. B. The percentage of Ly9.1+ (CD44'7') donor cells in each 
B cell subset. C. Ratio of CD21+ CD23+: CD21+ CD23' cells among 
total, CD44'7' and CD44+/+ CD19+ cells. The data are mean ± s.e.m. 
obtained from 3 groups of chimeras: 1 group of 2 and 2 groups of 3. P 
values, 2-sample t test; *, P<0.05
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Thus there were 4 CD44'7' follicular B cell to every CD44'/' marginal zone B cell, 
compared to 9 CD44+/+ follicular B cell to every CD44+/+ marginal zone B cell 
(Figure 3.79C). There appeared to be a difference in the contribution of CD44'/_ vs. 
CD44+/+ progenitors to the production of marginal zone B cells (CD21+CD23 B220+) 
where the B cell subsets had similar levels of contribution from the CD44/* 
progenitors (Figure 3.79).
Previously it was shown that the percentage of CD44'7' cells was lower among the 
B-1a (B220+, CD5+) cells than non B-1a (B220+, CD5') cells in the peritoneum 
(Figures 3.10, 3.80). This is in contrast to marginal zone B cells, where a 
constantly higher frequency of marginal zone B cells to follicular zone B cells has 
been observed in the CD44'7' populations. These HSC only RAG^' host mixed 
chimeras, did have B1a and B1b cells in both the spleen and the peritoneal cavity. 
The CD44';' progenitors again produced a lower frequency of B1a-B cells to B1b-B 
cells, which was significantly lower in the peritoneal cavity, but overall had similar 
had similar levels of B1 to B2 B cells in both the spleen and peritoneal cavity 
(Figure 3.80).
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Figure 3.80. Analysis of B1 and B2 cells in spleen and peritoneal 
cavity of HSC CD44+/+ (Ly9.1", Ly5.2+) & HSC CD447* (Ly9.1 \ Ly5.1+) 
RAG7* (CD44+/+, Ly9.1*, Ly5.1+) chimeras.
A. Percentage of Ly5.1+ cells in each B cell (CD19+) subset of 
spleen. B. Percentage of Ly5.1+ cells in each B cell (CD19+) subset 
of peritoneal cavity. Data are mean ± s.e.m. obtained from 2 groups of 
3 mice. P values, 2-sample t test; * * * \  P<0.001.
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3.3.10. Phenotypic description of littermate (LM) chimeras: LM 
CD44+ (Ly9.1+, Ly5.1+) & LM CD44’'' (Ly9.1‘, Ly5.1+) Or LM 
CD44+ (Ly9.1‘, Ly5.1+) ->  CD44+/+ (CD44+/+, Ly9.1‘, Ly5.2+) 
hosts.
Experiments so far have shown that there is a bias for CD44'/_ cells developing into 
B cells rather than T cells, and for producing a higher frequency of CD4+ cells, 
CD25+CD4+ cells and marginal zone B cells, and a lower frequency of CD5+ B1 B 
cells. This has been observed using a number of different approaches in the 
generation of radiation bone marrow chimeras. One possibility that has not been 
investigated is that differences in background genes, rather than CD44, accounted 
for the differential production of lymphocytes by different donor populations. This 
was a concern because the CD44'/_ mice are on a mixed background (129Sv X 
C57BI/6). Therefore it was decided to backcross these mice to C57BI/6 mice, and 
use the CD44+ and CD44’ offspring (littermates) to generate mixed bone marrow 
chimeras.
Female CD44'A mice were crossed with a male C57BI/6 mouse, the resulting
offspring were then mated. The offspring of this cross were screened by tail
bleeding, for Ly9.1 and CD44 expression. The correct combination of littermate
(LM) mice were then sacrificed (LM CD44+, Ly9.1+), (LM CD44';‘, Ly9.1') & (LM
CD44+, Ly9.1‘) their bone marrow T cell depleted by antibody mediated
complement cytotoxicity. The LM CD44+ (Ly9.1+) and LM CD44'/_ (Ly9.T) or as a
control the LM CD44+ (Ly9.1+) and LM CD44+ (Ly9.T) bone marrow cells were
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mixed in a 1:1 ratio and injected into irradiated (900 rads) host CD44+/+ (Ly9.1\ 
Ly5.2+) mice. Once immune reconstitution had occurred the mice were sacrificed, 
and their phenotype was analysed by FACS. Cells derived from the donor 
progenitor cells were identified using an anti-Ly9.1 (CD229.1) antibody in 
conjunction with an anti-Ly5.1 antibody. B cells were identified using the anti-Ly9.1 
antibody alone due to lack of radioresistant B cells. Donor T cells were identified 
using the anti-Ly9.1 antibody and anti-Ly5.1 of anti-Ly5.2 antibodies.
These chimeric mice had normal cell numbers in their spleens and LN (appendix 
1), and consistent percentages of total T and B cells (Figures 3.81 A & B, 3.82 A & 
B). The bias of CD44_/' progenitors to develop into B cells rather than T cells in 
chimeras generated with mixed CD44+Ly9.1+ and CD44_/'Ly9.T bone marrow cells 
was again significant in both the spleen and LN (Figures 3.81 C & E and 3.82C &
E). Notably, however differential production of T and B cells by the two donor 
populations was also observed in the control chimeras. Thus, although both donor 
populations were CD44+, the Ly9.1+ cells produced a higher proportion of B cells 
than the Ly9.T cells (Figures 3.81 D and 3.82D).
In the spleen of experimental chimeras, there was a significant difference in the 
ability of CD44 7' progenitors to develop into CD4+ rather than CD8+ T cells with a 
higher CD4:CD8 ratio for the CD44' than CD44+ cells as observed before (Figures 
3.83C & E). This was also seen in LN (Figure 3.84E), while significant differences 
in CD4.CD8 ratio between Ly9.1+ and Ly9.T cells was not observed in the control 
chimeras (Figures 3.83F & 3.84 F)
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and Ly9.T cells in each splenic population. E, F. The B:T cell ratio among total, 
and donor Ly9.1‘ and Ly9.1+ populations. A, C, E, are LM CD44+ & LM CD44'7' 
-> CD44+/+ hosts, and B, D, F, are LM CD44+ & LM CD44+ -> CD44+/+ hosts. 
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Ly5.1+) & LM CD44'7' (L y9 .r, Ly5.1+) / Or LM CD44+ (Ly9.1+, Ly5.1+) & LM 
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populations. A, C, D, are LM CD44+ & LM CD447' -> CD44+/+ hosts, and B, 
D, F, are LM CD44+ & LM CD44+ -> CD44+/+ hosts. The data are mean ± 
s.e.m. obtained from 2 groups of chimeras: 1 group of 8 and 1 group of 9. P 
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Ly5.1+) & LM CD44*'- (Ly9.r, Ly5.1+) / Or LM CD44+ (Ly9.1\ Ly5.1+) & LM CD44+ 
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CD44+ —> CD44+/+ hosts. The data are mean ± s.e.m. obtained from 2 groups of 
chimeras: 1 group of 8 and 1 group of 9. P values, 2-sample t test; *, P<0.05, ***, 
P<0.001.
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The bias previously found in the CD25+CD4+ T cell population in mixed chimeras 
(Figure 3.5, 3.6), was again demonstrated in these LM chimeras (Figures 3.85, 
3.86). There was a significantly higher contribution from the CD44'7' Ly9.1'cells to 
the CD3+CD4+CD25+ subset than in the CD3+CD4+CD25' subset in the spleen and 
LN (Figure 3.85C, 3.86C).
This bias was not found in the spleen of the control chimeras (Figure 3.85D), but a 
slight bias was demonstrated in the LN. When the CD25'CD4+: CD25+CD4+ T cell 
ratio in the spleen of the CD44'7' population was calculated, there was no 
significant differences in either the spleen or LN (Figure 3.85E & 3.86E). There 
was however a significant difference in the ratio in the control chimeras, both in the 
spleen and in the LN where there was a significantly lower ratio of CD4+CD25': 
CD4+CD25+ T cells in the CD44+Ly9.1', than the paired CD44+Ly9.1+ donor cells 
(Figure 3.85F & 3.86F).
The distribution of slgM+ and slgD+ in the CD19+ splenic populations of the mixed 
LM chimeras was unremarkable (Figure 3.87A & B). When the composition of the 
individual B cell subsets was examined it was evident there was a similar 
proportion of CD44'/_ and CD44+ B cells in each splenic subset (Figure 3.87C & D). 
The CD44+/+ and CD44"7' B cells of the spleen displayed similar slgD and slgM 
expression within their respective CD19+ populations (Figure 3.54E & F).
There was no significant differences in the contribution of CD44'7' vs. CD44+ 
progenitors or Ly9.1+ vs. Ly9.1' in the production of marginal zone B cells 
(CD21+CD23'B220+) (Figure 3.88C & D), or in the ratio of marginal zone B cells 
(CD21 +CD23'CD19+) and follicular B cells (CD21+CD23+CD19+), (Figure 3.88E &
F).
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Figure 3.85. Analysis of CD4 T cell subsets in spleens of LM CD44+ (Ly9.1\ 
Ly5.1+) & LM CD44';' (Ly9.1‘, Ly5.1+) / Or LM CD44+ (Ly9.1+, Ly5.1+) & LM CD444 
(Ly9.r, Ly5.1+) & -> CD44+/+ (CD44+/\  Ly9.1', Ly5.2+) chimeras.
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chimeras: 1 group of 8 and 1 group of 9. P values, 2-sample t test; **, P<0.01, ****, 
P<0.001.
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Figure 3.88. Analysis of follicular and marginal zone B cells in spleen of LM 
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3.4.Summary
The aim of this chapter was to compare the fitness of CD44+/+ vs. CD44'7' cells in a 
steady state. When initial chimeras were generated by injecting CD44+/+ and 
CD44'7' bone marrow cells into irradiated CD44+/+ recipients, it was discovered that 
there was a bias in the generation of CD44_/' T and B cells, in that there were over 
6 times more CD44'/_ B than T cells. It was unclear whether the low in T cell: B cell 
ratio was due to a decrease in the production of T cells or an increased production 
of B cells from CD447' progenitors. However, in the literature, it has been reported 
that CD44 is required for normal T cell development and, more specifically, that 
CD44 is required for pre-T cells to gain entry into the adult thymus. Therefore, it 
seems likely that deficient T cell production by CD44'7' progenitors may account for 
the high B:T cell ratio.
In these chimeras, it was also found that in the CD44‘/_ population there was 
increased generation of CD4+ rather than CD8+ T cells, CD25+CD4+ rather than 
CD25'CD4+ T cells, and an increased frequency of marginal zone B cells, as well 
as a decreased proportion of B1-a B cells. With regard to this latter finding, it 
should be noted that peritoneal B cells / B-1 cells are thought to be self-renewing 
cells derived from the foetal liver. Hence, it was surprising to find B1 cells derived 
from donor bone marrow present in the mixed chimeras. Until this phenomenon 
could be shown to be true and not an artefact, no further studies were carried out. 
When mixed bone marrow chimeras were similarly made in CD44_/' hosts, there 
was still a significant difference between the CD44+/+ progenitors and CD44*7' 
progenitors in their ability to develop into B vs. T cells, CD4+ vs. CD8+ T cells, 
CD25+CD4+ vs. CD25CD4+T cells, and marginal zone vs. follicular B cells. These
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findings indicated that the observed biases in lymphocyte generation were not 
dependent on CD44 expression in the host. This was of interest, since one target 
for CD44 binding is thought to be hyaluronic acid bound to CD44 on the surface of 
other cells.
To investigate the extent to which reduced production of CD44'/_ T cells in mixed 
chimeras simply reflected on an inability of CD44'7* progenitors to enter the thymus 
(as opposed to competition from CD44+/+ progenitors), chimeras were made by 
injecting CD44'/* bone marrow alone into irradiated CD44+/+ hosts. When this was 
done, only a slight deficiency in ability of the CD44'7' progenitors to develop into T 
cells in the CD44+/+ host thymus was observed; this was demonstrated by a 
number amount of total splenic CD3+ cells compared to CD44+/+-> CD44+/+ 
chimeras. This experiment suggested that CD44'/' progenitor T cells can enter the 
thymus and can reconstitute a wild type mouse, and that the major deficit in CD44'/_ 
T cells in the mixed chimeras, was related to direct competition between CD44'7* 
and CD44+/+ progenitors. It also became apparent that there was a significant 
proportion of radioresistant host T cells present after 900 rads irradiation. Since 
host T cells were not distinguishable from donor CD44+/+ cells in the initial mixed 
chimeras, their presence could have led to an overestimate of the deficiency of 
CD44‘a T cell generation.
Radioresistance was assessed in both CD44+/+ hosts and CD44'A hosts by 
reconstituting irradiated (900 rad) recipients with only CD44+/+ bone marrow, to 
minimise potential complications of CD44’7' progenitor deficiencies. There were a 
significant number of radioresistant T cells in the spleen and to a lesser extent in 
the LN in both strains. Slightly more CD8+ than CD4+ T cells persisted after 900rad
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irradiation. Therefore, some of the apparent biased contribution of CD44_/* cells to 
the CD4+ T cell population in the reconstituted mixed chimeras may have been due 
to the relative radioresistance of host CD8+ T cells. Conversely, CD25+CD4+ T cells 
appeared to be slightly more radioresistant than CD25'CD4+ T cells. This latter 
finding indicated that the greater contribution of CD44*7' cells to the CD25+CD4+ 
population was, if anything, underestimated in the mixed chimeras. Of note, the 
same differential radioresistance was not found in the CD44'7' host chimeras, 
where the CD4+ T cells were more radioresistant and there was no difference 
between the CD25+CD4+ and CD25'CD4+ populations. Overall there were less 
radioresistant cells found in the LN of these mice, and therefore the composition of 
cells present in the CD44-7' host chimeras were more representative of donor 
derived cells, with less of an influence from host radioresistant cells. Significant 
numbers of radioresistant B cells were not observed in any hosts given 900 rads 
irradiation.
Due to the presence of radioresistant T cells, another allotypic marker was required 
to fully distinguish donor and host cells. For this purpose, expression of Ly9.1 was 
investigated and found suitable; Ly9.1 was expressed on all lymphocytes being 
studied, and unlike CD2 was expressed at early stages of lymphocyte 
development.
Another approach to decreasing the possible contamination of radioresistant T 
cells on the results was to increase the amount of irradiation given. However, 
treating recipients with 1100 rads reduced but did not eliminate radioresistant T 
cells. Therefore, the allotypic markers Ly9.1, Ly5.1, Ly5.2 were used in 
combination to differentiate the three populations of T cells. The chimeras
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confirmed the previous results, namely that the CD44'7' cells were found 
preferentially among B cells vs. T cells, CD4+ vs. CD8+ T cells, CD25+CD4+ vs. 
CD25CD4* T cells and marginal zone vs. follicular B cells; these results were 
obtained on focusing specifically on donor-derived cells. As a note of caution for 
these experiments, 1100 rads is not an ideal amount of irradiation to routinely use, 
for the damage to the stromal layer increases with the amount of irradiation given. 
As the stromal layer of the thymus and bone marrow is essential in the 
development and differentiation of lymphocytes, minimal necessary doses of 
irradiation should be given.
Subsequently, mixed chimeras were generated in RAG'7' hosts. As these mice do 
not possess mature T and B cells, a lower amount of irradiation can be used which 
also reduces the damage to the stromal layer. In addition, using RAG'7' hosts 
eliminates any possible influence of mature T cells on the ability of donor marrow 
to reconstitute lymphocyte populations. The RAG'7' host chimeras confirmed the 
previous results, showing that the CD44'7' progenitors had an increased tendency 
to generate B2 B cells, CD4+ T cells, CD25+CD4+ T cells and marginal zone B 
cells. There was also a relative deficit in the production of CD44'7' B1a B cells of 
the peritoneal cavity and spleen as seen in the original chimeras. Since B cells 
present in RAG*7' host chimeras can only be derived from donor bone marrow this 
result implies that B1 B cell precursors are present in marrow as well as foetal liver. 
However an alternative explanation is that circulating B1 cells were present in the 
bone marrow preparations, these cells were capable of reconstituting the B1 
population in the host due to their self-renewing capabilities.
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To investigate further the nature of the competition between CD44_/' and CD44+/+ 
progenitors, reconstitution of lymphocytes was studied using different ratios of 
CD44+/+ and CD447' bone marrow cells in the reconstituting inoculum. The 
contribution of CD44'7' cells to all lymphocyte subsets increased as the fraction of 
these cells in the bone marrow inoculum increased, which is consistent with there 
being competition between progenitor cells for developmental niches. However, 
the biased production of lymphocyte sub-populations from CD44'7’ precursors was 
observed at all CD44_/':CD44+/+ starting ratios (From 1:3 to 3:1). This result implies 
a relatively high competitive advantage/disadvantage of CD44 expression in 
biasing production of these cells.
Among different chimeras, the percentage of CD44'7’ cells present in the mature T 
and B cells populations has been variable, even though the trends with respect to 
biased production of lymphocyte sub-populations have been consistent. One 
variable that could contribute to the differing levels of reconstitution is the number 
of haematopoietic stem cells (HSC) present in different bone marrow preparations. 
This was controlled for by generating chimeras in RAG'/_ hosts, by the injection of 
enriched HSC mixed bone marrow, that is bone marrow that has had the lineage 
positive cells removed. Significantly, the resulting chimeras still had all the bias 
found previously in the mixed chimeras (|B cells, |CD4+ T cells, |CD25+CD4+ T 
cells, fmarginal zone B cells, and J,B1a B cells). Interestingly, despite injecting 
putative HSC at a 1:1 ratio of CD44'7' and CD44+/+ cells, the overall reconstitution 
with CD44'7' cells was relatively low (e.g. 35% of B cells were CD44'/_). This could 
mean that CD44'7' HSC are relatively poor at reconstituting lymphocytes, or that
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more contaminating non-HSC are found in this phenotypic population in CD44_/' 
bone marrow.
To control for the possible differences in background genes between CD44 /‘ and 
CD44+/+ mice that could contribute to the biased production of T and B cells 
observed in mixed chimeras, additional chimeras were made using F2 offspring of 
matings between CD44+/+ (C57BI/6) and CD44 7' mice (littermates, LM) as a source 
of bone marrow; this was necessary because the CD44'/_ mice were not fully 
backcrossed onto a C57BI/6 background and still have some 129Sv 
characteristics, such as Ly9.1+ expression remaining. Mixed chimeras generated 
using CD44+ and CD44'/' LM bone marrow yielded, for the most part, results that 
were consistent with those obtained in other chimeras. Thus, in general CD44'/_ 
cells were biased in the production of B cells vs. T cells, CD4+ vs. CD8+ T cells, 
CD25+CD4+ vs. CD25'CD4+ T cells and marginal zone vs. follicular B cells (note 
that B1a B cells were not examined in these chimeras). However, these results 
were confounded by the observation that balanced production of T and B cell 
subsets did not occur in the control mixed LM chimeras. In these mice, generated 
by injecting Ly9.1+CD44+ and Ly9.1'CD44+ bone marrow into irradiated CD44+/+ 
(Ly5.2+) mice, uneven reconstitution of subsets was seen, although this did not 
resemble the pattern observed in CD44'/_ and CD44+ -» CD44+/+ mixed LM 
chimeras. For example, Ly9.1+ cells appeared to preferentially generate B cells 
over T cells and follicular B cells over marginal zone B cells, while showing no bias 
in CD4+ vs. CD8+ T cells and a bias with regard to CD25+CD4+ T cells, depending 
on whether spleen or LN were examined.
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The results in these control chimeras could indicate that either multiple genes are 
controlling the biased production of the different lymphocyte subsets, and that 
these segregate differentially in the F2 offspring. However if it were the case, one 
would have expected a more variable result in the CD44'7* and CD44+ mixed 
littermate chimeras.
Therefore in conclusion, while the variability in the control littermate chimeras is of 
potential concern, the overall consistency in the results generated in a variety of 
mixed chimeras supports the idea that CD44 plays an important role in biasing 
lymphocyte development.
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4. Chapter 4: Homing and altered adhesion profiles of 
CD44'/_ lymphocytes when placed in direct 
competition with CD44+/+ lymphocytes.
4.1. Introduction.
The main function for CD44 is as a cellular homing and adhesion receptor involved 
in lymphocyte migration and stem cell homing. As well as hyaluronate CD44 can 
also bind other extracellular matrix components, such as chondriton sulphate, 
heparin sulphate, fibrinogen, serglycin, and osteopontin; binding these ligands can 
also facilitate cell motility and adhesion. CD44 is thought to be involved in the 
homing and migration of lymphocytes by tethering the cells to the vessel wall via 
hyaluronate, and/or other extracellular matrix proteins. This adhesion supports the 
initiation of lymphocyte rolling and allows the selectin and integrin attachments to 
proceed (229-233). The attachment of lymphocytes to the endothelial walls allows 
the extravasation into the target organs and inflamed tissues. This process is 
facilitated by the cytoplasmic domain of CD44, which is present in lipid rafts on the 
cell surface lead to changes in cellular morphology via the interaction of CD44 via 
the cytoskeleton thus aiding extravasation. (123, 162, 195, 234-236). A more 
comprehensive review of the function of CD44 and its ligands can be found in 
Section 1.3.
CD44 has also been shown to have a role in stem cell homing and in the seeding 
of progenitors to the bone marrow and thymus (221, 224, 225, 237, 238) This has 
also been described previously in section 1.3 and briefly in Section 3.1.
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In the previous chapter it was observed that when CD44'7' progenitors were placed 
in direct competition with CD44+/+ progenitors, a bias in the production of T and B 
cells and some of their subsets was apparent. The CD44'7' cells were found 
preferentially amongst B cells vs. T cells, CD4+ vs. CD8+ T cells, CD25+CD4+ vs. 
CD25'CD4+ T cells and marginal zone vs. follicular B cell populations, there was 
also a deficit in the B1a B cells population of CD44'7' cells. The unequal production 
of CD44'7' and CD44+/+ populations was found in numerous chimeras, when using 
CD44+/+ and CD44'7' progenitors at different ratios (Sections 3.3.1, 3.3.3 & 3.3.8), 
and the biases observed were independent of the host environment, as they were 
observed when either CD44-7' or CD44+/+ mice were used as hosts (Section 3.3.2). 
Experimental evidence has shown that CD44+/+ is necessary for homing to both the 
bone marrow and thymus. It has also been demonstrated that CD44hl cells home 
better to the bone marrow than CD44l0 cells when in competition for bone marrow 
seeding (239). Although this was demonstrated using CD8+ T cells, this and 
previous reports raises the possibility that there may be a deficiency in the 
capability of the CD44'7" bone marrow to seed the thymus and/or when inoculated 
in conjunction with CD44+/+ bone marrow. In  v itro  experiments have demonstrated 
that HSC bind rapidly to the bone marrow stroma (240) As the extracellular matrix 
within the bone marrow has a high proportion of the CD44 ligands hyaluronate and 
fibrinogen, which have been secreted by the stromal cell layer, CD44'7' and 
CD44+/+ progenitors might differ in their efficiency to seed the bone marrow. CD44 
is not the only protein that can bind hyaluronate. For example, RHAMM also binds 
hyaluronate. However, it does so with five times less affinity then CD44, would 
make such ‘backup’ strategies much less efficient. Moreover, in one study it was
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demonstrated that leukocytes from CD44'7' mice could not bind to immobilised 
hyaluronate (241).
In adult mice, CD44‘/_ lymphocytes traffic normally under non-inflammatory 
conditions, and have a normal distribution within lymphoid organs (241). This fits 
with previous data showing that CD44 is not required for lymphocyte entry to 
splenic white pulp (242). As reported in the previous chapter, we found CD44+/+ 
lymphocytes present in all lymphoid organs examined. In contrast CD44 may play 
a role in the trafficking of Langerhans cells. In CD44'/_ mice, the cells were shown 
to emigrate from the epidermis but failed to reach the lymph nodes in response to 
an inflammatory stimulus (243).
4.2.Aim.
The aim of this chapter is to investigate two possibilities that could account for the 
unequal proportion of CD44'7' and CD44+/+ cells observed among lymphocyte 
populations. We will determine: (1) whether there is a biased lymphocyte 
production linked to a poor ability of CD44'7' progenitors to efficiently enter and 
seed either the bone marrow or thymus, (2) whether the CD44'7' lymphocyte have 
altered homing abilities compared to those of CD44+/+ lymphocytes when placed in 
competition.
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4.3. Results
4.3.1. Homing of BM cells to the bone marrow 
Although previous studies have suggested a requirement for CD44 in the homing 
of cells to the bone marrow, the results in the previous chapter did not indicate any 
deficiency in the ability of the CD44'7' cells to generate B cells in mixed bone 
marrow chimeras. On the other hand, reduced homing of progenitors to the 
thymus might have contributed to the lower production of CD44'7' T cells. To 
compare directly the ability of the CD44+/+ and CD44‘/* progenitor cells to home to 
the bone marrow and thymus, lineage depleted bone marrow cells were obtained 
from CD44+/+ and CD44'7' mice using a cocktail of antibodies against cell lineage 
specific molecules and dynal beads to remove all cells bound to antibody. CD44+/+ 
cells or CD44'7' cells were CFSE labelled and mixed with unlabelled CD44'7' or 
CD44+/+ cells respectively and inoculated into irradiated (450 rad) CD44+/+ hosts. 
The same number of labelled CD44+/+ or CD447' bone marrow cells was also 
injected alone into CD44+/+ recipients to analyse homing in the absence of 
competition from the other cell type.
Mice were sacrificed 12, 24, 48 hours after inoculation, and their bone marrow and 
thymus removed. Blood lymphocytes were also collected at 12 hours post 
inoculation. A sample of cells was analysed by FACS to measure the amount of 
CFSE labelled cells present in the tissue.
CFSE labelled cells were not detected in the thymus at any time points, but were 
found in the bone marrow of all mice. There was no significant difference in the 
percentage of CD44+/+ and CD44'7' bone marrow cells recovered, whether they 
were injected individually or in conjunction with each other (Figure 4.1A).
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There was a difference however, in the percentages of CFSE positive cells isolated 
from the blood of the mice sacrificed 12hr-post inoculation (Figure 4.1B). There 
were significantly more CD44+/+ cells in the blood than CD44'7' cells when injected 
individually, but there were significantly more CD44'7' than CD44+/+ cells in the 
blood when injected in conjunction with each other. Predictably there were more 
CD44+/+ cells recovered when injected alone than with CD44‘/* cells, as there were 
twice as many CD44+/+ cells injected initially. However, this was not observed with 
the CD44*/' cells, where more CD44'/_ cells were found in the blood of mice co­
injected with unlabelled CD44+/+ cells than those inoculated solely with CD44'7' 
cells.
CFSE also has the advantage that the MFI decreases with cell division. Therefore, 
it is possible to evaluate whether the cells injected have divided in the mouse 
(Figure 4.1 C). It was only possible to compare CD44+/+ and CD44_/" cells 
individually, due to a difference in the initial CFSE staining intensity. There was 
significant lower CFSE intensity in both the CD44+/+ and CD44'7' cells when 
injected alone compared to that when cells were mixed with unlabelled cells of the 
recipient phenotype, at both 12 and 24 hours post injection. This difference was 
not observed 48hrs post-injection.
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Figure 4.1. Analysis of CD44+/+ and CD44'/' progenitor homing after 
i.v. injection.
A. Recovery of CFSE labelled cells in the bone marrow expressed as 
a percentage of cells initially injected. B. Percentage of CFSE 
positive cells found in the blood 12h-post injection. C. MFI of CFSE 
intensity of recovered bone marrow cells at various time points after 
inoculation. The data are mean ± s.e.m from groups of 3. P values, 
2-sample t test; *, P<0.05, **, P<0.01, ***, P<0.005, ****, P 0 .0 0 1 . # 
indicates CFSE labelled cells. MFI, mean fluorescence intensity.
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4.3.2. Intra-thymic injections
In the previous experiment, the number of CFSE-labelled cells in the thymus was 
below the level of detection. Therefore, it was not possible to determine whether 
reduced homing of progenitors to the thymus contributed to the lower percentage 
of T cells derived from CD44A cells in mixed chimeras. As an alternative 
approach, we decided to examine T cell production when CD44+/+ and CD44'A cells 
were co-injected into the thymus. This experiment should reveal if the biased 
production of T cells is solely due to prior thymic homing, in which case the bias in 
T cells should disappear after intra-thymic injection.
Bone marrow cells were obtained from CD44+/+ (Ly5.2+, Ly9.T) and CD44'7' 
(Ly5.1+, Ly9.1+) mice, depleted of B cells and injected at a 1:1 ratio directly into 
each thymic lobe of sub-lethally (450) irradiated CD44+/+ (Ly5.1+ Ly9.T) mice. 
After 4 or 6 weeks the mice were sacrificed and their spleens analysed.
After 4 weeks there was significant difference in the overall T and B cell 
percentages. The mice injected with CD44+/+ bone marrow alone had a high 
percentage of B cells but few T cells. There were significantly fewer B cells in the 
mice co-injected with CD44+/+ and CD44'7’ cells, and in turn statistically fewer B 
cells in the mice injected with CD44 /_ cells than both the CD44+/+ and CD44_/" co- 
injected mice or the CD44+/+ mice. The percentage of T cells remained constant 
independent of reconstitution (Figure 4.2A).
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Figure 4.2. Analysis o f T and B cells 4 weeks after intrathym ic injection
of progenitor cells
A. Percent of total T and B cells in spleen. B. Percent o f donor 
CD44+/+ and donor CD44'7' cells in each splenic population from  co­
injection. C. Percent of donor CD44+/+ and donor CD44'7" cells in each 
splenic population from mice injected with either CD44+/+ or C D 44'/_ 
cells. D. The B:T cell ratio among total and CD44+/+ and C D 44'7' donor 
populations. The data are mean ± s.e.m from groups of 5. P values, 2- 
sam ple t test; *, P<0.05, ***, P<0.005, ****, P<0.001.
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In the co-injected mice there was no statistical difference in the percentage 
contribution of CD44+/+ or CD44'7' cells to the donor T cell population. The opposite 
was found in the B cell population, where approximately 15% of the B cells were 
CD44'a derived, and 85% of the donor B cells were CD44+/+ derived (Figure 4.2B). 
A similar phenotype was found in the mice which were injected with either CD44*7' 
or CD44+/+ bone marrow cells. In the mice injected with CD44'/' cells, 
approximately 20% of the total T cells were CD44'/' derived, this is statistically 
more than the mice which were injected with only CD44+/+ cells, where 15% of the 
T cells were donor derived. This again is reversed in the B cell population of the 
spleen, where 3% of the B cells are CD44'/_ derived, compared to 54% of the B 
cells being donor derived in the CD44+/+ only mice (Figure 4.2C).
These differences in T and B cell reconstitutional abilities were again more 
pronounced with the B/T cell ratios. In the co-injected mice there were 7 CD44'A B 
cells per T cell, compared to 40 CD44+/+ B cells per T cell. This phenomenon was 
more pronounced in the individually injected mice where there were 0.07 B cells 
per CD44*aT cell, and nearly 70 B cells per donor CD44+/+ T cell (Figure 4.2D). 
After 6 weeks, there was little variation between the total T and B cell populations 
in the various groups of mice (Figure 4.3A). However, the phenotype in the co- 
injected mice was very different from that observed at 4 weeks, and more similar to 
that of the original chimeras. Approximately 20% of the donor T cells were CD44'/' 
derived and 36% of the B cells were CD44’7' derived (Figure 4.3B).
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Figure 4.3. Analysis of T and B ceils 6 weeks after intrathymic injection of
progenitor cells
A. Percent o f total T and B cells in spleen. B. Percent of donor C D 44+/+ 
and donor CD44 ' cells in each splenic population from co-injection. C. 
Percent of donor CD44+/+ and donor CD44"7' cells in each splenic 
population from mice injected, with either CD44+/+ or CD44'7' cells. D. 
The B:T cell ratio among total, and CD44+/+ and CD44"7' donor 
populations. The data are mean ± s.e.m from groups of 5. P values, 2- 
sample t test; *, P<0.05.
In the mice which were injected individually with either CD44+/+ or CD44 /* cells, 
there was equal contribution of CD44_/' and CD44+/+ cells to the T cell population, 
but as at the earlier time points, there were fewer CD44'A than CD44+/+ B220+ cells, 
although this difference was not statistically significant (Figure 4.3C). The B:T cell 
ratio showed no statistical difference between donor CD44+/+ and CD44'/_ cells, 
whether they were injected together or individually (Figure 4.3D).
The CD4+ and CD8+ splenic T cells were investigated after 4 weeks. In both the 
co-injected and the CD44'’ only injected mice there was a high percentage of CD8+ 
T cells, whereas in the CD44+/+ only injected mice there was an excess of CD4+ T 
cells (Figure 4.4A). In the co-injected mice there was little difference between the 
donor CD44+/+ and CD44_/' cells in generating CD4+ T cells. However, more CD44' 
/_ than CD44+/+ cells CD8+ cells were generated (Figure 4.4B). In mice injected 
individually with CD44A and CD44+/+ cells, donor CD44+/+ cells made a greater 
contribution to CD4+ T cells, but comparable percentages of CD44‘/_ and CD44+/+ 
cells were found among CD8+ T cells (Figure 4.4C). The differences in T cell 
subset distribution in the co-injected mice showed that the CD44_/‘ cell ratio is 
significantly higher than the donor CD44+/+CD4+;CD8+ T cell ratio, there was no 
significant difference between the individually injected mice, or between the co- 
injected and individually injected mice (Figure 4.4D).
Among CD4+ T cells there was no difference in the total percent of CD25+CD4+ T 
cells and CD25CD4* T cells between the groups of mice (Figure 4.6A).
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Figure 4.4. Analysis of CD4+ and CD8+ T cells 4 weeks after 
intrathym ic injection of progenitor cells
A. Percent of total C D4+ and CD8+ T cells in the spleen. B. Percent of 
donor CD44+/+ and donor CD44'A cells in each splenic T cell population 
from mice co-injected with CD44+/+ and CD44'/_ cells. C. Percent of 
donor CD44+/+ and donor CD44~/~ cells in each splenic T cells subset 
from mice injected with either CD44+/+ or CD44'/_ cells. D. The 
CD4+:CD8+ T cell ratio among total, and CD44+/+ and C D 44'7' donor 
populations. The data are mean ± s.e.m from groups of 5. P values, 2- 
sample t test; **, P<0.01, ***, P<0.005, ****, P<0.001.
263
CDO+COOO
c<DOl_
CD
CL
90
80 \
70 I 
60 \
50
40
30
20
10
0 .
□  CD4+ 
■  CD8 +
CD44+/+ & CD44-/- CD44-/- CD44+/+
V) +=  co 
8 Qif o
o c  o
Cc — 
cd ~o
-  §  
0  n  CL *2
■  CD44-/- 
□  CD44+/+
50
2 v)
°  % u
****
■  CD44-/- 
□  CD44+/+
c S w 30 °  o ="O CD
~  .E °  20
CD T> 
p § 10
**
CD4+ CD8 +
Q =oy  o
h-Q p O cH- <U
W
TODC
14
12
10
8
6
4
2
0
CD8 +CD4+
□  Total
■  CD44-/-
□  CD44+/+
Co-injected CD44 -/- alone CD44+/+ alone
Figure 4.5. Analysis o f CD4+ and CD8+ T cells 6 weeks after
intrathym ic injection of progenitor cells
A. Percent of total CD4+ and CD8+ T cells in the spleen. B. Percent of 
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from mice co-injected with CD44+/+ and CD44'7' cells. C. Percent of 
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from mice injected with either CD44+/+ or C D 4 4 /' cells. D. The 
CD4+:CD8+ T cell ratio among total, and CD44+/+ and C D 44'/_ donor 
populations. The data are mean ± s.e.m from groups of 5. P values, 2- 
sample t test; **, P<0.01, ***, P<0.005, ****, P<0.001.
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F igure  4.6. Analysis of C D 25+ and CD25' CD4+ T cells 4 weeks after
intrathym ic injection of progenitor cells
A. Percent of total CD25+CD4+ and C D 25C D 4+ T cells in the spleen.
B. Percent of donor C D44+/+ and donor CD44'/_ cells in each splenic 
CD4+ T cell subset from mice co-injected with both CD44+/+ and CD44'/_ 
cells. C. Percent of donor CD44+/+ and donor CD44'7' cells in each 
splenic CD4+ T cell subset from mice injected with e ither C D 44+/+ or 
CD44’/' cells. D. The C D 25C D 4+:CD25+CD4+ T cell ratio among total, 
and CD44+/+and CD447' donor populations. The data are mean ± s.e.m 
from groups of 5. P values, 2-sample t test; *, P<0.05, ***, P<0.005.
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When the co-injected mice were analysed again there was no difference between 
the CD44_/' and donor CD44+/+ cells in their reconstitution of the two CD4+ subsets 
(Figure 4.6B). In the individually injected mice there was significantly fewer 
CD25+CD4+ and CD25'CD4+ CD44'* T cells than donor CD44+/+ T cells (Figure 
4.6C). The CD25CD4+:CD25+CD4+ T cell ratios in both the co-injected and 
individually injected were lower for CD44V' than CD44+/+ cells (Figure 4.6D).
When mice were analysed after 6 weeks, the composition of the T cell pool had 
changed. There were prominently more CD4+ T cells than CD8+ T cells in all of 
the groups of mice (Figure 4.5A). In the co-injected mice there were significantly 
more CD4+ and CD8+ donor CD44+/+ T cells than CD44'/_ cells (Figure 4.5B). In the 
individually injected mice, there were significantly more donor CD44+/+ CD4+ T cells 
than CD44'/ CD4+ T cells, but equal numbers of CD8+ donor CD44+/+ and CD44'/' T 
cells (Figure 4.5C). The CD4+:CD8+ T cell ratio was again significantly higher 
among the CD44_/‘ cells than the donor CD44+/+ in both the individually and co- 
injected mice (Figure 4.5D).
As at 4 weeks after reconstitution, there was no difference in the total percent of 
CD25+CD4+ T cells and CD25'CD4+ T cells between the groups of mice (Figure 
4.7A). In the co-injected mice, there were significantly fewer CD25+CD4+ and 
CD25CD4* CD44_/'T  cells than donor CD44+/+ T cells (Figure 4.7B). This was also 
the case in mice injected individually with CD44'/‘ vs. CD44+/+ cells, although 
differences were not statistically significant (Figure 4.7C). The CD25' 
CD4+:CD25+CD4+ T cell ratios, showed little difference between the CD44'A and 
donor CD44+/+ cells, whether they were injected individually or together (Figure 
4.7D).
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Figure 4.7. Analysis of CD25+ and CD25' CD4+ T cells 6 weeks after
intrathym ic injection of progenitor cells
A. Percent of total CD25+ and CD25‘ CD4+T cells in the spleen. B. 
Percent of donor CD44+/+ and donor CD44'/_ cells in each splenic C D 4+ 
T cell subset from mice co-injected with both CD44+/+ and CD44'/_ cells. 
C. Percent of donor CD44+/+ and donor CD44'/_ cells in each splenic 
CD4+ T cell subset from mice injected with either CD44+/+ or CD44"/_ 
cells. D. The CD25'CD4+:CD25+CD4+ T cell ratio among total, and 
C D 44+/+ and CD44"/_ donor populations. The data are mean ± s.e.m 
from groups of 5. P values, 2-sample t test; **, P<0.01.
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4.3.3. Distribution of CD44'7'cells between lymphoid organs and 
tissues when in competition with CD44+/+ cells.
Since CD44 has been suggested to participate in lymphocyte migration, it might be 
expected that CD44*7* and CD44+/+ lymphocytes would distribute differently 
between tissues when in direct competition. To determine if this is the case, the 
ratio of CD44+/+ to CD44'7' T cells and B cells was compared in different lymphoid 
and non-lymphoid tissues. This analysis should indicate any differences in the 
ability of the CD44‘/' cells to enter specific tissues when in competition with CD44+/+ 
cells. Lymphocyte distribution was examined in several different types of 
chimeras.
4.3.3.1. CD44+/+ (Ly5.2+) and CD44''" (Ly5.1+) donors -> CD44+/+ (Ly5.2+) 
chimeras.
Chimeras were generated as described in section 3.3.1. The total percentages of 
CD44+/+ and CD44*7' cells among CD3+ and CD19+ cells were compared to 
determine whether there was a difference in T and B cell distribution between the 
spleen and the LN. A significantly higher proportion of CD44_/' CD19+ cells was 
found in pooled LN than in the spleen of these chimeras. There also appeared to 
be more CD44+/+ CD3+ cells in the spleen than the LN of these chimeras, although 
this was not significant (Figure 4.8A & B). A lower proportion of CD44_/' B cells was 
observed in peyer’s patches compared to all other tissues examined.
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F igure  4.8. Analysis o f CD44+/+ vs. CD44 '" CD3+ and CD19+ cell 
ratios in spleen and lymph nodes of various chimeras.
A, B. Data obtained from 3 groups of 3 and a group o f 4 CD44+/+ 
(Ly5.2+) & CD44'/_ (Ly5.1+) ->  CD44+/+ (Ly5.2+) chimeras. C, D. Data 
obtained from 2 groups of 4 and a group of 3 CD44+/+ (Ly5.2+) & 
CD44'/_ (Ly5.1+) ->  CD44-/_ (Ly5.1+). E, F. Data obtained from 1 
groups of 3 and a group of 2 CD44+/+ (Ly5.1+ Ly9.1') & CD44"/_ (Ly5.1 + 
Ly9.1+) -> 1100rads CD44+/+ (Ly5.2+ Ly9.1). The data are mean ± 
s.e.m. P values, 2-sample t test; *, P<0.05, **, P<0.01.
The mesenteric LN also had a lower proportion of CD44'7* CD19+ B cells than the 
spleen, although these were not as statistically relevant compared to the Peyer’s 
patches and peritoneal cells (Figure 4.9B). The liver had a statistically higher 
proportion of CD44'/* T cells, than all other organs except the Peyer’s patches 
(Figure 4.9A). The peritoneal cavity had a higher proportion of CD44'/'T  cells than 
all other tissues examined. In addition a higher percentage of CD44'7' T cells was 
found in peripheral and mesenteric LN than in the spleen (Figure 4.9A).
4.3.3.2. CD44+/+ (Ly5.2+) and CD44'/' (Ly5.1+) donors -> CD44'7' (Ly5.1+) 
chimeras.
To determine whether CD44 expression by the host influenced the migration of 
CD44'/_ and CD44+/+ lymphocytes, chimeras were generated in CD44'7' recipients 
as described in section 3.3.2. In these chimeras, there was a significantly higher 
proportion of CD44_/' CD19+ cells in the LN than in the spleen, while there was a 
similar proportion of CD44+/+ CD3+ cells in the spleen and the LN (Figure 4.8C & 
D).
These results suggest that the difference in the ability of the CD44_/' B cells to enter 
the lymph node or spleen is independent of whether CD44 is expressed in the 
stromal environment, for example on the vascular walls.
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Figure 4.9. Analysis of CD44+/+ vs. CD44'/_ CD3+ and C D 19+ cell 
ratios in various tissues of CD44+/+ (Ly5.2+) & CD44‘/_ (Ly5.1+) -»  
CD44+/+ (Ly5.2+) chimeras.
A. Ratio of percentage CD3+CD44+/+:CD3+CD44'/'  in various tissues.
B. Ratio of percentage CD19+CD44~/':CD3+CD44+/+ in various tissues.
C. Table of P values of Figures B & C, CD3+ statistics are horizontal, 
CD19+ statistics are vertical. The data are mean ± s.e.m from  groups 
between 4 and 8. L.N., total lymph nodes. P.L.N. peripheral lymph 
nodes. M.L.N. mesenteric lymph nodes. P.C. peritoneal cavity, p.p. 
Peyer’s Patches. P values, 2-sample t test; *, P<0.05, **, P<0.01, ***, 
P<0.005, ****, P<0.001.
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4.3.3.3. CD44+/+ (Ly9.1', Ly5.2+) and CD44 '‘ (Ly9.1+, Ly5.1+) -> CD44+/*
(Ly9.1\ Ly5.1+) 1100 chimeras
To reduce the possible effects of radioresistant T cells on the distribution of donor 
cells chimeras were also generated using a higher dose of irradiation (1100 rads) 
as described in section 3.3.6. In addition, the Ly9 marker was used together with 
Ly5 to distinguish donor cells from any residual host T cells. In these mice there 
was a significantly higher proportion of CD44'A CD3+ cells in the spleen than in the 
LN, and a similar proportion of CD44+/+ CD19+ cells in the spleen and the LN 
(Figure 4.8E & F). A difference in the ratio of CD44'/':CD44+/+ T cells was observed 
in the liver and peritoneum when compared to the other tissues examined (spleen, 
LN, blood) (Figure 4.10). A greater proportion of T cells in the peritoneum were 
CD44‘A while the CD44_/:CD44+/+ ratio was significantly lower in the liver than all 
other tissues. A slightly higher CD44'A:CD44+/+ T cell ratio was found in blood and 
spleen than the LN. As Ly9.1 was used as an analytical marker, host T cells were 
no longer a source of contamination in the T cell ratios.
4.3.3.4. xCD44+/+ (Ly9.1', Ly5.2+) and yCD44'A (Ly9.1+, Ly5.1+) -» CD44+/+ 
(Ly9.1\ Ly5.1+) chimeras.
To determine whether the distribution of CD44_/‘ lymphocytes was influenced by 
their relative frequency compared to CD44+/+ cells, chimeras were generated using 
different ratios of CD44’A and CD44+/+ bone marrow as described in section 3.3.8. 
Ly9 and Ly5 antibodies were used to distinguish donor and recipient cells. In 
chimeras made at all ratios, a significantly higher proportion of CD44"A CD19+ cells 
was observed in the LN than the spleen.
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Figure 4.10. Analysis of CD44+/+ vs. CD44'/_ CD3+and C D 19+ cell 
ratios in various tissues of C D44+/+ (Ly5.2+) & CD44_/' (Ly9.1+) ->  
CD 44+/+ (Ly5.1+, Ly9.1') 1100 rads chimeras.
A. Ratio of percentage CD3+CD44+/+:CD3+CD44'/' in various tissues.
B. Ratio of percentage C D 19+CD44~/':CD3+CD44+/+ in various tissues.
C. Table of P values of Figures B & C, CD3+ statistics are horizontal, 
CD 19+ statistics are vertical. L.N., total lymph nodes. P.C. peritoneal 
cavity. P values, 2-sam ple t test; *, P<0.05, **, P<0.01. The data are 
mean ± s.e.m from 1 group of 3.
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This finding was consistent with the results in all previous mixed chimeras except 
the mice made with 1100 rads (Figures 4.11B, D & E & 4.8B & D). There was a 
similar proportion of CD44'/_ CD3+ cells in the spleen and the LN of all the chimeras 
except those reconstituted with the highest proportion of CD44'/_ bone marrow, 
where a higher proportion of CD44'7' T cells was present in the spleen than the LN 
(Figure 4.11).
4.3.3.5. CD44+/+ (Ly9.1\ Ly5.2+) and CD44'" (Ly9.1+, Ly5.1+) -> RAG2+
(CD44+,\  Ly9.1', Ly5.1+) chimeras
To eliminate any contribution of host T or B cells to the distribution of donor derived 
cells, chimeras were generated in RAG2‘/‘ hosts as described in section 3.3.7. The 
lower dose of radiation used in producing these chimeras (650 rads) potentially 
also induces less stromal cell and vascular damage.
In these mice there was a significantly higher proportion of CD44-/' CD3+ cells in 
the spleen than in the LN consistent with observations in some of the other 
chimeras. However, unlike in other chimeras proportion of CD44+/+CD19+ cells 
was found in the spleen and LN (Figure 4.12A & B).
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Figure 4. 11. Analysis of CD44+/+ vs. CD44'/_ CD3+ and CD19+ cell
ratios in various tissues of xCD44+/+ & yCD44"'"—► CD44+/+ chimeras..+/+
A & B, Data obtained from 1 group of 8 chimeras reconstituted with 
25% CD44v~bone marrow cells. C & D, Data obtained from 1 group of 
4 chimeras reconstituted with 50% C D 44 /_ bone marrow cells. E & F, 
Data obtained from 1 group of 6 chimeras reconstituted with 75% 
CD44';' bone marrow cells. The data are mean ± s.e.m. P values, 2- 
sample t test; *, P<0.05, **, P<0.01.
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F igure  4 .1 2 . Analysis o f C D 44+/+vs. C D 44 '* CD3+ and C D 19+ cell
ratios in various tissues of various chimeras.
A & B, data obtained from 1 group o f 2 and 2 groups o f 3 C D 44+/+ 
(Ly9 .1 \ Ly5.2*) & C D 44 ''' (Ly9.1+, Ly5.1*) RAG’' ’ (C D 44+/+, Ly9.1', 
Ly5.1 *)chim eras. C & D, data obtained from  1 group of 2 and 2 groups 
o f 3 HSC C D 44+/+ (Ly9.1‘ , Ly5.2+) & HSC CD44 '- (Ly9.1+, Ly5.1+) -> 
RAG 7' (C D 44+/+, Ly9.1', Ly5.1+) chimeras. E & F, data obtained from 2 
groups o f chim eras: 1 group of 8 and 1 group of 9LM C D 44+ (L y 9 .1 \ 
Ly5.1+) & LM C D 44 '/_ (Ly9.V, Ly5.1+) / Or LM C D 44+ (Ly9.1*, Ly5.1+) & 
LM C D 44+ (L y 9 .r , Ly5.1+) & C D 44+/* (CD44+/+, Ly9.1‘ , Ly5.2+)
chimeras. The data are mean ± s.e.m.
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4.3.3.6. HSC CD44+,+ (Ly9.1\ Ly5.2+) & HSC CD44 '" (Ly9.1\ Ly5.1+) -»
RAG'' (CD44+/+, Ly9 .r, Ly5.1+) chimeras.
To eliminate the possibility that contaminating mature lymphocytes in the donor 
bone marrow affected the distribution of CD44'/' cells in mixed chimeras, additional 
chimeras were generated using lineage depleted bone marrow as described in 
section 3.3.9. In contrast to chimeras made in RAG27* hosts, there was no 
difference in the ratio of CD44‘/':CD44+/+ T cells between LN and spleen (Figures 
4.12 A & C). There was also no difference in the proportion of CD44+/+ CD19+ cells 
in spleen and the LN (Figure 4.12 B & D). However, a significantly lower CD44'7' 
:CD44+/+ B cell ratio was observed in the peritoneum compared to both the spleen 
and the LN.
4.3.3.7. LM CD44+ (Ly9.1\ Ly5.1+) & LM CD44 /' (Ly9.1', Ly5.1+) Or LM 
CD44+ (Ly9.1\ Ly5.1+) -> CD44+/+ (CD44+/+, Ly9.1‘ , Ly5.2+) chimeras.
To eliminate any possible affects of differences in strain background, littermate 
(LM) chimeras were generated as described in section 3.3.10. A significantly 
higher proportion of CD44';‘ T cells was found in the spleen than the LN of mixed 
chimeras (Figure 4.12 E). However, no differences in the differences in the 
distribution of CD44'7' B cells were detected. No differences were seen in the 
distribution of CD44+ Ly9.1+ vs. Ly9.T cells in the control chimeras.
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4.3.4. Adhesion profiles indicate subtle differences between 
CD44+/+ and CD44 7' mice.
The previous section demonstrated that there were differences between CD44+/+ 
and CD44'7' T and B cells in their propensity to migrate into secondary and tertiary 
lymphoid tissues. Since adhesion molecules other than CD44 participate in 
lymphocyte migration, the expression profile of other adhesion markers was 
investigated. CD44+/+ and CD44'7’ T and B cells were compared in the LN and 
spleens of two sets of chimeras.
4.3.4.1. Adhesion profiles of T and B cells from CD44+/+ (Ly9.1*, Ly5.2+) and 
CD44’7' (Ly9.1\ Ly5.1+) -> RAG2'7' (CD44+/+, Ly9.1'f Ly5.1+) chimeras.
Chimeras were generated as described in section 3.3.7. T and B cells from the 
spleen and LN were isolated and a range of adhesion markers was investigated. 
As described below, subtle differences in expression were observed.
4 .3 . 4 .1 . 1 .  C D 1 9 + c e l ls :
CD447- B cells had an increased expression of CD62L, as assessed by both 
overall mean fluorescence intensity (MFI), and the MFI of the CD62Lhl cells. There 
were also more CD62Lhl CD44'7* cells than CD44+/+ splenic B cells. CD44'7' B cells 
CD48 had slightly lower overall CD48 expression than CD44+/+ cells, although a 
higher MFI was observed for the CD48hl CD44'7' B cells in both the spleen and LN. 
CD19+ CD44'7" cells of the spleen and LN had lower expression of ot4 integrin, 
CD103, and LPAM1 than CD44+/+ cells. In contrast there was higher expression of 
CD11b, CD54, CD48 and p2 integrin adhesion molecules on CD44‘7' B cells in the
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LN (Figures 4.13A, 4.14A, & 4.15A). Syndecan expression on slgMl0 and slgMhl 
CD19+ CD44+/+ and CD44'7' cells was also analysed in the spleen and lymph node, 
where CD44'7’ B cells from both tissues displayed lower syndecan expression than 
CD44+/+ cells in terms of overall MFI and the percentage of syndecanhl cells 
(Figures 4.16 and 4.17).
4 .3 . 4 .1 . 2 .  T  c e lls
There is a slight increase in the expression of CD11b, PECAM and CD102 in the 
spleen and CD11b and LPAM1 in the LN, as indicated by MFI, was observed for 
CD44'7' T cells when compared to CD44+/+ T cells. A significant increase in the 
percentage of in CD11bhl, and CD102hl CD44'7' T cells in the spleen and CD11bhl, 
CD102hl, LPAM1hl and p2integrinhl CD447' T cells in the LN was also apparent. In 
contrast there was a decrease in the percentage of CD54hl CD44'7' T cells. Finally, 
there was an increase in the MFI of CD11ahl and <x4 integrinh' CD44'7' splenic T cells 
and of CD11ahl, CD11bhl, LPAM1hl and a^ntegrin*1' lymph node CD44'7' T cells 
(Figures 4.18, 4.19, & 4.20).
4 .3 .4 .1 .3 .  C o - e x p r e s s io n  o f  in te g r in s
T and B cells that were double positive for either a^ntegrin and LPAM1, or, 
p2integrin and LPAM1, were also analysed. There was a reduction in the percent 
of CD44_/‘ cells found in p2integrin and LPAM1 double positive B cells in both the 
spleen and LN compared to total CD19+cells. CD44'7' T cells in the LN also had a 
reduction in the percentage of p2integrin and LPAM1 double positive cells.
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Figure 4.13. Expression o f adhesion molecules in CD19+ cells in 
CD44+/+ (Ly9 .r, Ly5.2+) & CD44'7' (Ly9.1+, Ly5.1+) -> RAG2'/_ 
(CD44+/+, Ly9.1‘ , Ly5.1+) chimeras.
A. Adhesion profile comparing CD44+/+ and CD44'7" CD 19+ cells 
in spleen. B. Adhesion profile comparing CD44+/+ and C D 44'7' 
CD19+ cells in lymph nodes. The data show the MFI for total 
cells for each marker and are mean ± s.e.m. from groups o f 3. P 
values, 2-sample t test; *, P<0.05, **, P<0.01.
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Figure 4.14. Expression of adhesion molecules in CD19+ cells in 
CD44+/+ (Ly9.r, Ly5.2+) & CD44 A (Ly9.1+, Ly5.1+) -> RAG2'7' 
(CD44+/+, Ly9.1", Ly5.1+) chimeras. II.
A. Adhesion profile comparing CD44+/+ and CD44~;' CD19+ cells in 
spleen. B. Adhesion profile comparing CD44+/+ and CD44'/'C D 1 9 + 
cells in lymph nodes. The data show percent positive cells for each 
marker and are mean ± s.e.m. from groups of 3. P values, 2-sample t 
test; *, P<0.05, **, P<0.01, ***, P<0.005, ****, P<0.001.
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Figure 4.15. Expression of adhesion molecules in CD19+ cells in 
CD44+/+(Ly9.r, Ly5.2+) & CD44’7'(Ly9.1+, Ly5.1+) ^  RAG2'7' 
(CD44+/+, Ly9.1', Ly5.1 +) chimeras. III.
A. Adhesion profile comparing CD44+/+and CD44'7' CD19+ cells 
in spleen. B. Adhesion profile comparing CD44+/+ and CD44_/' 
CD 19+cells in lymph nodes. The data shows MFI of cells gated 
for high expression of the indicated marker and are mean ± 
s.e.m. from groups of 3. P values, 2-sample t test; *, P<0.05, **, 
P<0.01, ****, P<0.001.
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Figure 4.16. Syndecan expression of splenic CD19+ cells in CD44+/+ 
(L y9 .r, Ly5.2+) & CD44"7' (Ly9.1+, Ly5.1+) -> RAG2_/' (CD44+/+, Ly9.1\ 
Ly5.1+) chimeras.
A. Expression of syndecan (MFI for total cells) in CD19+ slgM'° or 
slgMhl CD44+/+ or CD44'/' donor cells. B. Percent syndecan positive 
CD19+ slgM'° or slgMhi CD44+/+ or CD44'/* donor cells. C. MFI of 
syndecan positive CD19+ slgM'° or slgMhl CD44+/+ or C D 44/_ donor 
cells. The data are mean ± s.e.m from groups of 3. P values, 2-sample 
t test; *, P<0.05, **, P<0.01, ***, P<0.005, ****, P<0.001.
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Figure 4.17. Syndecan expression on CD19+ lymph nodes cells in
CD44 (L y9 .r, Ly5.2+) & CD44 7* (Ly9.1+, Ly5.1+) RAG2 (CD44 
Ly9.1', Ly5.1+) chimeras.
i+/+
A. Expression of syndecan (MFI of total cells) on CD19+ slgM 10 or 
slgM hl CD44+/+ or CD44'7' donor cells. B. Percent syndecan positive 
CD19+ slgM10 or slgMhi CD44+/+ or C D 447' donor cells. C. MFI of 
syndecan positive CD19+ slgM'° or slgM hl CD44+/+ or CD44'7' donor 
cells. The data are mean ± s.e.m from groups of 3. P values, 2-sample 
t test; *, P<0.05, **, P<0.01, ***, P<0.005.
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Figure 4.18. Expression of adhesion molecules in CD3+ cells in 
CD44+/+ (L y9 .r, Ly5.2+) & C D 447' (Ly9.1+, Ly5.1+) -► RAG2_/- 
(CD44+/+, Ly9.1', Ly5.1+) chimeras. I.
A. Adhesion profile comparing CD44+/+ and CD44'/'C D 3 + cells in 
spleen. B. Adhesion profile comparing CD44+/+ and CD44_/' 
CD3+ cells in lymph nodes. The data shows the MFI for total 
cells for each marker and are mean ± s.e.m. from groups of 3. P 
values, 2-sample t test; *, P<0.05, **, P<0.01.
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Figure 4.19. Expression of adhesion molecules on CD3+ cells in 
CD44+/+ (L y 9 .r, Ly5.2+) & CD44*'- (Ly9.1+, Ly5.1+) RAG2-/'
(CD44+/+, Ly9.1', Ly5.1+) chimeras. II.
A. Adhesion profile comparing CD44+/+ and CD44'7* CD3+ cells in 
spleen. B. Adhesion profile comparing CD44+/+ and C D 447" 
CD3+ cells in lymph nodes. The data shows the percent postive 
cells for each marker and are mean ± s.e.m. from groups of 3. P 
values, 2-sample t test; *, P<0.05, **, P<0.01, ***, P<0.005, ****, 
P<0.001.
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Figure 4.20. Expression of adhesion molecules on CD3+ cells in 
CD44+/+ (L y9 .r, Ly5.2+) & CD44'/' (Ly9 .1 \ Ly5.1+) -> RAG2'/_ 
(CD44+/+, Ly9.1', Ly5.1+) chimeras. III.
A. Adhesion profiles comparing CD44+/+ and CD44'/' CD3+ cells 
in spleen. B. Adhesion profiles comparing CD44+/+ and CD44'/_ 
CD3+ cells in lymph nodes. The data show MFI for cells gated 
for high expression of the individual markers and are mean ± 
s.e.m. from groups of 3. P values, 2-sample t test; *, P<0.05, **, 
P<0.01, ***, P 0 .0 0 5 .
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Figure 4.21. Analysis of a4 and p2 integrins expression in CD44+/+
(Ly9.1', Ly5.2+) & CD44’7' (Ly9.1+, Ly5.1+) ->  RAG2'7' (CD44+/+, Ly9.1',
Ly5.1+) chimeras.
A. Percentage of CD44'7' (Ly5.1+) cells found among total CD3+ or 
CD19+ populations compared to CD3+ or CD19+ LPAM +p2integrin+ 
(b2i) cells. B. Percentage of CD44_/' (Ly5.1+) cells found among total 
CD3+ or CD19+ populations compared to CD3+ or CD19+ 
LPAM +a4 integrin+ (a4i) cells. The data are mean ± s.e.m. from groups 
of 3. P values, 2-sample t test; *, P<0.05, **, P<0.01, ****, P<0.001.
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In the LN, there was a reduction among both T and B cells which were double 
positive for a4 integrin and LPAM1 (Figure 4.21).
4.3.4.2. Adhesion profiles of T and B cells from HSC CD44+/+ (Ly9.1‘,
Ly5.2+) & HSC CD44A (Ly9.1+, Ly5.1+) -» RAG‘a (CD44+/+, Ly9.1\ 
Ly5.1+) chimeras
Chimeras were generated as described in section 3.3.9. T and B cells from the 
spleen and LN were isolated and the expression of a range of adhesion markers 
was investigated.
4 .3 . 4 .2 . 1 .  C D  1 9 *  c e lls
The splenic CD44'7' B cells, again had an altered phenotype compared to that of 
the CD44+/+ splenic B cells, with decreased expression (total MFI) of PECAM, 
CD102, CD48 and LPAM1, but increased expression of CD62L. In the LN there 
was increased expression of CD11a and p2integrin but decreased expression of 
CD102, CD48 and LPAM1. The percentage of cells expressing high levels of 
certain markers also differs between CD44+/+ and CD44'7" splenic B cells, in that 
there was a decrease in the percentage of CD44'7' cells that were CD54hl, CD102hl, 
CD48hl, CD103hl, and LPAM1hl, but an increased percentage of CD44"7' cells that 
were CD62Lhl and a4 integrinhl. Among CD19+ cells of the LN there was a decrease 
in the percentage of CD44*7' cells that were CD11bhi, CD102hi, CD48hi, CD103hi, 
LPAM1hl, but an increased CD44"7' cell contribution CD11ahl, CD54hl, a4 integrinhl, 
and p2 integrinhl populations. The MFI of the cells expressing high levels of different 
markers was also different between CD44+/+ and CD44*7' splenic B cells. There
289
was an increased MFI among CD44'7' CD62Lhl, CD102hi, and unusually LPAM1hl 
cells. In the LN there was an increased MFI CD44'/' B cells that were CD11bhl, 
CD62Lhi, CD48hi, CD103hi, p2 integrinhi and LPAM1hi (Figures 4.22, 4.23, 4.24). 
Syndecan expression on slgM10 and slgMhl CD19+ CD44+/+ and CD44'7' cells was 
also analysed in the spleen and lymph node, where CD44'A B cells from both 
tissues displayed lowered syndecan expression in terms of overall MFI and the 
percentage of syndecanhl cells, than CD44+/+ B cells (Figures 4.25 and 4.26).
4 . 3 A . 2 . 2 .  C D 3 + C e l ls
In the spleen, CD44-7' T cells, again had an altered phenotype to that of the 
CD44+/+ T cells. There was increase expression (total MFI) of CD11a, CD11b and 
CD54 on the CD44'7' cells. In the LN there was an increased expression of CD11a, 
CD11b, CD54, CD48, CD103 and p2 integrin. There was also an increased 
percentage of cells expressing high levels of CD11a, CD11b, CD54, CD102, 
CD103, and p2integrin adhesion molecules among CD44'7' splenic T cells. In the 
LN this was true for CD11a, CD54, CD48, CD103, p2 integrin. The MFI of the high 
expressing cells was also significantly different between CD44+/+ and CD44'7' 
splenic T cells, with an increased MFI for CD11ahl, CD11bhl, PECAM1hl, CD54hl, 
a4 integrinhl and LPAM1hl CD44'/_ cells. The MFI for CD62Lhl CD44"7’ splenic T cells 
was reduced compared to that for CD62Lhl CD44+/+ cells. In the LN there was an 
increased MFI for CD44'7' T cells expressing high levels of CD11a, CD11b, 
PECAM, CD62L, CD48, CD102, CD103, p2integrin and LPAM1 (Figures 4.27- 
4.29).
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Figure 4.22. Expression o f adhesion molecules on C D 19+ cells 
in HSC CD44+/+ (Ly9.1', Ly5.2+) & HSC C D 44'A (Ly9.1 +, Ly5.1+) 
-> RAG'a (CD44+/+, Ly9.1‘ , Ly5.1+) chimeras. I.
A. Adhesion profile comparing CD44+/+ and C D 44 '/_ C D 19+ cells 
in spleen. B. Adhesion profile comparing C D 44+/+ and C D 44 '7' 
CD19+ cells in lymph nodes. The data shows the MFI for total 
cells for each m arker and are mean ± s.e.m. from groups o f 4. P 
values, 2-sample t test; *, P<0.05, **, P<0.01, ***, P<0.005, ****, 
P<0.001.
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F igure  4.23. Expression of adhesion molecules on CD19+ cells in 
HSC CD44+/+ (L y 9 .r, Ly5.2+) & HSC CD44 A (Ly9.1+, Ly5.1+) ->  RAG’ 
(CD44+/+, L y 9 .r, Ly5.1+) chimeras. II.
A. Adhesion profile comparing CD44+/+ and CD44'/_ CD19+ cells in 
spleen. B. Adhesion profile comparing CD44+/+ and CD44'/_ CD19+ 
cells in lymph nodes. The data shows the percent of cells expressing 
high levels of the indicated marker and are mean ± s.e.m. from groups 
of 4. P values, 2-sample t test; *, P<0.05, **, P<0.01, ***, P<0.005, 
****, P<0.001.
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Figure 4.24. Expression of adhesion on CD19+ cells in HSC CD44+/+ 
(L y 9 .r , Ly5.2+) & HSC CD44'7' (Ly9.1+, Ly5.1+) -> RAG"/_ (CD44+/+, 
L y 9 .r ,  Ly5.1+) chimeras. III.
A. Adhesion profile comparing CD44+/+ and CD44"/_ CD19+ cells in 
spleen. B. Adhesion profile comparing CD44+/+ and CD44'7' C D19+ 
cells in lymph nodes. The data shows the MFI for cells expressing 
high levels of the indicated marker and are mean ± s.e.m. from groups 
of 4. P values, 2-sample t test; *, P<0.05, **, P<0.01, ***, P<0.005, 
****, P<0.001.
293
c 16 1
§ f  *
$ +°l2  
g- 30
0  O o <= O8  1
ro oO o 
0  ^ 4
? l l >, ^ 2
* * *
• k r k - k - k
6
CD44+/+ IgM lo CD44-/- IgM lo CD44+/+ IgM hi CD44-/- IgM hi
c
(0o « 
0 =  "D 0  C O
0>
12
10
</)
0  £ 
y a0Q.
B
**
CD44+/+ IgM lo CD44-/- IgM lo CD44+/+ IgM hi CD44-/- IgM hi
jf>
ro £
250
200o v 0 +_
I s 1 5 0  
?  0 100
|  I  50 ^  o
CL
0
CD44+/+ IgM lo CD44-/- IgM lo CD44+/+ IgM hi CD44-/- IgM hi 
Figure 4.25. Syndecan expression on CD19+ spleen cells in HSC
CD44+/+ (Ly9.1‘, Ly5.2+) & HSC CD44'7' (Ly9.1+, Ly5.1+) -> RAG'/_
(CD44+/+, Ly9.1', Ly5.1+) chimeras.
A. Syndecan expression on CD19+ slgM 10 or slgM hl CD44+/+ or CD44'/_ 
donor cells. B. Percent syndecan positive of CD19+ slgM'° or slgM hl 
CD44+/+ or CD44 /_ donor cells. C. MFI of syndecan positive CD19+ 
slgM'° or slgMhl CD44+/+ or CD44"/_ donor cells. The data are mean ± 
s.e.m from groups of 4. P values, 2-sample t test; *, P<0.05, **, 
P<0.01, ***, P<0.005, ****, P<0.001.
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Figure 4.26. Syndecan expression on CD19+ lymph nodes cells in HSC 
CD44+/+ (L y 9 .r, Ly5.2+) & HSC CD44'7' (Ly9.1+, Ly5.1+) -> RAG'7’ 
(CD44+/+, Ly9.1', Ly5.1+) chimeras.
A. Syndecan expression on CD19+ slgM 10 or slgM hl CD44+/+ or C D 4 4 7' 
donor cells (MFI for total cells). B. Percent syndecan positive of CD19+ 
slgM'° or slgM hl CD44+/+ or CD44'7' donor cells. C. MFI of syndecan 
positive CD19+ slgM'° or slgM hl CD44+/+ or CD44'7' donor cells. The data 
are mean ± s.e.m from groups of 4. P values, 2-sample t test; *, P<0.05, 
**, P<0.01, ***, P<0.005.
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Figure 4.27. Expression of adhesion molecules on CD3+ cells in 
HSC CD44+/+ (Ly9.1', Ly5.2+) & HSC CD44'7' (Ly9.1+, Ly5.1+) -> 
RAG'/_ (CD44+/+, Ly9.1', Ly5.1+) chimeras. I.
A. Adhesion profile comparing CD44+/+ and CD44'/_ CD3+ cells in 
spleen. B. Adhesion profile comparing CD44+/+ and CD44'/_ 
CD3+ cells in lymph nodes. The data shows MFI cells for total 
cells for each marker and are mean ± s.e.m. from groups of 4. P 
values, 2-sample t test; *, P<0.05, **, P<0.01.
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Figure 4.28. Expression of adhesion molecules on CD3+ cells in 
HSC CD44+/+ (Ly9.1‘, Ly5.2+) & HSC CD44-7’ (Ly9.1+, Ly5.1+) -> 
RAG7’ (CD44+/+, Ly9.1', Ly5.1+) chimeras. II.
A. Adhesion profile comparing CD44+/+ and CD44'7' CD3+ cells in 
spleen. B. Adhesion profile comparing CD44+/+ and CD44'7' 
CD3+ cells in lymph nodes. The data shows the percentage of 
cells expressing high levels of the indicated marker and are 
mean ± s.e.m. from groups of 4. P values, 2-sample t test; *, 
P<0.05, ***, P<0.005, ****, P<0.001.
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Figure 4.29. Expression o f adhesion molecules on C D 3+ cells in HSC 
CD44+/+ (L y 9 .r , Ly5.2+) & HSC CD44 7' (Ly9.1+, Ly5.1+) RAG '* 
(CD44+/\  Ly9.1‘ , Ly5.1+) chimeras. III.
A. Adhesion profile comparing CD44+/+ and CD44'/_ C D 3+ cells in 
spleen. B. Adhesion profile comparing CD44+/+ and C D 44'7' CD3+ cells 
in lymph nodes. The data shows MFI for cells gated on high 
expression of the indicated marker and are mean ± s.e.m. from groups 
of 4. P values, 2-sample t test; *, P<0.05, **, P<0.01, ***, P<0.005, 
****, P<0.001.
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4 .3 . 4 .2 . 3 .  In te g r in  d o u b le  p o s it iv e  c e lls
The T and B cells that were double positive for either aVintegrin and LPAM1, or, 
p2 integrin and LPAM1, were analysed. There was a reduced percentage of CD44_/' 
cells found among p2integrin and LPAM1 double positive B cells in both the spleen 
and LN compared to the percentage of CD44'/' cells among total CD19+ cells. 
There was also a reduced contribution of CD44‘/' cells among spleen and lymph 
node T cells that were double positive for a^'ntegrin and LPAM1 (Figure 4.30).
4.3.5. CD44'/_ cells are still able to bind to hyaluronate.
We assessed the ability of CD44'7' cells to bind to the principle ligand of CD44, 
hyaluronate, focussing specifically on the ligand binding activity of dendritic cells 
(DCs). DCs were derived from either CD44+/+ or CD44_/' bone marrow and were 
incubated with a range of concentrations of FITC labelled HA (FITC-HA) for 10 
minutes at 4°C, before being thoroughly washed. Interestingly, there was no 
statistical difference between the amount of FITC-HA bound by CD44'A and 
CD44+/+ DCs, although the CD447' cells appeared to bind less FITC-HA at the 
lowest dilution (Figure 4.31).
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Figure 4.30. Analysis of cells positive for two integrins in HSC
CD44+/+ (L y 9 .r, Ly5.2+) & HSC CD44 7' (Ly9.1+, Ly5.1+) 
(CD44+/+, Ly9.1', Ly5.1+) chimeras
RAG
B
A. Percentage of CD44'/_ (Ly5.1+) cells found in total CD3+ or CD19+ 
populations compared to CD3+ or CD19+ LPAM+p2integrin+ (b2i) cells.
B. Percentage of CD44"/_ (Ly5.1+) cells found in CD3+ or CD19+ 
populations compared to CD3+ or CD19+ LPAM+cx4 integrin+ (a4i) cells. 
The data are mean ± s.e.m from groups of 4. P values, 2-sample t 
test; **, P<0.01, ****, P<0.001.
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Figure 4. 31. FITC-Hyaiuronate (FL1-HA) binding o f CD44+/* and 
CD A A'1' CD11c+ bone marrow derived dendritic cells.
A. Titration o f FL1-HA on CD44+/+ derived bone marrow cells. B. 
Titration o f FL1-HA on CDAA'1' derived bone marrow cells. C-E 
Comparison of titration of FLI-HA on CD44+/+ and CD44 /_ bone 
marrow derived cells. C. 5jJ FL1 -HA per 106 cells. D. 1jil FL1-HA 
per 106 cells. E. 0.5^1 FL-1HA per 106 cells. F. Summary FL-1-HA 
binding by CD44+/+ and CDAA'1' bone marrow derived cells (MFI). 
the data are mean ± s.e.m from groups of 3. A-E data 
representative of group of 3. Bone marrow derived cells obtained 
from age and sex matched CD44+/+ or CD44"/' mice.
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4.4.Summary.
To examine the role of CD44 in the homing of precursor cells to primary lymphoid
organs, fluorescently labelled CD44+/+ or CD44_/' lineage negative bone marrow
cells were injected into mice. Contrary to prediction, there was no difference in the
ability of the CD44_/' cells to enter the bone marrow compared to CD44+/+ cells,
whether they were co-injected or injected individually. No labelled cells were
detected in the thymus after 48 hours, although this was not unexpected. As the
majority of lineage positive cells were removed, it would take longer for the cell to
develop into thymic progenitors and migrate to the thymus, in sufficient numbers so
as to be detectable. There were however differences in the blood 12hrs post
injection, where more CD44_/‘ cells were found after co-injection with CD44+/+ cells.
This could be explained by the CD44+/+ cells being quicker to leave the blood
stream and filling niches in either the bone marrow or other tissues, therefore
leaving the CD44'/' cells in the circulation. Interestingly, there were more CD44'/_
cells isolated from the blood when co-injected with CD44+/+ cells than when
injected alone, even though twice as many cells were initially injected in the latter
situation. This could lend further support to the idea that the CD44+/+ cells
competed with CD44'/’ for exit from the blood stream. Any differences between the
division rates of CD44+/+ and CD44'/_ cells could not be deciphered due to unequal
CFSE staining. However, it was apparent was that there was a higher division rate
or a greater loss of CFSE staining in the cells that were injected singularly
compared to those that were co-injected, although this was not apparent by 48hrs.
The intra-thymic injections demonstrated that after 4 weeks there were
approximately the same number of CD44+/+ and CD44'A T cells in the spleen, either
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when the precursors were co-injected or when CD44+/+ or CD44'7' cells were 
injected individually. Thus, intra-thymic injections appeared to abrogate the deficit 
shown by the CD44'/_ precursors in producing T cells in the normal mixed 
chimeras. However, an unexpected finding was that donor B cells were generated 
in mice injected intra-thymically with precursors, indicating that injected cells were 
not restricted to the thymus. In addition, it is interesting to note that much lower 
numbers of B cells were produced from CD44'7' cells early after intra-thymic 
injection, irrespective of whether they were co-injected with CD44+/+ cells or 
injected individually. Therefore it is possible that the number of CD44+/+ and CD44* 
progenitors remaining in the thymus after intra-thymic injection was actually 
biased in favour of CD44'7' cells. If this were the case, the data would still be 
compatible with the idea that CD44'/_ cells have a reduced ability to produce T 
cells. Notably, 6  weeks after intra-thymic injection, the phenotype again resembled 
the mixed chimeras with the CD44'7' cells producing fewer T cells and more B cells. 
The T cell subsets, again showed variation between the two time points. After 4 
weeks, there were predominantly CD8 + T cells, except in the CD44+/+ only injected 
mice. After 6  weeks the normal CD4+ T cell dominance was observed. At 4 weeks 
there was no difference in the contribution of CD44+/+ or CD447' cells to the CD4+ T 
cell population, but among CD8 + T cells a significantly higher number were CD44'/_ 
derived. After 6  weeks there was normal CD44+/+ cells dominance in the CD4+ and 
CD8 + T cell populations, in the co-injected chimeras.
One explanation for these complicated findings is that they are linked to the timing 
of mature T cell migration from the thymus and the replenishment of the thymus 
with precursors from the bone marrow. For example CD8 + T cells derived from the
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intra-thymically injected cells may have matured and left the thymus in the co- 
injected and CD447* only injected mice increasing the percentage of CD8  T cells in 
the periphery, whilst the CD4+ cells derived from the intra-thymic injected cells are 
still in the thymus. Whilst in the CD44+/+ injected mice, the majority of the injected 
cells had migrated to the bone marrow and subsequently seed the thymus with T 
cell precursors, at a normal rate. Conversely intra-thymic injection may allow for 
the predominant generation of CD8 + T cells rather than CD4+ T cells. The bias of 
CD44+/+ CD8 + T cells versus CD447' CD8 + T cells only in the co-injected mice is 
compatible with the idea that CD447' cells remain in the thymus after intra-thymic 
injection, whilst the CD44+/+ cells migrate easily out. However in the CD447' only 
mice, the CD447' cells fill the empty niches in the thymus and the excess migrate 
out with difficulty. After 6  weeks, in the co-injected mice there were again fewer 
CD44'a T cells, among both CD4+ and CD8 + cells. In the individually injected mice, 
there were more CD447' than CD44+/+ CD8 + T cells.
There was little difference in the representation of CD447' cells among the CD4+ T 
cell subsets after 4 weeks in the co-injected mice. In the individually injected mice, 
there were significantly more CD4+ T cells generated from CD44+/+ than CD447* 
cells. The ratio of CD25CD4+:CD25+CD4+ T cells, was similar to that in the mixed 
chimeras in that the CD447' cells produced a higher frequency of CD25+ CD4+ T 
cells than the CD44+/+ CD4+ T cells, in both the co-injected and the individually 
injected mice.
Therefore, it appears as though the intra-thymic injection of precursors can not be 
used to fully address the reasons for the differences between CD44+/+ and CD447' 
cells in T cell production, as there appears to be differences in their migrational
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properties which make the reconstitution unequal. Nevertheless, it can be 
tentatively concluded that, partially of the defects exposed in the previous chapter 
can be explained by deficits in the ability of CD44‘/' to enter the thymus. Although 
they appear to develop normally once they have gaining entry into the thymus, 
there was still a difference in CD4+ vs. CD8 +T cell and CD25'CD4+ vs. CD25+CD4+ 
T cell development, which seems to be inherent to the CD44'/‘ T cells.
When the ratios of CD44+/+:CD44'/_ cells was calculated and compared in different 
organs, it appeared that there could be a difference in the migratory properties of 
the CD44+/+ and CD44'7' B and T cells, although the results were not wholly 
consistent. Mainly, it appeared as though there were proportionally more CD44_/' B 
cells in the LN than the spleen of most mice, regardless of the host environment. It 
was also found that the peritoneal cavity and the liver contained fewer CD44'7' B 
cells than most organs which was indicated in the previous chapter. Whether 
these differences are due to an impairment of the CD44'7' cells to enter the tissues, 
and/or remain there is not known.
The previous section exposed potential differences in migration of the CD44+/+ and 
CD44'/_ cells, and after examination of a panel of adhesion molecules in two groups 
of chimeras, it was found that there were differences between CD44+/+ and CD44'7" 
T and B cells. Many differences were found, but the following were consistent 
between groups. It appeared that CD44'A splenic B cells had an increased 
expression of CD62L, but a decreased expression of CD48 and LPAM1. In the LN, 
CD447' B cells had decreased in CD48, LPAM1 and CD103 expression, but 
increased expression of CD11b, P2 integrin, and CD48hl. CD44'/_ splenic T cells 
mainly had an increase in their expression of adhesion molecules, particularly
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CD11b and CD102, whilst in the LN CD44'7' T cells had an increased CD11b, 
CD11a and LPAM1 expression.
It was surprising to note that DCs derived from CD44'7' mice could also bind 
hyaluronate. This is in contradiction to a report by Stoop e t  a/, where they reported 
that neither CD44+/+ nor CD44'7' DCs could bind it. One difference could be the 
different background (DBA/2) of the mice used in the previous study. The lack of a 
negative control in this experiment could provide some doubt about the specificity 
of the FL1-HA. Therefore this experiment should be repeated using an anti-CD44 
antibody which has been demonstrated to block CD44-HA interactions. However 
other molecules could bind CD44 such as RHAMM. The lack of cell surface 
expression of CD44 on the CD44'7' mice had previously been confirmed by FACS 
analysis.
In conclusion, there do appear to be subtle defects in the ability of CD44'7' cells to 
enter both primary and secondary lymphoid tissues, though not the bone marrow. 
Nevertheless, it was also interesting to note from the intra-thymic injections that 
CD44+/+ but not CD44'7' cells appeared to migrate out of the thymus and into the 
bone marrow, even though they were co-injected.
Results in the previous chapter suggested that CD44'7' cells had a deficit in 
differentiating into T cells and certain T and B cell subsets. These differences in T 
cell subset differentiation were not eliminated by intra-thymic injections. This 
chapter has also shown that the CD44'7' cells also have a slight impairment in 
entering into tertiary tissues. In addition, when injected into the adult thymus 
CD44'7' progenitors still display deficits in generating T cells. Therefore, reduced
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generation of T cells is not solely a problem of homing of precursors to the thymus. 
Similarly, differences in B cell generation do not appear to be due to alterations in 
homing to the bone marrow, as the CD44+/+ and CD44'7’ cells homed equally to the 
bone marrow. These data suggest, therefore CD44 may be involved in directing 
lymphocyte differentiation at some stage.
These chimeras were also generated using a higher dose of irradiation and 
potential stromal and micro-endothelial damage could occur, which could alter the 
migratory abilities of the B and T cells.
As these were analysed using anti-Ly9.1 antibodies, T cell ratios were calculated 
eliminating host T cells, and the standard 900rads irradiation was used, thereby 
lessening the stromal and vascular damage.
307
5. Chapter 5: CD44 involvement in T and B cell 
development.
5.1. Introduction
T and B cell development in the adult begins in the BM where a pluirpotent self- 
renewing HSC is thought to develop using, the PU-1 transcription factor, into a 
common myeloid and lymphoid progenitor (244). Uptake of HSCs into the BM is 
thought to involved CD44 as both a receptor for HA and a ligand for E-selectin 
(155, 245). This common myeloid lymphoid progenitor then develops into a 
common lymphoid progenitor by the action of the Ikaros transcription factor. This 
common lymphoid progenitor can then differentiate into the T, B, NK or DC 
development pathway.
5.1.1. B cell development 
B cells develop from common lymphoid progenitors derived from pluripotent 
haematopoietic stem cells, with the action of E2A, early B cell factor (EBF) and 
PAX5, transcription factors (246). Their development can be divided into four 
stages, based on the work by Hardy. The first stage, consists of pro-B cells which 
are CD43+B220loslgM\ and represent 5% of the BM cells. The adhesive 
interaction between the pro-B cells and the BM stroma, essential for B cell 
development is mediated by CD44, and its variant isoforms (224-226, 247). This
early pro-B cell stage can be divided into many different stages based on gene
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rearrangement, enzymes present (e.g. TdT), and the responsiveness of cells to 
cytokines (e.g. IL-7). At the beginning of this stage, cells can differentiate into 
other lineages. However, by the end of this stage, the heavy chain genes have 
been rearranged and cells are committed to the B cell development pathway. In 
addition, many cells have been lost to apoptosis due to unsuccessful gene 
rearrangements. It is in this stage that the RAG'7' deficiency leads to the apoptosis 
of all RAG’7' B cells for they can not create the double stranded DNA breaks 
needed for the Ig-H chain gene rearrangements.
The next stage consists of pre-B cells, which are CD43'slgM'B22010, which 
represent 30% of BM cells. These cells have cytoplasmic pH chain expression, 
are rearranging their light chain genes, and express a pre-B cell receptor on the 
cell surface. They undergo negative selection at this stage and the majority of cells 
are deleted via apoptosis, although it has been found that immature B cells 
recognising an autogen, can also rearrange their light chain instead of being 
deleted.
The last developmental stage in the BM is that of immature B cells, which are 
CD43 B220loslgM+. These cells have undergone both Ig-L and Ig-H chain 
rearrangement, and express IgM on the cell surface. They undergo rapid
proliferation, producing approximately 20% of the BM cells. At this stage, B cells 
leave the BM to undergo the next stage of B cell development in the spleen. The 
majority of B cells are thought to die after entering the circulation, while a minor 
population undergoes positive selection in the spleen, before re-joining the 
circulation.
309
Finally, mature re-circulating B cells are also found in the bone marrow. These 
cells are CD43'lgM+B220h,slgD+ and make up 5% of BM cells.
5.1.2. T cell development
T cell progenitors are thought to develop from the common lymphoid progenitor in 
response to notch 1 signalling, which is activated by association of notch 1 with its 
ligands present on the stroma. Whether the activation of the common lymphoid 
progenitor to develop into a pre-T cell by notch signalling occurs in the thymus or in 
the BM is unclear. Interestingly, though in the absence of notch signalling,
lymphoid progenitors develop into B cells in the thymus (248).
T cell progenitors exported from the BM via the blood, enter the thymus through 
the venules into the medulla. The initial interactions between the pre-T cell and the 
thymic stroma has been shown to be blocked by CD44- and variant CD44-specific 
antibodies (128). Entry of the thymocytes into the double negative (DN, CD4', 
CD8  ) stage of T cell development is thought to occur in the sub-capsular zone of 
the thymus and takes approximately two weeks to complete. The DN stage of T 
cell development can be further split into four stages based on CD44 and CD25 
expression. In first stage, or DN1 (CD44+CD25‘), the cells are still pluirpotent they 
can give rise to B cells, NK cells and DCs, as well as T cells, and they also have a
low division rate. In second stage, or DN2 (CD44+CD25+), the cells are not as
pluripotent as in the previous stage as they can only give rise to DCs apart from T 
cells, and the cells have a very high division rate due to influences of the cytokines
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c-kit and IL-7. Survival of this subset is thought to also be dependent upon notch 
signalling (249). The cells in the third stage or DN3 (CD44'CD25+), is thought only 
to be capable of producing immature T cells; these resting immature T cells begin 
p, y and 6 TCR germline rearrangement, and the y8  T cells are thought to be 
generated. It is at this stage in T cell development, when RAG*7' host T cells 
undergo apoptosis, due to an inability to generate the double stranded DNA breaks 
needed for the rearrangement of the TCR germline. Cells in the fourth stage, or 
DN4 (CD44 CD25*), again have a high turnover. TCR p germline rearrangement 
has finished, and y  5 rearrangement will be completed at the end of this stage. In 
addition, the pre-TCR is expressed at the cell surface and TCRa germline 
rearrangement is being initiated. Adhesive interactions between the thymocytes 
and the thymic epithelium and mesenchymal fibroblasts allow the DN2 cells to 
progress to DN3, while the thymic epithelium alone is necessary for the DN3 to 
develop into the double positive stage (250).
CD4 or CD8  molecules are individually expressed on the surface of the DN 
thymocytes to generate a brief immature single positive stage (ISP). The 
significance of the ISP stage is not understood but this phenotype may be due to 
differential kinetics of the CD4 and CD8  molecules being expressed at the cell 
surface.
The immature cells subsequently enter the double positive (DP) stage of T cell 
development (CD4+ CD8 +), which typically lasts for about four days; these cells are 
found in the cortex of the thymus. During this stage, TCR a germline 
rearrangement takes place, and the TCR is expressed on the cell surface. There 
is little cell division occurring in this stage, and due to positive and negative
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selection, up to 95% of the cells will apoptose. A more detailed account of 
thymocyte selection can be found in the introduction.
Cells interacting productively with either MHCI or MHCII will then continue into the 
next stage of T cell development. Successful interaction with MHCI will result in 
the cell proceeding to the CD8  single positive stage, and successful interaction 
with MHCII will result in the cell proceeding to the CD4 single positive stage. 
Although the precise mechanisms involved are not fully understood, there is 
evidence that notch 1 is involved in the CD8  vs. CD4 T cell lineage decision. It 
appears as though a stronger notch 1 signal leads to CD8 + T cells whereas CD4+ T 
cells develop with a weaker notch signal (33, 251-253).
The final stage of thymocyte maturation is the single positive stage, which takes 
approximately two weeks to complete. During this stage thymocytes undergo the 
last processes of selection in the medulla and up-regulates CD3. The mature T 
cells leave the thymus through an active process via the blood and the lymph 
vessels at the corticomedullary junction. The precise mechanism by which this exit 
occurs is unknown.
Results in chapter 3 showed differences in T and B cell development of CD44+/+ 
and CD44‘/‘ cells when placed in competition with each other. Deficiencies that 
CD44_/' cells may have had in generating T cells were not eliminated by intra- 
thymic injection, and the differences observed in B cell generation were not due to 
altered BM homing. These findings suggest that CD44 may have a role in 
regulating the differentiation of lymphocytes within the primary lymphoid organs.
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5.2. Aim
The aim of this chapter is to investigate to possibility that CD44 is involved in T cell 
and/or B cell development. We will determine whether CD44 is involved in T cell 
development by examining T cell development in the thymus from donor CD44+/+ 
and CD44_/' progenitors. We will also determine whether CD44 is involved in B cell 
development by comparing donor CD44+/+ and CD44'7' B cells at different stages of 
development.
5.3.Results: A role for CD44 in T cell development
CD44 has been demonstrated to facilitate T cells in entering the thymus. In the 
previous chapters, CD44'/* progenitors had a reduced ability to produce mature T 
cells in chimeras made in either CD44'/' or CD44+/+ hosts. This was only apparent 
with the presence of competing CD44+/+ progenitors, since the CD44'/_ progenitors 
can fully fulfil the T cell quota without the presence of competing CD44+/+ 
progenitors. It has also been indicated, that CD44_/' T and B cells appear to have 
differences in their adhesion molecule profiles, possibly to enable them to enter 
tissues in the absence of CD44. These pieces of information lend support to the 
idea that CD44 may be more involved in T cell development in the thymus than just 
in thymic entry. Therefore the proportion of CD44'7' at different stages of T cell 
development were examined in several types of chimeras.
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5.3.1.1. CD44+/+ (Ly5.2+) and CD44 '' (Ly5.1+) donors -> CD44+/+ (Ly5.2+) 
chimeras.
Chimeras were generated as described in section 3.3.1. The percentage and 
distribution of total, Ly5.1+ and total Ly5.1‘ cells were analysed in the thymus of the 
chimeras. There was a significantly higher proportion of Ly5.1+ (CD44'A) cells than 
Ly5.2+ (CD44+/+) cells found among both the DN and the CD8 SP populations in the 
thymus of these chimeras (Figure 5.1 A). This was reinforced when the 
percentage of Ly5.1+ cells found in each thymic subset was analysed. 12% of the 
double negative cells were Ly5.1+, which was statistically higher than the other 
subsets, for which the percentage ranged between 5 and 8 %. CD8 SP also had a 
statistically higher percentage of Ly5.1+ cells than both CD4SP and DP populations 
(Figure 5.1B). As an approach to assess whether the rate of progression 
between developmental stages may differ between CD44'A and CD44+/+ 
thymocytes the proportion of Ly5.1+, Ly5.T or total cells present in a particular 
population was divided by the proportion present in the subsequent population 
(Figure 5.1C). Differences were observed between the Ly5.1+ and Ly5.T 
populations in the ratio of DN to DP cells, where Ly5.1+ cells had a higher ratio 
than Ly5.T cells. Conversely, Ly5.1+ cells had a lower ratio of DP to CD8 SP cells.
5.3.1.2. CD44+/+ (Ly5.2+) and CD44 A (Ly5.1+) donors -> CD44-'- (Ly5.1+) 
chimeras.
To determine whether CD44 expression by the host influenced the development of
CD44 A and CD44+/+ thymocytes, chimeras were generated in CD44'A recipients as
described in section 3.3.2. In these mice, there was a significantly higher
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proportion of Ly5.1+ (CD44'7') cells than Ly5.2+ (CD44+/+) cells in the double 
negative population, and a significantly lower proportion of Ly5.1+ cells in the 
double positive subset (Figure 5.2A).
Strikingly, 30% of the DN cells were Ly5.1+, whereas the percentage of Ly5.1 + 
cells in the double positive stage was only 2% (Figure 5.2B). There was also a 
statistically lower percentage of Ly5.1 + cells among DP cells than in both 
consecutive stages, the CD4SP and CD8 SP subsets. When the ratio of cells in 
progressive stages of differentiation was determined, there were differences 
between the Ly5.1+ and Ly5.1* populations in both the DP to CD4SP, the DP to 
CD8 SP stages where on both occasions, Ly5.1+ cells had a lower ratio than the 
Ly5.1 cells (Figure 5.2C). Although, there was again a higher DN to DP ratio 
among Ly5.1+ cells.
5.3.2. CD229 expression in T cell development
CD229 (Ly9) was utilised in experiments described in the previous chapter to help 
to elucidate the role of CD44 in T cell development. To ensure that it was of 
suitable use as a marker in T cell development, its expression was compared with 
that of CD2 on thymocyte subsets. Ly9.1 was found on thymocytes at all stages of 
thymic development in 129Sv mice but (as expected) was not expressed in B6  
mice (Figures 5.3 & 5.4). In contrast, CD2 was expressed only on a proportion of 
DN and DP thymocytes, but on virtually all CD4SP and CD8 SP cells. This finding 
was consistent in both strains of mice.
315
V)
a3o
H—o
(DO)ro
c .<DOi_(DQ_
(/)o
4->TOcn
80
70
60
50
40
30
20
10
0
□  Total
Ly5.1 +
□  Ly5.1-
* *
Double
Negative
Double
positive
CD4 Single 
Positive
CD 8  Single 
Positive
Double
Negative
Double
positive
CD4 Single 
Positive
CD8  Single 
Positive
30
25
20
15
10
5
0
□  Total
Ly5.1 +
□  Ly5.1-
DN: DP DP: CD4SP DP: CD8 SP CD4SP:
CD8 SP
F ig u re  5.1. A na lys is  o f th ym ic  subsets in C D 44+/+ (Ly5 .2+) & CD44 
(Ly5 .1+) ^  C D 44+/+ (L y5 .2+) ch im eras.
A. D is tribu tion  o f to ta l, Ly5 .1+ and Ly5 .1 ' ce lls  in d iffe ren t thym ic 
subsets. B. P e rcen tage  o f Ly5 .1+ (C D 44-/') ce lls  in d iffe ren t thym ic 
subsets. C. Ratio  o f to ta l, Ly5 .1+ and Ly5.1 ' cells in progress ive  T cell 
deve lopm enta l stages. The data are m ean ±  s.e.m . from  2 
independently  m ade ch im e ric  g roups o f 3. P values, 2 -sam p le  t test; *, 
P<0.05, ***, P<0.005, ****, P<0.001.
316
o3o
o
0
C O
CD -♦—< 
c. 0 u
0
CL
90 
80 
7 0  
60 -| 
50 
40 
30 
20 
10 
0
* * * *
**★*
□  Total
Ly5.1 +
□  Ly5.1-
Double
Negative
Double
positive
CD4 Single 
Positive
* * * *
Double
Negative
Double
positive
CD4 Single 
Positive
CD 8  Single 
Positive
l o  2 5  
20
* * * *8 10
CD8  Single 
Positive
COCL
35
30
25
20
15
10
5
0
□  Total
Ly5.1 +
□  Ly5.1-
DN: DP DP: CD4SP DP: CD8 SP CD4SP:
CD8 SP
F ig u re  5.2. A na lys is  o f th ym ic  subsets in C D 44+/+ (Ly5 .2+) & CD44"7" 
(Ly5 .1+) -► C D 44 /_ (L y5 .1 +) ch im eras.
A. D is tribu tion  o f to ta l, to ta l Ly5 .1+ and Ly5.1" ce lls  in d iffe ren t thym ic 
subsets. B. P e rcen tage  con tribu tion  o f Ly5 .1+ (C D 44 7 ) in d iffe rent 
thym ic subsets. C. R atio  o f d is tribu tion  o f total, to ta l Ly5 .1+ and Ly5.1‘ 
ce lls in p rogress ive  T  cell deve lopm en ta l stages. The data are mean ± 
s.e.m . from  2 ch im e ric  g roups o f 4. P values, 2 -sam p le  t test; *, P<0.05, 
***, P<0.005, ****, P < 0 .0 0 1 .
317
10° 10' ►CD4 IQ- 103 104
CD2 
A °
R2 B
* ;7-K*
0 Lnl ........................ .........
R3 c
• j;
*• .A* . - 
•* - •
----_■ ....... ..................... .—■ ...... .....7—........
R5 D
>•
-- - *
v" \
L « i ........... .................. 1 0 ' .
R4 E
'**.• .v •"* ** *
........A 104
F ig u re  5.3. D istribution of Ly9.1 and CD2 on various thym ic subsets in 
129/Sv m ice
A. CD4 and CD8 expression on thym ocytes. Polygons show gates 
used for defin ing 4 cell subsets. B. CD2 vs. Ly9.1 expression on CD8 
single positive cells. C. CD2 vs. Ly9.1 expression on double positive 
cells. D. CD2 vs. Ly9.1 expression on double negative thym ocytes. E. 
CD2 vs. Ly9.1 expression on CD4 single positive cells. Data are 
representative o f results from  2 129/Sv mice.
► Ly9.1
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5.3.3. T cell development in secondary mixed chimeras
5.3.3.1. CD44+/+ (Ly9 .r, Ly5.2+) and CD44 7' (Ly9.1+, Ly5.1+) CD44+/+
(Ly9.1‘ , Ly5.1+) 1100 chimeras
To reduce the possible contributions of radioresistant T cells to the distribution and 
composition of donor cells in the thymus, Chimeras were also generated using a 
higher dose of irradiation (1100 rads) as described in section 3.3.6. In addition, the 
Ly9 marker was used together with Ly5 to distinguish donor cells from any residual 
host T cells.
As in mixed chimeras made using a lower dose of radiation, there was a 
significantly higher proportion of Ly9.1+ (CD44'/_) cells than Ly5.2+ (CD44+/+) cells in 
the DN population, and a significantly lower proportion of Ly5.1+ cells in the DP 
subset. There was also a higher proportion of Ly9.1+ than Ly5.2+ cells in both SP 
thymic subsets (Figure 5.5A). While 4% of the DN donor cells were Ly9.1+, only 
0.5% of DP donor cells were Ly9.1+, in addition, significantly fewer Ly9.1+ cells 
were DP than either CD4SP or CD8SP subsets (Figure 5.5B). When the ratios 
between progressive differentiation stages were determined, significant differences 
were again observed in the DN:DP ratio, where, as previously, Ly9.1+ cells had a 
higher ratio than Ly5.2+ cells. There were also differences between the Ly9.1+ and 
Ly5.2+ populations in both the DP:CD4SP, and the DP:CD4SP ratios, where in 
both cases, Ly9.1+ cells had a lower ratio than the Ly5.2+ cells. This again is in 
agreement with the previous chimeras (Figure 5.5C).
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5.3.3.2. CD44+/+ (Ly9.1’, Ly5.2+) and CD44'A (Ly9.1\ Ly5.1+) RAG2''’ 
(CD44+/+, Ly9.T, Ly5.1+) chimeras
To eliminate any contribution of host T or B cells to the distribution of donor derived 
cells, chimeras were generated in RAG2'/_ hosts as described in section 3.3.7. 
Both Ly9 and Ly5 markers were utilised to exclude host pre-T cells, which could be 
generated.
There was again a significantly higher proportion of Ly9.1+ (CD44'/‘) cells than 
Ly5.2+ (CD44+/+) cells in the double negative population, and a significantly lower 
proportion of Ly5.1+ cells in the double positive subset, which is consistent with the 
other mixed chimeras. There was also a higher proportion of Ly9.1+ than Ly5.2+ 
cells in the CD4SP thymic subset (Figure 5.6A). A significantly higher percentage 
of DN cells than DP cells were Ly9.1+ (25%vs 6%) (Figure 5.6B). There were also 
fewer Ly9.1+ DP cells than CDSP or CD8SP cells. Reflecting these differences, 
the ratio of DN:DP was higher for Ly9.1+ than Ly5.2+ cells, while the ratio of 
DP:CD4SP or DP:CD8SP was lower for Ly9.1+ than Ly5.2+ cells (Figure 5.6C).
5.3.3.3. HSC CD44+/+ (Ly9.1\ Ly5.2+) & HSC CD44 '‘ (Ly9.1+, Ly5.1+) ->
RAG‘/_ (CD44+/+, Ly9.1‘, Ly5.1+) chimeras.
To eliminate the possibility that differing numbers of pre-T cells in the donor BM 
could alter the seeding balance of CD44 /_ cells to CD44+/+ cells in mixed chimeras, 
chimeras were generated using lineage depleted BM as described in section 3.3.9.
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rA significantly higher proportion of Ly9.1+ (CD44'/_) cells than Ly5.2+ (CD44+/+) cells 
was present in the DN population, while a significantly lower proportion of Ly5.1+ 
cells in the DP subset. These results are consistent with previous mixed chimeras. 
There was also a higher proportion of Ly9.1+ than Ly5.2+ cells in the CD4SP thymic 
subset (Figure 5 . 7 A ) .  15% of the DN donor cells were Ly9.1+, which was
significantly higher than the percentage among DP (4%) cells (Figure 5.7B). There 
was also a significantly lower representation of Ly9.1+ cells among DP cells than 
CD4SP or CD8 subsets. Similar to the original chimeras, there was a higher 
percentage of Ly9.1+ cells among CD8SP than CD4SP cells. In addition, the ratio 
of DN:DP cells was significantly higher for Ly9.1+ than Ly5.2+ cells, the ratio of 
DP:SP thymocytes was lower for Ly9.1+ cells than Ly5.2+ cells. Finally Ly9.1+ cells 
had a lower ratio of CD4SP:CD8SP cells than the Ly5.2+ cells (Figure 5.7C).
5.3.3.4. xCD44+/+ (Ly9.1', Ly5.2+) and yCD44'‘ (Ly9.1\ Ly5.1+) -> CD44+/+
(Ly9.1‘, Ly5.1+) chimeras.
To determine whether the production of T cells from CD44 7' progenitors was 
influenced by their relative frequency compared to CD44+/+ cells, chimeras were 
generated using different ratios of CD44’7' and CD44+/+ BM as described in section
3.3.8. Ly9 and Ly5 antibodies were used to distinguish donor and recipient cells.
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When the distribution of Ly9.1+ (CD44'/‘) cells among thymocyte subsets was 
examined, a trend was observed in which a higher starting ratio of CD44’7' BM was 
associated with a lower proportion of DN, higher proportions of DP and CD4SP, 
and a higher proportion of CD8SP (Fig 5.8A). However, these differences were 
only statistically significant for DN and CD8SP cells. Overall, an increased 
percentage of CD44'7' cells in the BM resulted in a higher percentage of CD44_/‘ in 
all thymic subsets (Figure 5.8B). These differences were all statistically significant 
except at the CD8SP stage, where the trend was identical. The ratio of DN:DP 
cells and DP:CD4SP cells, did not differ significantly between the various 
chimeras, although lower DN.DP ratios were observed in chimeras made with a 
higher percentage of CD44'/_ cells (Figure 5.8C). A significantly higher DP:CD8SP 
ratio was observed in the 75% CD44_/* BM than the 25% CD44'A chimeras. Overall, 
these data suggest that the defective development of CD44_/' thymocytes can be 
partially overcome by reducing the amount of competition from CD44+/+ cells.
5.3.4. Investigation of the double negative (CD4- CD8') thymic 
subset in various chimeras.
The previous section indicated that there were differences in T cell development 
found in the thymus of the mixed BM chimeras, which were irrespective of host. 
The mixed chimeras examined all consistently showed an increase in the 
percentage of CD44'7* cells present in the DN stage of thymic development, 
followed by a consistently low percentage of CD44'7' cells in the DP stage.
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The DN stage can be broken down into four further stages of development. These 
four stages are usually referred to as DN1 to DN4, and are normally defined on the 
basis of CD25+ and CD44+ surface expression. However, as the cells we are 
investigating are CD44_/\  an alternative marker, CD117, was utilised (254). CD117 
has the same expression profile as CD44, that is: DN1= CD44+CD117+CD25', 
DN2= CD44+CD117+CD25+, DN3= CD44 CD117 CD25+, and DN4= CD44 CD117' 
CD25'. Therefore as there appeared to be an increase in presence of CD44'/* cells 
in the double negative stage of T cell development, this stage was examined for 
the proportion of CD447' present in the various stages.
5.3.4.1. CD44+/+ (Ly5.2+) and CD44 7' (Ly5.1+) donors -> CD44+/+ (Ly5.2+) 
chimeras.
Chimeras were generated as described in section 3.3.1. The percentage of cells at 
each DN stage was examined for total, Ly5.1+ and total Ly5.T cells (Figure 5.9A). 
There was no a significant difference in the proportion of Ly5.1+ cells among DN 
thymocytes. There was a greater contribution of CD44_/* cells to DN1 cells and 
lower contribution to DN2 cells (Figure 5.9B). Consequently, there was a lower 
DN2:DN3 ratio among Ly5.1+ than Ly5.2+ cells (Figure 5.9C).
5.3.4.2. CD44+/+ (Ly5.2+) and CD44V‘ (Ly5.1+) donors CD44'' (Ly5.1+) 
chimeras.
To determine whether CD44 expression by the host influenced the T cell 
development during the DN stages, chimeras were generated in CD44'7' recipients 
as described in section 3.3.2.
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The percentage of cells at each DN stage was examined for total, Ly5.1+ and total 
Ly5.1" cells present in the DN subsets was determined. These differed from those 
obtained with the previous chimeras. There was a significantly higher proportion of 
Ly5.1+ cells than Ly5.1' cells among the DN3 thymocytes (Figure 5.10A). 
Moreover there were significantly fewer Ly5.1+ (CD44'7') cells than Ly5.2+ (CD44+/+) 
cells in the DN4 thymic subset.
In these mice Ly5.1+ cells made the greatest contribution to the DN3 subset, while 
the relatively greater production of DN1 cells seen in the previous chimeras was 
not observed (Figure 5.1 OB). Reflecting this, a significantly higher DN3:DN4 ratio 
was observed for Ly5.1+ cells than Ly5.1' cells (Figure 5.1 OC).
5.3.4.3. CD44+/+ (Ly9.1‘, Ly5.2+) and CD44 7' (Ly9.1+, Ly5.1+) -> CD44+/+
(Ly9.1', Ly5.1+) 1100 chimeras
To reduce the possible effects of radioresistant T cells on the distribution of donor 
cells in the double negative thymic subsets, chimeras were generated using a 
higher dose of irradiation (1100 rads) as described in section 3.3.6. In addition, the 
Ly9 marker was used together with Ly5 to distinguish donor cells from any residual 
host T cells.
There was a significantly lower proportion of Ly9.1+ (CD44'7') cells than Ly5.2+ 
(CD44+/+) cells in the DN2 populations, and relatively more Ly9.1+ cells in DN3 
populations (Figure 5.11 A). There was also relatively more Ly9.1+ cells in both the 
DN1 and DN3 subsets (Figure 5.11B). Significantly higher DN3:DN4 and lower 
DN2.DN3 ratios were observed for Ly9.1+ cells (Figure 11C)
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5.3.4.4. CD44+/+ (Ly9.1\ Ly5.2+) and CD44''' (Ly9.1+, Ly5.1+) RAG2'" 
(CD44+/+, Ly9.T, Ly5.1+) chimeras
To eliminate any contribution of host T or B cells to the distribution of donor derived 
cells, chimeras were generated in RAG2 7' hosts as described in section 3.3.7. 
Both Ly9 and Ly5 markers were utilised to exclude host pre-T cells that could 
interfere with the results.
A significantly higher proportion of DN3, and a lower proportion of DN4 populations 
was found in the Ly9.1+ (CD44_/') than Ly5.2+ (CD44+/+) cells (Figure 5.12A) a 
difference which was also seen in the mixed chimeras generated in CD44'7' hosts 
(Figure 5.10A). In addition there was a statistical increase Ly9.1+ cells in DN3 
population (Figure 5.12B) which has been observed in most of the chimeras. This 
was reflected in significantly higher DN3:DN4 and lower DN2:DN3 ratios for the 
Ly9.1+ cells (Figure 12C).
5.3.4.5. HSC CD44+/+ (Ly9.T, Ly5.2+) & HSC CD44 A (Ly9.1+, Ly5.1+) ->
RAG'/_ (CD44+/+, Ly9.T, Ly5.1+) chimeras.
To eliminate the possibility that differing amounts of pre-T cells in the donor BM 
could alter the seeding balance of CD44_/' cells to CD44+/+ cells in mixed chimeras, 
chimeras were generated using lineage depleted BM as described in section 3.3.9.
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In these mice, the distribution of Ly9.1+ and Ly5.2+ cells among the DN thymic 
subsets was generally similar, although slightly lower and higher proportions of 
Ly9.1+ cells were DN2 and DN3 respectively (Figure 5.13A). There was also a 
statistically significant increase in the percentage of Ly9.1+ cells in the DN3 subset 
compared to the DN4 subset (Figure 5.13B). Compared to Ly5.2+ cells, the 
DN1:DN2 and DN2:DN3 ratios were significantly higher and lower respectively for 
Ly9.1+ cells (Figure 5.15C).
5.3.4.6. xCD44+/+ (Ly9.1', Ly5.2+) and yCD44-7' (Ly9.1\ Ly5.1+) -> CD44+/+
(Ly9.1‘ , Ly5.1+) chimeras.
To determine whether the production of T cells from CD447' progenitors was 
influenced by their relative frequency compared to CD44+/+ cells, chimeras were 
generated using different ratios of CD44'/‘ and CD44+/+ BM as described in section
3.3.8. Ly9 and Ly5 antibodies were used to distinguish donor and recipient cells. 
Distribution of the DN thymic subsets was very similar in all chimeras (Figure 
5.14A), while the contribution of CD44‘7' cells to each subset was proportional to 
the composition of the donor BM (Figure 5.14B). Consequently the ratios of cells 
found at different stages of progression were virtually identical (Figure 5.14C).
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5.3.5. T  cell development following intrathymic injection of 
progenitors
As CD44 has been implicated in pre-T cell entry to the thymus, it was decided to 
perform intrathymic injections of lineage depleted BM so as to eliminate any 
contribution of reduced thymic entry to alterations in thymocyte development (see 
section 4.3.2.). BM cells (CD44+/+, CD44'7', or a mixture) were injected into the 
thymi of sub-lethally irradiated mice, and their thymic subsets were examined 4 
weeks or 6 weeks post-injection.
5.3.5.1. Investigation of the generation of thymocyte subsets in mice 
injected intrathymically.
5 . 3 . 5 . 1 . 1 .  4  w e e k s  p o s t  in je c t io n .
Four weeks after i.t. injection of a combination of CD44+/+ and CD44'/_ BM, CD44+/+ 
and CD44'7* cells were similarly distributed among DN.DP, CD4SP and CD8SP 
subsets (Figure 5.15A). It was notable, however, that the proportion of CD44'7' 
thymocytes was less than 30%, despite injecting equal numbers of CD44+/+ and 
CD44'7' progenitors (Figure 15B). Thus the deficit in producing thymocytes from 
CD44 7' progenitors was not strictly linked to reduced thymic homing.
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In addition, there was a statistically significant decrease in the percentage of CD44’ 
cells in the DN stage and the CD8SP stage, compared to the DP and the CD4SP 
stages respectively (Figure 5.15B). The ratios of progressive stages of thymocyte 
differentiation were similar for CD44+/+ and CD44'7' cells (Figure 5.15C). 
Comparable results were obtained when CD44+/+ or CD44'7' BM was injected 
individually (Figure 5.16).
Statistical analysis was carried out to compare the generation of thymocytes when 
CD44'/_ and CD44+/+ BM cells were injected i.t. separately vs. in combination 
(Figures 5.17 & 5.18). This comparison highlighted two effects of competition. 
First, there was a large decrease in the percentage of CD44‘/* cells in all thymic 
stages when injected together with CD44+/+ progenitors (Figure 5.17B & 18B). 
Second, competition appeared to reduce the rate of DN to DP transition for CD44‘/' 
cells, and increase this rate for CD44+/+ cells (Figure 5.17C & 18C).
5 . 3 . 5 . 1 . 2 .  6  w e e k s  p o s t  in je c t io n .
Mice were examined 6 weeks after i.t. injection of a combination of CD44+/+ and 
CD44"/_ BM, the contribution of CD44'/_ cells to all thymocyte populations remained 
low (<25%) (Figure 19B). At this time, there was a slight decrease in the 
percentage of CD44"7' cells in the CD8SP stage (Figure 5.19A). This was reflected 
in a higher CD4SP:CD8SP ratio for CD44'7' cells (Figure 5.19C).
When mice injected i.t. with CD44+/+ or CD44'7' BM individually were compared six 
weeks post-injection, there were significantly higher percentages of CD44'/_ cells in 
the DP and the CD4SP thymic stages compared to the donor CD44+/+ cells, but a 
decrease in the percentage of CD44'/_ CD8SP cells (Figure 5.20A).
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marrow and 1 chim eric group of 5, reconstituted with CD44-/~ and CD44+/+ 
bone marrow. P values, 2-sam ple t test; ***, P<0.005, ****, P<0.001.
342
100
80
<1) (/) O c 
f o
QO
TO
O
CL
o O c
c  o  a) "o
y E<u
CL
T3
<4—o
+->c<DOi —<U
Q l
80
70
.9  60
l |  50 sz wa> 40o
o
4 —'toCL
C7)
o  30
D.
20
10
0
60
40
20
0
**
□  CD44+/+=>CD44+/+
□  CD44+/+ & CD44-/- 
=> CD44+/+
Double
Negative
1 0 0  1 * *
Is o
o o
a)
°  60 -
+■
5  40 - 
□
°  2 0  - 
0
Double
positive
CD4 Single 
Positive
**
m
T
T T
I
Double
Negative
Double CD4 Single CD8  Sing 
positive Positive Positive
CD8  Single 
Positive
B
□  CD44+/+=> 
CD44+/+
□  CD44+/+ & 
CD44-/- => 
CD44+/+
**
□  CD44+/+=> 
CD44+/+
□  CD44+/+ & 
CD44-/- => 
CD44+/+
DN:DP DP:CD4SP DP: CD8SP CD4SP: CD8SP
Figure 5.18. A nalys is o f thym ic subsets in chim eras generated after 
intrathym ic injection o f C D 44+/+ (Ly5.2+) & C D 44'/_ (Ly9 .1+) or C D 44+/+ only 
progenitors 4 w eeks post injection.
A. D istribution o f donor C D 44+/+ cells in d ifferent donor thym ic subsets. B. 
Percentage contribu tion of donor C D 44+/+ cells in d iffe rent donor thymic 
subsets. C. Ratio o f progression of donor C D 44+/+ cells in progressive T 
cell developm ental stages. DN, Double Negative. DP, Double Positive. 
SP, Single Positive. The data are mean ± s.e.m. from  1 chim eric group of 4, 
reconstituted w ith C D 44 '7' bone m arrow and 1 chim eric group of 5, 
reconstituted w ith C D 44 '/_ and C D 44+/+ bone marrow. P values, 2-sample t 
test; *, P<0.05, **, P<0.01.
343
s  80
#  70 CD ( / )•M  
0
o |  50 
- 8  « 40 
o |  30
I t  20B 10
S. o 4
Double
Negative
Double
positive
CD4 Single 
Positive
■  CD44-/- 
□  CD44+/
CD8  Single 
Positive
c  35
=  300
°  J225 05 o20 
O c15O
c  -D10 
0
B 5 
0
0
g
If
s z  V)W)
0l_O)
o
0  Q .o:
* * * * B
Double
Negative
Double
positive
CD4 Single 
Positive
CD8  Single 
Positive
CD44-/-
□  CD44+/+
DN:DP DP:CD4SP DP: CD8 SP CD4SP:
CD8 SP
Figure 5.19. Analysis of thym ic subsets in chimeras generated after 
intrathym ic injection of C D 44+/+ (Ly5.2+) & CD44'/' (Ly9.1+) progenitors 6 
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A. D istribution of C D 44+/+ and CD44_/' cells in different thym ic subsets. B.
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These differences were reflected in lower DN:DP and DP:CD4SP ratios and higher 
DP:CD8SP and CD4SP:CD8SP ratios for the CD44'7' cells (Figure 5.20C). 
Comparisons between mice injected with a mixture of CD44‘7' and CD44+/+ BM vs. 
mice injected with CD44'7' or CD44+/+ cells alone again highlighted the same effects 
of competition as seen at 4 weeks post injection (Figure 5.21 & 5.22). Namely, that 
competition with CD44+/+ cells greatly reduced the contribution of CD44'7’ cells to all 
thymocyte subsets and appeared to have a specific effect on the DN to DP 
transition.
5.3.5.2. Investigation of double negative thymic subsets in intra-thymically 
injected mice.
One difference between mixed chimeras generated following i.v. vs. i.t. injection of 
BM cells was that a relative deficit in the DN subset was observed in the former but 
not the latter. Therefore it as of interest to investigate whether previously observed 
differences in the DN subset competition were also abrogated by i.t. injection.
5 .3 . 5 .2 . 1 .  4  w e e k s  p o s t  in je c t io n .
Distribution of CD44‘7" cells among DN thymocytes in i.t. injected mice is shown in 
Figures 5.23 and 5.24. The results are differ substantially from those in i.v. 
injected mice (e.g. Figure 5.9). In particular, the relative contribution of CD44'7' 
cells to DN1 vs. DN2 subsets was reversed, so that in the i.t. chimeras the DN:DN2 
and DN2:DN3 ratios were lower and higher respectively for CD44'7' than CD44+/+ 
cells. This was true whether BM cells were injected as a mixture or individually 
(Figures 5.23 -5.26)
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progenitors 6 w eeks post injection.
A. D istribution o f CD44"7’ cells in d ifferent thym ic subsets. B. Percentage 
contribution o f CD44"/_ cells in d ifferent thym ic subsets. C. Ratio of 
progression o f C D 44 '/_ cells in progressive T cell developm ental stages. DN, 
Double Negative. DP, Double Positive. SP, Single Positive. The data are 
mean ± s.e.m. from  1 chim eric group o f 4, reconstituted with CD44~y~ bone 
marrow and 1 chim eric group of 5, reconstituted with CD44'/_ and CD44+/+ 
bone marrow. P values, 2-sam ple t test; ***, P<0.005, ****, P<0.001.
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A. D istribution o f donor CD 44+/+ cells in d ifferent thym ic subsets. B. 
Percentage contribution o f donor C D 44+/+ cells in d ifferent thym ic subsets. 
C. Ratio o f progression of donor C D 44+/+ cells in progressive T cell 
developm ental stages. DN, Double Negative. DP, Double Positive. SP, 
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Figure 5.24. Analysis of DN thym ic subsets in chimeras generated from
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A. D istribution o f C D 44+/+ and CD44'/_ cells in different double negative 
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groups of 4. P values, 2-sam ple t test; *, P<0.05.
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F ig u re  5.25. Analysis o f DN thym ic subsets in chim eras generated from 
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progenitors 4 weeks post injection.
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4, reconstitu ted w ith C D 44 ‘/_ bone m arrow  and 1 chim eric group of 5, 
reconstituted with C D 44 ‘/_ and C D 44+/+ bone marrow. P values, 2-sample t 
test; ***, P<0.005, ****, P<0.001.
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P<0.001.
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5.3.5.2.2. 6 w e e k s  p o s t  in je c t io n .
Distribution of CD44'7' cells among DN thymocytes in i.t. injected mice is shown in 
Figures 5.27 and 5.28. The results are similar from those in i.v. injected mice (e.g. 
Figure 5.9). In particular, the relative contribution of CD44’7' cells to DN1 vs. DN2 
subsets, and DN3 vs. DN4 was repeated, so that in the i.t. chimeras the DN2:DN3 
ratios higher for CD447' than CD44+/+ cells. This was true whether BM cells were 
injected as a mixture or individually (Figures 5.27-5.30)
5.3.6. Distribution of CD4+ and CD8+ CD44'/‘ T cells between 
primary and secondary lymphoid organs when in competition 
with CD44+/+ cells.
Since CD44 has been suggested to participate in lymphocyte migration, it might be 
expected that CD44'7' and CD44+/+ lymphocytes would distribute differently 
between tissues when in direct competition. To determine if this is the case, the 
ratio of CD44+/+ to CD44 7' T cells and B cells was compared in different lymphoid 
and non-lymphoid tissues.
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Figure 5.27. Analysis of DN thym ic subsets in chimeras generated form 
intrathym ic injections CD44+/+ (Ly5.2+) & CD44'7' (Ly9.1+) progenitors 6 
weeks post injection.
A. Distribution of in CD44+/+ and CD44‘/_ cells in different double negative 
thym ic subsets. B. Percentage contribution of 0 0 4 4 ^  of donor cells in 
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Figure 5.28. Analysis o f DN thym ic subsets in chim eras generated from 
intrathym ic injections of C D 44+/+ (Ly5.2+) or CD44'/_ (Ly9.1+) progenitors 6 
weeks post injection.
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P<0.05, **, P<0.01, ****, P<0.001.
355
ICD44+/+ & CD44-/- => CD44+/+
v> 40
* * * ***★*
CD44 -/- 
=>CD44+/+
□  CD44+/+ & 
CD44-/- => 
CD44+/+
DN1 DN2 DN3 DN4
o
E
s z•*-*
o
o
roQL
QO
**—oco</)
V )0)
CDo
■  CD44-/-=>CD44+/+
□  CD44+/+ & CD44-/- => 
CD44+/+
V )
2 
1.8 
1.6 
1.4 
1.2 
1
0.8 
0.6 
0.4
Q. 0.2
0
DN1:DN2 DN2:DN3 DN3:DN4
F igure  5.29. A na lys is o f DN thym ic subsets in chim eras generated from 
intrathym ic in jection of C D 44+/+ (Ly5.2+) & C D 44'A (Ly9.1+) or CD44 7' only 
progenitors 6 w eeks post injection.
A. D istribution of C D 44 '/_ cells in d ifferent double negative thym ic subsets.
B. Percentage contribu tion of C D 44'7" cells in different double negative 
thym ic subsets. C. Ratio o f progression of C D 44'/_ cells in progressive T 
cell developm enta l stages. The data are mean ± s.e.m. from 1 chimeric 
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double negative thym ic subsets. C. Ratio of progression of donor CD44+/+ 
cells in progressive T cell developm ental stages. The data are mean ± 
s.e.m. from  1 ch im eric  group o f 4, reconstitu ted with C D 4 4 7 bone marrow 
and 1 ch im eric group o f 5, reconstituted with C D 4 4 7 and CD44+/+ bone 
marrow. P values, 2-sam ple t test; *, P<0.05, ***, P<0.005.
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5-3.6.1. CD44+'+ (Ly5.2+) and CD44'_ (Ly5.1+) donors -> CD44+/+ (Ly5.2+) 
chimeras.
Chimeras were generated as described in section 3.3.1. The percentages of 
CD44‘/‘ CD4+ and CD8+ T cells were compared to determine whether there was a 
difference in CD4+ and CD8+ T cell distribution between the spleen, LN and 
thymus. A significantly lower proportion of both CD4+ and CD8+ T cells were 
CD44_/* in the thymus compared to the spleen and the LN (Figures 5.31 A & B).
5.3.6.2. CD44+/+ (Ly5.2+) and CD44 A (Ly5.1+) donors -> CD44 7’ (Ly5.1+) 
chimeras.
To determine whether CD44 expression by the host influenced the distribution of 
CD44_/' and CD44+/+ lymphocytes, chimeras were generated in CD44V' recipients 
as described in section 3.3.2. A significantly lower proportion of both CD4+ and 
CD8+ T cells was again found in the thymus compared to the spleen and the LN 
(Figures 5.31 C & D).
5.3.6.3. CD44+/+ (Ly9.1', Ly5.2+) and CD44/_ (Ly9.1+, Ly5.1+) -> CD44t,+
(Ly9.1_, Ly5.1+) 1100 chimeras
To reduce the possible effects of radioresistant T cells on the distribution of donor 
cells, chimeras were also generated using a higher dose of irradiation (1100 rads) 
as described in section 3.3.6. In addition, the Ly9 marker was used together with 
Ly5 to distinguish donor cells from any residual host T cells.
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5.31. A na lys is  o f the percentage of CD 4+ and C D 8+ CD44'/_ 
the thym us, sp leen and lymph nodes of various chimeras, I.
A, B. C D 44+/+ (L y5 .2 +) & C D 447' (Ly5.1+) ->  C D 44+/+ (Ly5.2+). C, D. 
CD44+/+ (Ly5 .2+) & C D 44 '7’ (Ly5.1+) ->  CD44'7' (Ly5.1+). E, F. CD44+/+ 
(Ly5.1+ Ly9 .1 ') & C D 447' (Ly5.1 + Ly9.1+) ->  1100rads CD 44+/+ (Ly5.2+ 
Ly9.1). C D 4+ and C D 8 +thym ocytes are gated on SP cells. The data are 
mean ± s.e.m , A -D  from  2 groups of 8 chimeras, and E-F from 1 group 
of 6 chim eras. P va lues, 2-sam ple  t test; ***, P<0.005, ****, P<0.001,
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A significantly lower proportion of both CD4+ and CD8+ T cells was again found in 
the thymus compared to the spleen and the LN (Figures 5.31 E & F). There was 
also a difference found between the spleen and the LN in both the CD4+ and CD8+ 
CD44'7' populations where there was a lower percentage of CD44'/_ T cells found in 
the LN.
5.3.6.4. CD44+/+ (Ly9.1\ Ly5.2+) and CD44‘/' (Ly9.1+, Ly5.1+) -» RAG2'a
(CD44+/+, Ly9.1", Ly5.1+) chimeras
To eliminate any contribution of host T or B cells to the distribution of donor derived 
cells, chimeras were generated in RAG2'/_ hosts as described in section 3.3.7. In 
this case, a significantly lower proportion of CD4+ T cells but not CD8+ T cells was 
found in the thymus compared to the spleen and the LN (Figures 5.32A & B).
5.3.6.5. HSC CD44+/+ (Ly9.1\ Ly5.2+) & HSC CD44'/' (Ly9.1\ Ly5.1+) ->
RAG ' (CD44+/+, Ly9.1", Ly5.1+) chimeras.
To eliminate the possibility that contaminating mature lymphocytes in the donor BM 
affected the distribution of CD44'/_ cells in mixed chimeras, additional chimeras 
were generated using lineage depleted BM as described in section 3.3.9. As with 
the previous RAG2'/_ chimeras, a significantly lower proportion of CD4+ T cells but 
not CD8+ T cells was found in the thymus compared to the spleen and the LN 
(Figures 5.32C & D).
360
40
35
o  ^  30 
“  25o
20
re m- 15 
c  Q 10 <D O c o 5
0
0O) +
<u
CD +
TO CO
<D O
Thymus Spleen Lymph
nodes
B
Thymus Spleen
**
Lymph
nodes
o 15
CD + CD +TO ^  10 Q <D O
S3 X 10
Thymus Spleen Lymph 
nodes Thymus Spleen
CD +
□  Thymus
□  Spleen 
■  LN
Lymph
nodes
*★★★ E □ Thymus
□ Spleen
** *
O =  30
o 25
<d h  20
TO 00 15 ** *  *★ *
25%
CD44-/-
50% 
CD44 -/-
75% 
CD44 -/-
25%
CD44-/-
50%
CD44-/-
75%
CD44-/-
Figure 5.32. Analysis o f the percentage o f C D4+ and C D 8+ CD44"7' 
cells in the thym us spleen and lymph nodes of various chim eras, II.
A, B. CD44+/+ (Ly9 .1 \ Ly5.2+) and CD44*7' (Ly9.1+, Ly5.1+) ->  RAG2'7' 
(CD44+/+, Ly9.1‘ , Ly5.1+). C, D. HSC C D 44+/+ (Ly9.1‘ , Ly5.2+) & HSC 
CD44"7' (Ly9.1+, Ly5.1+) -»  RAG"7' (C D 44+/+, Ly9 .1 't Ly5.1+). E, F. 
xCD44+/+ & yC D 44'7'—> C D 44+/+. The data are mean ± s.e.m, A-D  from 
2 groups of 6 chim eras, and E-F from 3 group o f 4 chim eras, each 
reconstituted w ith 25, 50, or 75%  CD44 7 bone marrow. P values, 2- 
sample t test; *, P<0.05, **, P<0.01, ***, P<0.005, ****, P 0 .0 0 1 .
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5.3.6.6. xCD44+/+ (Ly9.1\ Ly5.2+) and yCD44'/_ (Ly9.1+, Ly5.1+) CD44+/+
(Ly9.1', Ly5.1+) chimeras.
To determine whether the distribution of CD44'7' lymphocytes was influenced by 
their relative frequency compared to CD44+/+ cells, chimeras were generated using 
different ratios of CD44 /‘ and CD44+/+ BM as described in section 3.3.8. Ly9 and 
Ly5 antibodies were used to distinguish donor and recipient cells. A significantly 
lower proportion of both CD4+ and CD8+ T cells was again found in the thymus 
compared to the spleen and the LN in all the chimeras (Figures 5.32E & F). There 
was also a statistical difference found between the spleen and the LN in the CD4+ 
population of the 25% and 75% CD44_/" BM chimeras. There was a statistically 
lower percentage of CD44'7' CD4+ T cells was found in the LN of 25% chimeras, 
but a higher percentage of CD44'7' CD4+ T cells was found in the LN of 75% 
chimeras. A statistical difference was also found between the spleen and the LN in 
the CD8+ population of the 25% CD44'7' BM chimeras. A significantly lower 
percentage of CD447' CD8+ T cells was found in the LN than the spleen.
5.3.7. Normal TCRvp usage in periphery of CD44+/+ and CD44'/_
T cells.
The relatively poor contribution of CD44_/‘ cells to the thymocytes when in
competition with CD44+/+ cells raised the possibility that surviving CD44'7' cells
might represent a selected subset, which could be linked to TCR specificity.
Selection on the basis of TCR usage might also occur in the periphery, given that
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the percentage of CD44_/" T cells is much higher in the spleen or LN than the 
thymus. Selective survival or expansion could potentially produce a more limited 
diversity of T cells with a narrowing of their TCRvp usage. To address this 
possibility, CD4+ and CD8+ splenic CD44+/+ and CD44'7' T cells from chimeras, 
generated in a RAG hosts, were stained with a panel of TCRvp antibodies and 
their frequencies analysed (Figure 5.33). There was little difference in the TCRvb 
usage in the CD4+ or CD8+ CD44_/‘ cells compared to the CD44+/+ cells. Although 
a couple of statistically significant differences were observed there were more 
CD4+ and CD8+ CD44'/' T cells using TCRvp7 and more CD4+ CD44'/_ cells using 
TCRvp12, there was an overall similar distribution showing normal TCRvp usage.
5.4. A role for CD44 in B cell development
5.4.1. C D 229 expression in B cell development 
CD229 (Ly9) has been utilised earlier in this chapter as well as in the previous 
chapter to help to elucidate a role for CD44 in T cell development. To ensure that 
it was also suitable for use as a marker in B cell development, its expression was 
investigated together with CD2 on B cells at different developmental stages. Ly9.1 
was found on all stages of B cell development in 129Sv mice but on none of the 
cells from C57BI/6 mice (Figures 5.34).
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■  CD4 CD44-/- 
□  CD4 CD44+/+
Figure 5.33. Analysis o f the usage o f vp in CD44'/_ vs. CD 44+/+ CD4+ 
and CD8+ T cells in the spleen of C D 44+/+ (Ly9 .1 \ Ly5.2+) and CD44_/' 
(Ly9.1+, Ly5.1+) ->  RAG 2'/_ (C D 44+/+, Ly9.1", Ly5.1+) chimeras.
A. D istribution of vp usage in C D 44 '/_ vs. C D 44+/+ CD4+ T cells. B. 
D istribution o f vp usage in CD44"/_ vs. C D 44+/+ CD8+ T cells. The data 
are mean ± s.e.m, from  1 groups of 4 chim eras. P values, 2-sample t 
test; *, P<0.05, **, P<0.01.
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 ► Ly9.1
Figure 5.34. Analysis of the Ly9.1 expression in B cell development.
A. Definition of three groups of B cell development, by surface expression of 
IgM and B220. B. Definition of two early stages of B cell development by 
slgM, CD43 and B220 staining gated on R2. C. Ly9.1 expression of R5. D. 
Ly9.1 expression of R6. E. Ly9.1 expression of R3. F. Ly9.1 expression of 
R4. Data are representative results from 2 129S/v mice, and 2 C57BI/6 
mice. C57BI/6 miced 129S/v mice—
In contrast, CD2 was only expressed on a subset of cells at an early (B22010 slgM') 
stage of B cell development, expressed on all cells at later stages (Figure 5.35). 
This finding was consistent in both strains of mice.
5.4.2. B cell development in mixed chimeras.
5.4.2.1. CD44+/+ (Ly5.2+) and CD44’7- (Ly5.1+) donors -► CD44+/+ (Ly5.2+) 
chimeras.
Chimeras were generated as described in section 3.3.1. The percentages of 
CD44'7' cells in the progressive stages of B cell development were compared to 
determine whether there was a difference in the composition of the developmental 
subsets. There was no statistical difference between the progressive stages, 
although there did appear to be a progressive increase in CD44'/_ cells through the 
developmental stages (Figures 5.36A).
5 . 4 . 2 . 2 .  CD44+/+ (Ly5.2+) and CD44 /_ (Ly5.1+) donors -» CD44'/_ (Ly5.1+) 
chimeras.
To determine whether CD44 expression by the host influenced B cell maturation, 
chimeras were generated in CD44‘/‘ recipients as described in section 3.3.2. When 
the mixed BM chimeras were generated in CD44_/‘ hosts, there appeared to be 
significantly fewer CD44'7' cells in the CD43‘ B220'° slgM' developmental stage 
than in the previous or following stage (Figures 5.36B).
366
Figure 5.35. Distribution of Ly9.1 and CD2 on various B cells subsets.
A. B220 and slgM  expression in bone marrow cells defining 3 stages of B 
cell developm ent. B, C. CD2 vs. Ly9.1 expression in R2. . D, E. CD2 vs. 
Ly9.1 expression in R3. F, G. CD2 vs. Ly9.1 expression in R4. A, B, D, F 
are C57BI/6 m ice and C, E, G, are 129S/v mice. Data are representative of 
results from 2 129S/v m ice and 2 C57BI/6 mice.
80
$ 70
5  60
8 50 Z. 40
S 30
^  20 
CDQ_ 10 
0
CD43+ CD43- B220lo lgM+ B220Hi
B220lo IgM- B220lo IgM- lgM+
★*** B
**
80
*L. 70
5  60
8 50 -  40
£ 30
y 20
CD
Q- 1 0  
0
CD43+ CD43- B220lo lgM+ B220Hi
B220lo IgM- B220lo IgM- lgM+
F ig u re  5.36. A na lys is o f the percentage of C D 4 4 7' cells in
various stages of B cell developm ent in various chimeras, I
I  ■
A, C D 44+/+ (Ly5.2+) & C D 44'7' (Ly5.1+) CD44+/+ (Ly5.2+).
B. C D 44+/+ (Ly5.2+) & C D 44'7' (Ly5.1+) CD44-7' (Ly5.1+). 
The data are m ean ± s.e.m, A-D from 2 groups of 6 
chim eras. P values, 2-sam ple t test; **, P<0.01, ****, 
P<0.001.
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5.4.2.3. CD44+/+ (Ly9.1\ Ly5.2+) and CD44'/_ (Ly9.1\ Ly5.1+) -> CD44+/+ 
(Ly9.1‘ , Ly5.1+) 1100 chimeras
To reduce the possible effects of radioresistant cells on the development of donor 
cells, chimeras were also generated using a higher dose of irradiation (1100 rads) 
as described in section 3.3.6. The mixed BM chimeras generated with a greater 
amount of irradiation in CD44+/+ hosts, appeared to have significantly fewer CD44'7' 
cells in the CD43" B220'° slgM' developmental stage than in the previous or 
following stage (Figures 5.37A). This phenotype was apparent in the previous 
chimeras.
5.4.2.4. CD44+/+ (Ly9.1", Ly5.2+) and CD44'7' (Ly9.1+, Ly5.1+) -> RAG2'7'
(CD44+/\  Ly9.1', Ly5.1+) chimeras
To eliminate any contribution of host T or B cells to the distribution of donor derived 
cells, chimeras were generated in RAG2'7' hosts as described in section 3.3.7. 
There appeared to be little change in the different B cell developmental stages in 
these chimeras (Figures 5.38A).
5.4.2.5. HSC CD44+/+ (L y9 .r, Ly5.2+) & HSC CD44'' (Ly9.1+, Ly5.1+) ->
RAG '" (CD44+/+, Ly9.1", Ly5.1+) chimeras.
To eliminate the possibility that contaminating mature lymphocytes in the donor BM 
affected the distribution of CD44'7' cells in mixed chimeras, additional chimeras 
were generated using lineage depleted BM as described in section 3.3.9.
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Figure 5.37. Analysis o f the percentage of C D 44_/' cells in 
various stages of B cell developm ent in various chimeras, II
A, C D 44+/+ (Ly5.1+ Ly9.1') & C D 4 4 /_ (Ly5.1+ Ly9.1+) -> 
1100rads C D 44+/+ (Ly5.2+ Ly9.1). b. xCD44+/+ & yCD44'/'->  
C D 44+/+. The data are mean ± s.e.m. A from 1 group of 6 
chim eras, and B from 3 groups o f 6 chimeras, each 
reconstitu ted with 25, 50, or 75% CD44~A bone marrow. P 
values, 2-sam ple t test; **, P<0.01, ****, P<0.001.
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A. C D 44+/+ (Ly9.1 ', Ly5 .2+) and C D 44'7' (Ly9.1+, Ly5.1+) ->  RAG2'/_ 
(C D 44+/+, Ly9.1", Ly5.1+). B. HSC C D 44+/+ (Ly9.1“, Ly5.2+) & HSC 
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There were no statistical differences in the progressive B cell developmental 
stages in these chimeras (Figures 5.38B).
5.4.2.6. xCD44+/+ (Ly9.T, Ly5.2+) and yCD447' (Ly9.1+, Ly5.1+) CD44+/+
(Ly9.1', Ly5.1+) chimeras.
To determine whether the development of CD44'7' B cells was influenced by the 
relative frequency of their precursor cells compared to CD44+/+ cells, chimeras 
were generated using different ratios of CD44‘7‘ and CD44+/+ BM as described in 
section 3.3.8. Ly9 and Ly5 antibodies were used to distinguish donor and recipient 
cells. There appeared to be little correlation between the composition of the 
reconstitution inoculum and the percentage of CD44'7" cells found within the 
different developmental pathways (Figure 5.37B). However, it was evident that a 
greater proportion of CD44'7" cells was found in the most mature (B220+lgMhl) stage 
at all ratios of reconstitution.
5.4.3. B cell development in thymectomised mice 
The role of CD44 in directing precursor cells to the thymus could, in an indirect 
way, impact on the production of B cells by CD44'7- cells in chimeric mice. Hence it 
is possible that CD44'7’ precursors that fail to gain entry to the thymus could 
potentially migrate to the BM and generate B cells. To investigate whether this 
could occur, a group of chimeric mice were generated with mixed BM using either 
irradiated thymectomised or sham thymectomised mice as recipients.
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If biased production of B cells by CD44"/_ precursors in mixed chimeras results from 
preferential homing of CD44+/+ precursors to the thymus, this bias should be 
eliminated in thymectomised mice.
Ly5.1+ mice were thymectomised or sham thymectomised and allowed to recover 
for 7 weeks. Lineage depleted BM cells from CD44+/+ (Ly5.2+, Ly9.1) and CD44 /_ 
(Ly5.1\ Ly9.1+) mice were injected in a 1:1 ratio into irradiated recipients. The 
mice were then left to reconstitute before their phenotype was analysed.
In sham-thymectomised recipients, normal percentages of total T and B cells were 
observed, (Figures 5.39A, 5.40A). As expected the thymectomised mice had few T 
cells and a higher percentage of B cells. Surprisingly, however, small numbers of 
donor T cells were present in thymectomised recipients (Figure 5.39B & 5.40B). 
This suggests either incomplete thymectomy in some recipients or incomplete T 
cell depletion from the donor bone marrow. Nevertheless, the key finding from this 
experiment was that the percentage of CD44'7' B cells was not reduced in 
thymectomised chimeras (Figure 5.39B & 5.40B). This suggests that failed 
circulation of precursors to the thymus does not contribute significantly to the 
biased B cell production of CD44'/_ cells. Analysis of mature B cell subsets 
(Figures 5.41 and 5.42) and immature B cells in the bone marrow revealed no 
differences between thymectomised and sham thymectomised mice (Figure 5.43).
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Figure 5.39. A nalys is of T and B cells in the spleens of thym ectom ised and 
sham thym ectom ised chim eras.
A. Percentages of T and B cells in spleen of the different chimeras. B. The 
percentage of C D 44 '/_ (Ly9.1+) cells in each splenic population. C. The B:T 
cell ratio am ong total and C D 44_/' and CD44+/+ donor populations in the 
thym ectom ised and sham thym ectom ised chimeras. The data are mean ± 
s.e.m. obtained from  2 groups of 5 chimeras. P values, 2-sample t test ; *, 
P<0.05, **, P<0.01, ****, P<0.001.
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Figure 5.40. Analysis o f T and B cells in lymph nodes of thymectomised 
and sham thymectomised chimeras.
A. Percentages of T and B cells in the lymph nodes of the different 
chimeras. B. The percentage of CD44 7'(L y 9 .1 +) cells in each lymph node 
population. C. The B:T cell ratio among total and CD44';" and CD44+/+ 
donor populations in the thymectomised and sham thymectomised 
chimeras. The data are mean ± s.e.m. obtained from 2 groups of 5 
chimeras. P values, 2-sample t te s t ; *, P<0.05, **, P<0.01, * * * \  P<0.001.
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Figure 5.41. Analysis of B cell subsets in the spleens of 
thymectomised and sham thymectomised chimeras.
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A. Percentages of total splenic B cell (CD19+) subsets defined by slgM 
and slgD expression in different chimeras. B. The percentage of 
CD44'/' (Ly9.1+) cells in each B cell subset. C. Distribution of slgM 
and slgD staining among CD44'/_ or CD44+/+ CD19+ cells in 
thymectomised or sham thymectomised chimeras. Data are mean ± 
s.e.m. obtained from 2 group of 5.
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Figure 5.42. Analysis of B cell subsets in the lymph nodes of 
thymectomised and sham thym ectom ised chimeras.
A. Percentages of total B cell (CD19+) subsets defined by slgM and 
slgD expression in the lymph nodes of the different chimeras. B. The 
percentage of CD44"/_ (Ly9.1+) cells in each B cell subset. C. 
Distribution of slgM and slgD staining among CD44'/_ or CD44+/+ CD19+ 
cells in thym ectom ised or sham thym ectom ised chimeras. Data are 
mean ± s.e.m. obtained from 2 group of 5.
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5.5. Summary of T cell development
In the previous chapters, it was shown that CD44'7' cells had a deficiency in T cell 
production when in competition with CD44+/+ cells, as manifested by reduced 
percentages of CD447' T cells in the secondary lymphoid organs and the peripheral 
tissues. In this chapter, the T cell developmental pathways were investigated in 
various chimeras.
In interpreting the data, it can be concluded that a block in T cell development will
result in an increase in a particular thymocyte subset. In this respect, it is
noteworthy that there was an increase in the percentage of CD44"7' cells in the DN
stage of T cell development in all chimeras. There was also a relative increase in
the proportion of CD44-7' cells at the SP stages and a reduction at the DP stage.
These results suggest that there is reduced development from the DN to the DP
stage among CD44'7’ cells, but that the DP to SP transition is not reduced.
As the DN stage of T cell development can be divided into four populations, further
investigations were carried out to determine whether CD44-7' cells were deficient in
progressing through any particular DN stage. This analysis was more difficult to
interpret, due to the very small percentages of cells in these subsets. However, the
data appeared to show a decrease in the transition of CD44'7" cells from DN1 to
DN2, an increase in the movement from DN2 to DN3, and a decrease in DN3 to
DN4 maturation. Although this trend appeared in most the various mixed chimeras
analysed, not all of the differences were statistically significant or consistent.
Perhaps surprisingly the analysis of chimeras four weeks after the intrathymic
injection of progenitor cells demonstrated fewer CD44"7" cells in the DN subset than
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the DP subset. This probably reflects limited renewal of progenitors injected into 
the thymus. As shown in the previous chapter, re-seeding of the thymus from BM 
progenitors still occurred after intrathymic injection, and this was evident in the 
greater percentage of CD44'/_ cells among DN cells at 6 weeks post-injection. This 
phenomenon was also observed with respect to the DN subsets. Four weeks post­
injection there was a higher percentage of CD44‘/_ cells among DN2 vs. DN1, and 
among DN4 vs. DN1 cells. By the following time point this trend had completely 
reversed to results comparable to i .v . injection, with DN1 having a higher 
percentage of CD44/_ cells than DN2 and DN4 a higher percentage than DN3. 
Overall, the main conclusion from the chimeras generated after i.t . injection was 
that the poor generation of T cells by CD44_/' progenitors in competition with 
CD44+/+ cells was not due strictly to reduced thymic entry.
Whist, analysing the thymic data it was also of interest to note there was a 
markedly lower percentage of CD44'7' CD4+ and CD8+ cells in the thymus 
compared than in the spleen and LN. This could potentially be due to peripheral 
proliferation of CD44/_ cells, although why they should expand faster than CD44+/+ 
cells is unclear. In this regard, it has been reported that CD44'7' cells are more 
resistant to AICD (255). Since the CD44'/_ cells have a normal TCRvp usage, any 
peripheral expansion would need to be polyclonal in nature. In addition, this 
finding suggests that CD44'/_ T cell development produces a full repertoire of CD4+ 
and CD8+ CD44 /_ T cells.
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5.6. Summary of B cell development.
The results of experiments investigating an influence of CD44 on B cell 
development were inconclusive. In two thirds of the chimeras there was a 
reduction of CD447' cells between the first (CD43+B220loslgM ) and the second 
(CD43‘B220loslgM) developmental stage. In five out of the six mixed chimeras 
there was an increase in CD44"7' cells from the second (CD43'B220loslgM’) to the 
third stage (B220loslgM+) of B cell development. Finally in two thirds of the 
chimeras, a decrease in the percentage of CD44'7' cells was observed between the 
third (B220,oslgM+) and fourth (B220h'slgM+) stages of B cell development. 
Although differences were observed, not all of these were statistically significant. 
Overall, it appeared that there was an increase in CD44-7' cells at stages 1 and 3. 
To determine whether production of CD44‘/_ B cells in mixed chimeras may have 
been boosted by precursors failing to gain entry to the thymus and returning to the 
BM chimeras were generated in thymectomised mice. In these mice, both CD44+/+ 
and CD44-7' cells destined for the thymus could return to the BM and join the B cell 
development pathway. These results were complicated by the presence of some 
donor T cells in the thymectomised mice, possibly generated in remnants of the 
host thymus. Nevertheless, the percentage of T cells produced was greatly 
reduced indicating that thymic function was largely abrogated. Importantly, there 
was no difference in the percentage of CD44 7' B cells between the thymectomised 
and sham-thymectomised chimeras. Therefore, depletion of CD44+/+ progenitors 
by homing to the thymus did not appear t play a role in the biased production of B 
cells by CD44'7' progenitors. It was also interesting to note that the CD44'7’ cells in
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the BM showed the same increases in stages 1 and 3 of B cell development as 
referred to above.
5.7.Conclusion
In conclusion it has been shown that there is an increase in CD44'/' cells present in
the DN stage of thymic development, meaning that there is a deficiency in the
ability of CD44'/_ cells to progress from the DN to DP stage. An accumulation of
CD44'7' cells at the DN stages 1 and 3 was also suggested, although the evidence
was less clear. The relative decrease among CD44'/_ thymocytes appeared to be
greater for the DP subset than for SP cells. There could be several possible
explanations. A, CD44'/_ DP cells may transit more rapidly than CD44+/+ DP cells
to the SP stages. B, CD44 7' DP cells not selected for progression may die more
rapidly than similarly unselected CD44+/+ DP cells. C, CD44'/_SP cells may persist
longer in the thymus than CD44SP cells, perhaps due to a deficiency in entering
circulation. The latter explanation seems unlikely since a consistently higher
percentage of CD44'/_ cells was observed among SP cells in the thymus. It may be
of interest to examine the turnover of thymocytes subsets in mixed chimeras to
investigate further the reasons for the altered subset composition.
Two conclusions can be made with respect to the role of CD44 in B cell
development. First failed homing of cells intended to become T cells does not
promote increased production of CD44'A B cells. Second, CD44'/_ B cells appear to
have an altered efficiency of differentiation that leads to an increase in the
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proportion of cells at developmental stages 1 and 3. The reasons for these 
differences are presently unknown.
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6. Chapter 6: Functional analysis of CD44'7' cells when 
placed in competition with CD44+/+ cells
6.1. Introduction
In the previous sections we have demonstrated that CD44 has a probable role in 
lymphocyte development apart from thymic and BM entry. In this next section we 
will investigate whether the CD44'/_ cells have any functional deficiencies when 
compared to CD44+/+ cells. Some investigation has been carried out by other 
groups using CD44‘/_ mice and comparing them to CD44+/+ mice. In addition, the 
role of CD44 has been studied using blocking antibodies and with transgenic cells 
that express only one variant exon. Both in  v iv o  and in  v it ro  experiments have 
been performed to identify any deficiencies or advantages that the CD44'/_ cells 
may have. In one example, CD44'7' NK cells were shown to be deficient in binding 
to and killing certain target cells (177). In another, the presence of v4-7 CD44 on 
the T cell surface was shown to increase the T cell response to mitogens (179). 
Variant isoforms of CD44 have been implicated in DC maturation and function. 
Human blood derived DCs upregulate v3, v6 &v9 after TNF-a stimulation, and anti­
variant CD44 antibodies subsequently induce DC aggregation, the upregulation of 
accessory molecules and the secretion of cytokines (117). Furthermore, v4, v5, 
v6, and v9 are upregulated by human Langerhan’s cells during migration. 
Blockage of these exons by antibodies in  v iv o  prevented Langerhan’s cell 
migration from the skin and binding to the T cell zones of the LNs (256). The same 
antibodies also severely inhibited induction of a delayed type hypersensitivity 
reaction in  v iv o  (257).
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CD44 has been implicated in cellular infiltration into inflammatory tissue, as treating 
mice with anti-CD44 antibodies was shown to decrease inflammation. However, 
whether anti-CD44 antibodies acted by preventing infiltration or by triggering 
apoptosis is unclear (241). CD44'7' mice have been shown to recover slowly after 
experimental induction of lung inflammation. It was proposed that this may be due 
to the presence of excess extracellular matrix proteins, such as HA, which 
continually triggered an inflammatory response combined with a reduced ability of 
CD44'7’ neutrophils to undergo apoptosis or to migrate out of the inflammatory site 
(258). This observation was repeated in tuberculosis infected mice, where there 
was an increased number of CD44'7' neutrophils present in the inflammatory site, 
demonstrating that CD44 was necessary for the resolution of the inflammatory 
response.
CD44 has also been linked to the production of cytokines. CD44'7' cells were also 
found to be deficient in TGF-p production in the context of an inflammatory 
response (139). In addition, CD44 has been linked to IFN-y production. 
to x o p la s m a  g o n d i i  infected mice had reduced IFN-y production when anti-CD44 
antibody was administered (258-260).
CD44'7* mice have been shown to have an elevated in  v iv o  primary and secondary 
response, to conalbumin and staphylococcal enterotoxin A, which has been linked 
to CD44‘7' cells being more resistant to activation induced cell death (AICD). The 
resistance to AICD was demonstrated for TCR-mediated apoptosis of thymocytes, 
which was not dependent on FAS. This group also demonstrated that injection of a 
blocking anti-CD44 antibody decreased the number of antigen specific T cells 
present during an immune response (255). In contrast, it has been reported that
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CD44''' epithelial cells are more susceptible to apoptosis, (261). In addition, CD44 
deficient mice were found to exhibit enhanced hepatitis after ConA injection. In this 
experiment the same amount of ConA was given to both wild type and knock out 
mice, while the result being that the knock out mice died of liver damage; CD44'/_ 
mice had increased levels of TNF-a, IL-2 and IFN-y. Finally, it was also shown that 
T cells from CD44'/_ mice were more resistant to activation induced cell death 
(262).
A role for CD44v7 in DTH responses has been suggested by studies showing that 
treatment with anti-CD44v7 could cure an inflammatory DTH response (180). It 
was proposed that the v7 exon provides survival signals and prevents the cell from 
undergoing apoptosis (183). CD44v10 has also been demonstrated to be involved 
in DTH (263). These data suggest that binding CD44 triggers survival and 
prevents apoptosis. This is in apparent contrast to the previously cited data 
suggesting the CD44 /_ cells were more resistant to AICD.
Further contradictory information on whether CD44 prevents or promotes apoptosis 
has come from studies of Fas mediated apoptosis. Stimulation of CD44 was 
shown to decrease FAS expression and therefore FAS mediated apoptosis on lung 
cancer cells (260). However, another study demonstrated that signalling through 
CD44 up-regulates FAS on rheumatoid synovial cells (264).
In summary, there are a number of observations that suggest that CD44 is an 
important functional molecule on T cells, and that its properties are altered by 
expression of variant exons and the type of cell that is involved. However, the 
precise expression pattern of CD44 isoforms on T cell subsets at different stages
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of activation and in different anatomical locations is not known. Furthermore, the 
importance of CD44 in immune functions overall remains unclear.
6.2.Aim.
To investigate the responses of CD44'7' T and B cells, to various immunological 
challenges when in competition with CD44+/+ cells.
6.3.Functional DCs responses
Preliminary investigations were carried out on splenic DCs from CD44+/+ & CD44'7' 
CD44+/+ chimeras mixed chimeras from section 3.3.1. It was also attempted to 
analyse BMDCs from these chimeras, but due to membrane swapping in culture, it 
was difficult to differentiate between CD44+/+ and CD44'/_ BMDCs. Cell-cell 
interaction can cause surface molecules to move from one cell to another, when 
BMDCs were generated from chimeric mice it was very difficult to distinguish the 
two populations based on Ly5.1+ staining (265). Therefore BM from either CD44'7' 
or CD44+/+ mice was used to generate BMDCs.
6.3.1.1. Phenotype of splenic DCs from CD44+/+ & CD44"7'—► CD44+/+ 
chimeras
The spleen from the chimeras was digested using Dnasel and Collagenase type 
IV, before the low density cells were collected by density centrifugation on
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nycodenz (Figure 6.1 A). The phenotype of the DC enriched fraction was analysed 
for subset composition and enrichment (6.1 B & C).
There were statistically more CD44'7' DCs present in the enriched sample than the 
pre-enriched sample, this could indicate that the CD44'7' DCs contained more low- 
density cells than the CD44+/+ cells. There also appeared to be statistical 
differences in the subset contribution of the DCs. There were more CD8+ and 
CD4+ DCs but fewer DN DCs derived from CD44‘/_ progenitors than in the CD44+/+ 
DC population.
6.3.1.2. CD44'7' splenic DCs express a more activated phenotype.
A profile of the activation markers on CD44+/+ and CD44 7' CD11c+ cells were 
compared using the enriched splenic DCs from CD44+/+ & CD44'7'—► CD44+/+ 
chimeras. The CD44"/_ DCs expressed significantly higher levels of the co­
stimulatory molecules CD80, CD86 and CD40 than CD44+/+ CD11c+ cells, as 
measured by MFI (Figure 6.2A). They also had higher expression of the adhesion 
molecule ICAM-1. This was associated with a higher percentage of CD44'7' 
CD11c+ showing positive expression of these markers (Figure 6.2B). In addition, 
ICAM-1 expression levels were the higher of ICAM-1+ CD44'7* than CD44+/+ CD11c 
(Figure 6.2C).
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Figure 6.1. CD11 c+ cells in spleen of CD44+/+ & CD44 7'- 
chimeras.
CD44+/+
A Percentage of CD44_/* CD11c splenic cells pre and post nycodenz 
enrichment. B, Purification of CD44+/+ and CD44*/' CD11c cells after 
nycodenz enrichment. C, Phenotypic distribution of CD44+/+ and CD44' 
'' CD11c splenic cells after nycodenz enrichment. The data are mean ± 
s.e.m. from 1 group of 4 chimeras. P values, 2-sample t test; *, P<0.05, 
**, P<0.01, ****, P<0.001. Black bars are CD44'7' cells (Ly5.1+), and 
white bars are CD44+/+ (Ly5.2+) cells.
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F ig u re  6.2. Expression o f activa tion  m arkers present on 
enriched D C ’s from  sp leens o f C D 44+/+ & C D 4 4 7'—► C D 44+/+ 
chim eras.
A E xpression (M FI) o f activa tion  m arkers on C D 11c+ cells from 
C D 44+/+ o r C D 4 4 7' cells. B, P ercen t C D 11c cells with positive 
expression o f co -s tim u la to ry  m olecu les, l-A b is percentage of 
cells w ith  high express ion . C. MFI o f C D 44+/+ or CD44V 
C D 11c+ cells, ga ted on positive  expression, or l-A b high 
expression. The data are m ean ± s.e.m . from  a group of 4 
ch im eras. P va lues, 2 -sam p le  t test; *, P<0.05, **, P<0.01, 
P<0.005, ****, P<0.001. B lack bars are C D 44 '/_ cells (Ly5.1+), 
and w h ite  bars are C D 44+/+ (Ly5 .2+) cells.
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6.3.1.3. CD44'/_ BMDCs express a more immature phenotype
BMDCs generated from CD44+/+ or CD447' mice were incubated at 37°C and at 
4°C with different sizes of fluorescent particles to measure their ability to internalise 
molecules in  v it ro . Different particle sizes were used measure the efficiency of 
different endocytic pathways: a fluorescent dye for pinocytosis, the latex beads for 
phagocytosis, and the FITC and APC particles for macro and micro endocytosis 
respectively. The resultant MFI then measures the efficiency of the different 
pathways. This is equal to the MFI after 30 minutes incubation at 37°C minus the 
MFI after 30 minutes incubation at 4°C. Initial results indicated that CD44‘/_ CD11c+ 
BMDCs cells uptake antigen better than CD44+/+ CD11c+ BMDCs (Figure 6.3A).
Among splenic DCs, CD44'/_ cells expressed a more mature phenotype by virtue of 
higher expression of activation markers than CD44+/+ CD11c cells. Since activated 
DC has a lower ability to uptake antigen, it was surprising to note that the CD44_/‘ 
BMDCs appeared to have a greater ability to uptake the fluorescent particles. 
However when the expression of the activation markers in the BMDCs were 
examined, the CD447’ cells appeared to be more immature (Figure 6.3B). This 
was consistent for all activation markers except ICAM-1, which had a greater 
expression on the CD44’7' BMDCs.
391
3500
3000
2500
2000
1500
1000
500
0
FITC Dye Latex APC
700 B
Figure 6.3. Expression of activation markers and uptake efficiency of 
CD44+/+ and C D 4 4 7' BMDC’s.
A, Resultant MFI o f CD11c+ cells after 30-minute incubation with 
different sizes o f fluorescent particles. B, Expression of activation 
markers on CD44+/+ and CD44'7' BMDC’s.
The data are from pooled BMDC’s from 3 CD44+/+ and 3 CD44‘/_ mice. 
Black bars are CD44"7' BMDC’s and white bars are CD44~ABMDC’s.
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6.3.1.4. CD44 '  and C D 447 cells stimulate Balb/c T cells differentially.
CD44+/+ or CD44'7' irradiated splenocytes or BMDC from CD44+/+ or CD44 7' mice 
were used to stimulate Balb/c LN T cells. Different numbers of CD44+/+ and CD44‘ 
1 stimulators were added (2x105, 1.5x10s, 1x10s, 5x104, 0) to a constant number of 
responders (10s cells/well). Tritiated thymidine was added to the cells 3 days after 
set up to measure the proliferation of the Balb/c effectors. The CD44'7' splenocytes 
stimulated the Balb/c cells to proliferate significantly more than the CD44+/+ 
splenocytes at all cell numbers except the lowest (Figure 6.4A). In contrast, the 
CD44+/+ BMDCs were more stimulatory than CD44_/‘ BMDCs, although this was 
only significant at the lowest concentration of BMDCs (Figure 6.4B).
6.3.1.5. CD44+/+ and CD44'/_ cells stimulate antigen-specific T cells 
differentially.
BMDC were derived from either CD44+/+ or CD44‘/_ mice. These were used to 
stimulate antigen specific transgenic CD4+ or CD8+ T cells. CD4+ T cells were 
obtained from OT2 mice and are specific for a peptide in ovalbumin (266). CD8+ T 
cells were obtained from 2C mice and are specific for Ld and also a Kb- restricted 
peptide (267). Spleens and LN were removed and pooled from the transgenic 
mice, B cell and MHCII depleted. Stimulation of CD4+ T cells from the OT2 mice 
was assessed after pulsing BMDCs with different concentrations of ovalbumin 
protein. The CD44+/+ BMDCs stimulated the T cells to proliferate more at higher 
concentrations of protein, whilst the CD44 7' cells appeared to stimulate the T cells 
better at lower concentrations.
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Figure 6.4. N on-spec ific  s tim u la tion  (M LR) o f C D 44+/+ C D 44'7' and 
Balb/C effectors.
A, Balb/C e ffec to rs  (LN ce lls ) s tim u la ted by d iffe ren t num bers of 
CD44+/+ and C D 44 '/_ irrad ia ted  sp lenocytes. B, Balb/C  effectors (LN 
cells) s tim u la ted by d iffe re n t num bers o f C D 44+/+ and C D 44 ';~ BM DC’s. 
C, CD44+/+ or C D 44_/" e ffec to rs  (LN cells) stim ulated w ith different 
numbers o f irrad ia ted  B a lb /C  sp lenocytes. The M LRs w ere carried out 
using 105 e ffec to rs  ce lls  pe r well, bu t a varied num ber o f irradiated 
stimulators rang ing from  2 x 1 05 to 5x104 in A  and C, and 1 x104 to 1 x103 
in B. The da ta  are m ean ±  s.e.m . from  4 identical wells, using cells 
pooled from  3 m ice, pe r stra in. P values, 2-sam ple t test; *, P<0.05,
**** P<o.ooi.
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Overall, the CD44 1 BMDC appeared to stimulate the T cells better (assessed by 
comparing all data in one statistical test) (Figure 6.5).
Stimulation of CD8+ T cells from 2C mice was investigated by adding different 
concentrations of specific peptide. The CD44+/+ BMDCs stimulated the 2C T cells 
to proliferate more at nearly all peptide concentrations (Figure 6.6).
6.4 . I n  v i t r o  T cell and B cell responses.
CD44+/+ and CD44_/" cells were sorted from spleens and LNs of mixed chimeras 
using Ly5.1 or Ly5.2 antibodies and tested for their ability to respond to different 
stimuli in  v itro . Proliferation of LN T cells was assessed using immobilised anti- 
CD3 and anti-CD28, while splenic B cell proliferation was measured in response to 
immobilised anti-lgM. There was very little difference between the CD44+/+ and 
CD44*/' cells with respect to the anti-lgM-induced proliferative responses (Figure 
6.7A). CD44+/+ cells appeared to be more proliferative in the first two days, but the 
CD44'/_ cells appeared to have a higher proliferation rate on days 4 to 5. This trend 
was also observed for the T cell response to anti-CD3 and anti-CD28 (Figure 
6.7B). During days 2-3, CD44+/+ cells appeared to be proliferating slightly more, 
although this difference was not statistically significant. However by days 4-5, 
CD44'/‘ cells had a statistically higher proliferative rate.
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C D 44+/+ and C D 44 '/_ spec ific  stim ulation of C D 4+ OT2 T
CD44+/+ and C D 44V' B M D C ’s w ere  incubated w ith a varying am ount of 
ova protein be fore  being added to OT2 cells a t various ratios. A, 
stim ulators w ere  incubated w ith  50|ug o f protein. B, stim ulators were 
incubated w ith 25pg o f protein. C, s tim u la tors  were incubated w ith 5jLig 
of protein. D, s tim u la to rs w ere  incubated w ith 1pg o f protein. The data 
are mean ±  s.d .m  from  4 identica l w ells, using cells pooled from  3 mice. 
P values, 2 -sam p le  t test; *, P<0.05, ****, P<0.001. The black bars are 
CD44'/_ and the  w h ite  bars are C D 4 4+/+. O verall C D 44+/+ BM DCs are 
statistica lly be tte r a t s tim u la ting  O T2 cells than C D 44'/_ BMDCs. 
P<0.005.
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F igure  6.6. S tim u la tion  o f C D 8+2C T cells by C D 44+/+ and CD44'7' 
BMDCs.
CD44+/+and C D 4 4 7' B M D C ’s w ere  incubated w ith a varying am ount of 
2C peptide be fo re  being added to 2C cells a t various ratios. A, 
S tim ulators w ere  incubated w ith 0.2nM  o f protein. B, S tim ulators were 
incubated w ith 0.1 nM o f peptide. C, S tim ula tors w ere incubated with 
0.05nM o f peptide . D, S tim ula tors  w ere  incubated with 0.01 nM of 
peptide. The da ta are m ean ± s.e.m . from  4 identical wells, using cells 
pooled from  3 m ice. P values, 2 -sam p le  t test; *, P<0.05, **, P<0.01, 
***, P<0.005, ****, P<0.001. The overa ll statistica l d ifference between 
the C D 44+/+and C D 44 '7' cells is P<0.001. The black bars are CD44 7' 
and the w h ite  bars are C D 44+/+.
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Figure 6.7. Stimulation of CD44+/+ and CD44'/_ T and B cells from 
CD44+/+ & C D 447'—► CD44+/+ chimeras.
A, Proliferation over time of CD44+/+ or CD44'/‘ sorted, pooled chimeric 
spleen cells which were stimulated using anti-IgM immobilised antibody.
B, Proliferation over time of CD44+/+ or CD44V‘ sorted, pooled chimeric 
LN cells which were stimulated using anti-CD3 & anti-CD28 immobilised 
antibody (+) or left unstimulated (-). The data are mean ± s.e.m from 4 
identical wells, from a group of 3 chimeras. P values, 2-sample t test; *, 
P<0.05, ***, P<0.005, ****, P<0.001.
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6.4.1. Allogenic stimulation
10 CD44 / and CD44/ LN cells from CD44+/+ and CD44‘/_ mice were stimulated 
with different numbers of irradiated Balb/c splenocytes. At two responder: 
stimulator ratios the CD44+/+ cells proliferated more than the CD44'7' cells (Figure 
6.4C). However, at other ratios no difference was observed, making interpretation 
difficult.
6.5 . I n  v i v o  B cell responses in CD44+/+ & CD44_/'—► CD44+/+ 
chimeras
As discussed in the introduction, B cells responses can be divided into two different 
types depending on the antigen: T-dependent and T-independent responses. We 
investigated B cell responses in  v iv o  to a T-independent antigen: DNP-ficoll, and a 
T-dependent antigen: chicken gamma globulin (CGG). The B cell response was 
measured by antibody production, which was aided by the fact that the CD44+/+ 
and CD44 7' mice have allotypically different Igs. CD44+/+ mice are lgHb, whereas 
CD44 7' mice are lgHa.
6.5.1. T-independent B cell responses
Mixed chimeras were immunised with DNP-ficoll, and the serum was collected 10 
days post immunisation. In addition, various tissues were removed and DNP-ficoll
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specific B cell elispots were performed to enumerate B cells secreting DNP-ficoll 
specific antibodies.
An allotope and DNP specific ELISA was performed to investigate the ability of 
CD44+/+ and CD44"/_ B cells to class switch. Endpoint titre were determined using 
pre-immune sera as the background (Figure 6.8A). No DNP-Ficoll specific 
antibodies of any isotype other than IgM were detected. lgMa or C D 4 4 '1' B cell 
antibodies predominated, although the difference was not statistically significant. 
The number of B cells producing DNP-ficoll specific antibodies was determined by 
a DNP-ficoll B cell specific elispot (Figure 6.8B). There were few specific cells 
isolated and all produced IgM isotype antibodies. There were more CD44'7' than 
CD44+/+ DNP-ficoll specific cells in the spleen and LNs. In contrast, the BM 
contained similar numbers of CD44+/+ and CD44’/_ DNP-ficoll specific B cells.
6.5.2. T-dependent B cell responses
Mixed chimeras were immunised with CGG, and the serum was collected from pre­
immunised mice, 10 days post-immunisation, 50 days post-immunisation and 10 
days post-secondary-immunisation. Upon sacrifice 10 days after secondary 
immunisation, various tissues were removed and CGG-specific B cell elispots were 
performed to enumerate B cells secreting CGG specific antibodies.
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An allotope CGG specific ELISA was performed to investigate the ability of CD44+/+ 
and CD44'/‘ B cells to respond to T-dependent antigens and to class switch. 
Endpoint titres were determined for all time points using the pre-immune sera as 
the background (Figure 6.9). Interestingly, while CD44‘/_ cells mainly produced 
significantly more IgM isotype antibodies at nearly all stages of the immune 
response. They produced less lgG2a and IgGi.
The number of B cells producing CGG specific antibodies was determined by a 
CGG B cell specific elispot. There were fewer CD44'7' CGG specific B cells 
producing antibodies of the three isotypes investigated in the spleen of the mixed 
chimeras (Figure 6.10). In the BM, the reverse was true, with more CD44'7" than 
CD44+/+ CGG specific B cells producing antibodies of all isotypes.
In the draining LN, there was a significantly higher number of CD447' cells 
producing IgM and IgGi CGG specific antibodies, but similar numbers of CD447 
and CD44+/+ cells producing lgG2a.
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Figure 6.9. CD44+/+ and CD44'/_ B cell responses to CGG in CD44+/'t‘ & 
CD44'7'—► CD44+/+ chimeras. I.
+/+
A,, Endpoint dilution of CGG specific IgM antibodies from CD44+/+ (lgMb) or 
CD44'/_ (lgM a) B cells. B, Endpoint dilution of CGG specific IgGi antibodies 
from CD44+/+ ( lg G ib) or CD44"/_ (IgG i3) B cells. C, Endpoint dilution of CGG 
specific lgG2a antibodies from CD44+/+ (lgG2ab) or CD44'/_ (lgG2aa) B cells. 
The data are mean ± s.e.m of endpoint dilutions, from a group of 4 
chimeras. P values, 2-sam ple t test; *, P<0.05, **, P<0.01, ***, P<0.005, 
****, P<0.001.
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A, CGG specific spot form ing cells from the spleen of mixed chimeras. B, CGG 
specific spot form ing cells from BM of mixed chimeras. C, CGG specific spot 
forming cells from the dLN of mixed chimeras. The data are mean ± s.e.m of spot 
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test; **, P<0.01.
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6.6 . I n  v i v o  T  cell responses in CD44+/+ & CD44'/_—► CD44+/+ 
chimeras
6.6.1. T  cell responses to soluble protein.
Mixed chimeras were immunised with ova and their T cell response was measured 
8 days after immunisation. Antigen specific CD8+ T cells were measured using 
MHCI tetramers and by intracellular IFN-y production by the CD8+ T cells after 
stimulation with the dominant ova epitope. A significantly lower percentage of 
CD44'/_ than CD44+/+ CD8+ T cells was tetramer positive in the spleen (Figure 
6.11 A). A higher proportion of CD44'/_ cells were tetramer positive cells in the LN 
than in the spleen. Although these results suggests a specific deficit of ova- 
specific, CD44‘/_ CD8+ T cells in the spleen, similar proportions of CD44_/' and 
CD44+/+ CD8+T cells were ova-specific as measured by intracellular IFN-y staining 
(Figure 6.11B). The reason for this discrepancy is unclear.
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Figure 6.11. CD44+/+ and CD44 7' CD8+ T cell responses to ova in
CD44+/+ & C D44'/_- CD44+/+ chimeras. I.
A, Percentage of ova-tetramer+ cells in the CD8+ CD44+/+ or CD447' 
populations from the spleen or dLN of mixed chimeras. B, Percentage 
of IFNy producing splenic CD8+ CD44+/+ or CD44'A cells in response to 
ova peptide. The data are mean ± s.e.m from a group of 5 chimeras. 
P values, 2-sample t test; *, P<0.05, **, P<0.01.
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As a further measure of the T cell response, splenic cells were sorted into Ly5.1 + 
and Ly5.2 populations and then set up in a proliferation assay with either an ova 
MHCI-restricted peptide or ova protein to stimulate the ova specific cells, 
stimulation with ova protein and peptide may elicit responses by both CD4+ and 
CD8+ T cells. There was very little difference in proliferation between the CD44+/+ 
and CD44'/_ cells in the first two days of peptide stimulation. At subsequent time 
points, CD44'/_ cells proliferated significantly more than the CD44+/+ cells (Figure 
6.12A). Similar results were observed with protein stimulation (Figure 6.12B). 
What was interesting to note was that with the peptide stimulation, the CD44+/+ cell 
proliferation rate appeared to peak at day 2, whereas proliferation of the CD44"A 
cells continued to increase until day 3, and then remained constant for at least two 
more days. With protein stimulation, the proliferation of CD44+/+ cells peaked at 
day 3 and had decreased by day 4. In contrast, proliferation of CD44'/_ cells was 
equally as high on day 4 as on day 3.
6.6.2. T  cell responses to LCMV
Mixed chimeras were infected with lymphocytic choriomeningitis virus (LCMV), and 
sacrificed 8, 14, 20, and 50 days post-infection. Pieces of spleen were taken and 
frozen so that the viral titre could be measured. Virus was found in 2 of the 3 
chimeras sacrificed at day 8, and in 1 of 2 chimeras at day 14, but was 
undetectable by day 20, indicating that the mice could successfully clear the virus 
(Figure 6.13).
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Figure 6.12. CD44+/+ and CD44''" CD8+ T cell responses to ova in 
CD44+/+ & CD44‘/"—► CD44+/+ chimeras. II.
A, Proliferation of sorted CD44+/+ and CD44'/' cells stimulated with an 
CD8 ova peptide. B, Proliferation of sorted CD44+/+ and CD44'7' cells 
stimulated with a ova protein. The data are mean ± s.e.m from a group 
of 5 chimeras, each with a triplicate well.. P values, 2-sample t test; *, 
P<0.05, **, P<0.01, ***, P<0.005, ****, P<0.001. The white bars are 
CD44+/+ and the black bars are CD44_/'.
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Figure 6.13. Individual viral titration from spleen of LCMV infected 
CD44+/+ & CD44'7'—► C D 44+/+ chimeras.
A pieces of spleen was removed from each sacrificed chimera. The 
viral titre was then m easured by plaquing a diluted amount of tissue. 
Each bar represents one chimera. 2/3 chimeras sacrificed on day 8 had 
virus, 1 o f 2 chim eras had virus present on day 13. 0/3 chimeras had 
detectable virus on day 20. Day 50 was not examined.
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6.6.2.1. CD8+T cell response
The frequency of antigen specific CD8+ T cells was investigated using a mix of 
tetramers for the 3 most-dominant epitopes of LCMV (Figure 6.14). In the spleen 
there was a significantly higher percentage of tetramer positive CD8+ T cells in the 
CD44+/+ population than in the CD44'7' population (Figure 6.14A). In the LNs a 
lower percentage of tetramer positive CD44'7’ cells was also observed at early 
(day8 and day 13) but not late times post-infection (Figure 6.14B). In the blood, 
due to the difficulties in recovering blood from sick animals, it was only possible to 
perform analysis on 2 chimeras, and therefore the results were not always 
statistically significant. Nevertheless, there was a higher percentage of tetramer 
positive CD44+/+ than CD44'7' cells at all time points (Figure 6.14C).
To compare the kinetics of the appearance/disappearance of CD44+/+ and CD44’7' 
antigen specific cells, the proportion of tetramer positive cells was plotted against 
time (using different scales for CD44+/+ and CD44'7' cells) (Figure 6.16). Within the 
spleen, the CD44+/+ and CD44'7- cell kinetics appeared to be identical for the first 3 
weeks post infection. However, by day 50, the percentage of tetramer+ CD44+/+ 
cells, continued to decrease. Whereas the percentage of tetramer+ CD44’7' cells 
appeared to increase compared to that at day 20 (Figure 6.15A). These differing 
trends were also observed in the blood (Figure 6.15C) and to a lesser extent within 
the LNs (Figure 6.15B).
These results suggest that there may be differences in the homeostatic survival 
and/or migratory patterns of CD44+/+ and CD447 memory CD8 T cells.
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Figure 6.14. CD8 + T cell response to LCMV in CD44+/+ & CD44*'*- 
CD44+/+ chimeras. I.
A, Percent of CD 8 + CD44+/+ or CD44'/' that are tetramer positive in the 
spleen at various times afte r infection. B, Percent of CD8+ CD44+/+ or 
CD44V‘ that are tetram er positive in the LN at various times after 
infection. C Percent o f CD 8 + CD44+/+ or CD44'" that are tetramer 
positive in the blood at various times after infection. The data are mean 
± s.e.m. Day 8  and 13 obtained from 3 chimeras, except blood where 
from 2. Day 20 obtained from 3 and day 50 obtained from 4 chimeras. 
P values, 2-sample t test; *, P<0.05, **, P<0.01, ***, P<0.005.
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Figure 6.15. CD 8 + T cell response to LCMV in CD44+/+ & CD44'/' 
CD44+/+ chimeras. II.
A, Percent o f CD 8 + CD44+/+ or CD44V' that are tetramer positive in the 
spleen at various times after infection. B, Percent of CD8 + CD44+/+ or 
CD44V' that are tetram er positive in the LN at various times after infection. 
C Percent o f CD8 + CD44+/+ or CD44V' that are tetramer positive in the 
blood at various times after infection. D, Culmination of tetramer positive 
cells, from the different organs examined at various times after 
development. The data are mean. Day 8  and 13 obtained from 3 chimeras, 
except blood where from 2. Day 20 obtained from 3 and day 50 obtained 
from 4 chimeras.
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Antigen-specific CD8+ T cells were also enumerated using intracellular staining for 
TNF-a and IFN-y. On day 8, CD44'7' CD8+ cells in the spleen, LN and blood of the 
infected mice showed a reduced percentage of IFN-y and TNF-a positive cells 
compared to CD44+/+ CD8+ cells, although this difference was not statistically 
significant (Figure 6.16 & 6.17). On day 20, these differences were more 
pronounced and statistically significant for both the spleen and blood lymphocytes 
(Figure 6.18 & 6.19). Interestingly, by day 50, although CD44-7' CD8+ T cells had a 
lower percentage of IFN-y and TNF-a producing cells than CD44+/+ cells in the 
spleen, the percentages of cytokine producing CD44'7' and CD44+/+ cells was 
similar in the LN, while CD44-7' CD8+ T cells had a higher percentage of IFN-y 
producing cells in the blood (Figure 6.20 & 6.21).
6.6.2.2. CD4+T cell response
The CD4+ T cell response was measured by intracellular cytokine staining after 
treatment of cells with MHCII restricted LCMV peptides. On day 8 there was no 
significant difference between CD44+/+ and CD44‘7' cells in the percentage of CD4+ 
cells producing IFN-y or TNF-a in the spleen, LN or blood (Figures 6.22 & 6.23). 
On day 20, although the CD44'7' CD4+ T cells appeared to have a reduced 
percentage of both TNF-a and IFN-y producing cells, in the spleen, LN and blood, 
these differences again were not statistically significant. By day 50 of the immune 
response, however a significantly higher proportion of splenic CD44 7 CD4 T cells 
expressed TNF-a (Figure 6.27). In the LN, similar proportions of CD44+/+ and 
CD44'7' cells produced IFN-y and TNF-a in response to peptide stimulation.
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Figure 6.16. CD 8 + T cell IFN-y production on day 8  in response to LCMV in
CD44+/+ & C D 44 '"—► CD44+/+ chimeras+/+
A, Percentage o f CD44+/+ or CD44''" CD 8 + cells from spleen producing 
intracellular IFN-y in response to various stimuli. B. Percentage of CD44+/+ 
or CD44'7* C D 8 + cells from LN, producing intracellular IFN-y in response to 
various stimuli. C, Percentage of CD44+/+ or CD44 ;’ CD 8 + cells from the 
blood producing intracellular IFN-y in response to peptide.
The data are mean ± s.e.m. Uninfected 1 chimera, infected spleen and LN 3 
chimeras, blood 2 chimeras. P values, 2-sample t test; ***, P<0.005.
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Figure 6.17. CD 8 + T cell TN F-a production on day 9 in response to
LCMV in CD44+/+ & C D 4 4 '--*  CD44+/+ chimeras.i+/+
A, Percentage of CD44+/+ or CD44'7' CD 8 + cells from spleen producing 
intracellular TN F-a  in response to various stimuli. B. Percentage of 
CD44+/+ or C D44'/'C D 8 + cells from LN, producing intracellular TNF-a in 
response to various stimuli. C, Percentage of CD44+/+ or CD44'/"CD8+ 
cells from the blood producing intracellular TNF-a in response to 
various stimuli.
The data are mean ± s.e.m. Uninfected 1 chimera, infected spleen and 
LN 3 chimeras, blood 2 chimeras. P values, 2-sample t test; ***, 
P<0.005.
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Figure 6.18. C D 8 + T cell IFN-y production on day 20 in response to 
LCMV in C D 44+/+ & CD44'/--> CD44+/+ chimeras.
A, Percentage o f C D 44+/+ or CD44'/_ CD 8 + cells from spleen 
producing in trace llu lar IFN-y in response to various stimuli. B. 
Percentage o f C D 44+/+ or CD44"7' CD 8 + cells from LN, producing 
intracellular IFN-y in response to various stimuli. C, Percentage of 
CD44+/+ or C D 44 '/_ C D 8 + cells from the blood producing intracellular 
IFN-y in response to peptide. The data are mean ± s.e.m. 
Uninfected 1 chim era, infected spleen, LN blood 3 chimeras. P 
values, 2-sam ple t test; **, P>0.01 ***, P<0.005.
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Figure 6.19. C D 8 + T cell TN F-a production on day 20 in response to 
LCMV in C D 44+/+ & CD44’7-— CD44+/+ chimeras.
A, Percentage o f C D 44+/+ or CD44'7' CD 8 + cells from spleen producing 
intracellular T N F -a  in response to various stimuli. B. Percentage of 
CD44+/+ or C D 44 '/‘ C D 8 + cells from LN, producing intracellular TNF-a in 
response to various stimuli. C, Percentage of CD44+/+ or CD44_/' CD8 + 
cells from the blood producing intracellular TN F-a in response to 
peptide. The data are mean ± s.e.m. Uninfected 1 chimera, infected 
spleen, LN and blood 3 chimeras. P values, 2-sample t test; **, 
P<0.01, ****P<0.001.
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Figure 6.20. C D 8 + T cell IFN-y production on day 50 in response to 
LCMV in CD44+/+ & CD44'/'->  CD44+/+ chimeras.
A, Percentage of CD44+/+ or CD44_/' CD 8 + cells from spleen 
producing in tracellu lar IFN-y in response to various stimuli. B. 
Percentage o f C D 44+/+ or CD44'7' CD 8 + cells from  LN, producing 
intracellular IFN-y in response to various stimuli. C, Percentage of 
CD44+/+ or CD44 7’ C D 8 + cells from the blood producing intracellular 
IFN-y in response to various stimuli.
The data are mean ± s.e.m. Uninfected 1 chimera, infected spleen, 
LN and blood 4 chim eras. P values, 2 -sample t test; *, P<0.05.
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Figure 6.21. C D 8 + T cell TN F-a production on day 50 in response 
to LCMV in C D 44+/+ & CD44 /'- ^  CD44+/+ chimeras.
A, Percentage o f C D 44+/+ or CD44'/_ CD 8 + cells from spleen 
producing in tracellu lar TN F-a in response to various stimuli. B. 
Percentage o f C D 44+/+ or CD44'/_ CD 8 + cells from LN, producing 
intracellular T N F-a  in response to various stimuli. The data are 
mean ± s.e.m. Uninfected 1 chimera, infected spleen, LN 4 
chimeras. P values, 2-sam ple t test; ***, P<0.005.
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Figure 6.22. C D 4 + T  ce ll IFN-y p roduction  on day 8 in response  to LC M V in 
CD44+/+ & C D 44 /'->  C D 4 4 +/+ ch im eras.
A, Percentage o f C D 4 4 +/+ o r C D 4 4 '/‘ CD4+ cells from  sp leen producing 
in tracellu lar IFN-y in resp on se  to  various stimuli. B. P ercentage o f C D 44+/+ 
or CD 44'7' C D 4+ ce lls  from  LN, producing in tracellu lar IFN-y in response to 
various stim uli. C, P e rcen tag e  o f CD44+/+ or C D 4 4 ; C D 4+ ce lls  from  the 
blood producing in tra ce llu la r IFN-y in response to various stim uli.
The data are m ean ±  s .e .m . U n in fec ted  1 chimera, infected sp leen and LN 3 
chimeras, b lood 2 ch im e ras . P va lues, 2 -sam ple t test; ***, P<0.005.
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6 .23 . C D 4 + T  ce ll T N F -a  p ro d u c tio n  on day 8  in response  to
in C D 4 4 +/+ & C D 4 4 '/‘-+  C D 4 4 +/+ ch im e ras .
A, P e rcen tage  o f C D 4 4 +/+ o r C D 4 4 '7' C D 4 + ce lls  fro m  sp leen  producing  
in trace llu la r T N F -a  in re sp o n se  to  va rio u s  s tim u li. B. P ercen tage  of 
C D 44+/+ o r C D 4 4  /_ C D 4 + ce lls  fro m  LN, p roduc ing  in tra ce llu la r T N F -a  in 
response to  v a rio u s  s tim u li. C, P e rce n ta g e  o f C D 4 4 +/+ o r C D 4 4 ; C D 4+ 
cells from  th e  b lood  p ro d u c in g  in tra ce llu la r T N F -a  in response  to 
various s tim u li.
The data  a re  m ean  ±  s .e .m . U n in fe c te d  1 ch im era , in fected  sp leen  and 
LN 3 ch im e ra s , b lood  2 ch im e ra s . P va lues, 2 -sam p le  t test; ***, 
P<0.005.
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Figure 6.24. C D 4+ T cell IFN-y production on day 20 in response to LCMV in 
CD44+/+ & CD44 7' —  C D 44+/+ chim eras.
A, Percentage o f C D 44+/+ or C D 44 '7' C D 4+ cells from spleen producing 
intracellular IFN-y in response to various stimuli. B. Percentage of CD44+/+ 
or C D44_/* C D 4+ cells from  LN, producing in tracellu lar IFN-y in response to 
various stim uli. C, P ercentage o f C D 44+/+ or C D 44’7’ C D 4+ cells from the 
blood producing in trace llu la r IFN-y in response to various stimuli.
The data are m ean ± s.e.m . Uninfected = 1 chimera, infected spleen and LN 
= 3 chim eras, b lood = 2 chim eras.
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Figure 6.25. C D 4+ T cell T N F -a  production on day 20 in response to 
LCMV in C D 44+/+ & C D 4 4 ''- *  C D 44+/+ chim eras.
A, Percentage o f C D 44+/+ or C D 44 '7' C D 4+ cells from  spleen producing 
in tracellu lar T N F -a  in response to various stimuli. B. Percentage of 
CD44+/+ or C D 44 '7' C D 4+ cells from  LN, producing intracellular TN F-a in 
response to various stim uli. C, Percentage o f C D 44+/+ or C D 4 4 ; CD4+ 
cells from  the  blood producing in trace llu lar TN F-a  in response to 
various stim uli.
The data are m ean ± s.e.m . Uninfected = 1 chim era, infected spleen 
and LN = 3 ch im eras, b lood = 2 chim eras.
423
(U
> 2
COo
CL 1.5
Z 1
Ll
-*-*
c
I 0.5o
a3
CL 0
C D 44+/+
infected
CD 44-/- infected C D44+/+
uninfected
□  Without peptide 
■  With peptide
CD44-/-
uninfected
o 0.1
B
□  Without peptide 
■  With peptide
C D 44+/+  infected C D 44-/- infected
a>
>
COo
CL
z
LL
-4-t
C
Cl)£2<u
o.
C D 44-/- infected CD44+/+
infected
C D 44-/- 
un infected
□  Without peptide 
■  With peptide
CD44+/+
uninfected
Figure 6.26. C D 4 + T  ce ll IFN -y p ro du c tio n  on d ay  50 in response
to LC M V  in C D 4 4 +/+ & C D 4 4 '" ^  C D 4 4 +,+ ch im e ra si + / +
A, P e rcen tag e  o f C D 4 4 +/+ o r C D 4 4 ';" C D 4 + ce lls  from  sp leen 
p roducing  in tra c e llu la r IFN -y in re sp on se  to  va rio us  stim u li. B. 
P ercen tage  o f C D 4 4 +/+ o r CD44*7' C D 4 + ce lls  from  LN, producing 
in tra ce llu la r IFN -y in re sp on se  to  va rio us  s tim u li. C, P ercen tage  of 
C D 44+/+ o r C D 4 4 ’7'  C D 4 + ce lls  fro m  the  b lood producing 
in tra ce llu la r IFN -y in re sp on se  to  va rio u s  s tim u li.
The da ta  a re  m ea n  ±  s .e .m . U n in fec ted  = 1 ch im era , in fected 
sp leen  and  LN = 4  ch im e ra s , b lood  = 3 ch im e ras .
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Figure 6.27. C D 4 + T  ce ll T N F -a  p ro du c tio n  on day  50 in 
response to  L C M V  in C D 4 4 +/+ & C D 4 4 '7*—► C D 4 4 +/+ ch im e ra s .
A, P ercen tage  o f C D 4 4 +/+ o r C D 4 4 _/' C D 4+ ce lls  fro m  sp leen  
producing in tra c e llu la r T N F -a  in re sp on se  to  va rio us  s tim u li. B. 
Percentage o f C D 4 4 +/+ o r C D 4 4 _/' C D 4 + ce lls  from  LN, p roduc ing  
in trace llu lar T N F -a  in re s p o n s e  to  va rio us  s tim u li. C, P e rcen tage  
of C D 44+/+ o r C D 4 4 '7* C D 4 + ce lls  fro m  the  b lood  p roduc ing  
in trace llu lar T N F -a  in re s p o n se  to  va rio us  s tim u li.
The data are  m ean  ±  s .e .m . U n in fec ted  = 1 ch im era , in fected  
spleen and LN = 4 ch im e ra s , b lood  = 3 ch im eras.
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As with the CD8 T cells, the CD44-/" CD4+ T cells in the blood had a higher 
percentage of IFN-y producing cells than CD44+/+ CD4+ T cells.
6.7.DC summary
DCs derived from the spleens of chimeric mice showed differences between CD44" 
'' and CD44+/+ cells in subset distribution, with more CD447' DCs expressing CD4 
and CD8 molecules. CD44'7* DCs also expressed a more activated phenotype, 
exhibiting up regulation of both co-stimulatory and adhesion molecules, especially 
ICAM-1.
In contrast BMDCs from CD44/_ mice expressed a more immature phenotype than 
those from CD44+/+ mice, having lower expression of both co-stimulatory and 
adhesion molecules. The exception was ICAM-1, which had a higher expression 
on CD44V' BMDCs than CD44+/+ BMDCs. As was observed in the splenic DCs.
The ability of BMDCs to take up antigen was briefly examined. The CD44"7' 
BMDCs could take up more antigen in the time allowed than the CD44+/+ cells. As 
the ability of DCs to take-up antigen decreases with maturity, the greater ability of 
CD44'7' DCs to take up antigen is consistent with their more immature phenotype.
The ability of CD44+/+ or CD44'7’ splenic cells and BMDC to stimulate allogenic T
cells was examined. CD44 7' splenocytes stimulated a higher level of proliferation
by Balb/c responders than the CD44+/+ splenocytes. This is consistent with the
previous data, which indicated that CD44'/_ splenic DCs were phenotypically more
mature and therefore expressed more co-stimulatory molecules. Conversely,
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CD44 1 BMDCs stimulated the Balb/c responders to proliferate more, in keeping 
with their more mature phenotype.
The ability of CD44+/+ and CD44'/_ BMDCs to stimulate antigen-specific CD4+ and 
CD8+ T cells was investigated using transgenic T cells. There were mixed results. 
At the high concentrations of ova CD44+/+ BMDCs appeared to stimulate more 
proliferation of OT2 cells, whereas at lower concentrations CD44_/' cells appeared 
to be more effective stimulators. However, the results obtained using higher 
concentrations of ova are likely more reliable, since there was a titration effect 
apparent with changing Tcell: BMDC ratios which was not observed at the lower 
concentrations.
The ability of CD44+/+ and CD44_/‘ BMDCs to stimulate antigen-specific CD8+ T 
cells was investigated using 2C transgenic T cells, whose CD8+ T cells are specific 
for 2C peptide. At nearly all peptide concentrations and T:DC ratios, the CD44+/+ 
cells were better at stimulating the T cells to proliferate.
6.8.B cell summary
Sorted CD44+/+ and CD44_/' B cells from mixed chimeras were stimulated In  v itro  by 
immobilised anti-lgM. As similar experiments had been performed by other groups 
using CD44+/+ and CD44_/' mice, this experiment was only to ensure that B cells 
obtained from mixed chimeras were capable of responding in a similar fashion as 
the CD44+/+ B cells. This proved accurate and there was very little difference in the 
proliferation of CD44+/+ and CD44'/_ B cells in response to immobilised anti-lgM.
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The in  v iv o  B cell responses demonstrated that CD44'7' cells produced the majority 
of the antibody in response to the T-independent antigen DNP-Ficoll. The majority 
of the SPC were found within the spleen, and were most likely B1-B cells or MZB 
cells. The in  v iv o  response to the T-dependent antigen CGG also showed that 
CD44‘/‘ B cells had a predisposition towards IgM production. Although CD44'7' B 
cells could class switch to both IgGi and lgG2a, there were still significant amounts 
of IgM present on day 50. Upon re-challenge, the CD44'7' cells appeared to 
produce primarily IgM rather than IgGi or lgG2a like the CD44+/+ cells. The 
localisation of the antibody secreting cells was also different. The CD44+/+ IgM 
secreting cells were mainly found in the spleen after re-immunisation, suggesting 
that the IgM secreting cells were newly recruited plasma cells. However the 
majority of CD447* IgM secreting cels were found in the BM, implying that these 
were memory plasma cells. With regards to IgGi production there were similar 
numbers of CD44+/+ and CD44-7' IgGi secreting B cells found distributed throughout 
the investigated tissues. This is in stark contrast to the ELISA data which suggests 
that the CD44'7' B cells produce little IgGi antibody in the serum. lgG2a-secreting B 
cells were also detected throughout the tissues investigated, with CD44+/+ and 
CD44’7' cells having similar numbers. However the ELISA data is inconclusive 
although it appears as thought the CD44"7’ B cells again produce very little lgG2a.
6.9.T cell summary
The ability of the CD44+/+ and CD44'7' T cells to respond were tested MLRs using 
Balb/c splenocytes and T cells from CD44 7 and CD44 mice. These results
indicated that as sub-optimum conditions the CD44+/+ cells responded better to 
stimulation than the CD44'7 cells. In  v it ro  T cell stimulation of chimeric T cells 
demonstrated that CD44+/+ and CD44'7' cells produced a similar early response but 
at later points CD44'7' cells proliferated significantly more than CD44+/+ cells in 
response to anti-CD3 and anti-CD28 stimulation.
In  v ivo  T cell responses were investigated in the chimeric mice using ova protein 
and LCMV. Measurement of the CD8+ T cell response to ova using tetramers 
indicated that the response was significantly lower for CD447' CD8+ T cells in the 
spleen. There were significantly more CD44'7’ ova specific CD8+ T cells present in 
the LN than in the spleen, possibly reflecting an altered migration of responding 
cells. However, when the response was investigated using ICS to detect IFN-y 
production by the CD8+ cells in the spleen similar percentages of responding 
CD44"7' and CD44+/+ CD8+ T cells were detected. Interestingly, upon re-stimulation 
In  v itro  CD44'7' T cells were able to maintain proliferation longer than CD44+/+ 
cells.
The T cell response to LCMV also showed surprising differences between CD44+/+ 
and CD44V‘ cells. Again there were fewer CD44'7' antigen specific CD8+ cells 
present in the spleen, LN and blood on most days after infection. Responses 
measured by ICS for IFN-y and TNF-a production mirrored the tetramer data. 
When the kinetics of the tetramer specific CD44+/+ or CD44‘/_ cells was examined, it 
appeared as though CD44'7’ may persist, at least in the blood longer than CD44+/+ 
cells. A reduced response among CD44’7" cells was also indicated for CD4 T 
cells, where more CD44+/+ CD4+ T cells producing TNF-a and IFN-y were detected.
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6.10. Discussion
There appeared to be a difference in the contribution of CD44'7' cells to different 
DC subsets. It is difficult to conclude whether this has any relevance to the 
developmental pathways of DC lineage, as DC lineages themselves remain poorly 
understood. The CD44'7' DC also appeared to be more mature in  v iv o  than 
CD44+/+ DCs; a hierarchy which was reversed for DC generated in  v itro  from BM 
precursors. The reasons for this are unknown. DCs can be activated by numerous 
triggers, including HA. Therefore, it is possible that in in  wYro-derived CD44+/+ DC’s 
receive a stimulus from HA produced by cells in tissue culture. Greater maturation 
of CD44'7* DC’s in vivo could be related to up-regulation of other adhesion 
molecules such as ICAM-1 on these cells. This could change the migrational 
properties of the CD44'7" DC and lead to migration-associated maturation.
During the B cell response to DNP-ficoll, CD44-7' cells produced a stronger 
response than CD44+/+ cells. Conversely, during responses to a T-dependent 
antigen, B cells did not appear to undergo efficient class switching. These results 
imply that CD44’7' B cells may not interact efficiently with helper T cells. This could 
be related to altered migration of activated B cells, or to changes in the way T cells 
and B cells actually interact.
The CD44'7* T cell responses were also lower than expected, although in response
to soluble protein a lower response was detected in the spleen but not in the LN.
This could be in part due to differences in migrational properties of the CD44'7’ cells
between the spleen and LN as demonstrated in a previous chapter. It was
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surprising to note that the CD447 CD8+ T ceils produced an equivalent percentage 
of IFN-y positive cells compared to the CD44+/+ CD8+ T cells, considering the 
reduced percentage of tetramer specific cells. Another surprising result was the 
proliferation data, in which the CD44'7' cells over time produced a higher and more 
sustained proliferative response than the CD44+/+ cells. This could be explained by 
the potential resistance of CD44'7' cells to AICD.
After infection with LCMV, the CD44 /_ CD8+ T cells again did not compete well 
against CD44+/+ T cells. This could be due to competition between the CD44+/+ 
and CD44*7' T cells for interactions with DCs. Over time however the LCMV- 
specific CD44'7" CD8+ T cells appeared to persist better than the CD44+/+ cells. 
This could again be a reflection of a relative resistance of CD44’7' T cells to 
apoptosis. Alternatively, it could be a result of less migration of CD44’7' cells into 
peripheral tissues.
Therefore, in summary, CD44'7' cells when generated in competition with CD44+/+ 
cells can still respond to in  v iv o  stimuli and mount a response, although this 
response is muted compared to the CD44+/+ response. We suggest that in the 
early stages of the response when in competition the CD44"7' cells are 
disadvantaged by weaker cell-to-cell contact which allows the CD44+/+ cells to 
mount a quicker and stronger response. However, after the immune response has 
decreased, the CD44‘7" cells, hampered by their inability to migrate into the 
inflamed tissues, re-circulate, as demonstrated by a significantly increasing 
percentage of CD44'7' tetramer positive cells present in the blood. As they are
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potentially more resistant to AICD, over time they recover their peak percentages 
due to turnover and a lack of apoptosis and cell death, and preferentially develop 
into central memory cells.
Another conclusion to be made is that although CD44'7' cells do not have the 
characteristic T cell activation and memory marker CD44, this does not prevent 
them from forming memory T or B cells.
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7. General discussion.
7.1. Phenotype
The aim of this thesis was to investigate the developmental and functional roles of 
CD44 on T and B cells. Considering that CD44 had been implicated in a range of 
lymphocyte activities, published studies on the CD44"7' mice have revealed 
surprisingly minor defects. Therefore it was decided to generate CD44+/+ and 
CD44'7" mixed bone marrow chimeras. These mice revealed a deficiency in the 
production of CD44'7’ T cells, and, amongst T cells a bias towards increased 
generation of CD4+ and more especially CD4+ CD25+ T cells. This was 
accompanied with an excess of CD44'7' B cells, especially MZB cells, but also a 
decrease in B-1a B cells. This phenotype was also observed, when mixed 
chimeras were generated in CD44‘7' hosts. Therefore the phenotype was not 
dependent on CD44 expression in the host, and probably a result of an inherent 
disadvantage of the CD44'7' cells themselves. Subsequent experiments then 
established that this phenotype was only apparent when CD44"7" cells were in 
competition with CD44+/+ cells.
When mixed BM chimeras were challenged with various immune stimuli, it was 
observed that the CD44'7' B cells had a deficiency in class switching and appeared 
to produce less antibody to T dependent antigens, even though they had similar 
numbers of antigen specific B cells. The response of CD447 CD8+ T cells was 
also diminished compared to CD44+/+ cells after challenge with ova or LCMV. In
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response to LCMV infection, the CD44’/_ T cells had an even greater reduction in 
IFN-y and TNF-a producing cells than tetramer binding cells, although this was not 
observed after ova immunisation.
In  v itro  studies demonstrated that CD44_/' BMDCs were phenotypically more 
immature than CD44+/+ BMDCs. This contrasted with splenic CD44'7’ DCs, in which 
case CD44_/' DCs were more mature than CD44+/+ DCs. The phenotypic 
immaturity of CD44 7’ BMDCs was associated with a reduced ability to stimulate 
CD4+ or CD8+ T cells.
7.2.CD44 in lymphocyte distribution, migration and homing
When mature T and B cells were examined, it was discovered that there were 
differences in the distribution of CD44'/_ cells between the spleen and LN. More 
CD44'a B and T cells were found in the LN than the spleen. CD44'/_ and CD44+/+ T 
and B cells also exhibited differences in the expression of adhesion molecules. 
For B cells, these differences included increased expression of CD62L and 
p2integrin and decreased expression of CD48, LPAM-1, and syndecan. 
Differences apparent in the CD44/_ T cell population included an increase in 
CD102, CD11a and a4integrin. These alterations in adhesion molecule expression 
could help to explain the distribution of the CD44'/_ cells. Since CD62L is a LN 
homing marker, an increase in CD62L on CD44 /_ B cells could be why there are 
more CD44*7’ B cells present in the LN.
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Upregulation of adhesion molecules could represent a cellular adaptation to the 
absence of CD44. For example, since CD44 has been demonstrated to interact 
with CD11a on the surface of cytotoxic cells (177), it is possible that without CD44, 
there is a compensatory increase in CD11a expression. This could also be true for 
cuintegrin expression. CD44 interacts with the a^ntegrin in phagocytosis, and 
therefore a lack of CD44 could necessitate a compensatory increase in o^integrin 
expression.
7.3.CD44 in B cell development
As CD44 had been extensively implicated in BM homing, it was surprising to find 
that CD44+/+ and CD44'7' HSC enriched BM cells homed equally as well to the BM, 
although more CD44V‘ cells were found in the blood after co-injection with CD44+/+ 
cells. Antibody blocking experiments have demonstrated that CD44 is involved in 
BM homing and attachment to the stromal cells. However CD44 was not the only 
molecule that has been implicated in BM homing; a^ntegrin and p2 intergrin have 
also been demonstrated to play a role (268, 269).Since mature B and T cells were 
shown to have increased expression of p2 integrin and ouintegrin respectively, it is 
possible that these molecules compensate for the lack of CD44 expression. 
Moreover, B cells have been demonstrated to develop without stromal cell 
interactions (270). Therefore a poor ability of CD44'/_ progenitor cells to interact 
with BM stromal cells might not lead to a deficiency in CD441 B cells.
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HSC have also been demonstrated to bind fibronectin, and a failure of HSC to bind 
fibronectin, leads to their development into myeloid cells. This could be occurring 
in the CD44'/‘ mice where there is an increased number of CFU-GM cells present 
in the BM. In the chimeras, increased expression of a^ntegrin, which also can 
bind fibronectin, could prevent a biased differentiation of CD44'7' cells to the 
myeloid lineage. In addition, triggering of vCD44 regions has also been 
demonstrated to release myeloid lineage influencing cytokines (198). Therefore, 
CD44'/' cells may also be less efficient in producing these cytokines (126, 238, 
271).
A possible explanation for the efficient production of B cells from CD44*/_ 
progenitors was that an inability to gain entry to the thymus could result in an 
increased return of these cells to the BM. Chimeras generated in thymectomised 
mice suggested that this was not the case, since there was no difference in the 
percentage of CD44_/' cells present in the B cell population between 
thymectomised and sham-thymectomised mice.
Another factor influencing B vs. T cell development is notch. It is thought that a 
strong signal between notch and its ligand, which is present on the stromal cell, is 
thought to promote T cell differentiation. However, if the lack of CD44 expression 
leads to weak cell-stroma interactions, this could result in weak notch signalling, 
and inhibit differentiation into T cells by allowing expression of PAX5 and 
encouraging B cell differentiation.
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Notch2 signalling is also thought to promote differentiation into follicular B cells as 
opposed B-1 and MZB cells (20, 272, 273). If lack of CD44 this leads to weaker 
interactions with stromal cells, then it would predicted that there would be less 
notch2 signalling and therefore more B1 and MZB cells (274). This was only 
partially observed, for there was an increase in MZB, but not a corresponding 
increase in B-1 cells. Of note, osteopontin deficient mice have a defect in their B1 
cells. Osteopontin is a CD44 ligand, which only binds certain forms of CD44. 
Hence poor interactions between B cells and osteopontin could reduce the 
efficiency of B-1 cell differentiation (198).
7.4.CD44 in T cell development
Many groups have demonstrated that CD44 is involved in thymic entry. A
deficiency in the ability of mature T cells to enter the adult thymus has been
observed in CD44'7" mice. However, C D 4 4 ' /~ mice do generate normal numbers of
T cells, indicating that there is not an absolute deficiency in the ability of T cell
progenitors to enter the thymus. We observed a reduced ability of CD44'7'
progenitors to produce T cells in chimeras only when the CD44'7' cells were in
competition with CD44+/+ cells. To investigate whether diminished production of
CD44'7" T cells in mixed chimeras was strictly due to inefficient thymic entry, T cell
development was examined after direct i.t. injection of progenitors. Interpretation
of these experiments was complicated by the fact that i.t. injected cells also
seemed to seed the BM (presumably due to leakage at the site of injection). At
early t im e  p o in ts  ( 4  w e e k s ) ,  C D 4 4  /_ a n d  C D 4 4 +/+ c e l ls  a p p e a r e d  to  p r o d u c e  s im ila r
n u m b e rs  o f  T  c e l ls ,  s u g g e s t i n g  t h a t  m o s t  o f  t h e  d e f ic i t  in  T  c e l l  p r o d u c t io n  b y  C D 4 4 ~
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cells was due to poor thymic entry. However, by 6 weeks post-injection, fewer 
CD44 T cells were observed. Whether this reflected a true deficit in even i.t. 
injected CD447 cells, or was related to re-seeding of the thymus by injected 
progenitors that had homed to the BM was unclear.
As with B cell homing, CD44 is thought to co-operate with other molecules, 
including ouintegrin and CD11a, to enter the thymus and interact with stromal cells 
(128, 221, 222, 250). The thymic epithelium has numerous CD44 ligands present, 
including the CD44v3 ligand heparin sulphate and GAG (275, 276). Fibronectin is 
also involved in the movement of T cells through the thymus (277, 278). However 
this is not thought to handicap the CD44'7' progenitors as a) T cells have been 
shown to develop without migration within the thymus, and b) a^ntegrin is thought 
to control movement within the thymus by binding fibronectin. RHAMM has been 
shown to co-operate with Piintegrin to bind fibronectin in the thymus (279). 
Therefore, other molecules could potentially replace the function of CD44 in thymic 
entry and migration within the thymus. As mentioned previously, mature CD44'7' T 
cells had an increased expression of a^ntegrin, p-iintegrin and CD11a in mixed 
chimeras.
When T cell development was investigated, it appeared that there was a deficiency 
in the transition between DN2-DN3 and DN4-DP stages of CD44'7' T cell 
development. Interestingly, it is at these stages where stromal-T cell interaction 
are thought to be important (280). Therefore, a lack of stromal cell factors could 
prevent the progression to the next developmental stage. CD44 is normally down 
regulated as cells progress from DN2 to DN3, consistent with an important role for
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CD44 at the DN2 stage. It is possible that the expression of putative
compensatory molecules can not be down regulated as CD44 would normally be, 
and that this would prevent developmental progression.
Weakened notch signalling could also be involved in changes in T cell
development observed for CD44‘/_ cells. Notch signalling is thought to encourage
CD8+ T cell development rather than CD4+ T cell development, by increasing the 
TCR signal strength. Reduced notch signalling would lead to a biased production 
of CD4+ T cells rather than CD8+ T cells, as observed in the mixed chimeras. Of 
note, notch has also been proposed to play a role in DN2-DN3 transition.
Regardless of the role of notch, lack of CD44 could more generally lead to weaker 
TCR signalling and hence favour CD4+ T cell development. CD44 has also been 
demonstrated to increase TCR strength by not only increasing the TCR-MHC 
interactions but also by recruiting more kinases into the TCR signalling cascade.
7.5.CD44 and functional responses
Data derived from CD44_/" mice demonstrated that there were no gross
abnormalities in their lymphocyte function, and preliminary data from the chimeric
mice agreed with this. However, further examination of B cell responses
suggested a deficiency in the ability of CD447' cells to produce class-switched
antibodies. This could be the result of a reduced ability of CD44'/_ B cells to
associate with T cells, possibly within germinal centres. Conversely CD441 B cells
were not deficient in their ability to respond to T-independent antigens. Reduced
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T-dependent antibody responses could also be due to a deficit in the BCR 
signalling cascade, since BCR signalling is dependent upon rac signalling, with 
which the intracellular region of CD44 is involved. The lack of CD44 in the 
immunological synapse could lead to a limitation of BCR signalling, which in turn 
could affect the generation of class switched CD44'/_ B cells (281, 282).
A deficit was also observed in the ability of CD44'7' CD8+ T cells to respond to viral 
challenge, as shown by reduced frequencies of cytokine producing antigen-specific 
cells. Osteopontin deficient mice also have an impaired Type 1 immunity to 
viruses, as they exhibit decreased IFN-y production. Therefore some of the 
deficiency demonstrated by CD44'7' cells could be due to their inability to efficiently 
bind osteopontin.
The relatively poor CD44'7" T cell response could be related to deficits in cell-cell 
contact and the immunological synapse. As mentioned above, CD44 is thought to 
stabilise the immune synapse and recruit more intracellular signalling molecules, 
facilitating a stronger signal. Therefore, a lack of CD44 could lead to weaker TCR 
signalling and a weaker response. This may have a particular effect on the 
production of cytokine expressing cells.
There are conflicting reports on the role of CD44 in regulating T cell apoptosis. 
Some groups have shown that binding CD44 triggered apoptosis (283), but other 
have demonstrated that it suppressed apoptosis (260). In our experiments CD44+/+ 
and CD44‘/_ cells were sorted after ova immunisation and then re-stimulated. At 
late time points after re-stimulation, the CD44‘/_ cells were clearly proliferating
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more, possibly suggesting a deficiency in AICD for the CD44'7' T cells. One reason 
that CD44-7' cells could be more resistant to apoptosis is that TGF-p1 is necessary 
to control apoptosis, and it has been demonstrated that CD44'/_ cells produces less 
TGF-p.
In conclusion, although CD44/' cells can develop into all investigated lymphocyte 
subsets and can produce functionally responsive cells there is an inherent 
deficiency in their fitness when placed in competition with CD44+/+ cells. CD44 
appears to be involved in maintaining cell-cell contact throughout the lifetime of the 
lymphocyte, thus facilitating interactions between important ligand pairs such as 
notch-notch ligand, and contributing to specific signalling through antigen 
receptors. Other molecules can clearly mediate similar functions and compensate 
in CD44’/_ mice. However the normal function of CD44 can be revealed by 
observing CD44 /_ cells in competition with CD44+/+ cells.
441
mf f / .
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9. Appendix 1: cell numbers 
9.1.Cell numbers in various tissues in various chimeras
9.1.1. Cell numbers of CD44+/+ & CD44+-» CD44+/+ chimeras.
Tissue Cell number x 10B ± s.e.m.
Spleen 77.21 11.51
LN 25.81 3.07
BM 60.89 4.32
Thymus 71.74 7.02
Liver 2.5 0.64
Peritoneal Cavity 5.37 1.86
Peyer’s Patches 4.25 0.45
9.1.2. Cell numbers of CD44+/+ & CD44'/"-> CD44'/_ chimeras.
Tissue Cell number x 106 ± s.e.m.
Spleen 104.53 10.7
LN 27.2 3.28
BM 58.75 3.21
Thymus 28.09 3.84
9.1.3. Cell numbers of CD44"7"—> CD44+/+ chimeras.
Tissue Cell number x 10b ± s.e.m.
Spleen 123.21 23.1
480
Tissue Cell number x 10b ± s.e.m.
LN 25.43 4.79
BM 63.5 6.84
Thymus 72.7 11.57
Liver 1.8 0.51
Peritoneal Cavity 1.91 0.08
Peyer’s Patches 2.45 0.76
9.1.4. Cell numbers of CD44+/+ (Ly5.1) & -► CD44+/+ (Ly5.2)
chimeras.
Tissue Cell number x 10b ± s.e.m.
Spleen 106.75 11.63
LN 32.69 7.05
BM 66.82 3.60
Thymus 86.25 12.30
Liver 2.22 0.22
Peritoneal Cavity 8.81 1.32
Peyer’s Patches 4.63 1.83
9.1.5. Cell numbers of CD44+/+ —> CD44+/+ chimeras.
Tissue Cell number x 10b ± s.e.m.
Spleen 94.25 12.33
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Tissue Cell number x 10b ± s.e.m.
LN 9.32 1.3
BM 70.25 7.02
Thymus 54.25 1.03
9.1.6. Cell numbers of CD44+/+ & CD44'/'-> CD44+/+ (1100 rads)
chimeras.
Tissue Cell number x 10B ± s.e.m.
Spleen 105.8 10.78
LN 39.20 4.49
BM 64.02 5.30
Thymus 83.22 5.12
Peritoneal Cavity 9.61 1.59
Blood 3.64 0.62
Peyer’s Patches 4.1 0.95
Liver 3.8 0.20
9.1.7. Cell numbers of CD44+/+ & CD44+-> RAG''’ CD44+/+
chimeras.
Tissue Cell number x 10b ± s.e.m.
Spleen 56.28 10.47
LN 52.11 7.58
482
Tissue Cell number x 10b ± s.e.m.
BM 62.49 6.75
Thymus 43.75 16.14
Peritoneal cavity 9.92 1.62
9.1.8. Cell numbers of xCD44+/+ & yCD44'/ —> CD44+/+ chimeras.
9.1.8.1. 75% CD44+/+ & 25% CD44 ' ^  CD44+/+ chimeras.
Tissue Cell number x 10b ± s.e.m.
Spleen 113.81 14.51
LN 41.69 3.93
BM 63.15 5.09
Thymus 105.58 8.32
9.1.8.2. 50% CD44+/+ & 50% CD44 / -> CD44+/+ chimeras.
Tissue Cell number x 10b ± s.e.m.
Spleen 92.52 24.13
LN 39.37 4.12
BM 72.36 3.26
Thymus 90.38 18.33
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9.1.8.3. 25% CD44+/+ & 75% CD 44'-. CD44+/+ chimeras.
Tissue Cell number x 10b ± s.e.m.
Spleen 56.13 11.82
LN 13.63 2.25
BM 39.4 7.45
Thymus 46.33 13.32
9.1.9. Cell numbers of HSC CD44+/+ & HSC CD44'/' ^  RAG''
CD44+,+ chimeras.
Tissue Cell number x 10b ± s.e.m.
Spleen 91.87 8.66
LN 52.35 11.06
BM 75.07 10.61
Thymus 57.31 10.47
Peritoneal Cavity 7.29 1.54
9.1.10. Cell numbers for LM chimeras
9.1.10.1. Cell numbers for LM CD44+/+ & LM CD44+/+-> CD44+/+ chimeras.
Tissue Cell number x 10y ± s.e.m.
Spleen 119.4 23.35
LN 35.94 1.96
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Tissue Cell number x 106 ± s.e.m.
BM 46.51 9.56
Thymus 68.46 7.95
9.1.10.2. Cell numbers for LM CD44t/+ & LM CD44 ' — CD44+/+ chimeras.
Tissue Cell number x 10b ± s.e.m.
Spleen 112.18 15.12
LN 32 3.99
BM 71.47 4.94
Thymus 80.61 9.82
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